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ABSTRACT 
People	access	health	services	to	preserve	or	improve	their	health	status.	In	
some	situations,	accessing	health	services	can	lead	individuals	to	pay	relatively	
high	proportions	of	their	available	income,	which	can	push	many	households	
into	poverty.	Universal	health	coverage	is	a	means	to	provide	health	coverage	to	
everyone	in	terms	of	effective	access	to	required	health	services	with	financial	
protection	against	catastrophic	spending.	In	Thailand,	the	Universal	Coverage	
Scheme	(UCS)	is	the	largest	public	insurance	scheme.	Launched	in	2001,	it	
covers	76%	(48	million)	of	Thais.	Its	members	are	households	mainly	in	the	
informal	sector,	lower	socioeconomic	groups,	the	elderly,	the	disabled,	and	all	
children	under	12.	In	2008,	7	years	after	its	launch,	the	UCS	introduced	the	
renal	replacement	therapy	(RRT)	benefit	intended	to	increase	access	to	health	
services	and	reduce	bottlenecks	of	treatment	for	end‐stage	renal	disease	
(ESRD).	Although	the	UCS	exists,	there	is	inadequate	health	care	infrastructure	
resulting	in	accumulated	patients	waiting	for	many	kinds	of	treatments	
including	RRT.	To	manage	this	problem,	the	UCS	has	introduced	various	so‐
called	disease	management	programmes	intended	to	increase	access	to	high‐
cost	health	services.		
The	purpose	of	this	study	is	to	explore	the	introduction	and	functioning	of	a	
high‐cost	health	benefit	programme	of	the	UCS	using	the	RRT	programme	as	a	
tracer	and	assess	how	a	disease	management	approach	facilitated	the	inclusion	
of	RRT	in	the	benefit	package.	Its	methods	involve	both	qualitative	and	
quantitative	techniques	to	explore	different	aspects	of	high‐cost	conditions	and	
a	disease	management	approach.	They	are	1)	qualitative	approaches	of	
document	review,	semi‐structured	interview,	focus	group	discussion,	and	
structured	observation	to	explore	the	rationale	of	the	RRT	programme,	also	
how	the	disease	management	approach	works	in	administering	and	arranging	
the	RRT	programme;	2)	age‐period‐cohort	analysis	based	on	administrative	
patient	data	of	the	National	Health	Security	Office	(NHSO)	to	assess	the	
changing	patterns	of	access	to	RRT	and	all‐cause	mortality	of	ESED	patients;	
and	3)	cost	modelling	and	time‐series	projection	of	RRT	patient	numbers	to	
estimate	the	long	term	financial	consequences	of	the	RRT	programme.		
4	
	
This	study	found	that	the	RRT	programme	was	the	outcome	of	lobbying	by	
various	stakeholders	responding	to	concerns	of	the	burden	of	ESRD	on	
households	and	inequitable	access	to	high‐cost	treatment.	Components	of	
disease	management,	such	as	evidence‐based	guidelines	and	collaborative	
practice,	were	crucial	to	organise	the	RRT	programme	and	rapidly	scale	up	
access	to	care.	The	family	played	an	important	role	in	patients’	decision	making	
to	enroll	in	the	RRT	programme.	Without	family	support,	patients	were	likely	to	
not	take	up	the	RRT	benefit.	Introduction	of	the	RRT	programme	has	resulted	in	
a	significant	increase	in	access	to	care	and	decrease	in	the	rising	all‐cause	
mortality	rate	of	ESRD	patients.	The	RRT	programme’s	long	term	implications	
involve	an	increasing	number	of	ESRD	patients	and	growing	budget	needs	for	
providing	care.	This	study	suggests	strengthening	involvement	of	various	
stakeholders,	particularly	community	participation	in	health	care	in	order	to	
create	efficient	services	that	are	responsive	to	the	local	needs.	Locally	made	
medications	and	budget	optimisation	and	allocation	should	be	put	in	place	to	
manage	the	programme’s	costs.	 	
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CHAPTER 1 Introduction 
1.1 Background 
People	access	health	services	to	preserve	or	improve	their	health	status.	In	
some	situations,	accessing	health	services	can	lead	individuals	to	pay	relatively	
high	proportions	of	their	available	income	which	can	push	many	households	
into	poverty	(Xu,	Evans	et	al.	2003).	Renal	dialysis	is	one	such	example:	care	
costs	have	been	described	as	catastrophic	and	can	drive	a	patient	into	
impoverishment	(Wyszewianski	1986).	Although	renal	dialysis	is	used	by	only	a	
small	percentage	of	individuals,	it	accounts	for	a	high	proportion	of	overall	
health	care	expenditures	(Berk	and	Monheit	1992).		
Chronic	kidney	disease	has	been	increasingly	recognised	as	a	global	public	
health	problem	(Levey,	Atkins	et	al.	2007;	Coresh	and	Jafar	2015;	Liyanage,	
Ninomiya	et	al.	2015).	This	is	not	only	because	of	the	rising	prevalence	across	
the	world	but	because	of	widening	inequities	in	accessing	the	treatment,	renal	
replacement	therapy	(RRT)1	(Grassmann,	Gioberge	et	al.	2005;	White,	Chadban	
et	al.	2008;	Coresh	and	Jafar	2015;	Liyanage,	Ninomiya	et	al.	2015).	It	is	
estimated	that,	worldwide,	only	a	half	of	those	needing	RRT	receive	it.	Of	those	
receiving	RRT,	only	7%	reside	in	low‐	and	middle‐income	countries,	yet	these	
people	make	up	4%‐12%	of	those	who	need	the	treatment.	In	these	countries	
therefore,	the	low	percentage	of	people	accessing	treatment	is	a	consequence	of	
the	high	cost	of	dialysis.		Although	the	treatment	is	less	expensive	than	in	high‐
income	countries,	it	is	still	unaffordable	for	most	people	(Jha	2013).		
Additionally,	inadequate	infrastructure,	or	supply	of	services,	may	make	it	
impossible	to	provide	quality	access	to	everyone	(Mogyorosy,	Mucsi	et	al.	
2003).	
Governments	in	many	countries	have	struggled	to	provide	access	to	essential	
health	services	as	well	as	to	protect	their	citizens	from	catastrophic	payments	
due	to	health	care	costs.	Within	the	given	national	budget,	the	government	
																																																								
1 A term that used to call treatment options for people who are suffering from last stages of chronic kidney 
disease 
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needs	to	contain	costs	and,	at	the	same	time,	maximize	the	health	of	the	
population.	This	commitment	may	create	a	significant	dilemma	for	policy	
makers	when	making	a	decision	about	some	diseases	that	are	very	expensive	to	
treat	and	also	expensive	for	patients	to	pay	out‐of‐pocket.	They	must	decide	
whether	costly	treatments	should	be	included	in	the	basic	health	benefit	or	not.	
Determining	health	service	inclusion	based	purely	on	an	economic	evaluation	
means	that	only	the	most	cost‐effective	treatments	are	likely	to	be	covered	in	
the	benefit	package.	When	comparing	RRT	with	other	health	care	interventions,	
RRT	modalities	are	usually	ranked	as	providing	inferior	value	for	money	
expressed	in	terms	of	incremental	cost‐effectiveness	ratios	(ICER)	
(Chaikledklew	2014).	In	addition,	renal	dialysis	is	less	cost‐effective	in	
comparison	to	transplantation	(Muirhead	1996),	but	it	is	essential	to	prolong	a	
patient’s	life,	and	since	organ	donors	tend	to	be	in	short	supply	transplantation	
is	not	available	to	every	patient.	Therefore,	making	decisions	on	the	basis	of	
cost‐effectiveness	might	be	a	barrier	to	access	to	expensive,	less	cost‐effective,	
but	nonetheless	essential	treatments	such	as	RRT.		
Even	if	expensive	treatment	is	provided	universally,	this	does	not	mean	that	
everyone	in	need	is	able	to	use	the	service.	This	may	be	because	the	benefit	
package	does	not	cover	all	essential	costs	of	treatment,	meaning	patients	need	
to	pay	high	amounts	out‐of‐pocket	(Himmelstein,	Thorne	et	al.	2009).	Limited	
geographic	accessibility	to	health	services	may	also	be	a	factor	which	inhibits	
treatment	take‐up	(Chan,	Hart	et	al.	2006).		
Governments	in	many	countries	have	tried	various	approaches	to	balance	the	
dual	objectives	of	cost	containment	and	achieving	health	outcomes	for	
expensive	treatments.	Examples	of	current	approaches	are:	health	technology	
assessment	(Ham	1997),	strictly	controlled	payment	mechanisms	(Dor,	Pauly	et	
al.	2007)	and	price	regulation	of	pharmaceuticals	(Sullivan,	Peppercorn	et	al.	
2011).	Alternatives	have	focused	on	reducing	demand	to	control	costs	of	
treatment.	These	include	approaches	to	increase	quality	of	care,	such	as	
individual	patient	chart	review,	modifying	patient	lifestyle,	and	promoting	
patient	health	education	that	aims	to	slow	down	the	progress	of	costly	diseases.	
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It	is	also	believed	that	investment	in	prevention	programmes	is	cheaper	than	
paying	later	the	full	cost	of	expensive	treatment	(Sović,	Pająk	et	al.	2012;	Png	
and	Yoong	2014).	
Disease	management	involves	the	use	of	a	number	of	approaches	for	identifying	
and	caring	for	patients	with	chronic	conditions	(Bodenheimer	and	Berry‐Millett	
2009).	By	systematically	reorganising	medical	care	for	chronic	illness	across	
delivery	systems,	disease	management	aims	to	improve	health	outcomes	and	
reduce	healthcare	costs	(Weingarten,	Henning	et	al.	2002;	Bodenheimer	and	
Berry‐Millett	2009).	A	range	of	disease	management	initiatives	have	been	
developed	in	the	US	and	Europe	to	cope	with	growing	health	care	costs	and	
fragmentation	in	the	health	system.	In	the	Universal	Coverage	Scheme	(UCS)	in	
Thailand,	the	disease	management	approach	was	adopted,	but	has	been	used	
with	different	intentions:	the	approach	aims	to	administer	and	arrange	service	
delivery	and	promote	patients’	access	to	health	services	that	have	accessibility	
problems	and	or	where	treatment	is	so	expensive	that	it	may	lead	patients	into	
impoverishment.	
1.2 What is known? 
Disease	management	programmes	target	patients	with	chronic	conditions.	
Despite	the	promise	offered	by	these	programmes,	questions	remain	about	
their	effectiveness	and	potential	for	application	in	large	populations	or	
nationwide.	Furthermore,	disease	management	programmes	can	be	costly	to	
develop,	implement,	and	evaluate	(Weingarten,	Henning	et	al.	2002).	Numerous	
research	studies	have	been	conducted	to	assess	the	effect	of	such	approaches,	
yet	findings	from	these	studies	have	been	inconsistent	in	terms	of	access	to	
care,	cost	saving,	and	quality	of	care	(Bodenheimer	and	Berry‐Millett	2009).	
Another	issue	is	that	these	studies	concentrate	mainly	on	developed	countries,	
and	studies	from	developing	countries	are	underrepresented.		
Among	existing	evidence	that	describes	the	applications	and	effects	of	the	
disease	management	approach	in	different	health	systems,	there	are	further	
challenges	for	countries	using	disease	management	programmes.	These	include	
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for	example,	how	to	enable	everyone	who	is	in	need	to	access	their	preferred	
health	care;	how	best	to	meet	the	infinite	need	for	health	care	while	health	
resources	are	limited,	and	how	a	country	can	sustain	essential,	high‐cost	health	
benefits	in	the	long	run.	
1.3 Scope of the thesis 
The	focus	of	this	study	is	to	assess	the	performance	of	one	approach	to	
managing	a	high‐cost	condition	in	Thailand,	a	developing	country.		This	study	
aims	to	explore	the	introduction	and	functioning	of	a	UCS	high‐cost	health	
benefit	programme,	using	the	RRT	disease	management	programme	as	a	tracer.		
It	will	then	assess	how	a	disease	management	approach	has	facilitated	the	
inclusion	of	RRT	in	the	benefit	package.	
The	thesis	has	three	main	objectives.	The	first	objective	is	to	describe	the	
rationale	behind	the	initiation	of	a	high‐cost	health	benefit	programme	and	the	
application	of	the	disease	management	approach.	It	employs	qualitative	
methods	to	triangulate	evidence	from	multiple	data	sources	to	explore	the	
rationale	of	the	RRT	programme,	and	how	the	disease	management	approach	
works	in	administering	and	arranging	the	RRT	programme.	These	qualitative	
methods	include	document	review,	semi‐structured	interview,	focus	group	
discussion,	and	structured	observation.	The	second	objective	is	to	assess	the	
changing	patterns	of,	firstly,	in	terms	of	access	to	RRT	services,	and	secondly,	in	
terms	of	the	mortality	of	patients	who	are	diagnosed	with	end‐stage	renal	
disease	(ESRD).	This	will	be	done	by	using	an	age‐period‐cohort	analysis.	The	
third	objective	is	to	develop	long	term	projections	of	the	RRT	programmes’	
likely	number	of	future	patients	and	estimated	budget	from	the	public	payer’s	
perspective.	It	employs	methods	of	cost	modelling	and	time‐series	analysis.	
Possible	future	scenarios	were	identified	to	define	probable	cost	drivers	of	the	
RRT	programme.	
Subsequently,	combining	with	reviews	of	relevant	documents,	this	study	
conveys	the	significance	of	the	study	and	makes	suggestions	which	contribute	
to	debates	about	how	the	disease	management	approach	can	facilitate	access	to	
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high‐cost	treatments	in	general,	and	in	developing	countries	in	particular.	
Although	the	UCS	has	many	disease	management	programmes,	this	study	will	
focus	only	on	the	RRT	programme,	in	addition	this	study	neither	assessed	nor	
made	comparison	with	the	other	two	public	schemes,	namely	the	Civil	Servant	
Medical	Benefit	Scheme	and	Social	Security	Scheme	because	the	NHSO	
possesses	more	comprehensive	data	and	better	administrative	functions.	
Secondly,	the	UCS	covers	76%	of	the	Thai	population.	Thirdly,	the	other	two	
schemes	do	not	provide	disease	management	programmes	to	their	members.		
1.4 How the thesis is organised 
The	rest	of	this	thesis	is	organised	into	eight	chapters	(chapters	2‐9),	they	are	
structured	as	follows.	
Chapter	2	offers	a	literature	review.	It	reviews	concerns	about	high‐cost	
treatment	from	a	health	policy	perspective,	beginning	with	how	high‐cost	
conditions	link	to	catastrophic	expenditure	and	impoverishment	of	patients.	
Next,	the	chapter	considers	evidence	as	to	the	benefits	of	universal	health	
coverage	in	every	country.	The	chapter	then	provides	a	brief	introduction	to	the	
disease	management	approach.	This	section	is	followed	by	an	introduction	to	
chronic	kidney	disease,	its	treatments,	and	reimbursements	for	treatments	as	
they	were	used	as	this	study’s	tracers	to	assess	effects	of	high‐cost	conditions.	
The	gap	in	knowledge	gained	from	prior	studies	that	lead	to	this	thesis’	
research	question	is	provided	in	the	final	section.		
Chapter	3	reports	findings	from	a	systematic	search	on	how	disease	
management	programmes	are	arranged	and	the	effects	of	population‐based	
disease	management	programmes.	The	results	are	reported	both	at	the	payer‐
provider	level	and	the	provider‐patient	level.			
The	next	chapter,	Chapter	4,	introduces	the	framework,	aim,	objectives,	and	the	
methodology	of	the	study.	The	framework	emphasises	the	main	factors	to	be	
studied	and	how	each	of	them	connects	to	the	others.	The	methodology	section	
presents	the	selected	study	designs,	study	subjects,	how	data	were	collected,	
analysed,	and	reported.		
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Chapter	5	provides	in‐depth	information	on	the	arrangements	of	the	RRT	
programme.	This	chapter	links	the	concepts	of	disease	management	and	the	
chronic	care	model	to	actual	services	provided	by	the	RRT	programme.	These	
components	include:	delivery	system	design,	resource	and	policy,	decision	
support,	and	self‐care	support.	The	chapter	describes	the	relation	between	
policy	makers,	providers,	and	patients	to	obtain	a	better	understanding	of	how	
these	people	in	different	levels	of	the	health	system	manage	and	respond	to	this	
high‐cost	condition.	
Chapter	6	analyses	and	reports	trends	of	1)	new	registrations	into	each	RRT	
modality:	peritoneal	dialysis,	hemodialysis,	and	kidney	transplant	and	2)	death	
rates	in	all	patients	who	were	diagnosed	with	end‐stage	kidney	disease	and	in	
patients	who	were	maintaining	RRT.	Age‐period‐cohort	analysis	was	taken	to	
model	the	effect	of	age	and	time	on	new	registrations	and	deaths.	At	the	end	of	
the	chapter,	surrounding	factors	which	might	influence	the	trends	of	
registration	and	death	are	discussed.	
Chapter	7	estimates	the	annual	cost	of	the	RRT	programme	from	the	health	care	
payer’s	perspective.	The	autoregressive	integrated	moving	average	(ARIMA)	
model	was	used	to	project	numbers	of	RRT	patients	in	the	next	ten	years.	
Results	from	these	two	parts	were	drawn	on	to	calculate	the	final	result	which	
was	the	programme’s	budget	needs	during	such	a	period.	
Chapter	8	draws	on	results	from	the	analytical	chapters	and	explains	how	they	
provide	broader	knowledge	of	disease	management	in	the	case	of	a	high‐cost	
health	benefit.	It	also	discusses	strengths	and	weaknesses	of	the	research	
design	and	the	methodology	employed	by	the	study.	
Finally,	Chapter	9	provides	a	conclusion,	suggests	policy	implications,	and	
proposes	future	research	in	this	area.	It	identifies	how	the	study	contributes	to	
knowledge	of	disease	management	in	cases	of	high‐cost	health	benefits.		
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CHAPTER 2 Literature review 
The	purpose	of	this	chapter	is	to	provide	the	context	of	high‐cost	conditions	and	
reveal	the	gap	of	knowledge	on	this	topic.	The	chapter	first	reviews	the	
characteristics	of	high‐cost	conditions	and	their	impacts	on	the	health	system.	
Next,	it	explores	why	universal	health	coverage	is	important	to	protect	patients	
against	the	impact	of	high‐cost	conditions,	and	why	it	is	crucial	to	have	
universal	health	coverage	in	every	country.	After	that	a	brief	introduction	of	the	
disease	management	approach	is	presented,	prior	to	a	more	detailed	discussion	
in	Chapter	3.	The	chapter	introduces	chronic	kidney	disease	as	an	example	of	a	
high‐cost	condition.	This	section	is	followed	by	a	review	of	reimbursements	and	
the	funding	of	renal	replacement	therapy	(RRT),	both	internationally	and	in	
Thailand.	After	that,	the	chapter	focuses	on	the	arrangement	of	the	UCS’s	RRT	
programme.	The	next	two	sections	review	the	methodology	on	RRT	cost	
modelling	and	the	UCS’s	RRT	programme	evaluations.	Knowledge	gaps	in	the	
literature	reviews	are	identified	in	the	final	section.	
2.1 Literature search and review sources 
The	review	has	three	key	themes:	high‐cost	and	catastrophic	conditions,	
universal	health	coverage,	and	chronic	kidney	disease.	These	themes	and	their	
related	issues	were	used	as	key	words	in	the	literature	search.	The	search	
included	both	published	and	grey	literature,	such	as	government	reports,	
research	reports,	books,	proceedings,	and	online	articles;	from	both	
international	and	Thai	sources.	The	majority	of	retrieved	articles	came	from	
online	databases	in	the	following	sources.		
Online	sources	of	international	articles:	
 LSHTM	databases:	
http://www.lshtm.ac.uk/library/resources/databases/	
 PubMed:	http://www.ncbi.nlm.nih.gov/pubmed	
 Google	Scholar:	https://scholar.google.co.uk/	
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Online	sources	of	Thai	articles:	
 Health	System	Research	Institute:	http://www.hsri.or.th/researcher	
 Health	Insurance	System	Research	Office:	
http://www.hisro.or.th/main/index.php	
 National	Health	Security	Office	Library:	http://library.nhso.go.th/	
In	addition,	Google	was	used	to	search	for	other	online	sources,	such	as	WHO,	
World	Bank,	European	Observatory	on	Health	Systems	and	Policies.	
2.2 High-cost conditions and their impacts 
It	is	important	to	differentiate	between	the	terms	‘high‐cost	condition’	and	
‘catastrophic	spending’	since	they	influence	policy	formulation	in	different	
ways.	While	there	has	long	been	an	interest	in	protecting	patients	against	
catastrophic	expenditure,	policy	concerns	over	high‐cost	illness	are	more	
recent.	Focusing	on	high‐cost	conditions	is	more	associated	with	an	attempt	to	
contain	health	care	spending	of	the	health	system	(Wyszewianski	1986).	
The	term	‘high‐cost’	is	taken	to	refer	to	a	specific	treatment,	intervention,	or	a	
patient	diagnosis	that	incurs	high	cost	to	the	patient	or	the	insurer.	It	is	
generally	characterised	by	expensive	medications	or	procedures.	To	be	more	
specific,	the	major	cost	drivers	of	expensive	treatments	seem	to	be	1)	the	aging	
population,	2)	the	advancement	of	new	technologies	such	as	medicines	and	
laboratory	tests,	and	3)	these	last	are	often	accompanied	by	improper	clinical	
guideline	use	(Sullivan,	Peppercorn	et	al.	2011).	Health	spending	on	a	small	
number	of	patients	with	high‐cost	conditions	can	account	for	a	significant	
proportion	of	national	health	expenditure	(Berk	and	Monheit	1992;	Sullivan,	
Peppercorn	et	al.	2011).	Conversely,	the	bottom	half	of	the	population	(as	
ranked	by	health	expenditures)	can	account	for	just	single	digit	percentages	of	
total	health	expenditures	(Berk	and	Monheit	1992).	
Wyszewianski	(1986)	reviewed	out‐of‐pocket	caps	on	several	health	insurance	
plans	in	the	US	in	order	to	develop	a	definition	of	a	high‐cost	case.	He	proposed	
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that	a	high‐cost	case	should	refer	to	a	patient	who	consumes	total	health	
expenditure	of	more	than	US$10,000	annually	(1986	prices).	The	meaning	of	
high‐cost	in	other	recent	literature	has	not	been	later	defined.		
Rapid	increases	in	health	care	spending	make	it	important	to	assess	what	
conditions	or	what	type	of	patients	account	for	a	high	proportion	of	the	total	
health	spending.	Cohen	and	Krauss	(2003)	defined	the	fifteen	most	expensive	
conditions	from	the	total	US	health	spending	and	a	household	survey	of	
healthcare	expenditure	in	1997.	Those	expensive	conditions	could	be	divided	
into	two	types	based	on	the	condition’s	onset	and	recovery	period,	and	acute	
and	chronic	conditions.	Acute	conditions	included,	for	example,	trauma,	
pneumonia,	and	infectious	diseases.	Chronic	conditions	included	diseases	such	
as	cerebrovascular	disease,	cancer,	and	renal	disease.	While	the	main	cost	
driver	of	chronic	conditions	was	hospitalisation,	renal	disease	was	unique	in	
that	most	of	its	spending	was	accounted	for	by	ambulatory	visits	for	dialysis,	
Figure	2‐1.	Although	the	total	expenditure	on	kidney	disease	ranked	twelfth	out	
of	fifteen	conditions,	the	mean	expense	per	person	was	the	third	most	
expensive,	or	US$12,476	per	year	(1997	prices)	after	cerebrovascular	disease	
and	cancer	(Cohen	and	Krauss	2003).	While	the	study	did	not	identify	what	
proportions	these	fifteen	conditions	accounted	for	in	US	total	health	
expenditure	(THE),	an	earlier	study	found	that	5%	of	Americans	accounted	for	
up	to	58%	of	THE	(Berk	and	Monheit	1992).	These	findings	provided	significant	
insights	for	policy	makers	to	know	what	diseases	should	be	targeted	and	
managed	in	order	to	control	overall	health	care	spending.		
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Figure 2‐1  Selected expensive conditions made up in US total health 
expenditure 1997 
	
Adapted from: Cohen and Krauss (2003) 
2.2.1 Catastrophic health expenditure 
Catastrophic	health	expenditure	occurs	when	a	household	pays	out‐of‐pocket	
for	health	care	costs.	A	financially	catastrophic	case	is	a	situation	where	
expenditure	is	overly	large	in	comparison	to	a	household’s	ability	to	pay,	for	
example	exceeding	15%	of	family	annual	income	(Wyszewianski	1986).	To	date,	
there	is	still	no	consensus	on	the	specific	threshold	for	catastrophic	
expenditure.	Most	literature,	however,	agrees	to	measure	catastrophic	
expenditure	relative	to	patients’	capacity‐to‐pay	rather	than	merely	to	income	
(Xu,	Evans	et	al.	2007).	The	World	Health	Organisation	proposed	that	
catastrophic	expenditure	should	be	measured	by	medical	spending	greater	than	
40%	of	non‐subsistence	income,	which	is	calculated	by	annual	family	income	
less	spending	on	basic	needs.	The	proposed	threshold	of	40%	can	be	varied	to	
suit	a	country’s	context	(Xu,	Evans	et	al.	2005).		
A	financially	catastrophic	case	can	be	caused	by	one‐off	expensive	medical	
interventions,	a	relatively	small	amount	of	spending	but	continued	over	a	long	
time	period,	or	multiple	episodes	of	illness	in	the	household	(Wyszewianski	
1986).	In	a	situation	of	financial	difficulty,	a	household	may	use	various	coping	
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strategies;	for	instance,	reducing	food	consumption,	withdrawing	children	from	
education,	taking	out	a	loan,	distress	sale	of	assets,	and	stopping	or	delaying	
treatment,	in	order	to	finance	health	care	costs	(Russell	1996).		
Current	measurements	of	catastrophic	expenditure	are	focused	on	the	impact	
on	individual	patients	and	quantifying	proportions	of	households	with	
catastrophic	spending.	The	intention	of	these	measures	is	to	assess	the	
effectiveness	of	public	health	financing	in	protecting	households	against	
impoverishment	due	to	health	care	costs	(Kawabata,	Xu	et	al.	2002).	
2.2.2 Relationship between high-cost conditions and catastrophic 
expenditure 
The	relationship	between	catastrophic	health	expenditure	and	high‐cost	
conditions	is	shown	in	Figure	2‐2.	A	high‐cost	condition	is	not	always	
catastrophic	(Wyszewianski	1986).	For	example,	if	a	high‐cost	illness	happens	
to	a	member	of	a	well‐off	family	who	is	able	to	pay	for	the	treatment,	the	family	
will	not	face	financial	catastrophe,	while	in	contrast,	poor	households	are	less	
able	to	cope	with	any	level	of	health	care	cost.	Even	a	common	disease	that	is	
not	high‐cost,	can	lead	a	poor	household	to	catastrophic	expenditure.		
Figure 2‐2   Relations between high‐cost and catastrophic 
expenditure from the household perspective 
	
Adapted from: Wyszewianski (1986) 
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Financial	protection	plays	an	important	role	to	prevent	individuals	with	
insufficient	ability	to	pay	for	health	care	costs	from	facing	financial	catastrophe	
(Table	2‐1).	A	high‐cost	disease	will	not	cause	catastrophic	spending	if	there	is	
financial	protection	to	cover	costs	of	treatment	without	creating	financial	
hardship	to	patients	(Wyszewianski	1986).		
Table 2‐1  Relations between high‐cost conditions, catastrophic expenditure, and 
financial protection 
  
Financially catastrophic Not financially catastrophic 
Financial protection No financial protection Financial protection No financial protection 
High cost Inadequate coverage Insufficient ability-to-pay Adequate coverage Sufficient ability-to-pay 
Not high cost Inadequate coverage Insufficient ability-to-pay     
Adapted from: Wyszewianski (1986) 
To	date,	numerous	studies	have	been	conducted	to	assess	to	what	extent	health	
care	financing	can	protect	households	from	catastrophic	expenditure	and	
impoverishment	from	health	spending.	Fewer	studies,	however,	focus	on	high‐
cost	conditions	that	can	lead	patients	to	catastrophic	payment	and	that	are	of	
concern	to	health	care	payers	given	their	significant	effect	on	total	health	
expenditure.	
2.3 Universal Health Coverage  
The	World	Health	Report	2010	called	for	all	countries	to	move	forward	to	
universal	health	coverage.	The	call	was	due	to	evidence	that	many	people	are	
suffering	from	excessive	out‐of‐pocket	payment;	in	particular,	those	who	rely	
the	most	on	direct	payment2	to	finance	health	care	costs	(WHO	2010).		
																																																								
2 According to WHO (2010), the term direct payments cover all forms of out-of-pocket payment and informal payment 
that people pay at the time they use services. Even in a country with universal coverage, people can be required to pay 
co-payment in various forms, such as co-insurance, co-payment, and deductible. 
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national	health	services”.	A	benefit	package	is	a	starting	point	to	focus	on	the	
highest	priority	services	and	gives	ideas	to	policy	makers	on	the	planning	of	
supply	for	equipment,	human	resources,	medicine,	and	medical	devices	
(Bobadilla,	Cowley	et	al.	1994).		
2.3.2 Should high-cost conditions be included in the benefit package? 
Some	may	argue	that	what	is	included	in	the	benefit	package	should	be	taken	on	
the	objective	of	equity	that	is	inherent	in	the	definition	of	universal	healthcare	
coverage	(Parmar,	De	Allegri	et	al.	2014).	However,	from	the	payer’s	
perspective,	there	is	constraint	in	limited	resources.	These	limitations	may	
include	financing	for	the	health	scheme,	numbers	of	health	workers,	and	health	
care	infrastructure.	Designing	the	benefit	package,	therefore,	always	involves	
priority	setting,	which	happens	at	many	stages	of	the	resource	allocation	
process.		
Many	countries	have	established	Health	Technology	Assessment	(HTA)	
agencies	and	take	advice	from	them	to	determine	which	health	interventions	
offer	best	value	for	money	and	at	what	price	these	should	be	covered	by	the	
public	health	care	budget.	HTA	is	a	key	input	into	the	resource	allocation	
process,	however	it	does	not	mean	that	decision‐making	is	based	solely	on	the	
economic	assessment.	It	is	evident	that	even	in	high‐income	countries,	HTA	is	
used	only	under	certain	circumstances	and	the	situation	can	vary	within	a	
country	and	from	one	country	to	another	(Paris	2014).	This	is	because	in	
reality,	priority	setting	is	primarily	a	social	and	political	exercise,	involving	the	
distribution	of	benefits	and	responsibilities	to	everyone	in	the	nation	
(Langenbrunner	and	Somanathan	2011;	Glassman,	Chalkidou	et	al.	2012).		
Even	in	a	system	with	well‐designed	universal	health	coverage,	the	rationing	
dilemma	of	priority	setting	may	create	a	conflict	over	the	benefit	package,	and	
in	particular	over	expensive	therapies	(Glassman,	Chalkidou	et	al.	2012).	High‐
cost	treatments	that	can	drive	a	patient	into	impoverishment	often	lead	to	
public	interest	and	debate.	The	issue	is	how	to	provide	those	in	need	with	
horizontal	equity	(equal	treatment	for	equal	need)	given	limited	resources	
(Ham	and	Robert	2003).	In	Mexico,	the	Seguro	Popular	health	scheme	has	been	
CHAPTER 2  Literature review 
32 
	
praised	as	an	example	of	best	practice:	a	developing	country	that	has	achieved	
universal	coverage	and	social	protection	through	a	comprehensive	benefit	
package	(Frenk,	González‐Pier	et	al.	2006).	While	the	population	covered	by	the	
Mexican	Social	Security	Scheme	has	access	to	RRT,	the	Seguro	Popular	is	
criticised	for	failing	to	reduce	inequality	in	access	to	health	care	as	it	does	not	
include	the	treatment	for	end‐stage	renal	disease	(Garcia‐Garcia,	Renoirte‐
Lopez	et	al.	2010;	Kierans,	Padilla‐Altamira	et	al.	2013).	
Application	of	cost‐effectiveness	principles	and	a	strong	cost‐containment	
policy	may	cause	barriers	to	treatments	that	are	relatively	cost‐ineffective	but	
essential	to	prolong	patient	life	and	may	cause	a	patient	catastrophic	spending.	
A	cost‐effectiveness	league	table	is	one	way	to	provide	information	to	policy	
makers	when	determining	the	economic	value	of	new	health	care	inventions.	
Table	2‐2	is	an	example	of	a	league	table	of	health	interventions	in	Thailand.	
Thailand	applies	the	threshold	of	1‐1.2	times	per‐capita	gross	domestic	product	
(GDP;	US$4,800	or	roughly	170,000	Baht	in	2011)	per	quality‐adjusted	life	year	
(QALY)	gained	to	determine	whether	any	health	care	interventions	are	cost‐
effective	and	should	be	established	in	the	UCS	benefit	package	(Mohara,	
Youngkong	et	al.	2012).	The	first	four	treatments	in	Table	2‐2	cost	less	or	
approximately	equal	to	the	threshold	and	were	covered	in	the	UCS	health	
basket.	Peritoneal	dialysis	and	hemodialysis	were	classified	as	less	cost‐
effective	interventions	and	were	therefore	excluded	from	the	benefit	package	
when	the	UCS	was	first	launched	in	2001	but	were	later	included	in	2008.	
Table 2‐2  Cost‐effectiveness league table of selected interventions in Thailand 
Treatments Baht/QALY 
(2009 prices) 
UCS coverage 
Antiretroviral treatment*  26,000 Yes 
Vertical HIV transmission prevention**  25,000 Yes 
Cardiovascular disease prevention (generic statins)**  82,000 Yes 
Cytomegalovirus retinitis (Gancyclovir)* 185,000 Yes 
Antidiabetic drugs: Pioglitazone compared with Rosiglitazone 211,000 No 
HPV vaccine at age 15 compared with smear test (women aged 35-
65) 
247,000 No 
Osteoporosis: Alendronate compared with Calcium+Vitamin D 296,000 No 
CHAPTER 2  Literature review 
33 
	
 
* = compared with palliative care, ** = compared with do nothing 
QALY=quality-adjusted life year, UCS= universal health coverage 
Adapted from: Chaikledklew (2014) 
2.4 Universal health coverage in Thailand  
The	Thai	government	launched	the	UCS	in	2001	to	cover	previously	uninsured	
citizens	that	were	not	covered	under	the	other	two	existing	public	schemes,	
namely,	the	Civil	Servant	Medical	Benefit	Scheme	(CSMBS)	and	Social	Security	
Scheme	(SSS).	To	date,	the	UCS	covers	48	million	beneficiaries	or	76%	of	all	
Thais.	The	remaining	21%	are	those	government	employees,	their	dependants,	
and	retirees	who	belong	to	the	CSMBS;	and	formal	employees	of	the	private	
sector	that	are	covered	under	the	SSS	(NHSO	2013).		
The	UCS	uses	a	contract	model	with	arrangements	for	private	and	public	
competition,	although	in	the	early	phase	most	UCS	contracting	units	were	public	
facilities	and	few	private	hospitals	joined	the	scheme.	The	contracting	unit	of	
the	UCS	was	called	the	contracting	unit	for	primary	care.	These	were	mainly	
community	hospitals	acting	as	main	contractors.	They	are	responsible	for	
arranging	primary	care	(including	GP	services	and	dental	care)	and	some	types	
of	hospital	based	care	for	registered	members	in	their	local	areas,	and	they	refer	
patients	to	a	higher	level	of	care	if	necessary.	A	closed‐end	payment	system	was	
used	to	control	cost	and	increase	efficiency	in	the	UCS.	Preventive	and	
promotive	care	and	outpatient	care	are	paid	by	capitation.	Inpatient	services	
are	reimbursed	by	diagnosis	related	groups	(DRG)	with	global	budget.	The	UCS	
tried	to	split	the	provider	and	payer	roles	by	setting	up	a	new	organisation,	
namely	the	National	Health	Security	Office	(NHSO)	to	be	the	payer	and	design	
the	UCS	benefit	package.	
The	UCS	offers	a	comprehensive	benefit	package	to	every	member	including	
essential	outpatient	services,	inpatient	services,	dental	care,	accident	and	
Osteoporosis: Residronate compared with Calcium+Vitamin D 328,000 No 
Peritoneal dialysis*  435,000 Yes 
Hemodialysis* 449,000 Yes 
Osteoporosis: Raloxifene compared with Calcium+Vitamin D 634,000 No 
Osteoporosis: Calcitonin compared with Calcium+Vitamin D 1,024,000 No 
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emergency,	and	prevention	programmes	(Tangcharoensathien,	Pitayarangsarit	
et	al.	2012).	All	costs	of	services	can	be	reimbursed	in	full.	Patients	are	not	
required	to	pay	any	form	of	co‐payment	except	a	voluntary	payment	of	30	Baht	
(approximately	60	pence)	per	visit.	In	the	commencement	of	the	UCS	in	2001,	
so	there	was	a	concern	on	the	scheme’s	fiscal	constraints	and	an	unprepared	
system,	UCS	policy	makers	decided	to	exclude	two	high‐cost	treatments:	
HIV/AIDS	and	RRT	from	the	benefit	package.	These	two	high‐cost	treatments	
however	have	been	later	added	in	the	benefit	package.	
2.4.1 High-cost conditions in the UCS 
The	newly‐launched	UCS	met	the	immediate	problem	of	a	large	number	of	
accumulated	patients	on	waiting	lists	for	many	kinds	of	treatments.	The	main	
cause	of	this	problem	was	the	inadequacies	of	the	existing	health	care	
infrastructure.	These	inadequacies	included	insufficient	funding;	lack	of	service	
provision,	health	care	staff,	equipment,	and	medications;	and	an	ineffective	
monitoring	and	evaluation	system	(Tangcharoensathien,	Pitayarangsarit	et	al.	
2012).		
To	relieve	the	bottlenecks,	the	UCS	has	introduced	many	so‐called	disease	
management	programmes	aiming	to	promote	access	to	health	services	and	
prevent	catastrophic	payment.	Some	programmes	have	their	own	specific	
objectives,	for	example,	to	promote	and	expand	the	use	of	Thai	traditional	
medicine	and	Thai	herbal	medicine.	Key	activities	of	most	programmes	include	
defining	the	target	population,	developing	standard	protocols	linked	to	a	new	
payment	mechanism3,	and	arranging	a	reporting	system	for	reimbursement.	All	
actions	are	intended	to	promote	increase	in	service	provision	or	health	
professionals	to	ensure	access	to	services.	The	use	of	the	standard	protocol	also	
facilitates	quality	of	care	in	these	programmes,	and	is	occasionally	used	as	a	tool	
to	indicate	a	specific	treatment	approach.	For	example,	the	RRT	protocol	
specifies	peritoneal	dialysis	as	the	first	line	treatment	option.		
																																																								
3 Most disease management programmes in the UCS are reimbursed per case, unlike those services in 
outpatient and inpatient departments which are paid by capitation and DRG respectively. 
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Since	there	is	no	specific	model,	each	UCS	disease	management	programme	may	
have	its	own	details	and	process,	designed	by	the	central	NHSO.	Consequently,	
each	programme	has	a	different	level	of	comprehensiveness	when	compared	to	
the	standard	disease	management	approach.	Therefore,	UCS	disease	
management	programmes	differ	from	those	in	the	US	and	Europe,	where	
disease	management	programmes	commonly	focus	on	chronic	diseases.	The	
UCS	disease	management	programme	focuses	on	any	diseases	or	conditions	
that	have	low	level	of	access	due	to	limited	service	provision.	The	focus	of	each	
programme	is	neither	necessarily	on	controlling	cost	nor	integrating	care,	but	
on	access	to	health	services.	This	study	viewed	the	disease	management	
approach	as	an	intervention	to	increase	access	to	high‐cost	or	hard	to	reach	
treatment	and	it	is	important	to	understand	how	this	approach	might	facilitate	
the	inclusion	of	RRT	in	the	benefit	package.		
2.5 Management of high-cost conditions: disease management and 
the chronic care model 
Growing	numbers	of	patients	suffering	from	chronic	diseases,	and	the	
advancement	of	treatment	and	management	technologies,	have	added	to	the	
financial	burden	on	countries’	health	care	budgets	(Martins,	de	la	Maisonneuve	
et	al.	2006).	Disease	management	is	one	strategy	used	to	cope	with	the	rapid	
increase	in	health	care	costs	(Bodenheimer	and	Berry‐Millett	2009).	The	idea	is	
to	improve	quality	of	care	delivered	to	patients	with	chronic	diseases.	By	
efficient	and	effective	use	of	health	care	resources,	the	application	of	disease	
management	principles	is	believed	to	bring	health	expenditure	down	(Geyman	
2007).	
Disease	management	comes	in	various	forms	and	there	is	a	range	of	terms	used	
to	describe	interventions	to	manage	patients	with	one	or	more	chronic	
conditions.	These	include:	integrated	care,	managed	care,	coordinated	care,	and	
disease	management.	All	of	these	programmes	share	a	very	similar	aim,	which	
is	to	increase	quality	of	care;	however,	the	contents	of	these	programmes	may	
differ	greatly	(Ouwens,	Wollersheim	et	al.	2005;	Krumholz,	Currie	et	al.	2006;	
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Hisashige	2012).	Note	that	a	systematic	search	from	population‐based	studies	
on	disease	management	programmes	is	provided	in	the	next	chapter	of	this	
thesis.		
The	chronic	care	model	is	an	advanced	form	of	disease	management	(Krumholz,	
Currie	et	al.	2006).	It	was	developed	by	Wagner	(1997)	and	colleagues	by	
reviewing	interventions	used	in	chronic	conditions	across	various	settings.	This	
is	because	many	patients	confront	difficulties	(such	as	symptoms	of	the	
diseases,	diet	and	life‐style	change,	and	complex	drug	regimens)	without	much	
support	from	health	care	professionals,	or	receive	help	that	fails	to	meet	
individual	needs.	Additionally,	current	policies	focusing	on	a	specific	disease	do	
not	offer	approaches	for	patients	with	multiple	chronic	conditions,	and	there	
are	no	general	models	applied	to	management	of	wide	range	of	chronic	
diseases.	The	model,	therefore,	was	designed	to	cope	with	common	challenges	
shared	by	most	patients	with	chronic	conditions	and	their	families	and	was	
intended	to	offer	a	generic	model	for	improving	provisions	of	chronic	care	
(Wagner,	Austin	et	al.	2001).		
The	chronic	care	model	was	designed	to	be	a	‘functional	blueprint’	to	improve	
service	delivery	systems	and	patient	outcomes,	corresponding	to	the	growing	
demand	for	chronic	care	(Wagner	1997).	Evidence	shows	that	a	combination	of	
six	areas	constituted	in	the	chronic	care	model	is	vital	to	the	success	of	
improving	patients’	outcomes.	They	include	1)	community	resources	and	
policies,	2)	health	care	organisation,	3)	self‐management	support,	4)	decision	
support,	5)	delivery	system	redesign,	and	6)	clinical	information	systems	
(Bodenheimer,	Lorig	et	al.	2002;	Epping‐Jordan,	Pruitt	et	al.	2004;	Ham	2010).		
Several	countries,	such	as	the	US,	UK,	and	Continental	European	countries,	have	
adopted	and	adjusted	the	care	model	according	to	induvial	countries’	health	
systems	and	political	opinions	(Epping‐Jordan,	Pruitt	et	al.	2004;	Coleman,	
Austin	et	al.	2009).	However,	significant	variations	still	exist	among	these	
arrangements	to	improve	the	performance	of	high‐cost	treatment,	both	in	terms	
of	how	these	arrangements	are	applied,	and	in	their	successful	combination	of	
two	outcomes.	It	remains	unclear	whether	it	is	consistently	possible	to	improve	
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patients’	health	while	controlling	health	care	costs	(Dor,	Pauly	et	al.	2007;	
Bodenheimer	and	Berry‐Millett	2009;	Knauf	and	Aronson	2009).		
Components	of	the	care	model	are	used	in	ambulatory	care	for	many	chronic	
conditions	such	as	diabetes,	hypertension,	asthma,	and	heart	failure.	Although	
they	produce	mixed	results	of	promising	and	disappointing	outcomes,	many	
review	studies	on	effectiveness	of	the	chronic	care	model	have	suggested	that	a	
combination	of	its	components	are	more	likely	to	produce	positive	outcomes	
(Bodenheimer,	Wagner	et	al.	2002;	Adams,	Smith	et	al.	2007;	Ham	2010;	
Stellefson	2013).	For	example,	using	the	delivery	system	design	component	to	
redesign	the	service	delivery	process	promotes	self‐care	management	and	other	
desirable	clinical	outcomes	(Ham	2010;	Stellefson	2013).	
2.6 Chronic kidney disease 
This	study	focuses	on	high‐cost	conditions,	and	the	treatment	for	the	last	stage	
of	chronic	kidney	disease,	namely	renal	replacement	therapy,	was	selected	to	
assess	the	effects	of	such	conditions.	This	section	will	start	by	giving	the	
overview	of	chronic	kidney	disease,	definitions,	and	treatment	modalities	that	
are	important	as	a	basis	for	a	better	understanding	of	end‐stage	renal	disease	
management.			
2.6.1 Overview of the disease  
Chronic	kidney	disease	(CKD)	is	a	common	condition	that	raises	the	risk	for	
other	health	problems,	such	as	cardiovascular	disease,	renal	failure,	and	other	
complications.	The	National	Kidney	Foundation	of	the	USA	defined	CKD	as	“the	
presence	of	objective	kidney	damage	and/or	the	presence	of	a	glomerular	
filtration	rate	of	60	mL/min/1.73	m2	body	surface	area,	or	less,	for	at	least	3	
months,	irrespective	of	the	underlying	etiology	of	the	kidney	damage”	(The	
National	Kidney	Foundation	2002).		
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CKD	is	divided	into	five	stages	according	to	kidney	function.	Early	stages	of	CKD,	
stage	I	–II,	are	characterised	by	kidney	damage4,	associated	with	the	presence	of	
decreased	kidney	function	(measured	by	glomerular	filtration	rate	‐GFR).	The	
late	stages,	stage	III‐IV,	of	CKD	are	defined	by	a	large	decrease	of	kidney	
function,	regardless	of	the	evidence	of	kidney	damage	(Eustace	and	Coresh	
2005).	The	last	stage	of	CKD,	kidney	failure,	is	characterised	by	either	1)	GFR	
less	than	15	ml/min	per	1.73m2	or	2)	a	need	to	start	renal	replacement	therapy	
(RRT),	which	is	either	dialysis	or	renal	transplant	(Levey,	Coresh	et	al.	2003),	
Table	2‐3.		
Table 2‐3  Classification of chronic kidney disease 
Stage Description GFR, mL/min per 1.73m2 Related terms Action* 
- At increased risk ≤ 60 (with 
chronic kidney 
disease risk 
factors) 
- Screening, CKD risk 
reduction 
1 Kidney damage with 
normal or increased GFR 
≤ 90 Albuminuria, proteinuria, 
hematuria 
Diagnosis and 
treatment, treatment of 
comorbid conditions, 
slowing progression, 
CVD risk reduction 
2 Kidney damage with 
increased GFR 
60-89 Albuminuria, proteinuria, 
hematuria 
Estimating progression 
3 Moderate decreased GFR 30-59 Chronic renal 
insufficiency, early renal 
insufficiency, early renal 
insufficiency 
Evaluating and treating 
complications 
4 Severe decreased GFR 15-29 Chronic renal 
insufficiency, early renal 
insufficiency, late renal 
insufficiency, pre-ESRD 
Preparation for RRT 
5 Kidney failure 15 (or need 
dialysis) 
Renal failure, uremia, 
end-stage renal disease 
Kidney replacement 
Adapted from: Levey, Coresh et al. (2003) and The National Kidney Foundation (2002) 
*includes actions from preceding stages. 
GFR= glomerular filtration rate, CKD= Chronic kidney disease, CVD=cardiovascular disease, RRT=renal replacement 
therapy 
In	this	study,	the	term	end‐stage	kidney	disease	(ESRD)	is	used	to	refer	to	the	
condition	of	patients	who	have	kidney	failure	and	are	diagnosed	with	the	last	
stage	of	chronic	kidney	disease.	However,	kidney	failure	is	not	always	
																																																								
4 presence of abnormalities in blood, urine, or imaging studies 
CHAPTER 2  Literature review 
39 
	
synonymous	with	ESRD.	In	the	US,	while	kidney	failure	refers	to	the	last	stage	of	
CKD,	ESRD	is	an	operational	term	without	a	precisely	defined	level	of	kidney	
function	(Levey,	Coresh	et	al.	2003).	In	the	US	renal	registry	and	regulation	
system,	it	is	understood	that	ESRD	refers	to	a	patient	who	is	undergoing	or	is	
eligible	to	receive	renal	replacement	therapy,	either	by	some	form	of	dialysis	or	
transplant	(Levey,	Coresh	et	al.	2003;	Eustace	and	Coresh	2005).		
2.6.2 Prevalence and incidence 
Chronic	kidney	disease	(CKD)	is	a	worldwide	public	health	problem	as	a	
consequence	of	two	major	factors:	1)	increasing	aging	population	and	2)	
prevalence	of	diabetes	(El	Nahas	and	Bello	2005).	A	study	estimated	that	the	
prevalence	of	people	needing	RRT	ranged	from	the	low	figure	of	920	per	million	
population	in	Africa	to	2,162	per	million	in	Europe	(Liyanage,	Ninomiya	et	al.	
2015).		
To	date,	there	is	still	a	lack	of	reliable	epidemiological	information	on	the	
various	stages	of	CKD	in	the	general	population,	especially	in	the	early	stages.	
This	is	because	CKD	is	a	silent	disease:	a	patient	may	be	living	asymptomatically	
until	the	condition	reaches	an	advanced	stage.	Renal	registry	systems	can	be	
used	to	identify	the	number	of	CKD	patients,	however	numbers	of	ESRD	
patients	in	this	sense	reflects	only	the	portion	of	CKD	patients	who	receive	RRT	
and	cannot	be	used	to	represent	the	entire	affected	population,	or	even	the	
number	of	patients	with	last‐stage	CKD	(Eustace	and	Coresh	2005).	For	many	
reasons,	most	available	figures	are	derived	by	estimation	and	tend	to	
considerably	underestimate	the	overall	number	of	CKD	patients	(El	Nahas	and	
Bello	2005;	Eustace	and	Coresh	2005).	The	main	limitation	of	this	estimation	is	
that	some	people	may	have	stable	impaired	kidney	function	that	does	not	
develop	into	the	advanced	stage	of	renal	failure	and	they	are	not	included	in	the	
pool	of	CKD	patients	(El	Nahas	and	Bello	2005;	Eustace	and	Coresh	2005).	
Another	limitation	is	that	the	estimated	prevalence	is	calculated	from	a	single	
laboratory	measure	called	serum	creatinine	level.	The	measured	serum	
creatinine	level	can	vary	due	to	diverse	calibration	systems	of	different	
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laboratories.	Additionally,	the	formula	used	has	not	been	fully	validated	in	
different	population	groups	and	CKD	stages	(El	Nahas	and	Bello	2005).		
2.6.3 Treatment options 
Secondary	prevention	should	be	provided	to	patients	with	risk	factors	of	CKD,	
such	as	hypertension,	diabetes,	and	obesity.	It	includes	many	forms	of	lifestyle	
modification	for	these	patients,	including	weight	reduction,	exercise,	and	
dietary	changes	(El	Nahas	and	Bello	2005).	If	a	patient	has	developed	CKD,	early	
detection	and	treatment	of	comorbidities	is	very	important	to	slow	down	the	
disease	progression,	otherwise	it	may	develop	into	renal	failure.	
All	patients	with	renal	failure	rely	on	renal	replacement	therapy,	either	dialysis	
or	renal	transplant,	in	order	to	sustain	their	lives.	Renal	transplant	is	the	
preferred	treatment,	regarding	the	patient’s	outcomes	and	cost‐effectiveness,	
and	is	solely	a	treatment,	not	a	cure.	A	patient	who	undergoes	a	renal	transplant	
can	survive	almost	like	normal	people,	however,	they	must	take	
immunosuppressive	drugs	to	ensure	that	the	organ	is	not	rejected	by	the	body's	
natural	immune	system.	Unfortunately,	due	to	the	limited	number	of	organ	
donors,	most	ESRD	patients	still	rely	on	regular	dialysis	for	the	rest	of	their	lives	
(Yeun	and	Depner	2005).		
Kidney	dialysis	can	be	roughly	categorised	into	two	types,	hemodialysis	(HD)	
and	peritoneal	dialysis	(PD).	For	HD,	dialysis	is	performed	outside	the	body	
starting	by	the	continuous	flow	of	blood	along	arterial	lines	to	the	membrane	of	
an	artificial	kidney	called	a	dialyser	or	hemodialyser.	Within	the	dialyser,	the	
blood	flows	against	dialysate,	a	fluid	that	removes	toxins	through	osmosis,	then	
returns	to	the	body	by	venous	lines.	Dialysis	in	the	PD	modality	occurs	in	the	
body	by	the	peritoneum	which	acts	as	a	natural	semipermeable	membrane	to	
perform	ultrafiltration	of	the	waste	substance.	Each	patient	has	a	catheter	
implanted	in	the	lower	abdomen	and	dialysis	fluid	is	infused	into	the	peritoneal	
cavity.	As	the	fluid	is	removed	from	the	abdomen,	waste	substances	flow	out	
along	with	the	dialysate.	Patients	who	are	undergoing	dialysis,	both	PD	and	HD,	
also	rely	on	a	medicine	called	erythropoietin	(EPO),	a	highly	expensive	drug,	to	
prevent	anemia	(Nesrallah,	Blake	et	al.	2005).	
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Both	HD	and	PD	are	diversified	into	many	subcategories.	Variations	of	HD	
include	conventional	HD,	high‐flux	HD,	hemodiafiltration,	and	hemofiltration	
which	are	differentiated	by	their	degrees	of	solvent	diffusion.	Subtypes	of	PD	
are	based	on	this	principle,	for	example,	continuous	ambulatory	PD	(CAPD),	
automated	PD	(APD),	tidal	PD,	and	intermittent	PD,	which	differ	by	their	time	to	
stop	and	start	the	dialysis	cycle	(Mohammed	2007).		
A	patient	who	is	on	CAPD,	which	is	the	type	of	PD	supported	by	the	Thai	NHSO,	
has	a	catheter	surgically	placed	through	the	abdominal	wall	into	the	peritoneal	
cavity.	Every	six	hours	or	four	times	a	day,	the	used	dialysis	fluid,	approximately	
2	litres,	is	drained	out	of	the	body	and	replaced	with	the	new	fluid.	This	process	
is	called	an	exchange	or	cycle.	It	allows	removal	of	the	waste	product	from	the	
bloodstream	and	takes	around	30‐45	minutes	per	exchange.	
No	dialysis	modality	is	perfect,	and	each	modality	has	its	advantages	and	
limitations	(Table	2‐4).	Ideally,	this	information	should	be	given	to	patients	
before	starting	dialysis	in	order	to	encourage	them	to	select	the	method	that	
best	suits	their	personal	situation	(Nesrallah,	Blake	et	al.	2005).	Among	the	
various	forms	of	dialysis	modalities	used	in	developed	countries,	only	CAPD	and	
in‐centre	HD	are	preferred	in	most	Asian	countries	(Li,	Lui	et	al.	2007).	
	
	
	
	
	
	
	
Table 2‐4  Comparison of selected dialysis modalities 
Characteristic CAPD HD 
Frequency everyday 3 times/week 
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Duration per session Every 6 hours  
(APD is performed during bedtime and 
patient is day-dry) 
3½-4½ hours 
Advantage Home-base, less travel cost  
Can be at work while using dialysis 
Patients feel safe when health 
staff manage dialysis  
Disadvantage Need carers to help self-management 
Might cause infection (peritonitis) 
Need to be absent from work to 
undergo dialysis 
Might cause anemia 
Examples of country of 
popularity 
Mexico, Hong Kong  USA, China, Japan  
Source: Nesrallah, Blake et al. (2005)  
CAPD=continuous ambulatory peritoneal dialysis, APD=automated peritoneal dialysis, HD=hemodialysis, both 
CAPD and HD are the most popular modalities in Thailand and are available for the UCS’s members 
2.6.4 Access to ESRD treatment and financial protection  
A	systematic	review	estimated	that	around	the	world	in	2010,	there	were	9.7	
million	patients	needing	renal	replacement	therapy	(RRT)	but	only	2.6	million	
patients	were	able	to	use	it	(Liyanage,	Ninomiya	et	al.	2015).	As	a	consequence	
of	the	costly	treatment,	a	report	(Grassmann,	Gioberge	et	al.	2005)	revealed	that	
access	to	dialysis	is	significantly	different	in	high	income,	middle	income,	and	
low	income	countries.	Around	80%	of	patients	who	are	currently	on	treatment	
live	in	Europe,	Japan	or	North	America	(Grassmann,	Gioberge	et	al.	2005).	In	
other	parts	of	the	world,	proportions	of	access	to	treatment	are	very	different.	
The	proportion	of	those	in	need	but	not	receiving	RRT	ranged	from	just	5%	in	
North	America	to	91%	in	Africa	(Liyanage,	Ninomiya	et	al.	2015).	Variations	
among	different	regions	were	found	to	be	more	associated	with	supply‐side	
factors	(such	as	macroeconomic,	health	system,	and	renal	service	provision)	
rather	than	health	status	or	demographics	of	the	general	population	(Caskey,	
Kramer	et	al.	2011).	Therefore,	ESRD	disparity	across	countries	does	not	only	
reflect	the	difference	in	underlying	disease	rates	(Levey	and	Coresh	2012),	but	
also	the	different	priorities	for	providing	access	to	high‐cost	health	services,	as	
well	as	an	insufficiency	of	health	resources	in	those	countries	(Hamer	and	El	
Nahas	2006).	
For	example,	Asia	has	the	highest	number	of	ESRD	patients	in	the	world,	with	
the	proportion	of	patients	receiving	this	treatment	ranging	from	17%‐36%	of	
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patients	with	ESRD.	Africa	has	the	lowest	access	to	RRT,	with	only	at	around	
9%‐16%	of	the	needy	receiving	treatment	(Liyanage,	Ninomiya	et	al.	2015).	The	
variation	in	the	proportion	of	patients	receiving	RRT	is	a	consequence	of	each	
country’s	burden	of	disease,	infrastructure,	and	financing	system	(Li,	Lui	et	al.	
2007).		
In	high	income	countries,	ESRD	care	is	publicly	financed,	and	provided	to	most	
citizens	regardless	of	how	the	health care	system	is	financed	and	organised	
(Durand‐Zaleski,	Combe	et	al.	2007;	Fukuhara,	Yamazaki	et	al.	2007;	Kleophas	
and	Reichel	2007;	Manns,	Mendelssohn	et	al.	2007;	Nicholson	and	Roderick	
2007;	Pontoriero,	Pozzoni	et	al.	2007).	Even	in	the	US,	where	universal	health	
coverage	is	inadequate,	RRT	services	have	long	been	provided	as	a	Medicare	
benefit	for	all	patients	based	on	a	patient’s	medical	diagnosis,	regardless	of	age	
or	economic	status	(Levinsky	and	Retig	1991).	Major	problems	in	those	
countries	involve	long	waiting	lists for	dialysis	or	transplant,	and	rapidly	
increasing	costs	for	the	health	care	payer	(Levinsky	and	Retig	1991;	Durand‐
Zaleski,	Combe	et	al.	2007;	Fukuhara,	Yamazaki	et	al.	2007;	Kleophas	and	
Reichel	2007;	Manns,	Mendelssohn	et	al.	2007;	Nicholson	and	Roderick	2007;	
Pontoriero,	Pozzoni	et	al.	2007).	
In	contrast,	there	is	greater	variation	of	accessibility	to	RRT	services	in	low	and	
middle	income	countries.	This	includes	availability	of	national	data	on	
prevalence	and	incidence	of	ESRD	(Vazelov,	Krivoshiev	et	al.	2004;	Sakhuja	and	
Kohli	2006;	Cueto‐Manzano	and	Rojas‐Campos	2007;	White,	Chadban	et	al.	
2008;	Odubanjo,	Oluwasola	et	al.	2011),	arrangements	of	RRT	service	provision	
(Odubanjo,	Oluwasola	et	al.	2011),	and	variation	in	universal	public	
reimbursement	for	services	(Sakhuja	and	Kohli	2006;	Pecoits–Filho,	Campos	et	
al.	2009).		
In	India,	for	example,	most	dialysis	services	are	for	those	who	are	waiting	for	
renal	transplant	or	have	acute	renal	failure,	not	for	maintenance	purposes,	and	
95%	of	ESRD	patients	pay	out‐of‐pocket	for	dialysis	(Li,	Lui	et	al.	2007).	Half	of	
that	number	has	to	sell	their	property	or	take	a	loan	in	order	to	access	services,	
ending	up	with	catastrophic	spending	and	impoverishment	(Sakhuja	and	Kohli	
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2006).	In	spite	of	massive	need,	there	are	very	few	arrangements	for	RRT	in	
Africa	due	to	the	lack	of	nephrorogists,	dialysis	centres,	and	funding	for	
treatment	(Abu‐Aisha	and	Elamin	2010;	Pozo,	Leow	et	al.	2012;	Luyckx,	Naicker	
et	al.	2013).	In	Nigeria,	a	study	found	that	of	those	patients	who	were	able	to	
access	dialysis,	only	5%	could	afford	to	continue	the	dialysis	longer	than	12	
weeks	(Luyckx,	Naicker	et	al.	2013).	
Evidence	of	inequalities	due	to	the	insurance	system	exists	in	Mexico,	where	
only	Social	Security	System	beneficiaries	(50%	of	the	overall	population)	have	
access	to	RRT	benefits	(Pecoits–Filho,	Campos	et	al.	2009).	Thailand	has	been	
able	to	provide	RRT	universally	from	2008	but	is	facing	challenges	regarding	
access	to	services	and	the	sustainability	of	the	system	(Tantivess,	
Werayingyong	et	al.	2013).	
2.6.5 ESRD as an example of high-cost and catastrophic condition 
End‐stage	renal	disease	(ESRD)	displays	the	characteristics	of	high‐cost	and	
catastrophic	diseases.	Firstly,	with	only	a	small	number	of	patients,	it	
nevertheless	accounts	for	a	significant	percentage	of	health	care	costs.	In	high	
income	countries,	it	is	estimated	that	around	2%‐3%	of	a	country’s	health	care	
budget	is	spent	on	caring	for	patients	with	ESRD	that	constitute	less	than	0.1%	
of	the	population	(Lee,	Manns	et	al.	2002;	Hamer	and	El	Nahas	2006).	For	
example,	new	data	from	the	US	revealed	that	5.6%	of	the	Medicare	budget	or	
28.6	billion	US$	was	spent	on	its	ESRD	programme	in	2012.	This	amount	went	
to	treating	525,481	Medicare	ESRD	patients	(United	States	Renal	Data	System	
2014).	In	Spain,	patients	with	ESRD	constitute	around	0.1%	of	the	total	
population	but	consume	up	to	2.5%	of	the	national	health	budget	(de	Francisco	
2011).	In	Thailand,	a	middle	income	country	with	a	much	younger	population,	
the	UCS	paid	6,023	million	Baht	(4%	of	its	total	health	care	budget)	in	2014	for	
maintaining	patients	on	RRT	that	constituted	0.07%	of	overall	UCS	members	
(NHSO	2014).		
Costs	of	RRT	including	essential	medications	can	drive	a	patient	or	household	
without	insurance	coverage	into	impoverishment	(Wyszewianski	1986).	In	
India,	Pakistan,	and	Sub‐Saharan	Africa,	provision	of	renal	replacement	therapy	
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is	limited	and	there	is	an	absence	of	public	health	insurance	support.	As	a	
consequence	of	poor	health	care	and	a	lack	of	timely	preventive	services,	
patients	develop	chronic	kidney	disease	at	a	younger	age,	ie.	in	their	most	
productive	years,	compared	to	patients	in	developed	countries	(Naicker	2009;	
Jha	2013).	In	the	countries	named	above,	patients	rely	greatly	on	treatment	
obtained	on	a	fee‐for‐service	basis.	RRT	is	very	expensive	and	therefore	
unobtainable	for	most	patients.	In	India,	with	a	gross	national	income	(GNI)	of	
US$1,5305	per	capita,	costs	of	two	HD	sessions	per	week	and	three	PD	
exchanges	per	day	were	estimated	to	be	US$7,308	and	US$7,020	annually	(Jha	
2013).	In	Sub‐Saharan	Africa,	where	GNI	per	capita	is	just	US$1,6636,	costs	of	
RRT	range	from	US$7,000‐55,000	per	year	(Abu‐Aisha	and	Elamin	2010).	
2.6.6 Disease management in chronic kidney disease 
Disease	management	involves	the	use	of	a	number	of	approaches	for	identifying	
and	caring	for	patients	with	chronic	conditions.	Most	chronic	kidney	disease	
management	programmes	aim	to	1)	identify	early	patients	with	chronic	kidney	
disease,	2)	slow	and	minimise	the	progression	of	chronic	kidney	disease	to	end‐
stage	renal	disease,	3)	manage	the	comorbid	conditions,	and	4)	smooth	the	
transition	to	renal	replacement	therapy	(RRT)	or	conservative	therapy	(without	
RRT)	when	appropriate	(Rastogi,	Linden	et	al.	2008;	Rayner,	Baharani	et	al.	
2014).		
Like	other	disease	management	programmes,	chronic	kidney	disease	
management	programmes	use	combined	interventions	to	deliver	care.	For	
example,	a	chronic	kidney	disease	management	programme	in	the	UK	
incorporates	disease	management	interventions	(such	as	patient	identification,	
routine	reporting,	use	of	clinical	guidelines,	self‐care	management,	and	
feedback	loop	among	the	multidisciplinary	team)	with	other	initiatives.	These	
include	pre‐ESRD	multidisciplinary	care	and	conservative	management,	weekly	
database	searching	for	patients	with	low	kidney	function	(estimated	glomerular	
filtration	rate:	eGFR	<15	mL/min/1.73	m2),	and	patient	empowerment	by	
																																																								
5 http://povertydata.worldbank.org/poverty/country/IND 
6 http://povertydata.worldbank.org/poverty/region/SSA 
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sending	patients	and	their	GPs	a	personal	report	after	each	consultation	
(Rayner,	Baharani	et	al.	2014).			
2.7 Financing of RRT 
In	countries	where	RRT	is	included	under	universal	health	coverage,	
governments	use	various	financing	strategies	to	ensure	quality	of	care,	contain	
costs	(Vanholder,	Davenport	et	al.	2012),	and	promote	access	to	service	
(Tantivess,	Werayingyong	et	al.	2013).	Most	countries	finance	RRT	provision	
differently	from	the	normal	mainstream	to	encourage	dialysis	service	provision	
and	there	is	a	large	variation	in	RRT	payment	mechanisms	across	countries	
(Dor,	Pauly	et	al.	2007).		
For	example,	Taiwan,	a	high‐income	country,	was	the	world’s	top	most	country	
having	highest	ESRD	incidence	and	prevalence.	Taiwan’s	NHI	programme	pays	
for	dialysis	facilities	via	a	global	budget.	All	patients	with	ESRD	are	eligible	to	
receive	any	kind	of	RRT	without	copayment.	While	the	number	of	patients	on	
RRT	was	less	than	0.2%	of	the	general	population,	the	RRT	cost	was	over	7%	of	
total	health	expenditure	(Yang	and	Hwang	2008).	In	Malaysia,	patients	pay	out	
of	pocket,	or	use	private	health	insurance,	or	take	funding	from	charity	sectors	
to	undergo	dialysis,	although	they	can	receive	publicly	funded	services	if	they	
meet	the	requirements	(Lim,	Goh	et	al.	2010).	Before	2000,	there	were	
inadequate	numbers	of	public	dialysis	facilities	to	serve	the	high	needs	of	
patients.	Consequently,	the	government	adopted	a	mixed	private	and	public	
model	for	providing	and	financing	dialysis	therapy	by	encouraging	the	private	
sector	to	provide	dialysis	services	to	eligible	patients.	In	this	case,	engaging	the	
private	sector	in	dialysis	care	increased	the	treatment	rate	which	was	
comparable	to	those	in	developed	countries	(Lim,	Goh	et	al.	2010).		
Costs	and	benefits	to	ESRD	patients	in	different	countries	also	vary.	In	general,	
most	countries	provide	all	essential	services,	including	dialysis	and	medications	
for	treating	anemia,	at	a	predefined	bundled	package	rate	(Ponce,	Marcelli	et	al.	
2012;	Vanholder,	Davenport	et	al.	2012).	Laboratory	tests	and	doctor	fees	may	
or	may	not	be	included,	depending	on	a	country’s	RRT	benefit.	In	Spain,	patients	
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are	paid	for	transportation	costs	in	addition	to	all	dialysis	services	and	
medications	(Luño	2007).	Patients	in	high‐income	countries		are	well	protected	
from	excessive	long‐term	spending,	for	example	through	limited	copayment	
levels	in	Germany	(Kleophas	and	Reichel	2007),	exemption	from	high	cost	
drugs	in	Japan	(Fukuhara,	Yamazaki	et	al.	2007),	and	entire	exemption	from	
copayment	in	Italy	(Pontoriero,	Pozzoni	et	al.	2007)	and	Spain	(Luño	2007).	
2.7.1 Bundled payments for renal replacement therapy programme 
In	line	with	the	increasing	numbers	of	RRT	patients,	costs	of	the	programme	put	
a	large	burden	on	government	spending.	Various	payment	strategies	have	been	
used	to	ensure	access	to	service,	and	at	the	same	time	contain	costs.		
In	countries	with	a	national	health	authority	or	social	security	system,	ESRD	
delivery	programs	are	sometimes	administered	separately	from	normal	
mainstream	services,	or	at	least	have	payment	rules	specific	to	ESRD	care	(Dor,	
Pauly	et	al.	2007).	These	countries	are	moving	toward	bundled	payments	as	a	
cost‐control	initiative	to	promote	the	rational	use	of	resources	(Vanholder,	
Davenport	et	al.	2012).	In	dialysis,	the	bundled	payment	is	introduced	to	pay	
per	treatment	which	may	include,	for	example	medications	and	fees	for	
physicians,	nurses,	and	RRT	units.	However,	there	is	a	great	degree	of	variation	
in	the	design	of	payment	systems	and	what	is	included	in	the	bundle	between	
countries.		
For	example,	in	the	US,	a	bundled	payment	for	dialysis	is	paid	to	dialysis	units	in	
an	equal	amount	regardless	of	dialysis	modality	and	the	location	where	dialysis	
is	performed	(at	home	or	in	a	dialysis	centre).	This	rate	also	includes	payment	
for	injectable	drugs,	while	nephrologists	are	separately	compensated	based	on	
the	frequency	of	their	presence	in	outpatient	care	(Golper,	Guest	et	al.	2011;	
Iglehart	2011).	In	Belgium,	as	hospital	HD	requires	the	attendance	of	medical	
personnel,	it	is	more	costly	than	alternative	dialysis	modalities	such	as	self‐care	
HD	or	PD.	The	hospital	HD	is	reimbursed	with	a	lump	sum	plus	a	physician’s	
fee‐for‐service	per	dialysis	session.	Other	dialysis	modalities	are	reimbursed	
only	by	means	of	a	weekly	lump	sum	to	a	hospital	(Cleemput	and	De	Laet	2013).	
Payments	for	dialysis	in	the	UK	and	Germany	are	more	complicated.	The	UK	
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adopted	a	mandatory	tariff	under	the	system	‘Payment	by	Results’.	Dialysis	
units	receive	‘Best	Practice	Tariff’	on	top	of	dialysis	treatment	rates	if	they	reach	
the	target	which	is	set	in	line	with	current	treatment	guidelines	(Abma,	Jayanti	
et	al.	2014).	For	example,	the	Best	Practice	Tariff	is	given	to	NHS	Hospital	Trusts	
if	they	provide	an	arteriovenous	fistula	(AV	fistula	or	an	AV	graft),	a	vascular	
access	that	is	believed	to	give	better	health	outcomes	to	a	patient	undergoing	
hemodialysis	(National	Health	Service	2013).	Germany	has	a	wide	range	of	
reimbursements	such	as	payments	related	to	type	of	dialysis,	whether	the	
patient	is	hospitalized,	reasons	for	that	hospitalisation,	and	the	region	or	state	
(Vanholder,	Davenport	et	al.	2012).	In	the	US,	UK,	and	Germany,	nephrologists’	
salaries	are	paid	separately	and	not	included	in	the	bundle	(Vanholder,	
Davenport	et	al.	2012).	
2.8 Cost of RRT in literature  
2.8.1 RRT costing  
Numerous	research	studies	have	assessed	costs	relating	to	dialysis	care	and	
kidney	transplant.	However,	cost	calculation	methods	and	results	can	vary	
depending	on	the	financing	system	of	the	country	assessed.	This	is	because	
different	systems	have	diverse	payment	mechanisms,	and	different	items	are	
reimbursed.	The	same	cost	heading	may	be	used	in	different	studies,	yet	may	
contain	many	different	parts.	For	example,	‘overheads’	in	some	studies	may	
consist	of	costs	for	staff	training,	education,	and	research	in	addition	to	the	cost	
for	hospital	administration	and	housing	(Karlberg	and	Nyberg	1995).	Another	
source	of	variation	is	the	perspective	that	is	the	focus	of	study.	Cost	calculations	
from	the	funder’s	perspective	usually	include	only	reimbursed	items,	for	
example	the	studies	of	De	Vecchi,	Dratwa	et	al.	(1999),	Lee,	Manns	et	al.	(2002),	
and	Icks,	Haastert	et	al.	(2010)	while	those	from	the	providers’	perspective	are	
always	through	activity‐based	costing,	which	accounts	for	most	cost	
components	such	as	labour	costs,	material	costs,	and	capital	costs,	for	instance	
in	the	studies	conducted	by	Goeree,	Manalich	et	al.	(1995)	and	Baboolal,	
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McEwan	et	al.	(2008).	In	studies	conducted	from	the	societal	perspective,	both	
direct	and	indirect	costs	are	included	(de	Abreu,	Walker	et	al.	2013).		
2.8.2 Number of patients and cost modelling approaches  
Various	studies	have	been	conducted	to	estimate	the	cost	of	RRT	modalities.	
Some	studies	go	beyond	that,	modelling	future	numbers	of	patients	or	financial	
resource	needs	of	a	health	care	programme.	As	seen	in	Table	2‐5,	these	studies	
used	historical	data	on	incidence	and	prevalence	of	ESRD	to	predict	future	
figures.	
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Table 2‐5  Studies on forecasting ESRD patients and cost of ESRD programmes 
Authors Setting Data sources Forecast for Method used Forecast years 
Quinn, Laupacis et 
al. (2009) 
Canada 1999-2005: 
1) Billing claims in the Ontario Health Insurance Plan database 
for identifying numbers of dialysis patients 
2) Registered Persons Database for demographic and vital 
status information and determining the eligibility for the benefit 
coverage    
3) Hospitalisations and kidney transplantation from Canadian 
Institute for Health Information Discharge Abstracts Database 
Incidence and prevalence of 
chronic and acute dialysis patients 
Exponential smoothing model, 
ARIMA model, stepwise auto-
regressive model and exponential 
smoothing model 
2006-2011 
Kasemsap, 
Prakongsai et al. 
(2006) 
Thailand 1) United States Renal Data System annual report 2004 
2) National Renal Registry of Malaysian Society of Nephrology 
2004 
3) Thailand Renal Replacement Therapy Registry report 1997-
2000 
Dialysis and kidney transplant 
costs to the Universal Coverage 
Scheme  
Estimations of unit costs of various 
activities multiplied by expected 
numbers of patients 
1st year to 16th  
year 
You, Hoy et al. 
(2002)* 
Northern Territory, 
Australia 
Patient data from 3 public hospitals, 1996-2000  Numbers of hemodialysis 
treatments 
ARIMA model 2001-2005 
Xue, Ma et al. 
(2001) 
USA United States Renal Data System annual report 1982-1997  
 
Incidence and prevalence of ESRD 
patients, dialysis patients, 
functioning transplants, and waitlist 
patients 
Stepwise auto regressive model 1998-2010 
Schaubel, 
Morrison et al. 
(1998) 
Canada Demographic data, clinical history data, and deaths from the 
Canadian Organ Replacement Register, 1981-1994 
Numbers of ESRD patients by 
each RRT modality 
Poisson and Markov models 1995-2005 
Motohashi and 
Nishi (1991) 
Japan 1985-2000: 
1) Population profile from Institute of Population Problems 
2) Annual Reports on Dialysis Therapy in Japan and vital 
statistics in Japan 
3) Renal transplants from Japanese Society for Transplantation 
Numbers of ESRD patients System dynamics model 1980-2000 
Note: ESRD= end-stage renal disease, ARIMA=auto-regressive integrated moving average, *costs of treatment during the studied period were estimated but not projected to the future 
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While	most	of	the	studies	forecast	numbers	of	ESRD	patients,	only	the	study	of	
Kasemsap,	Prakongsai	et	al.	(2006)	calculated	and	projected	costs	to	the	NHSO,	
a	health	care	payer	in	Thailand.		
The	study	of	Kasemsap,	Prakongsai	et	al.	(2006)	had	a	specific	aim	that	was	to	
inform	policy	makers	before	the	RRT	programme	launched.	Back	then,	the	
UCS’s	RRT	programme	was	not	in	existence,	and	the	authors	used	the	incidence	
rate	from	the	US	renal	registry,	which	was	300	patients	per	million	population,	
to	estimate	future	numbers	of	patients	and	budget	needs	of	the	UCS	RRT	
programme.	It	was	predicted	that	the	RRT	programme	would	consume	a	budget	
of	14	to	24	billion	Baht	in	2013	(Kasemsap,	Prakongsai	et	al.	2006).	To	date,	the	
actual	incidence	rate	is	254	patients	per	million	population.	Expenditure	of	the	
RRT	programme	has	not	reached	the	estimated	amount,	however,	it	has	
increased	substantially	and	reached	£87	million	Baht	in	2013.	
2.9 Renal replacement therapy of the UCS  
2.9.1 Background of the UCS RRT programme 
RRT	was	initially	excluded	from	the	benefit	package	when	the	UCS	was	
launched	in	2001	due	to	fiscal	constraints	and	an	unprepared	system.	
Gradually,	the	NHSO,	which	was	responsible	for	the	UCS,	was	pressured	to	
expand	benefits	to	include	RRT	by	civil	society	organisations	and	patient	groups	
(Tangcharoensathien,	Kasemsap	et	al.	2005).	Their	justifications	for	inclusion	
were	that	it	would	save	lives	and	prevent	indebtedness	and	health	
impoverishment	among	UCS	members.		
Before	launching	the	RRT	programme,	the	NHSO	commissioned	a	group	of	
researchers	to	conduct	a	set	of	comprehensive	studies	relating	to	RRT	
situations	and	the	possibilities	of	an	RRT	programme	for	UCS	beneficiaries.	The	
intention	was	to	present	viable	policy	options	to	the	NHSO	board.	Their	final	
decision,	supported	by	the	government	and	the	cabinet,	was	that	the	RRT	would	
be	provided	universally	regardless	of	age	and	socio‐economic	status	
(Dhanakijcharoen,	Sirivongs	et	al.	2011).		
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Despite	being	cost‐ineffective,	in	2008	RRT	was	adopted	into	the	benefit	
package	of	UCS.	The	new	health	benefit	covered	RRT	services	for	every	UCS	
member.	The	justification	was	to	help	patients	have	access	to	the	essential	
treatment	and	protect	them	from	catastrophic	spending	due	to	health	care	costs	
(Kasemsap,	Teerawatananon	et	al.	2006).		
The	RRT	programme	is	one	of	the	few	UCS	disease	management	programmes	
that	has	all	the	basic	elements	of	the	disease	management	concept.	The	issues	
about	how	the	RRT	programme	was	established,	managed,	and	linked	with	the	
disease	management	approach	are	explored	in	detail	in	Chapter	5	of	this	thesis.	
2.9.2 Evaluations of the UCS RRT programme 
After	RRT	programme	implementation,	greatly	increased	numbers	of	people	
accessing	UCS‐funded	RRT	of	the	UCS	was	a	consequence	of	the	large	number	of	
patients	who	had	been	waiting	for	the	extension	of	universal	health	coverage	to	
cover	RRT	in	2008	(Dhanakijcharoen,	Sirivongs	et	al.	2011).	There	were	two	
reports	that	assessed	the	arrangement	of	the	RRT	programme.	The	first	study	
(Limwattananon	and	Limwattananon	2013)	was	about	access	to	RRT	services	
and	patient	survival	rates.	Another	study	(Kasemsap,	Limwattananon	et	al.	
2013)	evaluated	the	programme	in	various	dimensions	including	comparison	of	
care	processes	among	the	three	public	insurance	schemes	and	costs	of	dialysis	
care.			
Limwattananon	and	Limwattananon	(2013)	estimated	that	the	proportion	of	
UCS	patients	with	ESRD	diagnoses	using	RRT	services	increased	rapidly	from	
only	15%	in	the	first	year	of	the	RRT	programme	to	41%	in	2010	and	36%	in	
2012.	However,	the	figures	indicated	that	many	patients	were	still	not	using	
dialysis.	The	study	also	reported	that	a	half	of	patients	who	were	able	to	
continuously	use	RRT	survived	at	least	5	years	while	a	half	of	patients	who	did	
not	receive	RRT	survived	less	than	20	months	(Limwattananon	and	
Limwattananon	2013).			
Regarding	the	low	number	of	patients	with	ESRD	diagnoses	with	access	to	the	
RRT	programme,	Kasemsap,	Limwattananon	et	al.	(2013)	clarified	that	this	was	
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because	generally,	patients	are	diagnosed	as	ESRD	when	they	have	eGFR	level	
lower	than	15	ml/minute	per	1.73	m².	However	according	to	the	Thai	
Nephrology	Society	guidelines,	patients	without	signs	or	symptoms	of	kidney	
failure	will	only	be	asked	to	enter	the	RRT	programme	once	the	eGFR	level	
reaches	6	ml/minute	per	1.73	m2.	This	partly	explains	why	the	study	of	patients	
with	ESRD	diagnoses	from	the	database	found	that	many	of	them	had	not	yet	
started	dialysis.	
2.9.3 RRT related costs in Thai literature 
In	Thailand,	most	published	studies	have	assessed	costs	from	the	health	care	
providers’	perspective.	From	the	perspective	of	providers	of	HD,	Meechai	
(2002)	evaluated	costs	of	hemodialysis	in	four	different	sizes	of	hemodialysis	
centres.	Tisayaticom,	Patcharanarumol	et	al.	(2003)	used	postal	questionnaires	
to	calculate	costs	relating	to	hemodialysis	in	108	public	and	private	facilities	
across	the	country.	Thanatchon	(2012)	conducted	a	cost	analysis	of	
hemodialysis	in	a	large‐size	medical	centre.	All	three	studies	identified	direct	
costs	which	consisted	of	(1)	labour	costs	(LC,	including	salary,	fringe	benefits,	
overtime),	(2)	material	costs	(MC,	including	fluid,	drugs,	and	overheads),	and	
(3)	capital	costs	(CC,	including	depreciation	and	maintenance).	Apart	from	the	
three	main	categories,	Meechai	(2002)	added	indirect	costs	which	were	travel	
costs	spent	on	traveling	to	dialysis	units.	Thanatchon	(2012)	added	costs	for	
erythropoietin	and	indirect	costs	allocated	from	hospital	non‐revenue	
producing	cost	centres.		
For	peritoneal	dialysis,	Laonapaporn,	Punthunane	et	al.	(2014)	conducted	an	
activity‐based	costing	of	peritoneal	analysis	in	a	general	hospital.	They	analysed	
costs	of	13	activities	relating	to	the	peritoneal	dialysis	service.	These	included	
the	treatment	for	peritonitis	and	erythropoietin	dispensing	in	the	follow‐up	
process.	All	activities	had	three	cost	categories:	labour	costs,	material	costs,	and	
capital	costs.	For	any	activity	which	needed	laboratory	tests,	costs	of	the	test	
were	included.		
For	kidney	transplant,	Suksamran,	Kongsin	et	al.	(2012)	collected	data	in	a	large	
university	hospital.	They	categorised	costs	into	labour	costs,	material	costs,	and	
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capital	costs;	and	separated	the	material	costs	into	medical	care	costs	and	
operating	care	costs	for	other	consumables.		
There	are	three	studies	(Thanatchon	(2012),	Laonapaporn,	Punthunane	et	al.	
(2014),	and	Suksamran,	Kongsin	et	al.	(2012))	that	included	the	cost	of	
medications	(erythropoietin	and	immunosuppressants)	in	calculations	of	
material	costs.	In	addition,	Laonapaporn,	Punthunane	et	al.	(2014)	took	account	
of	laboratory	tests	in	material	cost	calculations,	which	may	explain	the	high	
proportion	of	these	three	studies’	material	costs.	Proportions	of	costs	from	all	
reviewed	studies	are	summarised	in	Table	2‐6.	
Table 2‐6  Proportions (%) of three types of direct costs, indirect costs and the unit 
cost of RRT 
 
 
PD 
Laonapaporn(2014) 
HD 
Meechai(2002)     Tisayaticom(2003)1/    Thanatchon(2012) 
KT 
Suksamran(2012) 
Labour costs % 25 32 34, 47, 40 18 18 
Material costs % 74 42 46, 41, 43 60 79 
Capital costs % 1 24 21, 12, 17 13 3 
Indirect costs % N/A 19 N/A 9 N/A 
Unit cost (Baht)2/ 45,755 2,328-4,068 1,927, 1,525, 1,708 3,288 388,327 
    PD=peritoneal dialysis, HD= hemodialysis, KT =kidney transplant 
    1/ Public, private, and both public and private facilities 
    2/ Per PD patientyear, or per HD session, or per transplantation 
2.10 What is unknown? 
Given	current	studies,	little	is	known	about	the	following	issues:	
1) While	in	the	international	literature,	there	are	many	studies	conducted	
to	quantify	numbers	of	households	with	catastrophic	spending	and	
numbers	of	those	who	are	impoverished	from	health	care	costs,	there	
has	been	less	study	about	the	effect	of	providing	high‐cost	health	
benefits.		
2) The	number	of	disease	management	programmes	and	their	investments	
are	growing,	but	their	effects,	both	clinical	outcomes	and	cost	reduction,	
are	still	unclear.	Also,	a	scoping	review	in	Chapter	3	on	disease	
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management	found	little	evidence	from	low	and	middle	income	
countries.	
3) In	Thailand,	as	a	developing	country,	there	is	a	problem	of	inadequacy	of	
health	care	infrastructure.	Applications	of	disease	management	
programmes	vary	greatly	and	differ	somewhat	from	the	original	features	
of	the	disease	management	concept.	To	date,	there	has	been	limited	
study	in	Thailand	assessing	the	rationale,	process,	and	performance	of	
these	programmes.	Additionally,	no	empirical	research	connects	these	
programmes	to	the	disease	management	approach.		
4) In	cases	of	high‐cost	treatment	such	as	RRT,	while	there	is	a	concern	to	
control	programme	expenditure,	the	actual	expenditure	of	the	
programme	is	still	far	lower	than	the	original	estimation.	Nonetheless,	
there	is	no	empirical	evidence	showing	what	contributed	to	the	lower	
budget	spends.	It	is	unclear	whether	it	is	a	consequence	of	the	efficient	
RRT	disease	management	programme,	overestimation	of	expenditure,	or	
poor	patient	access.				
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CHAPTER 3 Evidence on Disease Management Programmes: 
results from population-based studies  
The	high	number	of	patients	suffering	from	chronic	conditions	places	a	
significant	burden	on	individuals,	society,	and	health	care	budgets	(Berk	and	
Monheit	1992;	Nolte	and	McKee	2008).	These	chronic	conditions	include,	for	
example,	coronary	heart	disease,	hypertension,	diabetes,	and	renal	disease.	One	
approach	to	coping	with	escalating	health	expenses	is	to	use	the	disease	
management	approach.	This	has	been	developed	as	a	means	to	improve	quality	
of	care	delivered	to	patients	with	chronic	diseases	as	well	as	bring	the	costs	
down	by	efficient	and	effective	use	of	health	care	resources	(Geyman	2007).		
Several	review	studies	have	described	the	designs	and	effects	of	disease	
management	programmes.	However,	just	a	few	of	them	focused	on	population‐
based	programmes	that	applied	to	a	wide	range	of	the	population.	Additionally,	
there	have	been	a	limited	number	of	review	studies	describing	programmes’	
arrangements	both	at	both	the	policy	and	provider	level.	
This	chapter	aims	to	provide	the	results	of	a	systematic	search	on	the	topic	of	
evidence	on	disease	management	from	population‐based	programmes	where	
disease	management	is	viewed	as	an	intervention	to	improve	quality	of	care	as	
well	as	to	reduce	health	care	expenditure.	Results	are	reported	in	terms	of	how	
these	programmes	are	arranged,	their	effects	on	patient	outcomes,	and	their	
effects	on	cost	containment	at	two	levels:	funder‐provider	level	and	provider‐
patient	level.	
3.1 Background to disease management programmes 
The	concept	of	disease	management	was	developed	in	the	US	in	the	1990s	as	a	
response	to	high	health	care	spending	(Krumholz,	Currie	et	al.	2006).	Although	
not	implemented	universally	in	the	country,	the	Centre	for	Medicare	and	
Medicaid	Services	has	launched	a	number	of	disease	management	
demonstration	programmes	for	its	beneficiaries	in	several	states.	In	the	private	
sector,	commercial	health	schemes	and	large	companies	commission	private	
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firms	to	provide	disease	management	programmes	that	help	individuals	
manage	their	chronic	conditions.	Because	of	the	claim	that	disease	management	
of	high‐cost	diseases	can	save	more	than	US$30	billion	a	year	(Mattke,	Seid	et	al.	
2007),	the	disease	management	industry	has	grown	rapidly.	The	annual	
revenue	of	this	sector	increased	from	US$78	million	in	1997	to	approximately	
US$1.2	billion	in	2005	(Mattke,	Seid	et	al.	2007).	
In	European	countries,	the	aims	of	disease	management	(DM)	are	different	from	
those	in	the	US.	DM	is	applied	as	a	new	model	to	deliver	health	services	for	
patients	with	chronic	diseases	in	response	to	a	set	of	problems.	They	include	
improper	utilisation	of	health	care	resources,	fragmentation	of	health	systems	
(Busse	2004;	Nolte	and	McKee	2008),	poor	access	to	care	and	catastrophic	
payment	(Stuart	and	Weinrich	2004;	Nolte,	Knai	et	al.	2008).	Sometimes,	the	
model	is	referred	to	as	Chronic	Care	Model	or	as	integrated	care,	which	is	a	
modified	form	of	disease	management.	The	diverse	models	applied	to	manage	
chronic	conditions	contribute	to	differences	between	health	systems.		
Therefore,	what	seems	to	be	a	successful	factor	in	one	health	system	might	give	
different	results	in	others	(Nolte	and	McKee	2008).		
3.2 Definitions and components of disease management 
One	challenge	of	disease	management	implementation	is	that	there	is	no	
common	definition	of	disease	management,	and	applications	vary	greatly	
(Krumholz,	Currie	et	al.	2006;	Schrijvers	2009;	Hisashige	2012).	Hisashige’s	
systematic	review	of	DM	definitions	(2012)	reported	that	out	of	28	studies,	7	
studies	use	their	own	definitions,	16	studies	adopted	the	definition	of	others,	
and	there	was	no	explicit	disease	management	definition	in	the	remaining	
studies.	Despite	the	inconsistent	definitions,	a	number	of	key	terms	were	
mentioned;	they	were;	comprehensive,	systematic	approach	(and	its	
similarities),	population‐based,	coordinated	health	care,	specific	disease,	
practice	guideline,	and	patient	education	(Hisashige	2012). 
The	Disease	Management	Association	of	America	(DMAA)	has	provided	one	of	
the	most	frequently	cited	definitions.	Disease	management	for	a	specified	
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disease	is	defined	as	“a	system	of	coordinated	health	care	interventions	for	a	pre‐
defined	group	of	population	with	application	of	evidence‐based	
guideline/protocol,	and	the	monitoring	and	evaluation	process	is	conducted	on	a	
regular	basis”	(Krumholz,	Currie	et	al.	2006),	Table	3‐1.		
Table 3‐1  DMAA definition of disease management 
Disease management: 
supports the physician or practitioner/patient relationship and plan of care; 
emphasizes prevention of exacerbations and complications through the use of evidence-based practice 
guidelines and patient empowerment strategies; and evaluates clinical, humanistic, and economic outcomes 
on an ongoing basis with the goal of improving overall health. 
Disease management components include: 
 population identification processes; 
 evidence-based practice guidelines; 
 collaborative practice models to include physician and support-service providers; 
 patient self-management education (may include primary prevention, behavior modification 
programs, and compliance/surveillance); 
 process and outcomes measurement, evaluation, and management; and routine reporting/feedback 
loop (may include communication with patient, physician, health plan, and ancillary providers, and 
practice profiling). 
*Full-service disease management programs must include all 6 components. Programs consisting of fewer 
components are disease management support services 
Source: DMAA (2005) cited inKrumholz, Currie et al. (2006) 
A	prior	scoping	review	by	the	researcher	found	that	numerous	research	studies	
on	DM	were	conducted	at	the	provider‐patient	level,	looking	at	various	provider	
disease	management	approaches	and	their	effects.	In	addition,	most	of	those	
studies	were	carried	out	on	a	small	scale	or	a	single	practice	of	health	care	
provider.	They	briefly	covered	policy	interventions	given	to	providers,	and	
therefore	little	is	known	about	disease	management	applications	and	their	
effects	on	a	larger	scale.	
3.3 Review questions 
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A	number	of	questions	arise	in	terms	of	types	of	arrangements	and	their	
differing	effects,	especially	at	the	population	level.	This	review	sought	to	answer	
the	questions	below.	Findings	from	the	review	were	expected	to	provide	a	
clearer	picture	of	disease	management	and	its	effects,	helping	to	plug	
knowledge	gaps	in	this	area.	
1) How	are	disease	management	programmes	arranged	at	the	policy	level,	
in	terms	of	types,	approaches	to	implementation	and	enforcement,	in	
different	health	systems?	
2) What	are	effects	on	the	health	system,	in	terms	of	costs	and	quality	of	
care?		
3) What	are	types	of	disease	management	content	and	services	provided	in	
health	facilities?	
4) What	are	effects	on	patients,	in	terms	of	access	to	services	and	clinical	
outcomes?	
3.4 Review methods 
Based	on	the	hypothesis	that	disease	management	programmes	can	be	
sustained	by	the	payment	mechanism	and	enforcement	supported	at	the	policy	
level,	this	review	identified	empirical	evidence	regarding	the	effect	of	various	
incentives	or	interventions	from	payers	to	providers	who	deliver	disease	
management	programmes.	This	review	aimed	to	explore	disease	management	
programmes	as	interventions	to	manage	chronic	conditions	and	their	effects.	
The	effects	were	examined	at	two	levels.	At	the	payer‐provider	level,	the	focus	
was	on	costs	and	quality	of	care.	At	the	provider‐patient	level,	the	focus	was	on	
service	provision,	patient	outcomes,	and	cost	containment.	Figure	3‐1	explains	
how	these	interventions	work,	how	they	relate	to	each	other,	and	which	effects	
to	be	assessed.	
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Figure 3‐1  Framework of disease management to be explored in this review 
	
The	nature	of	disease	management	interventions	is	diverse,	as	they	are	
composed	of	multiple	interventions,	participants,	settings,	and	outcomes.	
Because	of	this	diversity,	there	are	no	effective	formal	measures	or	study	
designs	for	a	systematic	review	(Centre	for	Reviews	and	Dissemination	2009)	
and	a	range	of	different	methodologies	have	been	used	to	evaluate	the	effects	of	
DM.	This	review	used	the	systematic	approach	to	find	relevant	articles	and	used	
narrative	synthesis	to	report	the	results.		
3.4.1 Search strategies for identification of studies 
The	system	of	disease	management	was	divided	into	two	levels;	payer‐provider	
level	and	provider‐patient	level.	Each	level	was	considered	and	reported	
separately.	At	payer‐provider	level,	because	there	was	a	limited	number	of	
research	studies	exploring	the	effect	at	the	payer‐provider	level,	most	studies	
were	commentaries	or	descriptive	papers.	Relevant	articles	in	this	part	came	
from	both	systematic	and	hand	searches.	Search	terms	used	for	primary	
research	and	hand	searches	included;	“disease	management”,	“effect”,	and	
“nation	or	region	or	county	or	country	or	state	or	decentralize”.	At	this	level,	
studies	were	identified	as	relevant	and	included	if	they	provided	sufficient	
information	about	the	detail	of	arrangements	or	interventions	of	disease	
management,	in	terms	of	types,	approaches	to	implementation	and	
enforcement.	Also,	these	studies	measured	effects	of	disease	management,	for	
example	access	to	services,	quality	of	care,	costs,	or	patient	outcomes.		
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Results	of	the	effects	at	provider‐patient	level	were	derived	from	a	systematic	
search	of	primary	studies	conducted	in	a	large	population	group.	Trial	
programmes,	demonstration	programmes,	or	non‐population	based	
programmes	which	include	only	30‐500	participants	of	patients	with	high	risks	
were	excluded.	Search	terms	for	primary	research	are	similar	to	the	payer‐
provider	level.	Detailed	results	for	each	search	term	can	be	found	in	Appendix	1.		
For	searching	primary	research,	the	review	used	the	Ovid	platform	to	access	the	
EMBASE	database.	Retrieved	articles	were	first	extracted	by	screening	their	
titles	and	abstracts.	After	that,	possible	relevant	articles	were	then	searched	to	
review	the	full	text.	Because	benefits	of	disease	management	programmes	are	
expected	to	occur	over	the	long	term	(Lind,	Kaplan	et	al.	2006),	this	review	
looked	for	studies	that	assessed	effects	of	disease	management	interventions	on	
patients	for	at	least	12	months.	Disease	management	has	multiple	components	
and	they	tend	to	be	effective	when	combined.	For	this	reason,	any	studies	which	
assessed	only	a	single	intervention,	such	as	database	management	or	telephone	
follow‐up,	were	excluded.	Also,	studies	that	explored	merely	attitudes	of	
providers	or	patients,	or	provided	solely	an	economic	evaluation,	were	not	
included	in	this	review.		
3.4.2 Inclusion criteria 
 Primary	research	exploring	the	effect	of	DM	programmes	at	
national,	country,	state,	county,	or	regional	level.	
 Patients	must	be	exposed	to	disease	management	interventions	at	
least	12	months.	
 At	least	two	disease	management	interventions	(such	as	patient	
education,	provider‐patient	communication,	use	of	clinical	
information	systems,	or	use	of	guidelines)	were	provided	to	
participants	in	the	study.	
 Published	in	any	peer	reviewed	journal	written	in	English	between	
2003	and	2015.	
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3.4.3 Search results of the primary research 
The	search	strategy	yielded	768	potentially	relevant	studies	from	EMBASE.	Of	
this	figure,	284	articles	were	conference	abstracts	or	study	protocols,	and	441	
articles	were	irrelevant.	Articles	were	excluded	if	they	were	not	related	to	the	
health	system	(such	as	clinical	trials,	animal	or	plant	studies);	not	implemented	
at	national,	regional,	or	state	level;	not	a	primary	study;	if	the	study	period	was	
less	than	12	months;	if	it	was	primarily	an	economic	evaluation;	if	it	duplicated	
another	study.	Also,	there	were	many	studies	(156)	that	mentioned	disease	
management	but	did	not	assess	its	effects	and	therefore	were	excluded.	After	
that,	there	were	43	potentially	relevant	articles.	It	was	not	possible	to	retrieve	
the	full	text	of	three	articles	and	26	articles	were	removed.	The	majority	of	
removals	were	because	there	were	less	than	two	disease	management	
interventions	mentioned	and	used	in	the	study	(8	articles),	or	because	there	
was	no	description	of	the	disease	management	interventions	studied	(8	
articles).	Some	articles	were	removed	for	more	than	one	reason,	but	only	the	
main	reason	was	stated.	Finally,	there	were	14	relevant	articles	to	be	
synthesised,	Figure	3‐2.	
Figure 3‐2  Process of screening for primary study 
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3.5 Results 
There	were	numerous	studies	about	disease	management.	Using	the	term	
‘disease	management’	in	the	PubMed	database	produced	the	result	in	Figure	
3‐3.	The	term	was	first	mentioned	in	the	1940s	and	became	of	more	interest	in	
the	late	1990s.	This	might	be	a	consequence	of	the	formulation	of	disease	
management	concepts	followed	by	the	approach	to	the	chronic	care	model	in	
this	period.	After	that	in	1996,	published	papers	increased	considerably.	In	
2014,	the	figure	rose	to	2,725	articles.	
Figure 3‐3  Numbers of published articles regarding disease management 
 
Results	are	reported	at	two	levels:	policy	level	and	provider‐patient	level.	At	the	
policy	level,	evidence	from	systematic	and	hand	searches	was	described.	At	the	
provider‐patient	level,	findings	are	reported	from	the	systematic	search	of	
primary	studies.	
3.5.1 Disease management arrangements at the policy level 
3.5.1.1 Types of disease management programmes 
There	is	a	large	variation	in	the	application	of	disease	management	
programmes.	It	may	vary	across	or	within	countries.	Based	on	the	level	of	
integration,	most	disease	management	programmes	can	generally	be	
categorised	into	two	basic	types:	1)	the	chronic	care	model	in	which	primary	
care	plays	the	key	role	in	integrating	the	programme	with	other	health	system	
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sectors	and	2)	separately	managed	programmes	for	a	specific	disease	without	
integration	or	coordination	(Geyman	2007).		
Examples	of	the	first	type	are	disease	management	programmes	based	on	the	
chronic	care	model.	These	are	used	in	regions	or	countries	that	have	strong	
primary	care	systems.	Primary	care	acts	as	a	central	component,	able	to	
coordinate	others	to	connect	patients	with	their	specialists	or	refer	the	patient	
from	primary	care	to	other	sectors,	for	example,	laboratory	or	x‐ray	tests,	
palliative	care,	or	inpatient	services	(Nolte,	Knai	et	al.	2008).	Many	disease	
management	programmes	in	European	countries	(Nolte,	Knai	et	al.	2008)	and	
non‐profit	health	insurance	plans	in	the	US	(Group	Health	Coorperative	and	
Kaiser	Permanente)	are	attempting	to	move	to	the	chronic	care	model	(Geyman	
2007).	Aims	of	these	programmes	are	to	improve	the	quality	of	health	service	
delivery,	control	costs,	and	decrease	fragmentation	of	different	health	system	
sectors.		
The	second	type	of	disease	management	programmes	administers	a	package	of	
services	focused	on	a	single	disease.	Since	this	category	is	often	applied	where	
there	is	a	weak	primary	care	system,	the	coordinating	role	of	the	primary	care	
and	advocate	function	of	collaborative	practice	are	minimal.	Examples	of	this	
type	are	disease	management	programmes	provided	by	private	companies	in	
the	US,	in	which	employers,	the	state	Medicaid	programme,	or	health	insurance	
plans	commission	these	companies	to	provide	DM	programmes	for	members	
suffering	from	chronic	diseases.	These	programmes	are	marketed	on	the	basis	
of	cost‐containment,	with	packages	focusing	on	patient	education	for	self‐
management	through	systems	such	as	telephone	calls,	mailing,	and	online	
information	(Geyman	2007).		
3.5.1.2 Approach to implementation and enforcement 
Disease	management	implementation	is	usually	voluntary	for	providers,	and	
patients	can	opt	out	(Busse	and	Riesberg	2004;	Lind,	Kaplan	et	al.	2006;	Nolte,	
Knai	et	al.	2008).	Patients	registered	with	these	programmes	benefit	from	
disease	management	services	and,	depending	on	their	specific	programme,	
exempted	or	reduced	co‐payments	(Nolte,	Knai	et	al.	2008).		
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Approaches	to	disease	management	implementation	can	be	classified	into	two	
types	(Gresharp,	Baan	et	al.	2009):	top‐down	approach	and	bottom‐up	
approach.		
i. Top-down approach 
The	top‐down	approach	is	characterised	by	policy‐making	at	the	national	level,	
financing	through	the	national	budget,	and	nationwide	regulation	and	
implementation.	Notable	of	this	type	are	England	and	Germany	where	
purchasers,	insurers	or	providers	have	financial	incentives	to	set	up	disease	
management	programmes,	generally	via	additional	payment,	separate	from	the	
normal	budget.	Support	and	regulation	from	the	national	level	mean	disease	
management	programmes	are	implemented	quickly,	and	health	care	providers	
have	to	follow	the	same	standard	protocols	(Gresharp,	Baan	et	al.	2009).	For	
example,	in	Germany,	sickness	funds	(health	care	purchasers)	receive	higher	
compensation	for	setting	up	certified	disease	management	programmes	and	
recruiting	participants	with	chronic	illness.	Sickness	funds	then	contract	with	
providers	to	deliver	accredited	DM	programme	packages	and	enroll	as	many	
members	as	possible	(Busse	and	Riesberg	2004;	Gresharp,	Focke	et	al.	2006).	
As	a	consequence	of	strong	regulation,	although	each	health	insurance	company	
offers	its	own	disease	management	programmes,	most	components	are	applied	
rather	similarly. Patients	must	consent	to	enrolment	and	agree	to	actively	
participate	in	their	care	according	to	the	requirements	of	the	programme	
(Stark,	Schunk	et	al.	2011).	
The	top‐down	disease	management	contract	models	in	Germany	and	the	UK	
provide	an	incentive	to	accelerate	the	implementation	of	disease	management	
programmes	(Gresharp,	Focke	et	al.	2006;	Gresharp,	Baan	et	al.	2009;	Ham	
2009),	increasing	benefits	to	family	physicians	and	recruitment	of	health	care	
staff	into the primary	care	sector	(Ham	2009).		
Financial	incentives	of	the	top‐down	approach	can	be	categorised	into	three	
types	according	to	their	purpose;	1)	for	establishing	infrastructure	and	
network,	2)	for	registering	members,	and	3)	for	providing	services	(see	Table	
3‐2).		
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Table 3‐2  Financial incentives to providers in selected countries 
Category England  
Germany 
Establishing 
infrastructure & 
network 
N/A Earmarked at 1% of total  
health care budgets at the 
beginning of nationwide 
implementation period 
(2004-2006)  
Registering members Global budget based on the 
number of registered patients 
with adjusted weight  
Additional compensation for 
a registered patient 
Providing services Additional pay-for-
performance payment for 
targeted outcomes 
Additional flat rate payment 
for documentation, patient 
education  
Source: Nolte, Knai et al. (2008), Gresharp, Focke et al. (2006), Ham (2009) 
Although	national	funding	is	a	promising	sign	for	the	continuity	of	disease	
management	programmes,	large	expenditures	resulted	in	criticism	of	money	
spent	on	chronic	care	programmes	(Ham	2009).	
ii. Bottom-up approach  
The	other	approach,	bottom‐up,	is	characterised	by	local,	state,	or	regional	
initiatives	within	the	existing	service	provision.	Although	such	disease	
management	programmes	are	developed	based	on	local	needs,	they	are	likely	to	
suffer	from	issues	with	long	term	funding.	This	is	because	these	disease	
management	programmes	are	mostly	financed	by	time‐limited	contracts	or	
grants	(Gresharp,	Baan	et	al.	2009)	or	from	available	regional	budgets	(Steuten,	
Palmer	et	al.	2007).	This	bottom‐up	approach	frequently	reflects	the	
fragmentation	within	the	health	system	and	the	government’s	inability	to	
support	integration	of	chronic	care	delivery	(Lankhorst	and	Spreeuwenberg	
2008).	Examples	of	this	type	are	the	asthma	management	programme	in	
Quebec,	Canada,	supported	by	local	public‐private	networks	(Boulet,	Dorval	et	
al.	2008);	the	diabetes	management	programme	in	Maastricht,	the	Netherlands,	
contracted	via	the	health	insurance	fund	(Lankhorst	and	Spreeuwenberg	2008);	
and	high‐cost	disease	management	for	Medicaid	beneficiaries	in	many	states	of	
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the	USA	(Martin,	Berger	et	al.	2004;	Lind,	Kaplan	et	al.	2006;	Zhang,	Wan	et	al.	
2008;	Katz,	Holmes	et	al.	2009;	Coburn,	Marcantonio	et	al.	2012).		
3.5.1.1 Effects on the health system: costs and quality of care 
A	well‐functioning	primary	care	provider	that	can	assess	patients’	clinical	
outcomes	and	medication	and	at	the	same	time,	coordinate	with	other	segments	
(such	as	specialists),	is	expected	to	provide	better	quality	of	care	and	reduce	
costs	by	cutting	unnecessary	medications	and	utilisation	of	health	care	
resources	(Nolte	and	McKee	2008).	Coordinating	mechanisms	are,	therefore,		
key	to	achieving	the	aims	of	disease	management.	Bodenheimer	(2009)	
summarised	a	number	of	studies	regarding	the	quality	and	costs	of	disease	
management	programmes	in	the	US.	They	found	that	disease	management	
based	on	the	primary	care	function	performed	better	than	disease	management	
programmes	supported	by	private	companies	in	terms	of	quality	of	care.		
However	cost	containment	results	were	inconsistent	(Bodenheimer	and	Berry‐
Millett	2009).		
Coleman	et	al	(2009)	reviewed	several	observational	studies	which	examined	
the	impacts	of	different	components	of	disease	management	and	chronic	care	
models.		Impact	was	assessed	in	terms	of	quality,	process	indicators	(such	as	
coordination	and	guideline	use)	and	clinical	outcomes.	They	found	that	the	
more	programme	components	implemented,	the	more	likely	the	programme	
was	to	gain	quality	improvements	(Coleman,	Austin	et	al.	2009).	
The	reviewed	studies	described	inconclusive	findings	on	costs	and	quality	of	
care	(Mattke,	Seid	et	al.	2007;	de	Bruin,	Heijink	et	al.	2011;	Hisashige	2012).	
This	was	true	even	in	large	pilot	disease	management	programmes,	such	as	that	
of	Medicare	in	the	US,	which	served	approximately	300,000	Medicare	
beneficiaries	with	chronic	diseases.		A	summary	of	overall	results	concluded	
that	these	programmes	did	not	show	common	evidence	of	improvement	in	
behaviour,	compliance	to	treatment	guidelines,	or	satisfaction	of	providers	or	
members,	although	some	programmes	reported	a	net	cost	saving	(Bott,	Kapp	et	
al.	2009).	
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While	there	is	inconclusive	evidence	on	the	issues	of	costs	and	quality,	some	
review	studies	(Bodenheimer	and	Berry‐Millett	2009;	Gresharp,	Baan	et	al.	
2009;	Nolte,	Knai	et	al.	2012)	suggest	that	there	are	three	possible	predictors	
affecting	programmes’	success.	They	include:	1)	design	of	an	individual	
programme,	2)	level	of	integration	of	primary	care	and	other	segments,	and	3)	
policy	support	at	the	national	level.	
3.5.2 Disease management at provider-patient level: results from 
primary research  
What	is	known	about	the	effect	of	approaches	on	disease	management	is	more	
likely	to	come	from	small	programmes.	These	programmes	are	likely	to	be	non‐
population	based	programmes	which	include	only	30‐500	participants	of	
patients	with	high	risks,	rather	than	the	whole	population	with	a	given	
condition	or	disease,	and	short‐term	studies	where	length	of	observation	was	
less	than	12	months	(Mattke,	Seid	et	al.	2007;	Conklin	and	Nolte	2013).	While	
the	results	of	large,	population‐based	programmes	are	unclear,	this	section	
sought	to	synthesise	effects	of	disease	management	that	can	be	generalised	to	a	
wider	population.		
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3.5.2.1 Description of included studies 
The	systematic	search	of	large	population‐based	studies	found	14	relevant	
studies.	Studies	from	the	US	(7	studies)	dominated,	while	other	studies	came	
from	Germany,	England,	Italy,	France,	and	Canada.	The	studies	varied	in	
duration	from	one	year	to	four	years.	The	majority	of	the	included	studies	(9	
studies)	were	quasi	experimental	or	observational	studies	(including	pre‐post,	
cohort,	and	cross	sectional	studies).	Four	studies	were	randomised	controlled	
trials,	and	one	study	was	a	descriptive	study.	Most	of	the	included	studies	had	
control	or	internal	comparison	groups	(programmes’	members	receiving	usual	
care	or	the	general	population).	Only	two	studies	used	benchmarks	(the	general	
population	and	targets)	for	counterfactual	comparison.	The	results	of	each	
study	are	presented	in	Table	3‐3.	
3.5.2.2 Service provision 
The	most	common	type	of	disease	management	service	in	the	US	and	France	
were	nurse‐led	clinics	or	nurse‐led	disease	management	services,	centralised	in	
the	offices	of	GPs.	Nurses	acted	as	a	health	educators;	mentors	of	patients’	
monitoring	programmes;	and	coordinators	between	primary	and	secondary	
care	systems,	and	patients	and	their	physicians,	either	GP	or	specialist.	The	level	
of	responsibility	of	a	nurse	was	based	upon	agreed	protocol	(Katz,	Holmes	et	al.	
2009;	Coburn,	Marcantonio	et	al.	2012;	Agrinier,	Altieri	et	al.	2013).	In	Italy,	GPs	
worked	in	their	own	offices	and	were	asked	to	share	clinical	experience,	adopt	
clinical	guidelines	and	organise	workshops	for	quality	and	prescribing	
assessment	with	other	general	practioners	in	the	same	group.	Other	
professionals	or	specialists	were	not	included	within	the	group	(Visca,	Donatini	
et	al.	2013).		
3.5.2.3 Patient outcomes 
Since	disease	management	programmes	in	each	study	in	this	review	were	
applied	in	multiple	sites,	detailed	activities	might	be	varied.	However,	all	
programmes	were	based	on	patient	education	for	self‐care	management	and	
follow‐up	communication.	All	studies	assessed	at	least	one	of	the	following	
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indicators:	patients’	access	to	services,	resource	utilisation,	clinical	outcomes,	
quality	of	care,	and	costs.	
i. Resource utilisation  
Resource	utilisation	was	quantified	by	a	number	of	measures,	such	as	
emergency,	outpatient	and	inpatient	use.	Results	found	that	disease	
management	reduced	emergency	visits	(Zhang,	Wan	et	al.	2008;	Campbell,	
Ronksley	et	al.	2012)	and	hospitalisations	(Windt	and	Glaeske	2010;	Campbell,	
Ronksley	et	al.	2012;	Agrinier,	Altieri	et	al.	2013).	However,	the	effect	might	not	
be	statistically	significant	across	all	diseases	if	measured	in	more	than	one	
disease.		
ii. Clinical outcomes/ quality of care 
In	terms	of	health	outcomes	and	quality	of	care,	disease	management	
interventions	seemed	to	be	effective	at	improving	most	indicators.	A	number	of	
studies	showed	statistically	significant	improvements.	These	included	
reductions	of	the	mortality	rate	(Coburn,	Marcantonio	et	al.	2012),	higher	rates	
of	receiving	proper	medical	care	(Windt	and	Glaeske	2010;	Stark,	Schunk	et	al.	
2011),	achievement	of	treatment	goals	(Gilmer,	Philis‐Tsimikas	et	al.	2005;	
Meng,	Wamsley	et	al.	2010;	Stark,	Schunk	et	al.	2011),	and	better	patient	quality	
of	life	(Zhang,	Wan	et	al.	2008;	Meng,	Wamsley	et	al.	2010;	Visca,	Donatini	et	al.	
2013)	in	comparison	to	non‐intervention	groups.	However,	results	from	more	
than	half	of	studies	were	mixed,	with	both	positive	and	negative	or	insignificant	
results,	within	or	across	providers	or	disease	and	regardless	of	patients’	risk	
levels.		
iii. Access to services 
By	applying	collaborative	practice,	emphasising	evidence‐based	guidelines	and	
feedback	reports,	a	study	in	Manchester,	UK	found	improvements	in	the	
numbers	of	patients	registering	with	a	chronic	kidney	disease	programme.	
However,	levels	of	improvement	varied	across	providers	(Humphreys,	Harvey	
et	al.	2012).	Disease	management	programmes	might	be	unable	to	fully	address	
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existing	disparities	if	they	served	patients	within	different	socioeconomic	status	
groups.	A	study	in	Alberta,	Canada	found	that	patients	with	low	socioeconomic	
status	and	indigenous	patients	had	higher	rates	of	hospitalisation	in	
comparison	to	general	patients.	Also,	indigenous	patients	were	less	likely	to	
receive	specialist	care	(Campbell,	Ronksley	et	al.	2012).		
3.5.2.4 Cost containment 
Results	regarding	cost	containment	of	disease	management	programmes	were	
mixed	with	statistically	significant	(Zhang,	Wan	et	al.	2008;	Katz,	Holmes	et	al.	
2009;	Agrinier,	Altieri	et	al.	2013)	and	not	statistically	significant	results	in	
terms	of	cost	containment	(Martin,	Berger	et	al.	2004).	In	comparison	with	the	
usual	care	group,	just	two	out	of	five	studies	assessing	the	costs	of	disease	
management	programme	(Martin,	Berger	et	al.	2004;	Gilmer,	Philis‐Tsimikas	et	
al.	2005)	found	significant	increases	in	the	cost	of	disease	management	
arrangements.	
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Table 3‐3  Characteristics and results of relevant primary studies 
Author Setting Study design Comparison strategy Diseases DM interventions Study’s Measures Effects 
Visca, Donatini et 
al. (2013) 
Italy Observational, 
cross-sectional 
study of general 
practioners 
working in teams  
Internal 
comparator: 
general 
practioners 
working in solo 
practice  
Diabetes, 
CHD, IHD 
Policy level: reforms of the primary 
health care to introduce team practice of 
GPs. Each GP is paid  extra for each 
patient on top of the capitation. 
Provider level: clinical practice 
guidelines and organizing workshops of 
the GP team for assessment of care 
quality and appropriate prescribing 
Proportions of patients 
receiving appropriate 
care 
In terms of quality of care, 
results were mixed and 
inconclusive. 
Agrinier, Altieri et 
al. (2013) 
Lorraine, France Descriptive and 
time-series study 
of patients 
enrolled in a DMP  
Benchmarking: 
overall French 
population 
HF Policy level: no detail specified 
Provider level: home-nurse visits and 
patient/family education 
Number of HF 
hospitalizations and 
difference of total cost of 
operating the DMP and 
the costs saved by the 
avoided hospitalizations 
In 2010, there was a 7.19% 
reduction in the risk of 
hospitalization in the region, 
estimated net savings 
associated with the DMP 
was €1,927,648. 
Campbell, 
Ronksley et al. 
(2012) 
Alberta, Canada Population-based 
cohort analysis of 
patients aged < 
65 years  
Internal 
comparator: 
general 
population 
Diabetes Policy level: primary care reform by 
establishing Primary Care Networks 
funded on a capitated basis to support 
health services that fall outside the fee-
for-service payment. 
Provider level: multidisciplinary teams 
and enhancing patient education as a 
basic 
Hospital admissions, 
physician visits, and 
emergency department 
visits  
 
Receiving care in a primary 
care network was associated 
with significantly lower rates 
of all measures and the 
effects were similar across 
each population group. The 
study noted a marked risk of 
higher hospital admissions 
and emergency visits of 
lower income and 
indigenous groups. 
Humphreys, 
Harvey et al. (2012) 
Primary care 
trusts in Greater 
Manchester 
Descriptive study 
of patients with 
Benchmark: 
target setting 
CKD 
 
Policy level: payment for initiating a 
DPM, attending training sessions, and 
Number of registered 
patients and level of 
Percentage of improvement 
of both indicators were 
observed but level of 
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Author Setting Study design Comparison strategy Diseases DM interventions Study’s Measures Effects 
region, UK CKD  final payment at the end of the DMP. 
Provider level: NICE guidelines on the 
identification and management of CKD, 
staff training 
blood pressure achievement varied across 
providers   
 
Coburn, 
Marcantonio et al. 
(2012) 
Traditional 
Medicare 
(administered by 
federal 
government) 
patients in 
primary care 
providers in 
Pennsylvania, 
USA 
 
RCT of a 
Medicare 
demonstration 
programme 
Control group: 
usual care 
HF,CHD, DM, 
HT, asthma, 
hyperlipidemia 
Policy level: Medicare’s FFS coverage 
and additional fixed negotiated fee per 
participant per month 
Provider level: Patient education, 
coordination mechanism, guideline use 
(detailed activities were varied across 
providers) 
Mortality rate 
 
Nurse care management 
associated with reduction of 
all-cause mortality in 
chronically ill elderly  
Stark, Schunk et al. 
(2011) 
Augsburg, 
Germany 
Cross sectional 
survey of a DMP  
Control group: 
usual care 
Diabetes Policy level: regulate responsibilities of 
doctors, patients, and social health 
insurance companies, as well as set up 
their treatment goals.  
Provider level: define eligible patients 
and regular follow-up, provide health 
education to patients and health care 
providers, coordination of complex 
medical care, and other support 
Patient’s self-care 
management, body 
examination, and other 
laboratory tests for 
diabetes 
In comparison to the usual 
care group, patients in DMP 
were more likely to received 
anti-diabetic medications, 
more frequent medical 
examination, diabetes 
educations, and achieve 
blood pressure goals. Both 
groups had satisfactory 
HbA1c but poor low-density 
lipoprotein levels. 
Meng, Wamsley et 
al. (2010) 
Medicare patients 
in New York, 
West Virginia and 
RCT of a 
Medicare 
demonstration 
Control group: 
usual care 
Disability Policy level: no detail specified 
Provider level: patient education, 
individualised health promotion and 
Body mass index and 
dependence in Activities 
of Daily Living 
DM interventions were 
statistically associated with 
less worsening in disability of 
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Author Setting Study design Comparison strategy Diseases DM interventions Study’s Measures Effects 
Ohio, USA programme disease self-management coaching, 
medication management, and physician 
care management. 
participants in normal weight 
group, but not in 
underweight, overweight, 
and obese groups 
Windt and Glaeske 
(2010) 
Germany Quasi-
experimental 
study of 
participants of the 
nationwide DMP 
Before and 
after launching 
a DMP 
Asthma Policy level: DMPs were introduced by 
the Act to Reform the Risk Structure 
Compensation Scheme in Statutory 
Health Insurance (SHI). Sickness funds 
received higher payments if they set up 
certified DMPs and motivated patients to 
enroll.  
Provider level: The Act provides 
recommendations on how to conduct a 
DMP and its preferred components. 
% of hospitalisation, risk 
to hospitalisation, and a 
set of prescription drugs 
for asthma 
Effects of DMP on patients’ 
outcomes were weak, no 
statistical difference 
observed on hospitalization 
or high risk for future 
emergency care. However, 
the DMP group had more 
statistically significant 
numbers of patients with 
prescriptions of 
corticosteroid inhalers which 
these drugs are 
recommending in the asthma 
guideline. 
Katz, Holmes et al. 
(2009) 
Indiana, USA Quasi-
experimental 
study of Medicaid 
members 
Matched 
comparison 
group (without 
interventions) 
Diabetes, 
CHF 
Policy level: Indiana Office of Medicaid 
Policy and Planning (OMPP) introduced 
the Indiana Chronic Disease 
Management Program to eligible 
Medicaid participants with diabetes 
and/or CHF. The OMPP is also 
responsible for hiring and training of 
personnel, and coordination of 
physicians and eligible Medicaid 
members.  
Provider level: nurse care management, 
clinical guidelines for physicians, 
Costs of paid claims Claim data showed slight 
improvements in cost control 
but results were statistically 
significant only in some 
sectors and regions. 
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Author Setting Study design Comparison strategy Diseases DM interventions Study’s Measures Effects 
collaborative groups for primary care 
practice. An individual patient’s risk was 
assessed for predicting annual health 
care claims. 
Gapp, Schweikert 
et al. (2008) 
Beneficiaries of 
Statutory Health 
Insurance, 
Germany 
Cross-sectional 
study of insured 
patients with a 
history of AMI 
Internal 
comparator: 
usual care 
AMI Policy level: Sickness funds are 
obligated to provide and evaluate DMP. 
They receive higher payment for a DMP 
enrollee.  
Provider level: patient education, 
programme review and assessment 
Quality of services 
(medications and 
counseling) 
The study was unable to 
conclude major health 
outcomes. Findings 
suggested no statistical 
differences in quality of life 
and body mass index, and 
only a minor reduction in 
smoking. 
Zhang, Wan et al. 
(2008) 
State managed 
Medicaid DMP, 
Virginia, USA 
Controlled quasi 
experimental 
study of Medicaid 
beneficiaries 
Matched 
comparison 
group (without 
interventions) 
Diabetes, 
HT/CHF, 
GERD, PUD, 
asthma/ 
COPD, 
depression, 
and co-
morbidity of 
these 
diseases 
Policy level: Medicaid FFS, no detail 
specified 
Provider level: monitoring, assessments, 
and interventions for patient self-
management by trained physicians and 
pharmacists. 
HRQoL questionnaire, 
medical utilization, drug 
utilization, adverse drug 
events and cost of 
average amount paid 
per member per month 
There were reductions in 
costs, utilisation, and 
adverse drug reaction 
among patients receiving 
interventions but results 
were inconsistent across all 
disease groups, especially in 
patients with co-morbidity 
Vickrey, Mittman et 
al. (2006) 
Southern 
California, USA 
RCT of elderly 
Medicare patients 
Control group: 
usual care 
Dementia Policy level: no detail specified 
Provider level: collaborative care 
planning with carers, carer’s self-
management support, ongoing follow-
up, and provider education 
Physicians’ adherence 
to clinical guideline, 
obtaining community 
services/resources, and 
patients and carers’ 
health and quality-of-
care measures 
Participants in DMP group 
had higher scores of most 
measurers than the usual 
care group except HRQoL of 
carers which were 
comparable between the two 
groups. 
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Author Setting Study design Comparison strategy Diseases DM interventions Study’s Measures Effects 
Gilmer, Philis-
Tsimikas et al. 
(2005) 
San Diego 
County, CA, USA 
Non experimental  
pre-post study of 
Medicaid 
beneficiaries 
Matched 
comparison 
group (without 
interventions) 
Diabetes Policy level: County Medical Services 
contracted with Project Dulce to provide 
diabetes DMP for  adults 
Provider level: trained nurse and other 
diabetes related health worker to use 
guideline protocols, patients’ self-care 
management, and trained peer 
educators recruited from the patient 
population to provide the training 
programme 
Diabetes related 
laboratory tests and 
project management 
costs 
The intervention group was 
related to significant 
improvements in HbA1c, 
both systolic and diastolic 
blood pressure, total 
cholesterol, and LDL-C. 
Expenditures for medicine 
and DMP arrangements 
increased. There was 
probability of reductions in 
hospitalisation costs within 
the first year after 
implementation. 
Martin, Berger et al. 
(2004) 
HMO managed 
Medicare network 
in Pennsylvania, 
USA  
RCT of Medicare 
beneficiaries  
Control group: 
usual care 
CHF, falls, 
Diabetes, 
depression, 
and nutrition 
Policy level: no detail specified 
Provider level: patient education for self-
care management, patient health 
assessment, physician education, 
medication review, and coordination with 
community service   
SF-36, satisfaction, paid 
claim costs, utilization, 
and mortality 
Except for satisfaction that 
favoured the intervention 
group, most results from 
intervention and control 
groups showed difference 
but not statistically 
significant. Health care costs 
rose considerably in both 
groups but not statistically 
significant difference. 
AMI= acute myocardial infarction, BP=blood pressure, CHD=coronary heart disease, CHF= congestive heart failure, CKD=chronic kidney disease, COPD=chronic obstructive pulmonary disease, DMP=disease 
management programme, FFS=fee-for-service, GERD=Gastro-esophageal reflux disease, HF=heart failure, HMO=Health Maintenance Organization, HRQoL=health-related quality of life, HT=Hypertension, 
IHD=ischemic heart disease, PUD=peptic ulcer disease, RCT=Randomised controlled trial, SF-36=Short form health survey
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3.6 Discussion and conclusions 
Disease	management	has	been	widely	adopted	as	a	tool	to	control	health	care	
costs	and	increase	quality	of	care,	in	particular	in	North	America	and	Europe.	
However,	the	approach	puts	challenges	to	implement,	and	also	ways	to	evaluate	
such	types	of	programmes.			
Because	of	the	blurred	definitions	and	boundaries	of	disease	management,	
great	variations	in	practice	exist	across	disease	management	programmes.		Of	
those	six	components	referred	to	in	the	DMAA	definition,	a	study	(Weingarten,	
Henning	et	al.	2002)	found	that	patient	education	was	the	most	frequently	used	
component	among	disease	management	programmes	(78%).	The	other	popular	
components	were	provider	education	(40%),	and	provider	feedback	(27%).	
This	current	review,	however,	argues	that	there	are	three	basic	components	
needed	for	setting	up	a	disease	management	programme,	namely;	predefined	
population	group,	evidence	based	protocols	and	guidelines,	and	routine	
reporting.	Although	most	disease	management	programmes	use	patient	
education	as	a	means	to	promote	self‐care	management,	without	the	three	basic	
components,	a	disease	management	programme	cannot	be	differentiated	from	
the	regular	health	care	delivery.	
Considerable	attempts	have	been	put	in	action	on	design	and	development	of	
disease	management	programmes.	Nevertheless,	some	characteristics	of	the	
health	system	might	impede	DM	programmes	from	their	aims	and	so	findings	
from	one	country	might	not	be	relevant	to	another.	Examples	from	this	review	
include	strong	segment	separation	in	Germany,	making	the	programmes	hard	to	
integrate	(Busse	2004).	Fee‐for‐service	payment	of	traditional	Medicaid	and	
Medicare	programmes	make	it	difficult	to	control	costs,	since	this	method	tends	
to	lead	to	escalating	health	care	costs	(Gottret	and	Schieber	2006).	Application	
of	disease	management	programmes	needs	to	be	tailored	to	patients	with	
various	health	care	needs	or	diverse	socioeconomic	statuses.		
An	interesting	issue	emerged	from	the	review	of	primary	studies	that	used	the	
RCT	method	(blind	and	randomised	allocation	of	patients	to	control	and	
intervention	groups).	These	studies	are	questionable,	given	that	it	is	difficult	to	
CHAPTER 3  Evidence on Disease Management Programmes: results from population-based studies 
79 
	
control	the	numbers	and	quality	of	interventions	given	to	the	patients.	In	
particular,	interventions	such	as	giving	patient	education,	counselling,	and	
treatment,	depend	on	individual	medical	and	communication	skills.		The	quality	
of	these	interventions,	therefore,	is	likely	to	be	diverse	across	providers.	
Interpreting	results	from	such	study	designs	in	any	disease	management	
programme	evaluations	should	be	done	with	caution.		
Disease	management	is	an	appealing	approach	to	help	patients	and	health	care	
providers	manage	high‐cost	conditions.	If	a	disease	management	programme	
achieves	its	goals	by	providing	a	better	quality	of	care	and	reducing	costs,	it	
could	be	a	powerful	tool.	To	date,	findings	from	disease	management	
evaluations	are	still	inconsistent,	particularly	in	terms	of	net	cost	savings,	which	
might	stem	from	the	difference	in	study	settings.	Additionally,	disease	
management	service	delivery	relies	heavily	on	investment	in	programme	set‐up	
and	administrative	functions,	especially	in	the	initial	phase.	Therefore	a	new	
disease	management	programme	might	not	be	cost‐saving	during	the	initial	
phase	(Burns	and	Pauly	2012).		
One	source	of	variation	in	the	results	from	population‐based	disease	
management	evaluations	is	differences	in	study	designs.	In	practice,	controlled	
trials	have	difficulties	in	randomly	assigning	subjects	to	the	control	and	
intervention	groups	and	providing	the	same	interventions	to	individuals,	and	
this	might	lead	to	an	ethical	issue	of	giving	interventions	to	just	one	group	but	
not	to	another	(Conklin	and	Nolte	2013).	This	is	the	reason	why	many	
population‐based	disease	management	evaluations	are	not	randomised	
controlled	trials	and	have	moved	towards	more	practical	study	designs	such	as	
various	types	of	non‐experimental	study	designs.	These	study	designs	have	a	
number	of	limitations,	in	terms	of	controlling	for	possible	biases	and	
confounders.	Combining	with	multifaceted	interventions	of	the	disease	
management	approach,	this	could	lead	to	mixed	and	inconclusive	results	in	
programme	evaluations.			
All	reviewed	studies	used	a	comparison	strategy	to	interpret	results,	whether	
disease	management	interventions	are	effective	and	produced	positive	results.	
Apart	from	controlled	trials,	a	comparator	group	(internal,	external,	or	general	
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population)	and	benchmarks	(general	population	or	target)	were	used	in	
weaker,	non‐experimental	and	descriptive	studies.		
From	this	review,	results	from	studies	in	low	and	middle	income	countries	have	
been	found	to	be	lacking.	This	may	be	a	consequence	of	limited	numbers	of	
population‐based	disease	management	programmes	and	their	evaluations	
applied	in	these	countries.	Future	research	should:	bring	about	experiences	
from	more	diverse	health	systems,	in	particular	low	and	middle	income	
countries,	identify	disease	management	approaches	which	are	most	suitable	for	
each	context,	and	assess	whether	disease	management	programmes	provide	
desired	outputs	or	outcomes.	Selected	evaluation	methods	should	fit	best	to	
each	system’s	available	resources	and	produce	minimum	biases	which	could	
lead	to	an	issue	of	the	validity	of	results.		
	
	
	
	
	
	
	
	
	
	
	
	
	
	
CHAPTER 3  Evidence on Disease Management Programmes: results from population-based studies 
81 
	
	
CHAPTER 4  Aims, objectives, and methodology 
82 
	
CHAPTER 4 Aims, objectives, and methodology 
This	chapter	introduces	the	aims,	objectives,	and	methodology	used	in	this	
study.	The	aims	are	described	first	and	lead	to	three	objectives.	Next	this	
chapter	will	discuss	the	study	framework	and	the	tracer	used	to	study	the	
effects	of	the	disease	management	programme.	This	is	followed	by	detailed	
methods	for	each	objective.	Finally,	the	study’s	limitations	are	discussed.		
4.1 Aims and objectives 
The	aim	of	this	study	is	to	explore	the	introduction	and	functioning	of	a	high‐
cost	health	benefit	programme	of	the	universal	coverage	scheme	(UCS)	in	
Thailand.	Using	the	UCS’s	renal	replacement	therapy	(RRT)	programme	as	a	
tracer,	the	study	will	then	assess	how	a	disease	management	approach	has	
facilitated	the	inclusion	of	RRT	in	the	benefit	package,	now	and	in	the	longer	
term,	and	with	what	results.		
The	aims	introduce	three	objectives,	which	are	to:	
1) Describe	the	rationale	behind	the	initiation	of	a	high‐cost	health	benefit	
programme	and	the	application	of	the	disease	management	approach	in	
the	RRT	programme;	
2) Explore	how	the	RRT	disease	management	programme	could	have	
contributed	to	the	changing	patterns	of	i)	entry	of	patients	into	the	RRT	
programme	and	ii)	mortality	of	adult	UCS	members	who	were	diagnosed	
with	end‐stage	renal	disease;		
3) Undertake	long	term	projections	of	the	number	of	patients	and	budget	
needs	for	the	RRT	programme	to	assess	financial	implications	into	the	
future.	
The	findings	of	this	study	are	intended	to	build	evidence	to	support	a	policy	of	
including	coverage	for	high‐cost	health	benefits	such	as	RRT	in	the	context	of	a	
developing	country.	
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4.2 Study framework 
The	study	framework	has	been	developed	from	the	literature	reviews	on	high‐
cost	conditions,	disease	management,	access	to	health	services,	and	financial	
needs	of	the	programme.	This	study	explores	two	elements	of	the	RRT	
programme:	1)	disease	management	programmes	as	a	result	of	the	response	to	
a	high‐cost	condition	and	2)	the	effects	of	disease	management,	in	terms	of	
access	to	services,	mortality,	and	future	implications.	The	framework	of	this	
study	is	shown	in	Figure	4‐1.	Study	objectives	are	marked	with	corresponding	
numbers	in	the	circle.		
Figure 4‐1  Framework of the study 
	
ESRD=end-stage renal disease 
The	disease	management	programme	in	this	study	is	viewed	as	an	intervention	
to	facilitate	access	to	a	high‐cost	treatment.	Objective	1	describes	the	
development,	rationale,	design,	and	application	of	the	RRT	Thai	disease	
management	programme	at	both	the	national	and	regional	levels.	Also,	it	
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defines	the	contextual	environment	and	linkages	within	the	programme	and	
between	other	components	in	the	health	system. 
Objective	2	explores	outputs	and	outcomes	of	the	RRT	programme,	which	are	i)	
patterns	of	access	to	services,	in	terms	of	new	registrations	for	the	programme,	
and	ii)	mortality	of	patients	with	an	ESRD	diagnosis	both	for	overall	patients	
and	patients	who	were	maintained	on	RRT	in	the	programme	and	then	
identifies	their	changing	patterns	overtime.	
Finally,	Objective	3	carries	out	long	term	projections	to	support	policy,	
planning,	and	decision‐making	regarding	the	burden	on	the	health	care	budget.	
It	quantifies	the	long	term	needs	of	the	RRT	programme	in	terms	of	number	of	
future	patients,	estimates	budget	needs	of	the	programme	from	the	perspective	
of	a	health	care	payer,	and	draws	conclusions	on	the	financial	implications	for	
the	next	ten‐year	period.	
4.3 Justification of tracer to study effects of disease management 
programme  
Renal	replacement	therapy	has	been	chosen	as	a	tracer	for	assessing	the	disease	
management	approach	when	including	a	high‐cost	treatment	in	the	benefit	
package	for	three	reasons;	
1) High‐cost	condition	
With	only	a	small	number	of	patients,	end‐stage	renal	disease	accounts	for	a	
significant	percentage	of	health	care	expenditure.	Costs	of	renal	replacement	
therapy,	whether	transplant	or	dialysis	and	essential	medications,	can	drive	a	
patient	or	a	household	without	insurance	coverage	into	impoverishment	
(Wyszewianski	1986).		
2) Policy	making	process		
Before	the	commencement	of	the	RRT	benefit,	there	were	actions	from	several	
entities,	both	inside	and	outside	government,	to	embrace	the	benefit	in	the	UCS	
health	care	basket.	They	involved	individual	leadership	and	strong	
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relationships	among	the	scholars,	civil	society,	and	politicians.	These	actions	
provided	important	practical	evidence	of	the	benefits	of	including	a	high‐cost	
treatment	in	the	benefit	package	in	the	context	of	a	developing	country.	
3) Disease	management	approach	of	the	UCS	
The	disease	management	approach	was	applied	to	the	implementation	and	
service	provision	of	the	RRT	programme.	In	the	UCS,	RRT	is	one	of	the	few	
disease	management	programmes	that	has	all	the	basic	elements	of	chronic	
disease	management.	They	include	for	instance,	design	of	the	service	delivery	
system,	self‐management	support,	use	of	a	guideline	protocol,	and	community	
support.	Other	so‐called	UCS	disease	management	programmes	have	only	a	few	
components	and	are	more	likely	to	focus	on	central	bargaining	for	purchases	of	
medicines	or	medical	devices,	not	the	arrangements	of	service	delivery.		
4.4 Methodology 
This	study’s	methodology	combines	multiple	approaches	to	answer	the	
research	questions.	The	methodology	section	is	divided	into	three	subsections	
according	to	each	objective.	Objective	1	incorporates	a	set	of	qualitative	
methods,	which	are	document	review,	semi‐structured	interview,	focus	group	
discussion,	and	structured	observation.	These	are	then	triangulated	to	draw	
conclusions.	The	method	for	objective	2	is	an	age‐period‐cohort	analysis	based	
on	UCS	databases.	The	method	for	objective	3	is	a	time‐series	projection	of	RRT	
patients	and	cost	modeling	of	the	RRT	programme	expenditure.	Findings	from	
all	three	methods	are	brought	together	and	used	to	formulate	policy	
implications	and	recommendations	for	future	research.		
In	the	data	analysis,	a	range	of	computer	software	was	employed.	For	
quantitative	analysis,	this	included	MS	Excel,	Stata,	and	R‐studio.	For	qualitative	
analysis,	MS	Word	and	Nvivo	were	used.			
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4.4.1 Objective 1: The rationale behind and the application of the disease 
management approach in the RRT programme 
Method of objective 1: qualitative approaches of document review, semi-
structured interview, focus group discussion, and structured observation 
Objective	1	describes	the	RRT	disease	management	system.	Collected	data	were	
analysed	thematically	by	using	multiple	data	sources	including	reviews,	
interviews,	a	focus	group	discussion,	and	observations.	Relevant	findings	were	
further	used	to	explain	RRT	programme	outputs	and	outcomes	in	greater	detail,	
in	addition	to	the	quantitative	analysis	of	objective	2.	Also,	interviews	with	
policy	makers	provided	possible	future	scenarios	for	budget	predictions	in	
objective	3.		
4.4.1.1 Document review  
The	document	review	was	conducted	to	understand	the	background	and	
operation	of	the	RRT	programme	and	how	the	programme	was	organised	
within	the	NHSO.	Document	reviews	also	provided	an	inside	picture	of	the	RRT	
programme	that	might	not	be	directly	observable.	In	addition,	it	helped	
formulate	questions	for	interviewing	and	developing	an	observation	guide,	as	
well	as	for	developing	data	collection	tools	for	the	next	study	objectives.	
The	review	of	documents	was	a	secondary	data	collection	procedure.	Many	
types	of	documents	such	as	annual	reports,	clinical	guidelines,	newspaper	
clippings,	newsletters,	and	the	constitution	were	available	online.	Key	words	
related	to	the	policy	change	of	the	RRT	programme	were	used	as	search	terms,	
these	included:	“dialysis	benefit”,	“kidney	disease	benefit”,	“chronic	kidney	
disease	patients”,	“renal	replacement	therapy”,	“universal	coverage	scheme”,	
and	names	of	people	or	entities	involving	in	the	policy	change	of	the	RRT.	Some	
documents	were	later	given	by	interviewees,	which	included	meeting	minutes	
and	research	studies	and	reports.	
Retrieved	documents	were	selected	according	to	the	study’s	framework	and	
then	read	by	the	main	investigator	to	input	data	for	the	analysis.	Document	
review	also	helped	generate	new	interview	questions,	and	the	development	of	
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the	observation	checklist	for	assessing	the	quality	of	patient’s	self‐care	
technique.    
4.4.1.2 Semi-structured interview and focus group discussion 
In	order	to	understand	the	arrangements	of	the	RRT	programme	in	the	central	
NHSO	and	implementation	of	the	RRT	programme	itself,	perceptions	and	
practices	of	interviewees	at	various	levels	were	assessed	from	semi‐structured	
interviews	and	focus	group	discussion.		
i. Study sites 
There	were	three	sites	of	data	collection:	central	NHSO,	Bangkok;	Phitsanulok	
province;	and	Kampangpet	province,	Figure	4‐2.	The	central	NHSO	was	where	
the	RRT	programme	was	formulated	and	administered.	This	site	also	included	
NHSO’s	supporting	functions	such	as	professional	body	of	the	nephrologists	and	
patient	representatives	who	act	in	NHSO’s	sub‐committee	boards	or	designing	
the	monitoring	process	of	the	RRT	programme.		
In	Phitsanulok	province,	the	regional	NHSO	and	a	large‐sized	university	hospital	
were	selected	to	represent	provisions	of	the	RRT	programme	at	the	regional	
level.	The	selection	criteria	for	the	hospital	were	1)	had	enough	capacity	to	
provide	all	three	modes	of	renal	replacement	therapy,	2)	the	catchment	area	
had	a	mixture	of	urban	and	rural	characteristics,	and	3)	willingness	of	providers	
to	participate.	
A	community	hospital	in	Kampangpet	province	was	selected	to	represent	the	
context	of	conservative	therapy	(living	without	dialysis	or	kidney	transplant)	in	
chronic	kidney	disease.	The	hospital	was	selected	to	be	one	of	the	study	sites	
because	a	number	of	informants	noted	that	it	offered	patients	with	chronic	
kidney	disease	palliative	care	via	a	multidisciplinary	team.	The	hospital	is	at	
district	level,	located	approximately	115	kilometres	southwest	from	the	
University	Hospital	in	Phitsanulok.	Although	the	hospital	itself	has	no	capacity	
to	provide	dialysis	services,	there	are	more	than	150	ESRD	patients	living	in	its	
area	who	are	undergoing	conservative	therapy.	This	study	site	provided	wider	
insights	into	patients’	decision	making	since	patients	who	go	to	large	size	
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Table 4‐1  Selected characteristics of Phitsanulok and Kampangpet 
Province Population1/ 
Average 
household 
size2/ 
Monthly income 
(THB)*3/ 
               No. RRT unit4/ 
           HD                     PD 
Phitsanulok 858,988 3.0 27,490 7 2 
Kampangpet 729,522 3.3 22,083 2 1 
The whole kingdom 65,124,716 3.2 25,194 533 102 
*Average monthly income per household in Thai Baht, based on the Household Socio - Economic Survey 
Source: 1/National Statistic Office (2014) available from 
 :http://service.nso.go.th/nso/nso_center/project/search_center/23project-th.htm 
2/National Statistic Office (2010) available from: http://popcensus.nso.go.th/upload/popcensus-08-08-55-E.pdf  
3/National Statistical Office (2010) available from:http://service.nso.go.th/nso/web/statseries/statseries11.html 
4/Thai RRT report (2012) available from: http://www.nephrothai.org/trt/trt.asp?type=TRT&news_id=418 
ii. Selection of interviewees 
In	order	to	collect	a	wide	range	of	information,	it	was	necessary	to	select	a	mix	
of	interviewees	from	different	roles	in	the	RRT	system.	They	included	
individuals	who	played	key	roles	in	developing	RRT	policy,	working	to	support	
the	RRT	system,	and	ESRD	patients.	Policy	makers	and	frontline	staff	were	
identified	by	their	positions,	while	patients	were	chosen	by	the	snowballing	
technique.	Patients	were	divided	into	four	types	according	to	their	treatment	
(the	three	RRT	modalities	and	one	non‐RRT	user	who	had	ESRD	and	was	
eligible	for	the	treatment	but	refused	to	have	it),	Figure	4‐3.	
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Figure 4‐3  Interviewees in different roles with methods of data collection  
	
NHSO=National Health Security Office, PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant 
iii. Tools 
A	checklist	of	questions	was	used	to	collect	information	from	interviews	and	the	
focus	group,	see	Appendix	2.	This	included	questions	to	elicit	opinions	on	high‐
cost	diseases	and	various	areas	of	the	RRT	programme.	These	questions	were	
developed	from	the	literature	review	on	high‐cost	conditions	and	caring	for	
patients	with	chronic	conditions,	for	example,	the	commentary	article	of	
Wyszewianski	(1986)	and	the	book	edited	by	Nolte	and	McKee	(2008).	A	
summary	of	questions	that	were	asked	to	each	group	of	interviewees	is	shown	
in	Table	4‐2.	Questions	might	be	slightly	adjusted	in	order	to	suit	the	context	of	
different	respondents.	All	conversations	were	recorded	and	were	later	
transcribed	in	Thai	for	data	analysis.	
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Table 4‐2  Summary of areas of questions and groups of informants to be asked 
ESRD=end-stage renal disease, RRT=renal replacement therapy, PD=peritoneal dialysis	
Area of question Issues of interest 
NH
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Me
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1. Perception of high-
cost diseases 
What kind of diseases/conditions 
that can cause a burden on 
patients when paying for health 
care costs? Have you ever 
experienced this issue and what 
was your response? 
     
2. Purpose of the  RRT 
programme 
Why ESRD is selected to be 
managed separately? 
How to select a disease/condition 
to be managed?  
 
 
 
    
3. Design of the RRT 
programme 
Why disease management and  
the PD-first are used?	      
4. Process of the RRT 
programme 
What is the patients’ journey? 
How about 
• patient selection 
• patient self-care education 
• reporting system 
• practice 
guideline/protocol? 
 
 
 
 
  
 
 
 
5. (For patients only) 
decision making 
Who made decision about getting 
in the programme? If chose not to 
get in, why? 
     
6. (For patients only) 
care costs and quality 
of life 
Do you have to pay anything to 
receive dialysis? 
How is quality of your life at the 
moment? 
     
 
 
7. Links between RRT 
programme and other 
components 
What are linkages between levels 
of care and within the health 
system? 
How do they work together? 
     
8. Programme 
implications 
 
After the programme started, what 
has been changed in your 
perception/experience? 
What are concerns of the 
programme in the future? 
What is the perceived success of 
the programme? 
What are programme’s barriers to 
success/access? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
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Where	interviewees	were	patients,	it	was	important	to	know	whether	they	
presented	characteristics	that	correlate	to	the	need	for	the	high‐cost	treatment	
and	whether	health	care	costs	pose	a	burden	on	them.	In	order	to	establish	this,	
a	range	of	questions	relating	to	individual	characteristics	and	other	factors	
influencing	health	service	use	(as	described	by	Aday	and	Andersen	(1974)	were	
asked.	They	included	1)	demographic	character:	age	and	chronic	illness,	2)	
social	structure:	education,	occupation,	income,	and	household	size,	3)	other	
factors:	health	belief	and	coverage	of	health	insurance.	
iv. Data collection 
After	the	interviewees’	permission	was	granted,	the	investigator	made	an	
appointment	either	by	a	phone	call	or	a	letter,	or	both	if	required	by	the	
interviewee.	Interviews	were	conducted	at	interviewee’s	workplaces.	If	they	
were	a	patient,	dialysis	nurses	helped	investigators	arrange	appointments	by	
phone	calls	or	asking	directly	while	patients	were	on	dialysis	care	in	the	
hospital.	As	each	HD	patient	has	to	spend	at	least	four	hours	on	a	hemodialysis	
unit,	all	HD	patients	asked	the	investigator	to	carry	out	the	interview	during	this	
time.	Since	PD	patients	are	on	home‐based	dialysis,	interviewing	at	their	houses	
suited	them	better.	Once	a	PD	patient	agreed,	the	investigator	went	to	the	
patient’s	house	for	an	interview	along	with	an	observation.	For	PD	patients	who	
lived	far	away	or	had	never	met	the	investigator	in	the	RRT	unit,	interviews	
were	accompanied	by	a	PD	nurse	or	an	NHSO	officer.	Patients	who	had	opted	
out	were	invited	to	be	interviewed	at	the	community	hospital.	Each	interview	
lasted	30‐45	minutes.		
A	focus	group	discussion	was	conducted	with	the	multidisciplinary	team	in	
Klongklung	hospital.	The	multidisciplinary	team	consisted	of	six	healthcare	
professionals	including	a	general	practitioner,	nurses,	a	pharmacist,	a	
nutritionist,	and	a	physiotherapist.	The	aim	of	the	focus	group	discussion	was	to	
identify	the	link	between	patients	and	their	healthcare	providers.		
The	data	collection	team	consisted	of	two	main	persons:	the	main	investigator	
and	a	research	assistant.	The	research	assistant	was	a	registered	nurse	with	a	
doctoral	degree	in	health	policy.	Her	main	roles	in	this	study	were	arranging	
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appointments	with	informants	and	accompanying	interviews.	Before	
interviewing,	the	team	was	briefed	on	each	interviewee’s	background	and	
questions	to	be	asked.	After	the	interview	was	finished,	the	team	shared	their	
opinions	about	the	interview’s	tone	and	key	messages	given	by	the	interviewee.		
There	was	no	compensation	for	interviewees.	Dialysis	nurses	and	NHSO	officers	
who	helped	with	communications	and	arrangements	for	interviews	with	other	
interviewees	were	given	compensations	which	were	enough	to	cover	
communication	costs	(such	as	travel	cost	and	phone	calls)	and	their	time	spent.	
These	amounts	were	in	accordance	with	local	practice.		
4.4.1.3 Structured observational study 
Being	able	to	independently	prepare	and	conduct	PD	with	or	without	assistance	
from	carers	is	an	indicator	of	the	success	of	the	PD‐first	policy.	Under	the	policy,	
NHSO	hopes	to	see	patients	having	good	health	outcomes	and	quality	of	life	
(NHSO	2013).	A	number	of	studies	have	demonstrated	that	a	positive	patient	
background	was	a	major	determinant	of	overall	quality	of	life	for	dialysis	
patients.	These	factors	may	include	for	example	gender,	comorbidity,	social	
deprivation,	time	on	RRT,	and lifestyle	provided	by	the	RRT	modality	(Hart	and	
Evans	1987;	Cameron,	Whiteside	et	al.	2000).	An	observation	study	was	
conducted	to	investigate	patients’	characteristics	and	ability	to	perform	self‐
care	PD	(so‐called	home	dialysis).	It	allowed	the	researcher	to	develop	a	deeper	
understanding	of	how	patients	managed	self‐care	and	how	it	might	affect	a	
patient’s	everyday	life.	
i. Patient 
Patients	were	selected	from	the	catchment	area	of	the	University	Hospital.	
Criteria	used	to	selected	samples	were:	1)	having	been	registered	with	the	
NHSO’s	PD	programme	for	at	least	3	months7,	2)	aged	between	20	and	89	years,	
and	3)	willingness	to	participate	in	the	study.	The	PD	nurse	was	asked	to	
identify	10	UCS	patients	who	matched these	criteria.		
																																																								
7Within a three-month period, a new patient is expected to be keen enough to independently perform PD. 
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ii. Tool 
Based	on	the	guideline	for	peritoneal	dialysis	(Busapavanich	2009),	a	checklist	
containing	key	points	to	observe,	main	behaviours,	and	environmental	domains	
relating	to	the	procedure	of	PD	were	used.	The	full	checklist	is	provided	in	
Appendix	3.	In	summary,	the	things	to	observe	were:		
 Features	of	house,	area	to	perform	dialysis,	and	storage	of	dialysis	
solution.	
 Practices	of	changing	bag	and	aseptic	technique.	
iii. Data collection 
Approaching	a	patient	
After	collating	the	list	of	potential	participants,	the	PD	nurse	who	acted	as	the	
patients’	case	manager	made	a	phone	call	to	each	patient	asking	for	the	patient’s	
agreement	to	be	observed	and	interviewed.	PD	patients	were	then	interviewed	
and	at	the	same	time,	their	PD	practices	were	observed	at	their	houses.	There	
were	some	patients	scheduled	for	a	follow‐up	in	the	week	of	data	collection.	In	
this	case,	patients	were	interviewed	in	the	RRT	unit	and	asked	if	the	
observation	team	could	go	to	observe	their	PD	practices	at	their	houses	in	the	
following	day.		
The	main	investigator’s	duties	were	interviewing	the	patient	and	taking	field	
notes	while	the	research	assistant	did	the	observation	checklist	and	noted	her	
personal	impressions.	After	each	observation	and	interviewing,	the	team	
discussed	what	each	member	thought.	
Implementing	data	collection	
In	general,	a	PD	patient	has	dialysis	7	days	a	week,	4	times	a	day	(at	6AM,	noon,	
4PM,	and	10PM	approximately).	One	bag	exchange	procedure	lasts	30‐40	
minutes.	For	these	reasons,	the	team	could	observe	up	to	2‐3	patients	a	day	at	
noon	and	at	4PM	appointments.	The	data	collection	period	was	13‐19	August	
2014.	Patients	were	asked	consent	to	being	observed,	tape	recorded,	
photographed,	and	to	having	the	information	used	in	the	research.	All	agreed.				
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4.4.1.4 Data analysis 
Thematic	analysis	was	conducted	to	understand	the	system	of	RRT.	Interviews	
and	the	focus	group	discussion	were	transcribed	verbatim	into	a	Microsoft	
Word	document,	in	Thai,	by	an	independent	transcriber.	Collected	information	
including	tape	records,	photos,	and	interview	transcripts	were	later	brought	to	
Nvivo	software	(version10)	for	data	management	and	analysis	purposes.	The	
documentary	data	were	analysed	together	with	data	from	interviews,	the	focus	
group	discussion,	and	observations,	so	that	themes	would	emerge	across	all	sets	
of	data.	
Coding	process	
A	primary	set	of	codes	was	developed	from	the	study	framework.	The	set	was	
then	used	to	analyse	data	collected	from	the	fieldwork.	Initial	coding	or	pre‐set	
coding	was	defined	before	the	interviews	began	and	was	accompanied	by	
subcategory	codes.		
A	subcategory	code	is	a	set	of	codes	embedded	in	a	main	category.	After	going	
through	the	very	first	interviews	(and	observations),	initial	codes	were	
reviewed	and	revised	in	order	to	allow	a	new	set	of	codes	to	emerge	from	the	
real	fieldwork.	Codes	were	revised	and	compared	to	each	other	and	to	collected	
information	in	order	to	generate	a	coding	framework	for	data	analysis,	
Appendix	4.	
4.4.1.5 Potential bias from investigators and the data collection 
process 
There	was	scope	for	investigators	and	the	data	collection	process	to	produce	
biased	results,	particularly	in	interviews	and	observations.	Before	each	of	these	
latter,	investigators	informed	each	participant	about	the	study’s	aim	(to	
describe	the	RRT	programme’s	arrangements	and	further	to	assess	the	
programme’s	outputs	and	outcomes).	For	this	reason,	policy	makers	who	
designed	the	RRT	programme	might	want	to	present	positive	results	to	
investigators	and	conceal	the	downside	of	the	programme.	Providers	tended	to	
report	what	they	should	do	but	less	on	what	was	actually	done.	Patient	
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informants	might	not	report	all	negative	feelings	about	providers,	and	because	
of	Thai	cultural	norms	they	were	unlikely	to	reveal	their	true	feelings,	especially	
about	suffering.	Archival	documents	might	have	some	limitations	in	terms	of	
the	accuracy	and	completeness	of	the	data.	Further	access	to	more	documents	
could	be	unlikely.	In	observations,	patients	who	were	observed	might	change	
their	self‐care	practices	as	a	result	of	being	studied.		
4.4.1.6 Validity and reliability 
The	analysis	process	employed	three	methods	to	reduce	bias	and	improve	the	
validity	of	the	qualitative	research.	These	included	1)	triangulation	which	
compared	results	from	document	reviews,	interviews,	and	observations;	2)	
respondent	validation	which	involved	telephoning	or	asking	interviewees	to	
give	feedback	on	some	part	of	the	findings;	and	3)	attention	to	negative	cases	
which	seemed	to	contrast	with	the	general	pattern.	This	study	sought	to	
reexamine	and	explain	these	cases	until	there	was	no	new	theme	emerged.		
There	was	a	pretesting	for	questions	and	points	to	be	observed	prior	to	the	real	
interviews	and	observations.	After	the	pre‐test,	investigators	had	a	discussion	
to	see	if	any	adjustments	were	necessary.		
4.4.1.7 Research ethics 
i. Ethical approval 
Ethical	applications	were	submitted	to	the	London	School	of	Hygiene	and	
Tropical	Medicine	(LSHTM)	ethical	committee,	and	to	two	ethical	committees	in	
Thailand,	namely	the	Institute	for	the	Development	of	Human	Research	
Protections	(IHRP)	and	the	Khon	Kaen	University	Ethics	committee	for	Human	
Research,	see	Appendix	5.		
ii. Consent 
Permission	request	letters	with	information	sheets	and	consent	forms	were	
sent	to	the	NHSO	and	hospital	administrators	two	weeks	before	interviews	
started.	Before	each	interview	started,	the	interviewee	was	asked	to	read	and	
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sign	the	information	sheet	and	consent	form	in	order	to	give	permission	for	the	
interview	and	photography.	This	action	conformed	to	the	guidelines	of	the	
British	Medical	Journal	(1998,	316,	10091011).	All	forms	were	translated	into	
Thai	by	the	investigator.	Participants	were	informed	that	they	could	withdraw	
from	the	study	at	any	time	without	giving	a	reason.	
Some	patient	participants	felt	uncomfortable	about	signing	the	forms.	This	
might	be	because	patients	were	worried	about	what	would	happen	after	
signing.	Instead,	the	investigator	read	the	consent	and	asked	whether	the	
patient	allowed	the	team	to	interview,	voice	record	(and/or	take	pictures),	and	
to	quote	their	words	in	the	report	anonymously.	All	patients	said	that	was	fine.	
These	conversations	were	recorded	as	a	verbal	agreement	from	patients.	
iii. Confidentiality and anonymity 
Confidentiality	and	anonymity	were	central	to	this	study’s	practices.	
Participants	were	interviewed	or	observed	in	a	private	room	or	private	location	
to	ensure	their	privacy.	Each	participant	was	identified	using	a	code	which	
refers	to	their	role.	PM	refers	to	a	policy	maker,	PV	refers	to	a	provider,	PD	and	
HD	refer	to	peritoneal	dialysis	and	hemodialysis	patients	respectively,	KT	and	
OO	stand	for	kidney	transplant	and	opted‐out	respectively.	Note	that	some	
participants	have	more	than	one	role.	For	example,	a	health	care	provider	also	
acted	as	a	policy	maker	and	a	patient	had	another	role	as	policy	maker.	All	
participants	had	the	right	to	access	information	that	related	to	them,	and	to	be	
provided	with	a	copy	of	the	information	on	request.	
Investigators	made	every	effort	to	protect	participants’	confidentiality	and	
anonymity.	All	forms	of	information	given	in	this	study,	such	as	quotes	and	
pictures,	are	anonymised	or	otherwise	presented	so	that	participants	cannot	be	
traced	back.	Access	to	such	information	will	be	restricted	to	the	primary	
investigator	and	will	be	destroyed	five	years	after	the	end	of	the	study.	
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4.4.2 Objective 2: The changing patterns of access to service and 
mortality of ESRD patients overtime 
Method of objective 2: Age-period-cohort analysis based on administrative 
data of the National Health Security Office  
This	method	focuses	on	the	longitudinal	assessment	of	the	renal	replacement	
therapy	programme	(RRT)	in	terms	of	access	to	the	programme	and	mortality.	
Access	to	the	RRT	programme	was	represented	by	registration	for	the	
programme.	Mortality	is	one	of	the	indicators	used	to	measure	population	
health	outcomes.	In	this	study,	mortality	referred	to	all‐cause	mortality,	
assessed	in	both	groups	of	patients	who	were	maintaining	RRT	and	overall	end‐
stage	renal	disease	(ESRD)	patients.		
4.4.2.1 Justification of using the age-period-cohort analysis 
Regarding	changing	patterns	of	birth,	morbidity,	and	mortality,	it	is	important	
to	account	for	three	factors:	age,	period,	and	cohort.	Age	effects	are	defined	as	
variations	associated	with	biological	and	social	processes	of	aging.	They	
represent	development	of	changes	across	individuals’	life	times.	Period	effects	
are	defined	as	variations	over	time	periods	that	affect	everyone	equally,	
regardless	of	age	or	birth	cohort.	These	variations	can	be	an	immediate	change	
of	any	event	such	as	economic	crisis,	endemic,	and	health	care	treatment	or	
intervention.	Cohort	effects	can	be	characterised	by	changes	that	individuals	
experienced	in	early	life.	Members	of	the	same	cohort	group	age	together	and	
share	similar	historical	and	social	events	at	the	same	ages	(Yang	and	Land	
2008).	For	these	reasons,	cohort	effects	are	sometimes	referred	as	longitudinal	
effects	and	period	effects	are	known	as	cross‐sectional	effects	(Clayton	and	
Schifflers	1987).	
	
Conventional	models	are	solely	based	on	assessment	of	age,	yet	ignoring	effects	
of	cohort	and	period	could	result	in	misinterpretation	of	results.	This	is	because	
such	effects	can	be	a	mixed	consequence	of	various	time‐related	factors.	To	give	
an	example,	older	age	groups	and	older	generations	experience	higher	
mortality,	and	consequently,	dominate	the	overall	death	rate	and	mask	real	
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events	occurring	in	recent	age	groups	and	cohorts.	Age	period	cohort	analysis	is	
one	approach	that	allows	us	to	separate	the	effects	of	age,	period,	and	cohort	
through	a	statistical	model	and	to	understand	why	disease	trends	change	over	
time	by	taking	account	of	such	three	variables	(Glenn	2005).		
4.4.2.2 Data source 
This	method	used	four	databases.	Three	databases	were	obtained	from	the	
NHSO	and	were	collected	from	health	care	facilities	all	over	the	country.	They	
were:	inpatient,	outpatient,	and	renal	replacement	therapy	(hemodialysis	and	
peritoneal	dialysis).	The	NHSO	has	audit	procedures	to	ensure	quality	as	well	as	
prevent	duplicates	of	the	claims	data	at	both	central	and	regional	NHSO.	The	
last	database	used	in	this	study	was	mortality	data	which	was	obtained	from	the	
Ministry	of	Interior’s	civil	registration	system.	All	four	databases	keep	
information	at	the	individual	level	and	can	be	linked	together	by	using	the	13‐
digit	citizen	identification	number.	These	numbers	will	be	encoded	before	
handing	to	any	third	party.	
i. Inpatient database 
The	inpatient	database	provides	individuals’	profiles	(such	as	name,	date	of	
birth,	address,	occupation,	and	so	on)	and	individuals’	health	information	while	
they	are	hospitalised	(such	as	diagnoses,	care	given,	medications,	laboratory	
tests,	hospital	code,	and	admission/discharge	date).	The	inpatient	database	
consisting	of	18	sub‐files	was	well	designed;	its	structure	has	rarely	been	
changed	since	the	beginning	of	the	UCS.	A	patient’s	diagnosis	is	the	compulsory	
field	since	the	NHSO	has	to	calculate	the	relative	weight	for	the	diagnosis	
related	group	(DRG)	payment.	
ii. Outpatient database 
The	outpatient	database	contains	patient‐level	information	including:	
individuals’	profile	and	their	ambulatory	visits,	such	as	outpatient,	
accident/emergency,	prevention/promotion	programmes,	referral,	and	
medications.	Because	of	this	diversity,	the	structure	and	details	of	the	database	
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have	been	adjusted	several	times	and	became	quite	stable	from	2012.	Currently	
the	outpatient	database	consists	of	21	sub‐files.	It	is	noted	here	that	outpatient	
data	used	in	this	study	was	from	the	period	2008	to	2013,	while	data	from	the	
inpatient	database	was	taken	from	2005	to	2013.	
iii. RRT database 
Renal	replacement	therapy	databases	can	be	divided	into	three	categories	
according	to	the	three	modalities	of	RRT	available	under	the	NHSO’s	disease	
management.	These	are	1)	peritoneal	dialysis,	2)	hemodialysis,	and	3)	renal	
transplant.	These	three	databases	are	separately	kept	and	administered.	All	
RRT	units	are	obliged	to	use	these	databases	in	activities	regarding	RRT	service	
provision,	such	as	patient	registration,	records	of	given	services,	medications,	
and	laboratory	tests.		
iv. Mortality database 
The	mortality	database	was	obtained	from	the	Ministry	of	Interior’s	civil	vital	
registry.	Data	from	the	civil	vital	registry	have	been	computerised	since	1980	
and	use	ICD‐10	as	diagnosis	code	to	identify	causes	of	death.	One	drawback	of	
the	mortality	database	is	the	reliability	of	the	reported	causes	of	death.	The	
majority	of	deaths	(about	65%)	in	Thailand	occur	outside	hospitals	and	in	the	
absence	of	medical	examiners.	In	most	cases,	causes	of	these	deaths	are	
recorded	by	nonmedical	civil	registrars	based	on	lay	reports	from	relatives,	
occasionally	informed	by	medical	opinion	obtained	during	the	illness	leading	to	
death	(Tangcharoensathien,	Faramnuayphol	et	al.	2006).	Even	in	the	case	of	
deaths	which	occurred	in	hospitals,	a	study	in	Thailand	reviewed	cause‐of‐
death	certificates	and	compared	to	the	patients’	medical	record	found	that	51%	
of	deaths	contained	certification	errors	(Pattaraarchachai,	Rao	et	al.	2010).	
Additionally,	ESRD	patients	usually	suffer	from	multiple	illnesses,	therefore	
ESRD	may	not	be	reported	as	their	cause	of	death.	For	these	reasons,	this	
current	study	avoided	bias	by	using	all‐cause	of	death	instead	of	cause‐specific	
death.	
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4.4.2.3 Cohort selection  
Cohorts	in	this	study	were	limited	to	adult	UCS	members	aged	20	to	89	who	
were	diagnosed	with	ESRD.	ESRD	patients	were	selected	from	patients	who	had	
ICD‐10	code	N180	or	N1858	in	either	primary	diagnosis	or	secondary	diagnosis	
in	NHSO	databases.	The	patient’s	first	hospitalisation	or	first	visit	with	end‐
stage	renal	disease	diagnosis	(ICD‐10=N180	or	N185)	in	the	obtained	databases	
were	used	to	define	the	point	at	which	a	patient	started	having	end‐stage	renal	
disease.		
There	are	few	ESRD	patients	younger	than	20	or	older	than	90	years,	patients	
outside	these	age	groups	give	unstable	rates	and	may	affect	the	reliability	of	
analyses,	therefore	they	are	not	included	in	the	analyses	of	this	study.		
To	assess	registration	rates	of	the	RRT	programme,	the	study	period	was	1	
January	2008	to	31	December	2013.	The	follow	up	period	for	assessing	death	
rates	was	from	1	January	2005	to	31	December	2013,	except	the	death	rate	
among	RRT	patients,	data	were	collected	from	1	January	2008	to	31	December	
2013.	Censoring	for	deaths	was	at	the	end	of	the	data	collection	period	(31	
December	2013).	
4.4.2.4 Variables  
Three	main	variables	in	this	study	(age,	period,	and	cohort)	were	modelled	in	
terms	of	the	year	unit.	Age	of	the	entry	into	the	RRT	programme	model	was	
determined	by	the	time	between	the	year	of	birth	and	the	year	of	registration	in	
the	programme,	and	age	in	the	mortality	model	referred	to	the	time	between	
the	year	of	birth	and	the	year	of	death.	The	period	in	all	models	denoted	
calendar	years	of	studied	period	and	cohort	was	the	individuals’	years	of	birth.	
In	entry	into	the	RRT	programme	models,	the	three	modalities	of	RRT	were	
separately	used	as	covariates.		
																																																								
8 The ICD10 code for ESRD stage 5 was changed to N185 in April 2012. 
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4.4.2.5 Data analysis 
Data	were	analysed	in	two	ways;	descriptive	analysis	and	age‐period‐cohort	
analysis.	Each	analysis	is	presented	in	two	sections	according	to	the	two	
models:	entry	into	the	RRT	programme	model	and	mortality	model.	Within	the	
entry	into	the	RRT	programme	model,	the	three	modalities	of	renal	replacement	
therapy	are	separately	presented.	
i. Descriptive analysis 
According	to	Carstensen	(2005),	before	conducting	the	age‐period‐cohort	
analysis,	it	is	important	to	look	at	rates	of	observed	events	and	explore	whether	
rates	are	proportional	between	periods	or	cohorts.		
In	the	descriptive	analysis,	age	groups	were	first	tabulated	against	the	calendar	
year	(or	referred	to	as	period)	and	the	year	of	birth	(or	referred	to	as	cohort)	to	
display	numbers	of	events	(either	numbers	of	registration	of	each	modality	or	
deaths).	Next,	numbers	of	events	(registrations	or	deaths)	were	computed	as	
rates	and	then	graphically	presented	as	rates	for	age	at	registration	(or	age	at	
death),	for	calendar	year,	and	for	birth	cohort.		
Descriptive	analyses	of	this	study	provide	four	classical	plots:	
a) Rate	versus	age	and	period:	observations	within	each	period	are	
connected,	
b) Rate	versus	age	and	period:	observations	within	each	birth	cohort	group	
are	connected,	
c) Rate	versus	period	and	age:	observations	within	each	age	group	are	
connected,	and	
d) Rate	versus	cohort	and	age:	observations	within	each	age	group	are	
connected.	
The	first	(a)	and	the	third	(c)	plots	will	exhibit	fairly	parallel	lines	if	age‐specific	
rates	are	proportional	between	periods	in	the	graphs.	The	second	(b)	and	the	
fourth	(d)	plots	will	also	show	fairly	parallel	lines	if	rates	are	proportional	to	
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cohorts.	These	plots	can	be	used	as	the	first	overview	of	the	data	but	may	not	
reflect	the	result	of	the	entire	analysis	(Carstensen	2005).		
In	mortality	models,	age‐standardised	mortality	rates	(ASMR)	for	UCS	patients	
aged	20‐89	years	who	were	on	RRT	and	those	of	overall	patients	who	had	ESRD	
diagnosis	are	presented.	All	ASMRs	were	calculated	using	the	World	Health	
Organization’s	world	population	in	the	year	2000	as	the	standard.	
ii. Age-period-cohort analysis 
The	general	form	of	the	age‐period‐cohort	model	for	rates	(a,	p)	is:	
ln [(a, p)]   =   f(a) + g(p) + h(c) 
where	f,	g	and	h	are	functions,	and	a,	p	and	c	are	age,	period	and	cohort	
respectively.	This	model	can	be	used	to	predict	the	incidence	or	mortality	rate	
for	any	combined	effect	of	age,	period,	and	cohort.	However,	due	to	the	direct	
relationship	between	the	terms	where	date	of	registration	(or	death)	is	the	sum	
of	the	date	of	birth	and	the	age	at	death	(or	death),	p=c+a,	there	will	be	a	
constraint	in	any	model	that	includes	these	three	variables	on	a	linear	scale.	
Consequently,	the	components	of	this	model	cannot	be	directly	determined	by	
conventional	linear	regression	(Clayton	and	Schifflers	1987;	Carstensen	2007;	
Yang	and	Land	2008).		
Age,	period	and	cohort	effects	need	to	be	modeled	in	order	to	separate	their	
effects.	Various	approaches	have	been	introduced	to	cope	with	the	so‐called	
identifiability	problem	(Clayton	and	Schifflers	1987;	Carstensen	2007;	Yang	and	
Land	2008).	Clayton	and	Schifflers	(1987)	described	an	approach	to	model	
mortality	rates	in	terms	of	age,	period,	and	cohort	over	time.	Their	proposed	
models	were	to	overcome	problems	of	the	constraint	in	any	model	which	
included	age,	period,	and	cohort	variables	on	a	linear	scale.	This	is	in	line	with	
Heuer	(1997),	Holford	(1983),	and	Carstensen	(2007)’s	parametisation	
technique.		
This	study	used	restricted	cubic	(natural)	splines	to	model	effects	of	age,	period,	
and	cohort	within	a	Generalised	Linear	Model	framework	with	a	Poisson	family	
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error	structure,	a	log	link	function	and	an	offset	of	log	(person	risk‐time)	which	
was	suggested	by	Carstensen	(2007).	This	was	done	by	adding	a	drift	term	(a	
combined	slope	for	period	and	cohort	effects)	with	a	selected	number	of	
parameters	(or	knots)	to	either	period	or	cohort	effect.	Placement	of	the	drift	on	
period	or	cohort	depended	on	the	subject	of	interest.		
In	this	study,	the	main	focus	was	on	the	effect	of	period,	therefore	the	drift	was	
allocated	to	the	period	variable.	In	the	analysis,	a	point	of	period	was	fixed,	and	
cohort	fitted	values	were	constrained	to	have	zero	slope.	Age	effect	was	then	
interpreted	as	age	specific	rate	regarding	the	reference	period.	
As	a	result,	the	age‐period	model	was	written	as	the	first	derivative	functions	of	
age,	f(a)	and	period,	g(p)as:	
    ln[(a,p)]  = f(a) + g(p) 
When	a	non‐linear	regression	model	is	estimated,	the	multiplicative	age‐period	
model	can	be	fitted	by	choosing	a	reference	period	p0	and	a	constraint	g(p0)=0.	
The	model	can	be	expressed	as	the	function	of	rate	as:	
    ln [(a,p)] = fp0 (a) +   (p-p0) + g(p); 
where	fp0	(a)	is	the	function	for	age,	denoting	age‐specific	rates	in	the	reference	
period,	p0;			is	the	slope	of	the	log‐linear	trend	in	period	(the	drift);	and	g(	p)	is	
the	period	function,	which	can	be	interpreted	as	a	log	relative	risk	of	any	period	
compared	to	the	reference	period,	p0.	
All	tabulations	of	cohorts	and	population,	descriptive	analysis,	and	age‐period‐
cohort	modelling	were	conducted	using	Stata	version	12.	Only	goodness‐of‐fit	in	
age‐period‐cohort	analyses	was	assessed	using	R	studio.	All	confidence	
intervals	are	95%	confidence	intervals.		
4.4.3 Objective 3  Long term projections of RRT population and 
payments of the RRT programme 
Method of objective 3: cost modelling and time-series projection of RRT 
population 
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The	method	of	this	study	involved	three	main	steps.	First,	the	study	modelled	
yearly	numbers	of	patients	in	the	three	RRT	modalities	into	the	future.	Next,	it	
estimated	the	annual	costs	of	the	RRT	programme	from	the	public	payer’s	
perspective	using	the	NHSO	claims	data.	Finally,	an	estimated	figure	of	the	
future	budget	needs	was	forecast.				
4.4.3.1 Forecasting numbers of RRT population 
This	section	looks	at	the	method	to	forecast	future	numbers	of	RRT	patients.	
The	auto‐regressive	integrated	moving	average	(ARIMA)	technique	was	taken	
to	develop	a	set	of	models	to	predict	numbers	of	patients	enrolling	in	the	RRT	
programme	by	each	modality:	PD,	HD,	and	KT.		
i. Data source 
Information	on	patients	who	registered	in	the	RRT	programme	(including	
peritoneal	dialysis,	hemodialysis,	and	functioning	kidney	transplant)	in	the	
period	of	fiscal	year	2008	to	2013	(1	October	2007‐30	September	2013)	were	
obtained	from	the	Disease	Management	System	of	the	NHSO.	The	data	
contained	claims	data	of	individuals,	for	example	encrypted	identification	
number,	modality	(PD,	HD,	or	KT),	registration	date,	exit	from	the	programme	
date	with	the	reason,	and	dispensed	medications.		
ii. Study population 
Patients	of	all	ages	who	were	registered	and	retained	in	the	RRT	programme	
between	the	fiscal	years	2008	and	2013	were	included.	This	study	also	
identified	anyone	who	had	modality	changes	including	kidney	transplant	during	
the	study	period.	It	excluded	patients	who	had	a	history	of	temporary	treatment	
with	hemodialysis	in	a	period	shorter	than	30	days	and	self‐pay	HD	patients.	KT	
patients	who	had	transplantation	before	the	RRT	programme	started	in	2008,	
although	they	received	free	erythropoietin	from	the	NHSO,	were	excluded.	Since	
the	RRT	programme	is	designed	to	cover	patients	with	chronic	kidney	disease,	
those	who	are	diagnosed	with	acute	renal	failure	are	not	included	in	the	
database.		
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iii. Data analysis 
This	study	employed	ARIMA	modelling	to	forecast	numbers	of	the	RRT	
population	by	RRT	modality	consisting	of	1)	peritoneal	dialysis,	2)	
hemodialysis,	and	3)	kidney	transplant.	In	order	to	construct	time	series	
datasets,	patient‐level	data	were	collapsed	into	a	monthly	basis	for	each	RRT	
modality.		
Time‐series	is	a	technique	that	can	be	used	to	predict	future	behaviour	of	a	
variable	of	interest	by	taking	previous	observations	as	the	basis.	The	analysis	of	
a	time‐series	model	does	not	count	on	various	independent	variables	that	may	
influence	the	variable	of	interest	(Linden,	Adams	et	al.	2003).	In	this	study,	
forecasting	models	are	used	to	predict	numbers	of	renal	replacement	therapy	
users	in	the	next	ten‐year	period.		
In	healthcare,	the	time‐series	modelling	technique	has	been	widely	used	in	
many	areas	such	as	medicine,	epidemiology,	and	health	services.	Generally,	
time‐series	analysis	is	used	to	discover	the	historical	pattern	in	data	series	and	
forecast	that	pattern	into	the	future	(Makridakis,	Wheelwright	et	al.	1998;	
Linden,	Adams	et	al.	2003).	There	are	many	categories	of	time‐series	technique,	
of	which	the	auto‐regressive	integrated	moving	average	(ARIMA,	so	called	Box‐
Jenkins)	is	shown	to	be	useful	when	the	series	exhibit	any	trend	or	seasonal	
variation	(Makridakis,	Wheelwright	et	al.	1998;	You,	Hoy	et	al.	2002;	Linden,	
Adams	et	al.	2003).		
A	stationary	series	is	the	key	feature	that	needs	to	be	accomplished	before	
fitting	an	ARIMA	model.	This	can	be	done	by	taking	first	differences,	that	is,	
making	a	new	series	of	the	present	value	less	the	past	value	(Xt	‐	Xt‐1).	After	a	
time	series	has	been	stationarised	by	differencing,	the	next	step	is	to	determine	
whether	AR	(autoregressive)	or	MA	(moving	average)	terms	are	needed	to	
correct	any	autocorrelation	that	remains	in	the	differenced	series	(Nau	2014).	
Numbers	of	AR	and	MA	terms	can	be	identified	by	looking	at	the	
autocorrelation	function	(ACF)	and	partial	autocorrelation	(PACF)	plots	of	the	
original	and	differenced	series.	An	ARIMA	model	is	always	represented	by	
ARIMA(p,d,q),	where	p	is	the	number	of	autoregressive(AR)	parameter,	d	is	the	
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order	of	differencing	(or	integration,	I)	needed	to	remove	the	non‐stationary	
from	the	series,	and	q	is	the	number	of	moving	average(MA)	parameter	(Linden,	
Adams	et	al.	2003).		
Makridakis,	Wheelwright	et	al.	(1998)	suggested	an	approach	which	was	
applied	to	Box‐Jenkins’	time	series	modelling.	They	propose	three	phases	of	
ARIMA	modelling;	Phase	1:	Identification,	Phase	2:	Estimation	and	testing,	and	
Phase	3:	Forecasting.	First,	the	identification,	the	data	are	plotted	against	time	
and	determined	if	a	transformation	of	the	data	is	needed	to	stabilise	the	
variance.	If	the	data	seem	non‐stationary,	the	first	differences	of	the	data	are	
taken	until	the	data	are	stationary.	Next,	the	estimation	and	testing,	when	the	
stationarity	has	been	achieved,	examine	the	autocorrelation	function	(ACF)	and	
partial	autocorrelation	(PACF)	plots	to	determine	numbers	of	appropriate	
AR(p)	or	MA(q)	terms	for	the	appropriate	model.	After	that,	the	chosen	
model(s)	is	fitted,	and	the	Akaike	Information	Criterion	(AIC)	is	used	to	
determine	a	better	model.	Then	the	residuals	from	the	chosen	model	are	
checked	by	plotting	the	ACF	of	the	residuals,	and	a	portmanteau	test	of	
residuals	conducted.	If	they	do	not	look	like	white	noise	(residuals	are	
uncorrelated	or	independently	distributed),	a	modified	model	is	tried	until	the	
white	noise	is	achieved.	Finally,	the	selected	model	can	be	used	to	calculate	
forecasts.	
4.4.3.2 Estimating annual costs of the RRT programme 
The	cost	of	the	RRT	programme	was	conducted	from	the	NHSO’s	perspective.	
Cost	objects	are	PD,	HD,	and	KT	for	the	one‐year	period.	Only	direct	costs	
accounting	for	RRT	services	were	included.	Indirect	costs	such	as	travel	costs	
and	other	costs	impacting	on	patients’	families	were	excluded.	The	RRT	
programme’s	claims	and	reimbursements	in	2014	were	acquired	from	the	
NHSO.	Data	were	summarised	into	payments	by	each	reimbursed	item	on	a	
monthly	basis	by	the	NHSO.	Material	costs,	labour	costs,	and	investment	costs,	
although	were	not	separately	identified	in	the	NHSO’s	payments,	were	
estimated	here	using	proportions	from	selected	past	studies	in	order	to	provide	
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each	element	of	the	cost	from	the	public	payer’s	perspective.	Costs	were	
measured	and	reported	in	Thai	Baht	(50	Baht		₤1,	year	2014	price).	
Table	4‐3	shows	proportions	of	the	material	cost,	labour	cost,	and	capitation	
cost	used	in	estimating	their	amounts	in	the	total	payment	of	each	RRT	
modality.		
Table 4‐3  Proportions (%) of three types of costs by RRT modality 
 PD1/  HD2/ KT3/  
Material costs 74 43 79 
Labour costs   25 40 18 
Capital costs 1 13 3 
PD=peritoneal dialysis, HD= hemodialysis, KT =kidney transplant 
1/ Laonapaporn, Punthunane et al. (2014) 
2/ Tisayaticom, Patcharanarumol et al. (2003) 
3/ Suksamran, Kongsin et al. (2012) 
The	researcher	used	these	figures	to	calculate	the	unit	cost	per	patient‐year	
composed	of	the	three	main	cost	objects:	material,	labour,	and	capital.	
4.4.3.3 Future budget needs 
Results	from	the	previous	sections	(costs	and	numbers	of	patients	by	each	RRT	
modality)	were	drawn	on	to	estimate	future	budget	needs	2014‐2023.	The	
estimated	future	costs	for	the	RRT	modalities	were	further	used	to	assess	
effects	of	four	cost	drivers:	number	of	patients,	labour	costs,	material	costs,	and	
capital	costs.	This	is	to	explain	effects	of	these	drivers:	how	they	influence	the	
unit	cost	of	each	RRT	modality,	and	how	to	control	programme	costs	during	the	
ten‐year	period.	In	this	study,	forecast	budget	needs	are	presented	and	
discussed	in	terms	of	2014‐constant	Baht.		
After	obtaining	the	predicted	numbers	of	renal	replacement	therapy	users,	the	
total	cost	of	each	modality	over	the	next	10	years	(to	the	end	of	2023)	was	
estimated	by	multiplying	the	number	of	users	by	unit	costs.	Since	there	might	
be	policy	changes	in	the	future,	total	costs	of	the	programme	were	calculated	
under	different	scenarios.		
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Selected scenarios  
Three	scenarios	that	were	most	likely	to	occur	were	obtained	from	interviews	
with	policy	makers	in	objective	1.	They	were	selected	to	explain	effects	of	the	
three	cost	drivers	on	future	costs	of	the	RRT	programme.	All	scenarios	assumed	
that	numbers	of	RRT	patients	would	increase	as	projected.	Capital	costs	would	
remain	unchanged,	not	vary	as	the	patient	number	increases.	Labour	costs	and	
material	costs	would	increase	by	the	increasing	number	of	patients.	Material	
costs	would	vary	in	the	three	scenarios.	
 Scenario	1	assumed	material	costs	would	remain	unchanged.	
 Scenario	2	assumed	material	costs	would	increase.	
 Scenario	3	assumed	material	costs	would	decrease.		
4.5 Summary of objectives and methodology used in the study 
The	study’s	objectives	and	their	corresponding	methods	are	summarised	in	
Table	4‐4.		
Table 4‐4  Summary of objectives and the methodology of the study 
Objective Method Measures Source of data 
1. Describe the rationale 
behind and the application of 
the disease management 
approach in the RRT 
programme 
Qualitative approaches: 
1) document review, 2) 
semi-structured 
interview, 3) focus 
group discussion, and 
4) observation	
Responses of payers, 
providers, and patients 
to the RRT programme 
and effects of the 
programme on them 
Various archival 
documents, 41 
interviews, 1 focus group 
discussion, and 10 
observations 
2. Explore the changing 
patterns of access to service 
and mortality of ESRD 
patients overtime  
 
Age-period-cohort 
analysis 
 
Access to RRT services 
and mortality of ESRD 
and RRT patients 
NHSO’s administrative 
data and vital registry 
 
3. Undertake long term 
projections of the number of 
patients and budget needs for 
the RRT programme 
Cost modelling and 
time-series projection of 
the RRT population   
Long term costs, number 
of patients, and RRT 
programme cost drivers 
NHSO’s administrative 
data 
NHSO=National Health Security Office, ESRD=end-stage renal disease, RRT=renal replacement therapy 
4.6 Limitations 
4.6.1 Data sources 
Data	obtained	in	this	study	came	from	both	primary	and	secondary	sources.	
Primary	data	were	collected	from	interviews,	a	focus	group	discussion,	and	
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observations,	where	there	were	opportunities	for	the	interviewer	and	observer	
to	bias	and	mediate	the	discussion.	Other	sources	of	bias	came	from	
interviewees,	who	tend	not	to	reveal	their	true	feelings	and	beliefs	to	the	
interviewer	(Bowling	2009).		
Secondary	data	used	in	this	study	were	mainly	intended	for	administrative	
purposes,	consequently,	there	were	some	limitations.	For	example,	data	for	
many	fields	which	were	not	used	for	budget	claims,	were	not	routinely	
recorded.	Claims	data	given	for	any	given	year	may	not	be	completely	up	to	
date,	since	the	NHSO	allows	its	health	facilities	to	claim	reimbursements	for	
treatment	up	to	a	year	later.	Additionally,	linking	various	databases	resulted	in	
losing	a	number	of	records	that	could	not	be	merged	and	might	threaten	follow	
up	of	the	cohort	population	and	patient	projections.		
4.6.2 Lack of a counterfactual to assess cause-effect relationships 
The	age‐period‐cohort	analysis	in	this	study	is	a	tool	to	describe	the	changing	
patterns	in	registrations	and	deaths	among	ESRD	patients.	This	method	of	
analysis	does	not	establish	a	cause‐effect	relationship.	In	other	words,	it	does	
not	have	a	control	or	comparison	group	to	assess	whether	the	RRT	disease	
management	programme	really	causes	an	effect	on	the	outcomes	of	interest	
(registration	and	death).	In	general,	age‐period‐cohort	studies	cope	with	this	
limitation	by	providing	and	interpreting	the	study	results	with	environmental	
circumstances	to	explain	the	likely	causes	of	the	changes	occurred	in	the	
studied	period.			
4.6.3 Assumptions used in projections 
Predictions	in	this	study	are	vulnerable	to	inaccuracies	due	to	a	number	of	
factors.	First,	they	used	results	of	past	studies	to	estimate	costs	of	material,	
labour,	and	investments	for	each	RRT	modality.	Next,	assumptions	used	to	build	
scenarios	have	an	effect	on	the	estimated	budget	needs.	If	what	happens	in	
reality	deviates	from	what	was	assumed,	it	threatens	the	accuracy	of	the	
forecasts.	
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CHAPTER 5 Disease management of the RRT Programme 
5.1 Introduction 
High‐cost	conditions	can	be	a	challenge	to	policy	makers	when	designing	
benefit	packages.	It	can	be	even	more	challenging	when	making	a	decision	to	
include	their	treatments	in	the	health	basket	when	they	were	not	available	
before.	
Disease	management	programmes	involve	a	multidisciplinary	approach	and	
comprehensive	care	along	the	patient’s	journey	through	the	health	care	delivery	
system.	With	slightly	different	aims,	disease	management	is	a	key	approach	
used	in	the	Universal	Coverage	Scheme	(UCS)	to	care	for	patients	with	high‐cost	
conditions	which	entail	treatments	with	accessibility	problems.	In	the	UCS,	the	
renal	replacement	therapy	(RRT)	programme	is	a	result	of	advocacy	from	
various	stakeholders	responding	to	the	implications	of	high‐cost	conditions.			
The	objective	of	this	chapter	is	first,	to	describe	the	development	and	rationale	
behind	the	inclusion	in	a	health	benefit	programme	of	a	high‐cost	treatment.	
Second,	it	will	describe	the	application	of	the	Thai	disease	management	
approach	in	the	RRT	programme,	in	terms	of	the	relation	between	people	at	
different	levels	of	the	health	system:	policy	makers,	providers,	and	patients.	
This	is	to	obtain	a	better	understanding	of	their	views	on	high‐cost	conditions:	
how	patients	have	coped	with	financial	constraints,	how	policy	makers	and	
providers	responded	to	patients	with	end‐stage	renal	disease,	and	what	was	
done	to	initiate	the	RRT	benefit.	In	addition,	this	chapter	will	explore	how	the	
disease	management	approach	was	applied	and	practised	in	the	RRT	
programme	by	such	people.	Finally,	the	chapter	will	discuss	why	some	patients	
agreed	to	use	RRT	and	why	some	patients	did	not.			
This	chapter	first	provides	a	background	and	features	of	the	UCS	RRT	
programme.	Next,	it	introduces	a	brief	methodology	summary	on	data	collection	
and	the	data	analysis	procedure.	This	is	followed	by	results	of	data	analysis,	
discussion,	and	conclusion.		
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5.2 Renal replacement therapy of the UCS  
5.2.1 Background of the RRT programme 
RRT	was	initially	excluded	from	the	benefit	package	when	the	UCS	was	
launched	in	2001	due	to	fiscal	constraints	and	an	unprepared	system.	
Gradually,	the	National	Health	Security	Office	(NHSO)	responsible	for	UCS	was	
pressured	to	expand	benefits	to	include	RRT	by	civil	society	organisations	and	
patient	groups	(Tangcharoensathien,	Kasemsap	et	al.	2005).	Their	justifications	
for	inclusion	were	that	it	would	save	lives	and	prevent	indebtedness	and	health	
impoverishment	among	UCS	members.		
Before	launching	the	RRT	programme,	the	NHSO	commissioned	a	group	of	
researchers	to	conduct	a	set	of	comprehensive	studies	relating	to	RRT	
situations	and	the	possibilities	of	an	RRT	programme	for	UCS	beneficiaries.	The	
intention	was	to	present	viable	policy	options	to	the	NHSO	board.	Their	final	
decision,	supported	by	the	government	and	the	cabinet,	was	that	the	RRT	would	
be	provided	universally	regardless	of	age	and	socio‐economic	status	
(Dhanakijcharoen,	Sirivongs	et	al.	2011).		
Despite	being	cost‐ineffective,	in	2008	RRT	was	adopted	into	the	benefit	
package	of	UCS.	The	new	health	benefit	covered	RRT	services	for	every	UCS	
member.	The	justification	was	to	help	patients	have	access	to	the	essential	
treatment	and	protect	them	from	catastrophic	spending	due	to	health	care	costs	
(Kasemsap,	Teerawatananon	et	al.	2006).		
5.2.2 Features of the RRT programme 
5.2.2.1 The PD-first policy 
The	UCS‐funded	RRT	has	the	‘PD	first’	characteristic.	That	means	all	new	end‐
stage	renal	disease	(ESRD)	patients	without	contraindication	to	peritoneal	
dialysis	(PD)	must	use	continuous	ambulatory	peritoneal	dialysis	(CAPD)	as	the	
first‐line	therapy,	otherwise	they	need	to	shoulder	the	costs	of	the	other	
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modality	of	dialysis	(hemodialysis)	themselves9.	HD	patients	who	were	on	HD	
before	the	‘PD	first’	policy10,	and	patients	with	contraindications	to	CAPD,	are	
eligible	for	full	reimbursement	of	the	cost	of	HD.	Under	the	PD‐first	policy,	renal	
transplant	and	all	essential	high‐cost	medications	are	also	included	in	the	
benefits	(Kasemsap,	Chungsaman	et	al.	2009).		
Before	launching	the	RRT	benefits,	HD	use	was	almost	everywhere	(352	HD	
centres	across	the	country	in	comparison	with	59	PD	centres),	but	the	
underlying	reasons	for	the	PD	first	policy	were	1)	CAPD	requires	fewer	health	
professionals,	and	there	were	not	enough	nephrologists	and	trained	nurses	to	
provide	universal	access	to	HD;	2)	CAPD	is	based	on	self‐management	which	
means	patients	in	rural	areas	do	not	need	to	come	frequently	for	dialysis	in	
town;	and	3)	CAPD	showed	evidence	of	cost‐effectiveness	over	HD	in	some	
countries,	plus	CAPD	costs	might	be	lower	under	the	condition	that	the	cost	of	
the	dialysis	solution	is	cheaper	(Kasemsap,	Chungsaman	et	al.	2009).	In	contrast	
to	PD’s	advantages,	patients	who	are	on	PD	face	a	risk	of	infection,	called	
peritonitis,	due	to	unclean	environment	or	contaminated	devices.	
5.2.2.2 Separate payment mechanism and administrative function 
In	the	Thai	UCS,	costs	of	RRT	are	reimbursed	according	to	the	three	modalities:	
PD,	HD,	and	KT.	While	staff	salary	is	a	part	of	the	capitation	payment	of	out‐
patient	services,	the	RRT	budget	is	administered	separately	and	costs	are	
reimbursed	on	a	fee	schedule	basis.		
The	NHSO	introduced	bundled	payments	that	combined	multiple	services	into	a	
single	payment	for	each	modality.	Recently,	it	stopped	paying	for	individual	
activities	such	as	launching	a	PD	centre,	PD	catheter	(Tenckhoff	catheter)	
insertion,	home	visit,	and	volunteer	programmes	that	were	originally	meant	to	
persuade	providers	to	expand	the	service	provision	of	PD.	Reimbursements	of	
PD	and	HD	cover	most	activities	associated	with	dialysis	including	counselling,	
catheter	implantation	in	PD	or	vascular	access	in	HD,	consumables	such	as	
																																																								
9 In this case, the NHSO supports the cost for EPO to prevent anemia in patients receiving HD. 
10 These patients had to pay copayment approximately £11 per session, but this rule was abolished in 2012. 
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medical	supplies	and	PD	solution,	and	follow‐up.	Erythropoietin	and	PD	
solutions	are	centrally	purchased	and	allocated	when	they	are	requested	from	
dialysis	units.	Reimbursements	for	kidney	transplants	cover	all	costs	related	to	
kidney	operations	of	the	patient	and	the	donor,	follow‐up	process,	and	
immunosuppressant	drugs	(NHSO	2013).		
In	addition	to	the	separate	payment	system,	supply	constraints,	including	
limited	numbers	of	CAPD	nurses,	nephrologists,	CAPD	centres,	and	limited	fiscal	
capacity,	challenged	the	implementation	of	the	RRT	programme.	Policy	makers	
of	the	UCS	decided	to	manage	the	programme	separately	from	the	mainstream	
by	splitting	the	RRT	budget	and	setting	up	an	ESRD	administrative	unit	within	
the	central	NHSO.	The	intention	of	this	split	was	to	provide	a	managerial	
function	for	the	RRT	system	(Tantivess,	Werayingyong	et	al.	2013).		
5.2.2.3 Co-ordinated system of RRT programme 
The	UCS’s	RRT	programme	is	a	system	of	coordination	between	various	sectors:	
the	NHSO,	the	Government	Pharmaceutical	Organization,	the	Central	Office	for	
Healthcare	Information,	the	Renal	Registry	under	the	Thai	Red	Cross,	the	
professional	body	of	the	Thai	Nephrology	Society,	public	and	private	RRT	
providers,	primary	care	units,	and	patients	and	their	communities.	
The	local	RRT	centres	are	mandated	to	register	patients	diagnosed	with	renal	
failure	or	patients	who	need	RRT.	A	patient	needs	to	be	approved	by	the	
regional	NHSO	before	starting	RRT	at	an	RRT	centre.	Once	an	RRT	service	is	
given	to	a	patient,	the	RRT	centre	sends	information	about	activities	and	PD	
solutions	or	erythropoietin	(EPO)	use	to	the	central	NHSO	in	order	to	be	
reimbursed	the	dialysis	and	staff	fees	according	to	the	agreed	guideline	
protocol.	The	Central	Office	for	Healthcare	Information	is	responsible	for	claims	
from	HD	patients.	Medications,	namely	EPO	and	PD	solutions,	are	reimbursed	in	
the	Vendor	Managed	Inventory	System	by	the	Government	Pharmaceutical	
Organisation.	The	Government	Pharmaceutical	Organization	is	in	charge	of	
delivering	EPO/dialysate	to	RRT	centres,	as	well	as	delivering	dialysate	to	CAPD	
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patients’	houses.	The	renal	registry	acts	as	a	middleman	to	collect	ESRD	
prevalence	and	incidence	data	(NHSO	2013),	Figure	5‐1.		
Figure 5‐1  Coordinated system of RRT management 
	
 RRT=renal replacement therapy, CAPD=continuous ambulatory peritoneal dialysis, HD=hemodialysis,  
GPO=Government Pharmaceutical Organization, CHI=Central office for Health care Information 
 Source: NHSO (2013), ESRD administrative unit (2011) 	
Figure	5‐2	shows	a	patient	journey	along	the	NHSO’s	RRT	protocol.	In	the	usual	
care	system,	if	the	patient	has	diabetes	or	hypertension,	chronic	kidney	disease	
may	be	detected	by	the	screening	programme	when	the	patient	meets	a	GP	in	a	
primary	care	unit	or	an	internist	in	the	outpatient	department	of	a	larger	health	
facility.	When	the	patient	presents	with	decreased	kidney	function,	they	will	be	
referred	and	looked	after	by	professionals	in	the	RRT	unit	to.	A	nephrologist	
confirms	the	ESRD	diagnosis	when	the	patient’s	GFR	level	reaches	15	
mL/min/1.73	m2.	If	the	patient	presents	no	signs	or	symptoms	of	kidney	failure,	
they	will	be	provided	with	information	on	the	treatment	options	when	their	
GFR	level	drops	to	6	mL/min/1.73	m2.	If	the	patient	agrees	to	start	dialysis,	they	
will	be	registered	with	the	RRT	programme,	or	alternatively	they	will	be	living	
with	conservative	therapy	(without	dialysis).	
The	RRT	programme	uses	PD	as	the	first	treatment	modality.	A	patient	without	
contraindications	to	PD	will	be	trained	for	self‐care	management.	During	the	
training	process	(approximately	3	months),	nephrologists	and	PD	nurses	
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provide	dialysis	care,	a	pre‐PD	programme,	to	the	patient.	This	includes	
laboratory	tests,	educational	sessions	for	the	patient	and	carer,	and	catheter	
insertion.	Once	the	patient	has	completed	the	assessment	for	commencing	PD,	
the	regional	NHSO	committee	has	the	next	role	to	approve	the	patient	for	
entering	the	RRT	programme.	The	committee	also	has	a	role	in	approving	
initiating	dialysis	on	HD	or	switching	to	HD	if	the	patient	is	contraindicated	to	
PD	or	fails	using	PD.	The	patient	can	register	for	a	kidney	transplant	and	have	
an	operation	once	they	are	accepted	as	a	transplant	candidate	(NHSO	2013).	
Once	the	patient	has	established	PD,	they	will	be	followed	up	by	the	
nephrologist	and	other	PD	staff	for	evidence	of	complications	and	peritonitis,	
and	routine	medication	every	1‐2	months.	The	patient	is	also	referred	to	their	
local	primary	care	unit	and	is	offered	occasional	home	visits.	A	family	member	
is	encouraged	to	come	along	with	the	patient	during	the	training	period	in	order	
to	be	able	to	support	the	patient	with	PD	exchanges	at	home.			
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Figure 5‐2  A patient journey in the RRT programme 
	
CKD=chronic kidney disease, CAPD or PD=continuous ambulatory peritoneal dialysis, HD=hemodialysis, KT=kidney 
transplant, RRT=renal replacement therapy 
5.3 Summary of methodology 
Three	qualitative	methods	were	used,	consisting	of	1)	document	review,	2)	
semi‐structured	interview	and	focus	group	discussion,	and	3)	structured	
observational	study.	Bringing	the	three	methods	together	ensures	the	
completeness	of	findings.	
Data	was	first	collected	by	reviewing	available	documents	regarding	the	RRT	
programme,	procedures,	and	reports.	Then	in‐depth,	open‐ended	interviews	
were	conducted	to	know	views	and	behaviours	of	interviewees.	Finally,	
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observations	of	PD	patients	provided	information	on	their	self‐care	
management.	Data	collection	periods	for	in‐depth	interviews	and	observations	
were	from	1st	July	to	31st	August	2014	and	from	16th	to	20th	March	2015.	
5.3.1 Documents selected to review 
Document	reviews	were	conducted	at	the	beginning	of	the	study	in	order	to	
have	a	comprehensive	understanding	of	the	RRT	programme.	Table	5‐1	shows	
types	of	retrieved	documents	and	information	that	were	selected	to	review.	
Table 5‐1  Collected quantitative information 
Type of document         Information selected 
NHSO board meeting minutes • RRT benefit 
NHSO’s RRT manual for providers • UCS’s RRT protocol 
• Payment system and reimbursements 
NHSO’s M&E reports • Indicators on the RRT programme 
• Numbers of registered patients  
National Health Security Act B.E. 2545 (2002) • Budget allocation of the NHSO 
Clinical guidelines • Guidelines on caring patients with CKD  
• PD’s self-care management 
Newspaper clippings • Kidney patient protests 
• RRT benefit 
• Interviews of key persons 
Research reports • Incidence and prevalence of ESRD in Thailand 
• Numbers of RRT human resources and facilities 
Research articles • Access to RRT 
• RRT benefits 
5.3.2 Numbers and characteristics of interviewees 
A	mix	of	respondents	from	different	roles	in	the	RRT	system	were	invited	to	
take	part	in	interviews.	A	multidisciplinary	team	who	looked	after	patients	with	
conservative	therapy	was	invited	to	participate	in	a	focus	group	discussion.	
Altogether	there	were	35	interviews,	10	observations,	and	one	focus	group	
discussion.	They	were	divided	into	three	levels;	policy	level,	provider	level,	and	
patient	level.	The	patient	level	consisted	of	patients	who	were	maintaining	
peritoneal	dialysis,	hemodialysis,	kidney	transplant,	and	those	who	declined	
and	chose	to	opt	out	from	the	RRT	benefit,	Figure	5‐3.		
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Figure 5‐3  Sampling framework with number of interviewees in brackets 
 
 NHSO=National Health Security Office, PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant 
In	terms	of	policy	makers	and	providers,	the	majority	of	policy	makers	were	
male	with	a	background	as	physicians.	Three	out	of	five	policy	makers	also	
worked	as	providers	in	hospitals.	A	policy	maker,	the	patient	representative,	
had	another	role	as	a	patient.	In	terms	of	providers,	more	than	half	of	them	
were	female	with	a	background	in	nursing	(see	Table	5‐2).	
      Table 5‐2  General characteristics of policy maker and provider informants 
Characteristics Policy maker Provider	
Gender 
• Male 
      Female	
 
7 people 
2 people	
 
3 people 
7 people 
Years of experience* 5-30 years 3-15 years 
Background or occupation 
• Physician 
       Nurse 
      Other 
 
6 people	
2 people 
1 person 
 
2 people	
5 people 
3 people 
Total number 9 people 10 people 
* in the current position 
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Patient	interviewees	were	categorised	by	their	economic	status	‐
poorer/middle/richer‐	as	judged	by	investigators.	Criteria	used	to	determine	
the	rough	classification	were	the	income	level,	source	of	income,	job,	and	
characteristic	of	place	of	residence	in	comparison	to	their	peers	in	this	study.		
The	patient	group	of	22	persons	can	be	subcategorised	into	4	types	according	to	
RRT	modalities	they	were	maintaining;	peritoneal	dialysis	(PD),	hemodialysis	
(HD),	kidney	transplant	(KT),	and	patients	who	chose	to	opt‐out	(OO).	Their	
ages	ranged	from	23	to	75	years.	Just	over	half	of	the	patients,	especially	those	
who	aged	60	years	or	higher,	were	educated	up	to	primary	school	level.	Sizes	of	
households	varied,	ranging	from	just	one	member	to	ten	members.	Due	to	their	
illness,	patients	could	not	work	full‐time	except	that	those	who	were	
maintaining	a	functional	transplant	could	go	back	to	work.	Two	opt‐out	patients	
had	to	continue	working	after	the	illness	as	they	were	the	head	of	household	
and	the	other	members	in	the	household	could	not	work	and	earn	money.	Only	
5	out	of	22	patients	were	judged	richer,	while	the	majority	of	patients	were	
poorer	or	middle	(see	Table	5‐3).				
Table 5‐3  General characteristics of patients with numbers in brackets 
Mode Gender Age Education Started RRT Household size Job at present 
Economic 
status1/ 
PD Female (6) 
 
 
32-70 
 
 
P (3) 
S (2) 
B (1) 
2009-2013 
 
 
1-5 people 
 
 
None (5) 
Occasional job (1) 
 
Poorer (2) 
Middle (2) 
Richer (2) 
Male (4) 36-70 P (1) 
S (3) 
2006-2014 1-8 people None (3) 
Occasional job (1) 
Poorer (1) 
Middle (3) 
HD Female (2) 
 
49,50 
 
P (1) 
S (1) 
2008,2012 
 
3,10 people 
 
None (2) 
 
Poorer (1) 
Middle (1) 
Male (2) 57,70 P (2) 2006,2012 2,6 people None (1) 
Occasional job (1) 
Poorer (2) 
 
KT Male (1) 
Female (1) 
40,52 S,B 2003,20072/ N/A Full time job (2) Richer (2) 
OO Female (2) 64,75 P (2) 2010,20123/ 2 people None, farmer Poorer (2) 
Male (4) 59-74 P (4) 2007-20123/ 2-4 people None (3) 
Tailor (1) 
Middle (3) 
Richer (1) 
PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant, OO=opt-out; 
P=none or primary school, S= secondary school, B=bachelor’s degree or higher; 
1/as judged by investigators, 2/year having kidney transplant, 3/year diagnosed with ESRD 
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5.3.3 Data analysis procedure 
The	findings	of	the	study	were	brought	together	from	information	collected	by	
the	three	data	collection	methods.	To	describe	the	system	of	the	RRT	
programme in	the	context	of	disease	management,	results	are	described	from	
the	perspectives	of	the	NHSO,	providers,	and	patients.		
Figure	5‐4	shows	the	conceptual	framework	for	describing	the	rationale	and	
practices	of	the	RRT	programme.	After	the	implementation	of	the	UCS	in	2002,	
the	scheme	expanded	to	cover	48.6	million	people,	74.7%	of	the	Thai	
population	(NHSO	2013).	UCS	members	are	required	to	receive	health	care	at	
the	registered	primary	care	units,	which	can	be	a	community	hospital	or	a	
health	centre.	Almost	all	of	them	are	public	facilities.		
Different	groups	in	the	health	system	responded	to	patients	with	end‐stage	
renal	disease	in	various	ways,	according	to	their	roles.	The	funder	or	the	NHSO’s	
main	role	is	to	provide	access	to	essential	treatments	and	protect	its	
beneficiaries	from	catastrophic	health	spending.	With	its	supporting	agencies,	
the	NHSO	took	the	concept	of	disease	management	as	an	intervention	to	design	
the	delivery	system	of	RRT	for	providers.	Responding	to	the	RRT	programme,	
providers	have	taken	action	to	care	for	patients	with	end‐stage	renal	disease.	
Consequently,	the	RRT	programme	affects	providers’	attitudes	and	practices.	In	
this	study,	disease	management	and	the	chronic	care	model	provide	a	detailed	
framework	to	describe	the	elements	used	in	the	system	for	caring	for	people	
with	chronic	diseases.	They	were	adjusted	to	the	UCS’s	RRT	programme	by	
focusing	on	1)	the	system’s	resources,	policies,	and	delivery	system	design	and	
2)	actions	and	perceptions	of	disease	management	interventions	given	by	policy	
makers	and	providers.	The	components	included	i)	evidence‐based	guideline	
protocols,	ii)	population	identification,	iii)	collaborative	practice,	and	iv)	self‐
care	management	support.	
Patients’	performance	is	viewed	as	one	of	the	key	components	in	a	disease	
management	programme’s	success.	Patients	are	supported	to	make	day‐to‐day	
decisions	about	their	illnesses	and	to	hold	responsibility	to	manage	their	own	
condition	(Bodenheimer,	Lorig	et	al.	2002).	In	the	RRT	programme,	patients	can	
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choose	if	they	need	RRT.	Some	patients	may	agree	to	receive	the	high‐cost	
treatment	of	the	RRT	programme	but	some	patients	may	not	and	instead	
choose	conservative	therapy	or	self‐pay	dialysis.	Some	of	this	can	be	explained	
by	individuals’	characteristics,	beliefs,	and	other	factors	such	as	their	social	
structures.		Other	factors	may	also	play	an	important	role	in	individuals’	
decisions	such	as	health	benefit	coverage	(Aday	and	Andersen	1974),	as	well	as	
the	number	of	RRT	facilities	and	their	location.		
On	the	patients’	side,	community	groups	such	as	community	health	care	
providers	and	health	volunteers	are	supported	to	integrate	into	the	RRT	
programme	as	part	of	the	government’s	strategy	to	mobilise	community	
resources	in	supporting	patients	with	end‐stage	renal	disease.	Moreover,	
communities	can	support	patients	by	bridging	the	gap	between	the	arranged	
service	provision	and	the	real	world	of	patients	and	their	families	(Epping‐
Jordan,	Pruitt	et	al.	2004).	
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Figure 5‐4  Conceptual framework for describing rationale and practices  
of the RRT programme 
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 ESRD= end-stage renal disease, RRT= renal replacement therapy 
5.4 Results 
Results	are	reported	according	to	the	framework	for	qualitative	analysis.	The	
text	starts	with	views	on	end‐stage	renal	disease,	responses,	and	actions	from	
interviewees	at	different	levels,	and	considers	past	attempts	to	initiate	the	RRT	
programme.	This	is	followed	by	all	interviewees’	rationale	for	use	and	
application	of	disease	management	as	an	intervention	to	manage	the	high‐cost	
condition.	Next,	networking	between	components	in	the	RRT	system	is	
highlighted.	Finally,	the	chapter	reports	patients’	perspectives	on	what	
determines	the	use	of	dialysis.	This	chapter	aims	to	see	how	well	the	system	of	
RRT	is	functioning,	how	people	respond	to	the	system’s	design,	and	how	they	
respond	to	the	disease	management	approach.	
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5.4.1 Views on high-cost, catastrophic diseases perceived by 
interviewees and their responses 
Interviewees in	this	study	had	different	views	on	high‐cost,	catastrophic	
diseases.	Patients	took	account	of	both	direct	and	indirect	costs	that	they	had	to	
pay	when	they	fell	ill.	Providers	viewed	high‐cost	treatments	as	a	barrier	for	
patients	to	receive	health	services,	while	policy	makers	considered	this	issue	as	
part	of	their	mission	to	provide	access	to	care.	The	key	factor	responsible	for	
the	significant	development	of	the	RRT	benefit	was	how	policy	makers	and	
providers	responded	to	patients	with	end‐stage	renal	disease.	
5.4.1.1 Patients 
Direct	costs	for	treatments,	combined	with	indirect	costs,	could	cause	patients	
trouble	when	they	needed	health	care.	For	an	expensive	treatment	like	RRT,	
patients	who	started	having	ESRD	before	the	RRT	benefit	or	who	have	recently	
discovered	the	existence	of	the	benefit	have	already	experienced	a	form	of	
financial	catastrophe.	This	includes	taking	out	loans,	making	distressed	sales	of	
assets,	stopping	sending	children	to	school,	or	thoughts	about	suicide.	Patients	
shared	their	experiences	and	said	that:	
“I	spent	all	I	had	for	hemodialysis.	We	are	not	rich.	When	I	started	having	
kidney	failure,	my	son	was	studying	at	university.	He	had	to	stop	and	find	a	
job	to	make	money	for	our	family.	His	life	was	then	finished.	[…]	I	once	had	
an	infection,	and	a	doctor	rescued	me	because	the	shock	to	my	body	would	
have	killed	me	because	it	would	have	been	better	if	he’d	let	me	die.”(HD2)	
“When	I	first	knew	that	I	had	it	(ESRD),	I	felt	so	depressed.	Just	think	about	
it,	I	used	to	have	everything	like	a	great	job	and	there	used	to	be	many	
customers.	But	when	I	got	sick	I	lost	everything	too.	I	have	tried	
committing	suicide	a	couple	of	times.	That	was	why	my	family	asked	me	to	
enter	a	monkhood.”(PD8)	
A	patient	mentioned	the	loss	of	opportunity	cost	of	herself	and	a	family	
member:	
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“While	I	was	studying	at	university,	I	went	back	and	forth	between	school	
and	hospital	to	change	my	bag.	[…]	Before	I	could	do	this	by	myself,	my	
mum	had	to	quit	her	job	to	take	care	of	everything	for	me.”	(PD4)	
Since	the	RRT	benefit	became	available	to	everyone,	situations	have	become	
better.	Patients	were	eligible	for	free	health	services,	however,	some	of	them	
mentioned	difficulties	such	as	travel	cost	and	opportunity	cost	to	themselves	as	
well	as	family	members.	Altogether,	these	costs	could	bring	a	patient	to	incur	
financial	catastrophe.	As	one	patient	pointed	out:		
“Now	the	dialysis	cost	is	free	but	the	travel	cost	is	not,	I	pay	500	Baht11	
each	week.	It’s	really	tough	since	I	don’t	earn	much.	Having	dialysis	is	just	
like	waiting	to	die.”	(HD2)		
5.4.1.2 Providers 
In	the	providers’	view,	high‐cost	diseases	were	conditions	that	needed	
expensive	treatments.	Without	coverage	from	a	third‐party,	they	could	lead	
patients	to	catastrophic	health	spending.		For	chronic	conditions	or	treatment	
for	accidental	injuries,	although	costs	for	multiple	treatments	were	expensive,	
most	conditions	were	covered	by	universal	health	coverage	for	a	long	period.	
They	could	not	bring	patients	into	bankruptcy.		
The	barrier	of	access	to	care	was	a	consequence	of	high‐cost	conditions	making	
them	the	main	concern	among	providers.	Before	there	was	universal	health	
coverage	of	the	UCS,	a	physician	recalled:	
“There	were	ESRD	 patients	who	 came	 to	 the	 hospital	 for	 hemodialysis,	
asking	help	from	the	subsidy	fund	for	the	poor.	Most	of	them	were	turned	
down.	Some	were	offered	peritoneal	dialysis	and	had	it	temporarily	for	3‐
5	days.	For	around	2‐4	weeks	they	came	back.	After	a	couple	of	times	they	
no	longer	came	again	which	was	really	sad.”	(PM5)	
																																																								
11 Approximately 10 pounds 
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5.4.1.3 Policy makers 
The	 policy	 makers’	 attention	 was	 focused	 on	 access	 to	 care	 and	 equity.	
Providing	 access	 to	 essential	 healthcare	 and	 preventing	 beneficiaries	 from	
financial	 catastrophe	 due	 to	 high	 cost	 health	 care	 are	 NHSO’s	 goals.	 As	 an	
interviewee	stated:	
“Suffering	 from	diseases	with	are	costly	 to	 treat,	 such	as	 stroke,	cancer,	
and	cardiovascular	disease	may	not	be	a	big	burden	for	the	rich,	but	what	
about	the	poor?	This	is	why	we	need	a	health	insurance	scheme	to	cover	
these	costly	treatments.”	(PM7)	
In	 terms	 of	 high‐cost	 conditions,	 the	 NHSO	 used	 criteria	 to	 distinguish	 these	
conditions	from	others.	First	they	looked	for	treatments	that	were	not	available	
in	 the	benefit	package.	Next,	 the	 focus	was	put	on	health	problems	with	new,	
expensive	treatments,	which	meant	they	were	most	likely	to	be	inaccessible.	For	
high‐cost	 treatments,	 policy	makers	 believed	 that	 it	was	 essential	 to	 set	 up	 a	
special	arrangement	 in	order	 to	 increase	access	 to	care.	This	was	because	 the	
closed‐end	payments	of	the	NHSO	discouraged	providers	from	providing	high‐
cost	treatments.	As	an	interviewee	from	the	NHSO	explained:	
“We	 think	 patients	 can’t	 use	 these	 services	 because	 there	 are	 gaps	
between	 the	policy	and	providing	health	 services.	 […]	This	 is	why	 these	
costly	 treatments	need	 some	kind	of	 special	arrangement.	For	example,	
HIV/AIDS	and	RRT,	we	were	pressured	every	year	to	put	their	treatments	
in	the	health	benefit	basket.	We	then	made	arrangements	 for	HIV	drugs	
and	the	RRT	system.”	(PM2)	
5.4.1.4 Responses to ESRD patients 
In	Thailand,	treatments	for	kidney	disease,	such	as	transplantation,	
hemodialysis	and	peritoneal	dialysis	had	been	developed	during	the	1990s	
(Supaporn,	Krairittichai	et	al.	2005).	Technologies	in	kidney	disease	were	
successful	enough	that	patients	could	spend	their	everyday	lives	almost		
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normally,	whether	at	work	or	socialising.	But	only	the	well‐off	or	civil	servant	
patients	could	access	these	new	treatments.		
Before	RRT	benefit	was	included	in	the	core	benefit	of	the	UCS,	there	were	very	
limited	numbers	of	dialysis	units	and	dialysis	nursing	staff.	Only	rich	patients	
could	undergo	dialyses	(Tangcharoensathien,	Kasemsap	et	al.	2005).  It	was	
therefore	in	the	public	interest	to	provide	funded	treatment	for	end‐stage	
kidney	disease	which	could	otherwise	cause	a	patient	financial	catastrophe.	
However,	concerns	about	the	high‐cost	and	poor	cost‐effectiveness	were	the	
main	reasons	that	NHSO’s	administrators	decided	not	to	include	the	benefit	in	
the	UCS	since	its	beginning	in	2002	(Tantivess,	Werayingyong	et	al.	2013).	
A	nephrologist	once	said	that	it	felt	like	giving	the	death	sentence	to	the	patient;	
the	effective	inaccessibility	of	treatment	for	the	majority	of	the	population	had	
put	huge	pressure	on	nephrologists.	They	started	the	idea	to	put	the	RRT	into	
the	health	benefit	even	before	the	initiation	of	the	UCS	(in	2002).	At	first,	
nephrologists	believed	that	they	should	work	without	contact	with	politicians	
otherwise	people	would	think	of	them	as	dishonest	and	corrupt.	An	interviewee	
as	a	nephrologist/academician	shared	his	opinion	that:	
“[…]	from	another	point	of	view,	we	cannot	change	anything	because	the	
power	lies	within	the	politicians.	So	we	changed	our	minds	and	asked	to	
have	a	meeting	with	the	Minister	of	Public	Health.”	(PM4)	
Therefore,	they	thought	about	approaching	the	government,	the	Ministry	of	
Public	Health,	and	academicians	whose	work	related	to	financing.	It	was	an	
effortful	and	time‐consuming	process,	as	an	interviewee	recalled:	
“We	had	several	meetings,	first	we	went	to	see	the	minister	(of	the	Ministry	
of	Public	Health),	and	told	him	what	we	had	experienced.	He	understood	us	
well	and	invited	his	working	team	and	ones	who	had	important	positions	in	
the	Ministry	to	listen.	It	went	well,	everyone	agreed	that	there	should	be	
some	action.	Unfortunately,	the	government	was	changed	shortly	after	
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that.	When	the	new	minister	came,	we	started	a	new	talk.	Then,	after	just	a	
while,	the	minister	was	moved	again.”	(PM5)	
On	the	patients’	side,	there	were	efforts	to	make	connections	with	policy	
makers	and	politicians	in	order	to	strengthen	the	patient	group	and	push	for	the	
RRT	benefit.	They	had	several	meetings	to	accomplish	the	RRT	benefit,	despite	
the	reshuffle	and	change	of	the	government.	The	following	is	a	newspaper	
archive	of	an	interview	with	Subin	Noksakun	(see	Box	1),	former	chair	of	the	
Friends	of	Kidney	Patients	Society:		
Last	mission	with	the	remaining	breath	
ASTV	online,	26	December	2006	
“Once	I	had	a	discussion	with	the	Public	Health	Minister,	Pinij 
Jarusombat12	of	the	Thai	Rak	Thai	party.	He	agreed	upon	a	tripartite	
copayment.	The	proposal	was	ready	but	the	government	was	then	
abolished	by	the	coup.	[…] After	the	new	government	was	in	place	(from	
the	military	coup),	we	proposed	that	the	government	give	free	treatment	
to	chronic	kidney	patients	via	the	UCS	in	fiscal	year	2007.	The	proposal	
was	then	taken	to	present	to	Dr	Mongkol	Na	Songkla13,	the	new	Public	
Health	Ministry.	He	understood	and	told	us	that	the	NHSO	and	some	
public	hospitals)	was	launching	a	pilot	programme	to	see	how	this	benefit	
could	go.”	
																																																								
12 Pinij Jarusombat was in the position between October 2005 and September 2006 
13 Dr Mongkol Na Songkla was appointed to be the minister between October 2006 and February 2008 
CHAPTER 5  Disease management of the RRT Programme 
130 
	
Box 1  Friends of Kidney Patients Society  
From a small society of kidney patients formally established in 2006, the Society has now expanded to 
more than 40,000 members. This figure covers just beneficiaries of the UCS, many more members are in 
the other two public health insurance schemes: Social Security Scheme and Civil Servant Medical Benefit 
Scheme. Its members are the patients who suffer from the last stage of kidney disease, carers, and people 
who are at risk of kidney disease.
Going back ten years, the Friends of Kidney Patient Society was set up by Subin Noksakun, known as 
Uncle Subin, the first chairman of the society and the champion of kidney patients’ rights. Subin once 
belonged to a rich family. He had a family business, properties, and savings of more than 10 million Baht: 
but most of it is gone due to 20 years of treatment for his kidney disease. At the time he gave the interview, 
just a house and a few hundred Baht savings were left. Chronic kidney disease ran in Subin’s family, as his 
elder brother and son also suffered from the condition. One day Subin went to receive his treatment as 
usual, he listened to old, repeated conversations on how to control body weight and salt intake and felt that 
there was no improvement in benefits for kidney patients. He had once acted as a member in the 
Employee Labour Congress, and this inspired Subin to do something so that kidney patients would not 
face financial catastrophe like him. 
With support from several networks such as the NHSO and other patient groups for cancer, heart disease, 
and HIV/AIDS sufferers, the Friends of Kidney Patient Society was set up. After several visits and talks 
with politicians, and together with the movement of academicians/policy makers, the RRT was included in 
the health benefit of the UCS, starting in January 2008. From this success, the group moved to call for 
expanding the RRT benefit to those who had developed ESRD before they became members of the Social 
Security Scheme. The success took two years to achieve, and is indebted to  Subin’s significant effort. He 
once mentioned, “When I do the visit, I go alone. Other members are not allowed to come along, otherwise 
they can’t earn money for their dialyses. I don’t have much too but I have no choice. My daughter asked ‘Is 
it better to just stay home?’ But I can’t. I haven’t got much time left so I have to do something worthwhile. 
Can Thailand have decent health benefits like those developed countries? The answer is ‘Yes, we can’ but 
there needs to be someone to start it.” 
According to the Director of AIDS Access Foundation, “Before the establishment of the Friends of Kidney 
Patients Society, kidney patients did not gather into groups and there was no existing relationship between 
kidney patients and other patient groups. Because of the movement since Subin coming in and Dr 
Sanguan’s (NHSO’s first secretary general) intention to help kidney patients, the establishment of the RRT 
benefit succeeded in a short amount of time, less than a year. Compare that to the HIV/AIDS benefit, 
where we spent almost ten years.” 
Subin passed away at the age of 62 on 6th May 2012, six months after the death of his son. Now the 
Friends of Kidney Patients Society has a new chairman and has been contributing to many activities; 
building up knowledge of self-care management to patients and carers, and also movements for public 
participation. The society has its branches in every province across the country, where the core members 
run monthly visits and set up forums in order to expand the network and develop collective approaches, 
such as building up knowledge and friendship support groups, and how to fundraise for spending on 
various activities. Besides the effort to put RRT in the health benefit basket and improve the benefit 
thereafter, the group, with its networks, also plays important roles in a number of actions to assure equal 
opportunities in society. For example, they called for the abolition of the rule prohibiting patients with 
chronic kidney disease and tuberculosis from positions in the civil service in 2009. Recently, in 2015, they 
gathered to request that the minister of the Ministry of Public Health reconsider the changes in the NHSO’s 
budget allocation and the introduction of patient charges/ co-payment under the UCS.  
- Based on interviews and archival sources (Manager Online, 26 December 2006; Consumerthai, 12 
February 2009; Bangkokbiznews,19 May 2012; NHSO newsletter, July 2013; Matichon, 3 February 2015
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On	the	political	side,	the	1997	Thai	constitution	and	the	subsequent	2007	
constitution	(Constitution	of	the	Kingdom	of	Thailand	B.E.2550	(2007))	
emphasise	human	rights	and	equality,	stating	that	everyone	will	receive	equal	
benefits	and	protection	from	the	government.	Equality,	therefore,	became	a	
mindset	of	political	promises.	Despite	the	political	transition	due	to	the	military	
coup	in	2006,	the	new	governments	led	by	the	appointed	General	Surayuth	
Chulanont14,	and	the	Public	Health	Minister,	Dr	Mongkol	Na	Songkla,	still	relied	
on	the	principle	of	equality.	
Another	advantage	of	the	UCS	was	that	the	scheme	is	supported	by	the	National	
Health	Security	Act	B.E.	2545(2002),	in	which	Section	39	clearly	states	that	the	
cabinet	are	obligated	to	consider	and	approve	the	budget	for	the	NHSO.	This	is	
advantageous	to	the	NHSO	because	the	spending	plan	is	sent	directly	to	the	
cabinet	to	make	decisions.	In	contrast,	other	government	department	budgets	
have	to	be	set	up	by	the	Bureau	of	Budget	(which	estimates	the	budget	based	on	
the	final	year	spending)	and	sent	to	the	cabinet	to	approve.	Each	year	the	NHSO	
has	a	large	budget	demand,	approximately	5%	of	the	total	government	
expenditure.	Also,	new	health	benefits	are	always	being	introduced,	causing	
additional	budget	allocations	to	the	NHSO	which	are	not	based	on	the	previous	
year’s	spending.	Given	this	legitimacy,	the	NHSO	can	request	its	expected	
budgets	with	extra	amounts	and	pass	them	directly	to	the	cabinet.	If	the	cabinet	
decides	to	initiate	the	new	health	benefit,	they	can	support	extra	funding	at	this	
stage.	However,	other	public	sectors	have	to	negotiate	via	the	Bureau	of	Budget,	
who	may	not	be	motivated	to	push	a	new	policy.	
5.4.2 Initiation of the RRT programme 
There	were	combined	efforts	to	introduce	the	RRT	programme	to	the	UCS	
beneficiaries.	The	three	factors	that	facilitated	the	remarkable	achievement	of	
the	new	benefit	were	creation	of	knowledge,	social	movements,	and	political	
actions.	
																																																								
14 acting as the Prime Minister during 2006-2008 
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5.4.2.1 Creation of knowledge 
The	NHSO	sought	support	from	various	supporters	when	generating	policy	
recommendations	regarding	the	RRT	benefit.	By	the	end	of	2004,	the	NHSO	had	
commissioned	a	working	group	consisting	of	representatives	from	various	
stakeholders	to	identify	overall	conditions	of	the	available	RRT	system	in	
Thailand;	this	working	group	included	the	Thai	Red	Cross,	the	Thai	Renal	
Replacement	Therapy	Registry,	the	Nephrology	Society	of	Thailand,	the	Kidney	
Foundation	of	Thailand,	and	a	number	of	researchers.	The	working	group	was	
to	investigate	six	aspects	relating	to	renal	replacement	therapy	(RRT	Benefit	
Research	Committee	2004):	1)	what	had	been	done	in	other	countries,	2)	
available	infrastructures	of	the	RRT	system,	3)	estimated	numbers	of	patients	
who	needed	RRT,	4)	cost‐effectiveness	of	peritoneal	dialysis	and	hemodialysis,	
5)	budget	needs	for	the	RRT	benefit,	and	6)	public	opinion	of	the	new	RRT	
benefit.	
Results	of	the	research	studies	showed	that,	in	countries	with	well‐developed	
health	insurance	systems,	RRT	is	included	in	health	care	benefits.	In	countries	
with	tight	government	budgets	and	insufficient	numbers	of	hemodialysis	units,	
peritoneal	dialysis	is	the	option	the	government	usually	prefers	for	the	health	
benefit	(Tangcharoensathien,	Kasemsap	et	al.	2005).	In	Thailand,	access	to	RRT	
was	limited	only	to	those	who	were	well‐off,	at	around	23%	of	overall	ESRD	
patients	(Kasemsap,	Tangcharoensathien	et	al.	2001).	There	were	14,000	RRT	
patients	in	2005,	and	this	amount	was	expected	to	increase	to	50,000	in	2009	
(Kasemsap,	Teerawatananon	et	al.	2006).	In	the	case	that	every	ESRD	patient	
would	use	RRT,	the	first	year	of	the	programme	would	require	4,000‐6,500	
million	Baht	to	treat	patients.	This	amount	would	increase	to	more	than	50,000	
million	Baht	per	year	in	the	fourteenth	year	(Kasemsap,	Prakongsai	et	al.	2006).	
A	survey	of	public	opinion	showed	that	most	Thais	supported	including	the	RRT	
benefit	into	the	UCS.	Just	half	of	respondents	agreed	with	paying	a	small	
contribution	of	less	than	800	Baht	(approximately	₤17per	month)	
(Tangcharoensathien,	Vasavid	et	al.	2006).	A	full	list	of	research	studies	is	
shown	in	Appendix	6.	
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Given	concerns	over	the	financial	constraints	on	the	government	health	care	
budget,	a	set	of	policy	options	was	proposed.	The	options	comprised	four	
alternatives	to	select	patients	into	the	RRT	programme	ranging	from	high‐
intensity	to	low‐intensity	RRT	benefits.	In	addition,	policy	recommendations	
were	developed	and	proposed.	They	suggested	a	marked	improvement	for	
several	issues	including	primary	and	secondary	prevention	of	ESRD,	adequate	
and	sustainable	health	care	financing	for	the	extension	of	RRT,	an	efficient	RRT	
service	provision	system,	the	establishment	of	central	purchasing	and	
bargaining	systems	on	PD	solutions	and	erythropoietin	injections,	a	reporting	
system	of	the	renal	registry,	incentives	for	promoting	the	PD	first	policy,	and	an	
effective	kidney	transplantation	system	(Tangcharoensathien,	Kasemsap	et	al.	
2005).	
The	results	and	policy	options	were	first	brought	to	the	executive	board	of	
NHSO	in	March	2005.The	board	adopted	resolutions	(NHSO	Executive	Board	
2005)	to:	
1)	launch	a	pilot	project	of	‘PD	first	policy’	to	develop	the	RRT	benefit	in	
three	sites;	Banpaew	Hospital,	Samutsakhon	province;	Srinagarind	Hospital,	
Khonkaen	province;	and	Sonklanagarind	Hospital,	Songkla	province.	The	pilot	
project	would	be	extended	to	more	areas	in	2006.	The	final	decision	on	the	new	
RRT	policy	was	expected	to	be	announced	in	2007.	
2)	coordinate	with	all	relevant	parties	such	as	RRT	units,	local	
administration	in	each	province,	patients	and	carers,	and	their	societies	all	over	
the	country	in	terms	of	the	budget	need,	staffing,	and	service	provision.		
A	policy	maker	shared	his	opinions	that:	
“I	really	used	the	recommendations	to	make	a	plan	for	the	system	and	get	
it	ready	for	the	new	policy.	[…]	We	(the	NHSO)	had	specific	objectives	in	
the	pilot	project.	First,	to	respond	to	social	pressure	about	the	RRT	
benefit:	by	starting	in	3	pilot	centres	we	could	buy	time,	and	promise	a	
real	start	in	the	next	3	years.	Second,	to	answer	some	questions,	which	
were:	‘Will	providers	and	patients	accept	PD	first	(because	in	that	time,	
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PD	use	was	limited	in	terms	of	numbers	of	facilities,	healthcare	staff,	and	
patients)?’,	‘Can	patients	and	communities	pay	contributions?’	Also,	we	
wanted	to	make	managing	guidelines	for	service	provision	and	staffing.	
And	finally,	we	wanted	to	pilot	service	provision	for	3	years.”	(PM1)	
5.4.2.2 Societal movement 
Not	long	after	the	action	of	the	academician	group,	there	were	movements	led	
by	patients.	A	small	group	of	kidney	patients	who	had	been	given	funding	
support	for	dialyses	by	the	Kidney	Foundation	of	Thailand15	formed	a	formal	
patient	group	called	Friends	of	Kidney	Patients	Society	in	2006	(see	previous	
Box	1).	The	Society,	reinforced	by	the	NHSO,	sought	to	extend	the	UCS	benefit	
package	to	cover	RRT	services.		
When	patients	gathered	into	a	large	group,	their	voices	were	powerful	and	got	
the	public’s	attention.	They	asked	for	the	RRT	benefit	via	the	Kidney	Foundation	
of	Thailand,	government,	and	mass	media,	as	well	as	directly	to	the	NHSO,	as	
newspapers	reported:	
Kidney	patient	plea	for	free	treatment		
(Kom	Chud	Leuk,	16	May	2006)	
Over	200	members	of	the	Friends	of	Kidney	Patients	Society	gathered,	
requesting	that	the	government	put	renal	replacement	therapy	in	the	
Universal	Coverage	Scheme’s	benefit	package.	
Kidney	patient	plea	to	the	government		
(Delinews,	30	August	2007)	
[…]	more	than	300	kidney	patients	gathered	in	front	of	the	Ministry	of	
Public	Health,	asking	to	meet	Mongkol	Na	Songkla,	the	Minister	of	Public	
Health	as	they	cannot	shoulder	costs	of	the	expensive	treatments	at	
several	thousand	Baht	per	month.		
Friends	of	Kidney	Patients	marching	to	government	house	
(Kom	ChudLeuk,	10	October	2007)	
																																																								
15 A humanitarian organisation for kidney patients, patronised by Her Royal Highness Princess Galyani Vadhana 
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[…]	around	50	members	of	the	kidney	patient	supporters	gathered	at	the	
government	house	to	deliver	a	letter	to	the	Prime	Minister,	General	
Surayuth	Chulanont,	asking	for	support	for	the	kidney	patients	by	putting	
the	benefit	in	the	UCS.	
5.4.2.3 Political action 
The	RRT	issue	was	considered	by	the	meeting	of	the	NHSO	executive	board	in	
September	2007,	where	research	studies	commissioned	by	the	NHSO	were	
presented.	The	board	then	resolved	to	fully	fund	kidney	transplant	and	
peritoneal	dialysis.	Hemodialysis	was	fully	funded	only	if	a	patient	was	
contraindicated	to	peritoneal	dialysis.	Old	hemodialysis	patients	who	wanted	to	
retain	on	hemodialysis	would	be	subsidised	just	two‐thirds	of	the	price,	and	the	
rest	would	be	patients’	responsibility.	Because	of	the	large	amount	of	need	for	
RRT	(the	expected	spend	was	17,000	million	Baht,	almost	10%	of	the	UCS	
budget	for	outpatients),	a	member	of	the	executive	board	suggested	separating	
the	budget	for	the	RRT	programme	from	outpatient’s	capitation	(NHSO	
Executive	Board	2007).	UCS	beneficiaries	could	go	to	receive	services	from	any	
RRT	units	that	had	enough	capacity	and	were	ready	for	the	new	policy.		
It	was	near	the	end	of	the	Surayuth	government,	and	there	was	a	concern	that	
what	had	been	done	so	far	would	be	wasted.	On	30th	October	2007,	the	Public	
Health	Minister,	Dr	Mongkol	Na	Songkla	,who	had	continuing	concerns	over	this	
matter,	presented	the	policy	recommendations	to	the	cabinet	and	allowed	the	
academicians	to	give	reasons	to	support	his	judgement	by	the	end	of	cabinet	
meeting.	An	interviewee	who	worked	closely	with	NHSO	gave	details:	
“[…]	At	first,	the	research	group	gave	the	cabinet	alternatives	to	the	free	
RRT	benefit,	such	as	copayment	and	age	limitations,	but	the	cabinet	and	
audiences	still	doubted	whether	the	recommendations	could	be	met.	
Finally,	the	Prime	Minister	took	his	role	and	asked	to	make	the	final	
decision.	He	said	‘our	people	have	been	suffering	and	waiting	painfully.	
Could	we	just	start	by	doing	what	we	can	then	gradually	develop	it?”	
(PM5)	
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Another	interviewee	shared	his	opinion:	
“In	my	opinion	it	was	a	perfect	mixture.	We	had	General	Surayuth	who	
supported	equality	and	Dr	Mongkol	who	understood	the	health	system	as	
a	physician,	accompanied	by	research	knowledge	and	societal	
movement.”	(PM2)	
Finally,	the	resolution	was	passed	by	the	cabinet	to	include	the	RRT	service	to	
the	UCS	benefit	package	(Cabinet	Resolution	2007).	Since	the	cabinet	resolution	
was	announced	in	October	and	would	become	effective	the	following	January,	
there	was	a	concern	that	the	large	budget	for	RRT	programme	had	not	been	set	
up	in	advance.	In	order	to	have	enough	funds	for	the	first	year,	the	NHSO’s	
coordination	committee	proposed	to	use	the	remaining	budget	of	HIV/AIDS	
programme	at	the	amount	of	836	million	Baht	for	initiation	of	the	new	RRT	
programme	(NHSO	Executive	Board	2007).		
5.4.3 Disease management approach to the RRT programme 
This	section	is	divided	into	two	sub‐sections.	The	first	sub‐section	is	about	the	
surrounding	context	relating	to	the	implementation	of	the	RRT	programme.	The	
other	sub‐section	describes	effects	of	the	RRT	programme	as	perceived	by	
policy	makers,	providers,	and	patients	as	well	as	their	actions	on	the	
programme.	The	content	of	this	sub‐section	is	arranged	according	to	four	
components	of	disease	management:	use	of	evidence‐based	guidelines,	patient	
identification,	collaborative	practice,	and	patients’	self‐care	management.	
5.4.3.1 System’s resources, policies, and delivery system design 
i. RRT staff and facilities 
Before	the	RRT	programme	started,	numbers	of	RRT	centres	were	limited	and	
mostly	concentrated	in	the	vicinity	of	Bangkok.	In	21	out	of	76	provinces	there	
was	only	one	RRT	centre.	Around	70%	of	nephrologists16	and	65%	of	dialysis	
nursing	staff	were	working	in	the	vicinity	of	Bangkok	(Supaporn,	Krairittichai	et	
																																																								
16 including trained kidney doctors from other subspecialties including internists and pediatricians 
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al.	2005).	Therefore,	it	was	important	to	rapidly	increase	the	number	of	RRT	
facilities,	particularly	PD	centres	and	nursing	staff	to	ensure	patients’	access	to	
the	PD	first	programme.	Table	5‐4	shows	numbers	of	PD	and	HD	centres	in	
2006	to	2012.		
Table 5‐4  Numbers of peritoneal dialysis and hemodialysis centres 2006‐2012 
 2006 2007 2008 2009 2010 2011 2012 
PD centres 57 61 105 120 139 144 178 
HD centres 399 395 428 440 447 497 533 
Source: Thailand Renal Replacement Therapy Registry Report 2012 
Before	the	initiation	of	the	RRT	benefit,	the	NHSO	spent	three	years	to	make	
universal	access	to	RRT	possible	under	the	UCS	system.	PD	first	and	disease	
management	were	key	strategies	used	to	arrange	for	provision	of	the	service	
and	to	overcome	system	inadequacies.		
ii. PD first policy 
As	it	was	anticipated	that	there	would	be	huge	demand	for	dialysis	after	the	
announcement	of	the	new	benefit,	PD	was	the	best	choice	given	the	short	
staffing	of	the	health	workforce.	In	comparison	to	HD,	PD	requires	fewer	
amounts	of	nurses	to	look	after	patients.	Given	PD	as	home	dialysis,	patients	
residing	in	rural	areas	can	be	trained	to	rely	on	self‐care	management.	This	is	in	
contrast	to	HD,	which	requires	patients	to	receive	care	at	a	hemodialysis	unit,	
and	therefore	suits	patients	who	live	in	the	city	and	have	no	problem	with	
frequent	travel.		
In	addition,	from	the	NHSO’s	point	of	view,	the	costs	of	PD	to	the	NHSO	are	
expected	to	be	lower,	or	at	least	controllable	in	the	future.	One	example	is	the	
expected	scenario	that	PD	solutions	can	be	locally	made.		
iii. Disease management initiatives 
Disease	management	interventions	were	used	to	administer	the	RRT	system,	
including	setting	up	guideline	protocols	and	reporting	systems.	An	interviewee	
from	the	NHSO	explained	how	the	disease	management	approach	was	adopted:	
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“A	member	of	our	staff	reviewed	experiences	from	other	countries	and	
suggested	we	use	the	disease	management	approach,	which	the	NHSO	
applied	to	tertiary	care	and	treatments	for	many	specific	conditions	such	
as	cancer,	stroke,	heart	disease,	RRT,	and	so	on.	We	also	tried	to	cover	all	
aspects	of	the	care	process	from	prevention	programmes,	patient	
identification,	service	provision,	payment	reform	to	quality	control.”	(PM1)	
5.4.3.2 Actions and perceptions on disease management 
components 
Most	components	of	disease	management	are	included	in	the	UCS’s	RRT	
programme.	The	processes	of	population	identification,	guideline	protocols,	
reporting	systems,	collaborative	practice,	and	patients’	self‐care	management	
are	explicitly	stated	in	the	NHSO’s	manual	for	providers.	All	RRT	providers	are	
obliged	to	follow	these	processes	as	they	are	bound	with	the	programme’s	
registration	system	and	the	payment	system.	Process	and	outcome	
measurements	for	providers	are	optional	and	may	vary	depending	on	which	
indicators	RRT	units	adopt.	The	case	manager,	dialysis	nurse,	and	the	
nephrologist	act	as	main	care	providers.	Collaborative	practice	is	applied	but	
the	degree	of	coordination	with	professionals	in	other	sections	is	based	upon	
the	level	of	integration	within	the	facility	and	between	its	networks	(see	Table	
5‐5).			
Table 5‐5  RRT programme features linking to disease management components  
Components Features 
Evidence-based guideline 
protocol 
Protocols for providers are developed from evidence-based-
guidelines and linked to the payment system 
Population  identification Secondary prevention programme to identify patients with CKD 
risk factors. Patients are referred to a nephrologist if they reach 
advanced stages of CKD 
Reporting system  Electronic reporting system to manage the care process: 
registration, service delivery, medications that link to the 
payment system 
Process & outcome measurement National level: indicators such as number of patients in the 
programme, survival rate, and  PD-related infection rate 
Facility level: may vary 
Collaborative practice Dialysis nurses act as a case manager or central person to 
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Components Features 
communicate with patients and nephrologists. Patients may be 
referred to other professionals upon nephrologists’ requests. 
Self-care management support All patients are taught to perform self-care PD, as well as 
monitoring their clinical conditions, medicines and dietary intakes 
CKD= chronic kidney disease, PD= peritoneal dialysis 
i. Evidence-based guideline  
Evidence‐based	guidelines	in	the	RRT	programme	were	mainly	used	for	
payment	purposes.	This	is	because	the	NHSO	facilitates	the	RRT	delivery	system	
by	separating	the	programme	from	conventional	payment	mechanisms	
(capitation	and	DRG	with	global	budget),	so	services	in	the	RRT	programme	are	
reimbursed	by	a	fee	schedule	with	global	budget.	As	a	result,	protocols	were	
crucial	for	providers	as	a	standard	for	reimbursements	and	reporting	system,	as	
a	policy	maker	stated:		
“The	protocol	benefits	health	care	providers,	particularly	case	managers,	
they	know	what	else	needs	to	be	done.”	(PM9)	
A	policy	maker	explained	why	a	fixed	price	per	session	or	per	procedure	is	used	
as	a	strategy	to	manage	the	common	system	failure	to	motivate	providers	to	
provide	the	costly	services:	
“Providers	can	estimate	the	amount	of	profit	they	will	earn	for	a	case.	
Although,	the	financial	risk	for	unexpected	events	is	transferred	to	
providers,	they	seem	to	like	this	kind	of	payment.	This	is	how	the	NHSO	
stimulates	service	behaviour	of	providers.”	(PM2)	
As	guideline	protocols	were	linked	to	the	provider	payment,	some	providers	
had	concerns	about	the	blurred	boundaries	of	guidelines	(particularly	between	
health	care	sectors)	and	how	these	might	affect	their	hospitals’	income.		
 “In	my	opinion,	this	programme	is	good	but	the	procedure	(for	payment)	is	
confusing.	The	money	went	to	the	hospital	where	the	patient	registered.	
But	if	that	patient	has	a	complication	due	to	PD	and	goes	to	another	
hospital,	the	cost	of	this	treatment	can’t	be	claimed	because	it’s	already	
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paid	to	the	first	hospital.	[…]	and	there	is	no	guideline	about	who	the	
money	goes	to.”	(PM4)	
Providers	also	felt	it	was	unclear	exactly	which	items	could	be	claimed,	and	that	
the	list	was	complex	and	subject	to	change.	
“The	protocol	always	changes.	My	hospital	director	never	knows	in	details	
of	what	can	or	cannot	be	done	(for	the	claim/reimbursement).	So	the	
burden	is	put	on	us,	the	frontline	staff.”	(PV3)	
It	is	true	that	some	issues	of	the	NHSO	manual	for	providers	do	not	contain	
proper	information	about	reimbursable	items,	which	might	therefore	make	
providers	unsure	how	they	should	proceed.	For	example,	the	manual	for	
providers	in	2015	did	not	provide	reimbursement	rates	on	PD	and	did	not	
indicate	which	items	were	included	in	the	PD	bundle.	Furthermore,	sometimes	
reimbursable	items	in	the	manual	are	just	general	instructions/guidelines	but	
not	the	exact	items	which	the	NHSO	reimburses.						
ii. Patient identification process 
Policy	maker	and	provider	interviewees	agreed	that	the	separation	of	the	RRT	
programme	from	the	normal	healthcare	mainstream	was	to	ensure	patients’	
access	to	service,	as	an	interviewee	described:	
“In	 this	 first	period,	 separating	 the	administration	of	RRT	 from	normal	
system	 is	 good.	 Patients	 are	 targeted	 and	 selected	 to	 enroll	 for	 the	
programme	according	to	the	guideline	protocol.”	(PM9)	
Beyond	the	ease	of	access	to	treatment,	providers	also	thought	that	patients	
fully	benefited	from	the	programme	as	they	were	supported	along	their	journey	
in	the	care	process	and	could	live	longer	without	catastrophic	payment.	At	the	
same	time,	providers	did	not	feel	they	were	burdened	by	this	process,	as	an	
interviewee	explained:	
“It	is	our	normal	routine	to	screen	and	select	patients	into	the	dialysis	
system.”	(PV2)	
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However,	the	programme’s	mission	to	find	patients	who	developed	early	stages	
of	kidney	disease	in	communities	had	not	been	fully	achieved.	Most	patient	
interviewees	in	this	study	found	out	they	were	suffering	from	chronic	kidney	
disease	when	they	were	already	in	the	last	stage	and	needed	urgent	treatment.	
“I	had	hypertension	for	two	years,	then	one	day	I	became	very	ill	and	
vomited	a	lot	and	when	I	went	to	a	doctor,	he	told	me	I	had	end‐stage	
kidney	disease.”	(PD2)	
A	nephrologist	also	confirmed	that:	
“Around	half	of	the	ESRD	patients	weren’t	aware	they	had	chronic	kidney	
disease.	They	found	out	that	they	had	reached	the	last	stage	when	they	
got	very	sick	and	were	taken	to	the	hospital.”	(PM4)	
iii. Collaborative practice 
The	inclusion	of	various	groups	in	the	health	system	into	the	RRT	programme	
was	to	strengthen	linkages	between	system	components	and	consequently	
improve	quality	of	care.	The	network	covers	policy	makers,	health	care	
providers,	patients,	and	patients’	communities.	
a. NHSO-provider 
The	NHSO	developed	partnerships	with	providers	in	other	governmental	
sectors,	private	sectors,	and	health	care	professional	groups.	One	key	purpose	
was	to	increase	the	number	of	RRT	facilities.	Working	as	a	network	made	
covering	and	building	more	RRT	centres	possible	even	in	remote	areas.	Firstly,	
the	central	NHSO	asked	the	regional	NHSO	to	deal	with	health	facilities	in	their	
area	of	responsibility,	particularly	provincial	hospitals.	They	were	supported	
and	encouraged	to	join	the	programme	until	all	of	them	had	enough	capacity	to	
provide	dialysis	care.	Next,	large‐size	community	hospitals	and	hospitals	in	
remote	areas	with	availability	of	nephrologists	or	trained	internists	were	
targeted.		
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In	the	first	phase	of	the	RRT	programme,	the	NHSO	once	thought	about	inviting	
the	private	sector	to	take	part	in	expanding	RRT	services,	as	there	were	a	large	
number	of	private	RRT	facilities.	However,	there	were	concerns	about	quality	
control,	and	the	private	sector	has	just	begun	recently	to	enter	the	field	via	a	
pilot	model	which	is	expected	to	expand	in	the	near	future.	
Another	purpose	was	to	increase	the	production	of	PD	nurses,	regarding	which	
one	interviewee	provided	further	detail:	
“Before	the	introduction	of	the	RRT	programme,	PD	nurses	were	barely	
trained.	So	we	talked	with	professors	of	nursing	schools	about	the	amount	
of	new	PD	nurses	needed	for	the	new	programme.	For	any	school	that	
could	produce	such	an	amount,	we	would	support	funding	to	set	up	
training	courses	and	scholarships	for	student	nurses.	(PM3)	
Unlike	nurses,	physicians	were	supported	by	sponsoring	conferences	and	
meetings	using	connections	between	NHSO	and	the	Nephrology	Society	of	
Thailand	in	order	to	increase	their	interest	in	PD.	
b. NHSO-patient 
Coordination	between	NHSO	and	patient	groups	played	an	important	role	in	
convincing	patients	of	the	value	of	RRT	and	of	the	PD	first	policy.	Also,	working	
as	a	group	can	increase	bargaining	power	of	patients	in	negotiating	the	health	
benefit	package.	Since	the	RRT	policy	was	formulated,	representatives	from	the	
patient	society	have	been	allowed	to	sit	in	the	meeting	of	NHSO’s	sub‐
committee	and	are	able	to	express	opinions	regarding	the	benefit.	An	
interviewee	pointed	out	about	how	the	RRT	programme	empowers	patients	to	
take	an	active	role	in	their	health	care	benefit:	
“It’s	good	that	kidney	patients	have	chance	to	voice	their	concerns	and	
needs:	some	others	(patient	groups	for)	long	term	conditions	have	not	been	
as	lucky	as	we	are.	The	thing	is	if	you	(the	NHSO)	want	to	know	what	is	
going	on	here,	you	need	us	to	tell	you.	I	always	convince	the	board	about	
this.	So	far,	I	act	as	a	member	of	the	NHSO	subcommittee,	at	which	I	have	
equal	rights	to	those	of	physicians	to	express	my	opinions	on	what	kidney	
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patients	should	have.	Once	there	are	developments	on	this	issue,	I	put	them	
on	our	Facebook	to	tell	everyone	in	the	network.	We	also	have	our	own	
newsletters	which	are	issued	quarterly.	These	are	how	we	introduce	new	
health	benefits	and	updates	to	patients.	[…]	We	have	working	groups	of	
kidney	patients	in	every	province.	Each	working	group	has	similar	
activities	and	has	its	committee	which	links	to	their	regional	hospital.	
Every	year,	members	are	selected	from	each	region	to	make	policy	
recommendations.”	(PM8)	
c. Patients and community groups 
Communities	could	provide	services	that	complemented	the	RRT	service	
provision.	For	example,	local	health	centres,	although	they	had	no	RRT	
professionals	or	equipment,	took	part	in	screening	patients	with	chronic	kidney	
disease	and	cared	for	them	with	what	they	could.	If	the	patient	needed	to	use	
the	injection	(erythropoietin),	the	patient	could	keep	prefilled	syringes	at	a	
health	centre	and	come	back	when	it	was	time	to	use	them.	This	practice	helped	
strengthen	their	relationships	as	an	interviewee	from	a	health	centre	stated:	
“By	doing	so,	we	meet	the	patient	2‐3	times	a	week.	When	he	comes,	we	
measure	the	patient’s	blood	pressure,	examine	his	feet,	and	ask	if	he	needs	
anything	else.	Before	this,	patients	had	to	buy	dressing	sets	themselves	
which	are	a	bit	pricey.	So	I	asked	the	hospitals	to	provide	a	stock	of	
dressing	sets	at	the	health	centre	and	patients	can	get	them	for	free.”		
(PV5)	
Health	volunteers	were	another	community	group	who	helped	bridge	the	gap	
between	the	RRT	provision	and	patients.	However,	the	long‐term	future	of	the	
collaboration	was	uncertain	due	to	the	lack	of	concrete	guidelines	and	funding.	
A	provider	gave	details:	
“At	first,	we	promoted	health	volunteers	to	do	home	visits	to	PD	patients	
and	assess	if	their	house	was	qualified	for	home	dialysis,	we	got	good	
response	rates.	Sometimes	we	came	along	with	them	to	the	remote	area	
and	sometimes	to	other	provinces.	To	be	frank,	it	was	successful	because	
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there	was	budget	for	this	activity.	At	the	moment,	we	don’t	do	home	visits	
very	frequently	because	the	NHSO	no	longer	supports	this	activity.”	(PV2)	
Patients	also	built	up	connections	among	themselves,	which	could	be	via	
informal	talking	or	the	Friends	of	Kidney	Patients	Society.	The	society	
developed	networks	working	in	communities	by	educating	students	and	young	
people	about	kidney	disease	and	other	chronic	conditions.		
“Before	these	people	grow	up	and	become	chronically	ill,	they	need	to	know	
how	to	have	a	healthy	lifestyle	and	how	to	prevent	themselves	from	chronic	
conditions.”	(PM8)	
However,	the	degrees	of	patient‐community	network	varied	and	depended	on	
the	area.	An	interviewee	from	a	local	health	centre	said:	
“As	far	as	I	know,	there’s	no	kidney	patient	group	in	this	area.	What	I	saw	
is	that	patients	talk	about	their	experiences	while	they’re	waiting	for	
treatments	in	the	hospital.”	(PV5)	
iv. Self-care management 
This	section	focuses	on	the	bag	exchanging	technique	of	ten	PD	patients.	The	
patient	who	had	the	longest	dialysis	period	started	the	treatment	in	2009.	Most	
patients	had	diabetes	with	or	without	hypertension.	Six	patients	had	never	
experienced	peritonitis	(infection	of	the	peritoneum).	The	majority	of	patients	
were	living	with	their	family	and	received	support,	such	as	expenses,	a	place	to	
live	in,	instruments	for	PD,	or	care,	from	their	family	members.		
a. Places to perform exchange and dialysis bag storage 
There	were	three	patients	who	had	a	separate	room	in	their	house	to	perform	
exchanges.	The	rest	did	the	exchange	in	their	bedrooms	in	which	an	extra	wash	
basin	for	hand	washing	was	fixed	in	order	to	perform	the	exchange.	Patients	
used	a	corner	inside	or	outside	their	house	to	place	the	stock	of	dialysis	bags.	
Five	out	of	ten	patients	had	proper	storage.	This	means	dialysis	bags	were	kept	
in	a	clean	place	where	there	was	good	airflow	and	no	direct	sunlight.	
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b. Equipment and exchange technique 
Seven	patients	always	changed	the	dialysis	bag	by	themselves	while	the	others	
needed	help	from	carers.	From	observations,	5	out	of	10	patients	had	all	the	
essential	equipment	in	line	with	the	CAPD	self‐care	guidelines.		
Patients’	exchange	techniques	were	generally	good.	Effective	hand	washing	was	
the	behaviour	that	30%	of	patients	failed	to	perform	correctly.	All	patients	
knew	well	how	to	combine	individual	pieces	and	could	follow	each	step	
correctly.	After	patients	finished	loading	the	dialysis	fluid,	the	majority	of	them	
correctly	weighed	the	used	solution,	recording	the	result	in	their	diary,	and	then	
discarded	the	waste	(see	Table	5‐6).	
Table 5‐6  Observed behaviours and percentage of compliance 
Behaviour % compliance 
1) Arranging equipment 80 
2) Hand washing 70 
3) Surface cleaning 80 
4) Checking the unused bag 90 
5) Combining and connecting exchange devices 100 
6) Weighing of used dialysis solution 90 
7) Updating health records 90 
8) Waste disposal 100 
5.4.4 Patients’ decision making 
Patients’	treatment	decision	is	critical	when	making	up	their	mind	on	the	use	of	
care.	Once	diagnosed	with	ESRD	and	the	need	for	dialysis,	patients	and	their	
families	are	informed	about	the	condition	and	treatment	alternatives.	If	there	is	
no	contraindication,	patients	are	obligated	to	use	PD.	Because	PD	is	a	self‐care	
management	and	relies	heavily	on	support	from	the	patient’s	family,	the	
characteristics	of	the	patient	and	their	family,	as	well	as	their	relationships,	are	
crucial	to	the	decision	to	accept	or	refuse	PD.		
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i. Reasons to accept PD 
In	the	PD	first	policy,	in	addition	to	being	a	normal	PD	patient,	a	number	of	
patients	had	turned	to	PD	after	they	were	no	longer	able	to	afford	self‐pay	HD.	
PD	patient	interviewees	gave	advantages	of	PD	that	PD	relied	on	them	taking	
responsibility,	meaning	they	could	manage	their	daily	life	almost	as	usual:	
“I	like	taking	responsibility	of	my	own	care.”	(PD1)	
“It	fits	my	lifestyle	well,	I	can	manage	it.	When	I	need	to	travel,	I	just	take	
the	dialysis	kit	along.”		(PD8)	
“I	live	30	kilometers	from	the	hospital,	I	can’t	make	frequent	journeys	(like	
HD	patients),	it	makes	me	too	tired.”	(PD5)	
The	advantage	about	travelling,	a	provider	interviewee	added:	
	“After	starting	the	RRT	programme,	patients	can	easily	access	dialysis	
care,	even	ones	who	reside	far	away.	It’s	true	that	my	patients	who	live	on	
a	mountain	can	have	the	treatment.” (PV1) 
ii. Reasons to refuse PD 
One	out	of	the	six	patient	interviewees	was	wealthy	enough	to	opt	out	and	was	
having	self‐pay	hemodialysis,	in	spite	of	age.	Others	were	on	conservative	
treatment,	living	without	dialysis.	The	main	reason	they	reported	was	‘dialysis	
is	too	burdensome’.	Common	characteristics	found	in	these	five	opt‐out	patients	
were	advanced	age	with	multiple	comorbidities,	low	literacy	levels,	being	in	an	
underprivileged	family,	residing	in	rural	areas,	and	lacking	strong	family	
support.	These	conditions	together	made	patients	worry	about	putting	a	burden	
on	their	family.	
However,	patients	would	not	say	this	directly,	instead	they	mentioned	‘I’m	not	
afraid	of	dying’.	They	also	mentioned	they	were	‘scared	of	being	hurt’	or	‘can’t	
do	it’	which	could	be	a	response	or	an	excuse	for	unwillingness	to	have	PD.	A	
patient	on	conservative	therapy	stated:	
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“I	was	afraid,	didn’t	want	to	be	hurt,	and	didn’t	want	more	burdens.	
Doctors	taught	and	told	me	everything.	They	even	had	a	dummy	to	show	
me	how	to	do	it.	My	daughter	wanted	me	to	try	but	I	just	didn’t	want	to.	
She	worked	so	hard	and	had	too	many	burdens	so	I	didn’t	want	to	burden	
her	any	more.	[…]		I’ll	finally	die	someday,	and	I’m	not	afraid	of	it.”	(OO2)	
Some	patients	with	conservative	therapy	had	sole	responsibility	for	taking	care	
of	a	family	member.	Therefore,	dialysis	was	too	burdensome:	
“I	told	the	doctor	I’d	like	to	wait	(for	starting	treatment).	I	didn’t	have	
much	money	and	have	no	one	to	help	me	take	care	of	my	son	who	is	
mentally	ill.	He	can	just	sit	without	saying	a	word.	There’re	just	two	of	us,	
no	money,	no	car.	Treatment	is	free	but	not	the	travel	costs,	and	some	
medicines,	there	are	so	many	things	to	pay	for.	[…]	I	took	out	a	loan	to	
rent	some	land	for	growing	rice	and	hired	someone	to	help	me,	so	I	don’t	
have	time	to	do	(dialysis).	(OO4)	
The	GP	added	his	opinions	on	how	people	in	rural	communities	are	concerned	
about	their	families,	particularly	when	they	fall	ill.	Also,	an	issue	about	the	social	
norm	of	rural	communities	was	raised:	
“Family	is	a	very	important	factor.	They	(patients)	worry	that	doing	
dialysis	will	take	money	from	the	household,	or	that	their	children	will	
have	to	leave	their	job	to	take	care	of	them,	and	that	they	will	become	a	
burden	on	the	family.	[…]	Several	patients	here	aren’t	happy	having	some	
medical	equipment	sticking	on	their	body.	They	feel	like	a	severely	ill	
person.	‘I’d	rather	die	than	have	that	thing	in	me’,	they	say.”	(PV6)	
iii. Conservative management of end-stage renal disease 
Along	with	renal	replacement	therapy,	conservative	therapy	is	an	alternative	
approach	for	patients	who	prefer	not	to	have	dialysis.	Palliative	care,	therefore,	
can	support	conservative	management	of	ESRD	by	the	practice	
multidisciplinary	team.	It	involves	multiple	dimensions	of	care	which	have	close	
links	to	patients’	families.		
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In	health	facilities	where	there	was	a	multidisciplinary	team,	palliative	care	for	
patients	with	chronic	kidney	disease	appeared	to	facilitate	better	quality	of	life	
and	patient	self‐care.	Because	the	family	was	encouraged	to	be	involved	in	care	
management,	another	effect	on	patients	was	that	family	members	were	more	
bound	together.		
“We	found	that	families	who	have	no	choice	but	to	take	care	of	their	sick	
members	mostly	wanted	to	get	on	with	their	daily	lives	and	ignore	the	ill.	
This	left	the	ill	alone	and	lacking	in	emotional	support.	This	condition	
makes	the	ill	feel	as	if	they	were	a	burden	but	after	their	family	came	to	
look	after	them	properly,	it	relieved	the	feeling	of	being	a	burden.”	(PV10)	
5.5 Discussion 
This	section	is	divided	into	four	parts	according	to	findings	from	this	study.	It	
begins	with	a	discussion	on	perceptions	of	high‐cost	disease	by	different	
components	in	the	health	system.	Next,	the	policy	change	and	the	disease	
management	of	the	RRT	programme	are	discussed.	Finally,	this	section	ends	
with	discussions	on	patients’	decision	making	and	self‐care	management.		
5.5.1 High-cost diseases 
Policy	makers	and	providers’	views	on	high‐cost	diseases	focused	more	on	the	
financially	catastrophic	definition	than	the	high‐cost	definition	which	proposed	
by	Wyszewianski	(1986).	This	may	be	because	the	UCS	already	covers	
treatments	for	chronic	conditions	(such	as	heart	disease	and	diabetes)	that	are	
inexpensive	to	treat	once	but	require	multiple	visits,	meaning	costs	soon	add	
up.	Patients’	views	on	high‐cost	diseases	were	slightly	different	in	that	they	not	
only	looked	at	cost	of	treatments	but	also	indirect	costs	when	they	fell	ill.	For	
example	in	this	study,	although	eligible	for	free	treatment,	a	number	of	patients	
commented	that	paying	for	travel	costs,	no	carers,	and	being	the	sole	working	
member	in	the	family	were	barriers	to	receive	services.	Altogether,	these	
situations	can	cause	a	patient	to	incur	catastrophic	payment	or	decline	health	
care.	
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5.5.2 Creating an environment conducive to policy change 
The	UCS	policy	change	to	include	the	high‐cost	benefit,	RRT,	is	best	explained	by	
the	‘Triangle	that	moves	a	mountain’	framework	proposed	by	Wasi	(2000).	The	
triangle	model	of	Wasi	has	been	widely	used	in	explaining	policy	process	in	
Thailand	(Wibulpolprasert,	Chokevivat	et	al.	2011).	This	could	be	the	reason	
that	interviewees	who	were	working	in	the	health	policy	area	had	this	model	in	
their	mind,	so	they	always	mentioned	keywords	relating	to	this	model	while	
giving	interviews.		
Wasi’s	triangular	model	highlights	the	essential	interaction	between	three	
components.	The	first	component	is	knowledge	generation,	which	studies	the	
issue	until	it	can	explain	the	possibility	of	the	policy	implementation.	This	may	
be	accompanied	by	lessons	learnt	from	pilot	studies.	The	next	component	is	the	
public,	who	raise	the	issue	to	the	attention	of	politicians.	The	last	component	is	
the	politicians,	who	ensure	that	the	issue	is	ranked	as	top	priority	(Wasi	2000).		
Figure 5‐5  Triangle that moves a mountain model 
       Creation of knowledge 
	
	
	
            Societal movement            Political involvement 
         Adapted from: Wasi (2000) 
The	process	of	including	the	RRT	benefit	is	one	example	of	Wasi’s	model.	The	
creation	of	knowledge	presented	various	aspects	that	needed	to	be	considered.		
These	included	numbers	of	available	health	care	staff	and	facilities,	budget	
needs,	public	opinion,	and	policy	options	and	recommendations	on	this	issue.	
Meanwhile,	the	public	were	aware	that	renal	failure	could	bring	patients	into	
catastrophic	health	spending.	This	corresponded	to	the	desire	of	UCS	policy	
makers	who	aimed	to	protect	its	beneficiaries	from	financial	catastrophe.	The	
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government,	which	at	the	time	had	the	full	power	of	the	military	coup	and	
government	leaders’	intention	to	support	equality,	meant	that	the	move	to	
introduce	the	RRT	benefit	was	successful.	
5.5.3 Disease management of RRT in Thailand 
Generally,	applications	of	disease	management	programmes	vary	in	terms	of	
common	definitions	of	concepts,	levels	of	integration	among	sectors	in	the	
health	system,	and	each	programme’s	focus	(Krumholz,	Currie	et	al.	2006;	Nolte	
and	McKee	2008;	Hisashige	2012).	The	UCS	adopts	the	disease	management	
approach	to	address	the	issue	in	its	normal	mainstream	where	the	capitation	
and	DRG	payments	are	not	persuasive	to	treatment	providers,	particularly	in	
terms	of	providing	treatment	for	patients	who	are	suffering	from	high‐cost	
conditions.		
In	arranging	the	RRT	programme,	its	administrative	functions	and	financing	
system	were	separated	from	mainstream	UCS	services.	By	doing	this,	the	
disease	management	approach	was	more	focused,	and	providers	were	
motivated	by	fee	schedule	payment	to	provide	this	high‐cost	care	as	they	could	
earn	more	by	providing	more	services.			
The	key	disease	management	interventions	used	were	evidence‐based	
guidelines	and	reporting	systems.	The	evidence‐based	guidelines	lay	down	the	
procedure	based	on	medical	evidence	for	providers.	The	guidelines	were	bound	
with	the	payment	mechanism	and	led	to	other	components	of	disease	
management	which	were	patient	identification,	collaborative	practice,	reporting	
systems,	and	self‐management	by	patients	and	families.	In	the	RRT	programme,	
patients	are	targeted	and	selected	to	enroll	for	the	programme	according	to	the	
guideline	protocol.	Payments	are	paid	to	RRT	units	by	the	reporting	system.	The	
collaborative	practice	is	an	integral	part	of	the	RRT	programme	between	and	
within	the	groups:	policy	maker,	provider,	and	patient.	It	is	used	as	a	means	of	
improving	the	quality	and	efficiency	of	caring	for	patients	with	end‐stage	renal	
disease.		
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Some	providers	mentioned	difficulties	they	had	about	guideline	protocols.	This	
might	reflect	the	fact	that	making	a	guideline	protocol	that	suits	everybody’s	
preference	is	a	challenge	to	policy	makers,	particularly	linking	a	protocol	with	
payment	and	frequent	updating	with	new	information.	This	is	because	guideline	
protocols	are	made	at	the	central	NHSO	and	are	used	by	providers	at	different	
levels	of	care,	protocols	should	be	practical	and	new	information	should	be	
clear	for	providers	what	they	should	do	to	fulfill	their	duty.		
5.5.4 Patients’ self-care management 
Patient’s	self‐care	management	is	a	crucial	part	in	the	RRT	disease	management	
programme.	It	was	a	result	of	limitations	in	UCS	resources	since	numbers	of	
RRT	units	and	health	care	professionals	were	poorly	distributed	and	were	not	
numerous	enough	to	meet	the	high	need	of	patients	with	end‐stage	renal	
disease.	Policy	makers	of	the	UCS	agreed	that	peritoneal	dialysis	was	best	suited	
to	the	UCS	context	as	it	had	enough	capacity	to	expand	the	RRT	health	benefit	to	
reach	patients	quickly	once	the	policy	was	launched.	Given	the	developing	
country	setting	of	the	UCS,	the	benefits	of	peritoneal	dialysis	outweigh	those	of	
hemodialysis	as	the	former	requires	fewer	nurses	to	look	after	patients	and	
fewer	visits	to	hospitals.	
Patients	who	first	enroll	in	the	RRT	programme	rely	upon	PD.	PD	is	a	home‐
based	dialysis	and	the	patient	characteristics	can	influence	their	practices	and	
performance.	All	patients	and/or	their	carers	in	this	study	know	how	to	
perform	the	exchange	procedure,	but	due	to	being	poor	or	unaware	of	the	
infection,	there	was	some	lack	of	essential	equipment	for	bag	exchange,	
violating	sterile	technique,	and	having	unclean	environment	for	PD	bag	
exchange.	Consequently,	these	situations	may	lead	to	the	infection	of	the	
peritoneum.		
Family	plays	an	important	role	in	patients’	decision	making	before	they	enroll	
in	the	RRT	programme	and	in	supporting	patients	once	they	have	joined	in.	
Encouragement	and	help	from	family	were	mentioned	by	all	interviewees	who	
chose	to	undergo	dialysis	and	those	who	were	functioning	post‐renal	transplant	
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in	this	study.	Conversely,	family	support	was	lacking	among	those	who	declined	
to	start	dialysis.		
Although	the	RRT	programme	is	carefully	designed,	a	number	of	patients	who	
are	eligible	for	the	programme	decided	not	to	enroll	because	dialysis	is	viewed	
as	too	burdensome.	Common	characteristics	of	these	patients	include	advanced	
age,	belonging	to	an	underprivileged	family,	low	levels	of	education,	and	no	
carer	to	help.	Social	norms	can	also	determine	the	use	of	care.	In	particular,	
having	dialysis	instruments	on	them	makes	some	patients	feel	they	cannot	
maintain	their	ordinary	life	like	others.	These	patients	refuse	dialysis	so	as	to	
avoid	social	exclusion.	An	alternative	to	dialysis,	conservative	therapy,	is	
efficiently	applied	in	some	health	facilities	where	a	multidisciplinary	team	
exists.	A	constraint	to	this	approach	may	include	the	limited	number	of	health	
facilities	in	Thailand	offering	multidisciplinary	team	management,	as	well	as	
variation	in	practices	and	the	level	of	collaboration.		
5.6 Conclusions 
This	study	has	highlighted	how	the	combination	of	three	components:	the	
academicians,	public	actions,	and	politicians,	in	long	effort	to	launch	the	UCS	
RRT	programme,	has	achieved.	Despite	Thailand,	in	the	first	place,	is	a	
developing	country	lacking	nationwide	RRT	staff	and	facilities.	A	disease	
management	approach	was	used	to	arrange	RRT	service	provision	aiming	to	
increase	ESRD	patients’	access	to	care.		
From	the	UCS	experience	with	the	RRT	programme,	building	the	system	
resources	and	designing	policies	are	the	basic	elements	which	support	the	
reform	of	delivery	system	design.	This	includes	the	application	of	disease	
management:	evidence‐based	guidelines,	patient	identification	process,	self‐
care	management,	and	reporting	systems	by	means	of	collaboration	between	
people	at	different	levels	in	the	health	system.			
After	launching	the	RRT	programme,	the	majority	of	patient	interviewees	
reported	that	they	had	good	quality	of	life,	however	some	patients	felt	indirect	
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costs	of	travelling	to	the	RRT	unit	were	too	large	for	them.	This	study	found	a	
number	of	patients	in	a	community	hospital	refused	to	start	dialysis	but	were	
looked	after	by	a	multidisciplinary	team.	This	multidisciplinary	approach	was	
found	to	be	able	to	fill	a	gap	between	primary	care	providers	and	ESRD	patients.	 
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CHAPTER 6 The changing patterns of access to service and 
mortality of the RRT programme overtime 
6.1 Introduction 
This	chapter	aims	to	assess	the	changing	patterns	of	1)	entry	into	the	RRT	
programme	of	adult	UCS	patients	diagnosed	with	end‐stage	renal	disease	
(ESRD)	and	2)	mortality	of	adult	UCS	members	who	had	an	ESRD	diagnosis,	
using	descriptive	analysis	and	an	age‐period‐cohort	analysis.	The	main	point	to	
establish	is	whether	launching	the	RRT	programme	promoted	entry	into	the	
programme	and	reduced	the	mortality	rate	over	time.		
Next	section,	6.2	provides	the	framework	for	data	analysis,	a	summary	of	
variables	used	in	all	models,	and	explains	how	the	datasets	were	constructed	
and	analysed.	A	number	of	indicators	to	measure	access	to	RRT	services	and	
mortality	are	described	here.	Section	6.3	presents	the	results	of	an	analysis	of	
these	indicators.	Sections	6.4	and	6.5	discuss	findings	and	limitations	of	this	
chapter.	
6.2 Data analysis and modelling approach 
The	conceptual	framework	for	the	analysis	of	this	objective	is	presented	in	
Figure	6‐1.	From	the	general	UCS	population,	a	number	of	patients	develop	
chronic	kidney	disease.	After	that,	a	number	of	them	develop	the	final	stage	and	
need	RRT.	Access	to	RRT	is	measured	by	new	registrations	into	each	RRT	
modality	as	a	proportion	of	the	number	of	new	patients	diagnosed	with	ESRD.	
Death	while	on	RRT	is	measured	as	the	proportion	of	all‐cause	mortality	among	
patients	who	were	maintaining	RRT.	Because	there	are	many	untreated	
patients,	all‐cause	mortality	of	all	patients	with	an	ESRD	diagnosis	would	be	
assessed	as	an	indicator	to	show	patients’	overall	health	status.	
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Figure 6‐1  Conceptual framework for analysing access and mortality  
 
 
UCS=Universal Coverage Scheme, RRT=renal replacement therapy, PD=peritoneal dialysis, HD=hemodialysis, 
KT=kidney transplant, death=all-cause of death  
6.2.1 Summary of models and variables 
Table	6‐1	provides	a	summary	of	models	and	variables	used	in	both	descriptive	
analysis	and	age‐period‐cohort	analysis.	In	terms	of	entry	into	the	RRT	
programme,	the	study	period	is	between	2008	and	2013.	In	this	study,	mortality	
refers	to	death	by	any	cause,	assessed	between	2005	and	2013.		
To	assess	the	pattern	of	entry	into	the	RRT	programme,	three	models	were	
separately	analysed	in	line	with	the	UCS’s	RRT	modalities:	peritoneal	dialysis	
(PD),	hemodialysis	(HD),	and	kidney	transplant	(KT).	To	assess	changes	in	
death	rates,	all‐cause	mortality	is	assessed	in	two	groups	of	patients:	all	
patients	with	an	ESRD	diagnosis	and	patients	who	were	maintaining	any	RRT	
modality.		
Age	of	the	entry	into	the	RRT	programme	model	was	determined	by	the	time	
between	the	year	of	birth	and	the	year	of	the	programme’s	registration	where	
age	in	the	mortality	model	referred	to	the	time	between	the	year	of	birth	and	
the	year	of	death.	Cohort	was	the	individuals’	years	of	birth.	The	period	in	all	
models	denoted	calendar	years	of	studied	period.	As	a	short	duration	was	
available	for	period	(6‐9	years	in	comparison	to	durations	of	age	and	cohort),	
period	was	used	as	a	single	year	interval.	In	entry	into	the	RRT	programme	
models,	three	modalities	of	RRT	were	separately	used	as	covariates.		
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Table 6‐1  Summary of models and variables 
Model 1. Entry into the RRT programme 2. Mortality 
Follow-up 
period  
Jan 2008 – Dec 2013 Overall ESRD mortality: Jan 2005 - Dec 
2013  
CFR and RRT mortality: Jan 2008-Dec 
2013 
Measure ESRD patients who have 
experienced dialysis registration or 
kidney transplant  
ESRD patients who died due to any 
cause or patients who died on RRT  
Numerator Number of new registrations or 
transplantation 
Number of deaths 
Denominator New ESRD diagnoses of UCS Mortality of ESRD patients: mid-year UCS 
population 
Case fatality: UCS patients with ESRD 
diagnosis 
RRT mortality: UCS patients who used 
RRT 
Variable: Age Number of years between the year of 
birth and registration with the RRT 
programme (or transplantation)  
Range: 20-89 years (dialysis) 
           :   20-60 years (KT) 
Number of years between the year of birth 
and the year of death 
Range:  20-89 years 
Variable: Period Calendar year of registration or 
transplantation 
Range: 2008-2013 
Calendar year of death  
Range: 2005-2013 or 2008-2013 
Variable: Cohort Calendar year of birth  
Range: 1908-1993 
Calendar year of birth  
Range: 1905-1993 
Covariates HD, PD, and KT  None 
UCS=universal coverage scheme, ESRD=end-stage renal disease, CFR=case facility rate, RRT=renal 
replacement therapy, HD=hemodialysis, PD=peritoneal dialysis, KT=kidney transplant 
The	data	analysis	involved	three	main	steps;	1)	constructing	main	dataset,	2)	
descriptive	analysis,	and	3)	age‐period‐cohort	analysis.	
6.2.2 Constructing main datasets 
To	construct	the	main	dataset	for	all	types	of	analyses	in	this	study,	the	first	
step	was	to	select	all	patients	who	were	diagnosed	with	end‐stage	renal	disease	
from	the	inpatient	and	outpatient	databases.	Next,	their	encoded	citizen	
numbers	were	matched	with	encoded	citizen	numbers	in	the	RRT	database	and	
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vital	registry.	This	stage	yielded	189,059	UCS	patients	with	an	ESRD	diagnosis.	
Table	6‐2	gives	an	example	of	the	dataset	at	this	point.		
Table 6‐2  First ten observations of the main dataset 
 Encoded citizen number Date of Birth 
Year of 
Diagnosis 
Year of 
Registration 
Year of 
Death Modality 
1 ++GlXQAecEU+pRH01JSPEg== . 2011 . 2013 None 
2 ++GlXQAecEU3g9P0Vpp5ow== . 2009 . . None 
3 ++GlXQAecEUbnKTSWrSB+w== . 2008 . . None 
4 ++GlXQAecEUvA3rv2+ZMyA== 02-Sep-64 2011 2011 2012 PD 
5 ++GlXQAecEV2J/Jw/D9uJw== 25-Sep-63 2013 2014 . PD 
6 ++GlXQAecEV7qhDaldT8xg== . 2012 . 2013 None 
7 ++GlXQAecEVDUCjKc6qO/Q== . 2004 . 2005 None 
8 ++GlXQAecEVMHvANBIlfCA== . 2011 . 2012 None 
9 ++GlXQAecEVN4i514t1G2g== 09-Mar-45 2008 2011 2011 HD 
10 ++GlXQAecEVUyXW6hqRF+A== 01-Jul-53 2008 2009 2012 HD 
Next,	individuals	were	grouped	into	14	five‐year	age	at	registration	(or	at	
death)	groups	(aged	20‐24	to	85‐89),	15	five‐year	cohort	groups	and	a	two‐year	
cohort	group	(5‐year	group	from	1916‐1990	and	1991‐1993).	Period	is	used	as	
a	1‐year	interval	(from	2005‐2013).	Table	6‐3	provides	an	example	of	the	
dataset	when	individuals	were	grouped	into	ranges	of	age,	cohort,	and	period.		
Table 6‐3  First ten observations of the aggregated dataset of the death model 
 Age Cohort Period Age Group 
Cohort 
Group 
Period 
Group 
Death 
Counts Population 
1 20 1988 2008 35-39 1986-90 2008 13 51 
2 21 1987 2008 20-24 1986-90 2008 12 73 
3 22 1986 2008 20-24 1986-90 2008 8 71 
4 23 1985 2008 20-24 1981-85 2008 8 70 
5 24 1984 2008 20-24 1981-85 2008 11 94 
6 25 1983 2008 25-30 1981-85 2008 14 71 
7 26 1982 2008 25-30 1981-85 2008 11 112 
8 27 1981 2008 25-30 1981-85 2008 17 107 
9 28 1980 2008 25-30 1976-80 2008 16 126 
10 29 1979 2008 25-30 1976-80 2008 16 128 
Age=age at death, Cohort=calendar year of birth, Period=year of death, death counts=number of deaths in a particular 
group, population=number of patients in a particular group 
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6.2.3 Descriptive analysis 
The	descriptive	analysis	is	presented	in	two	sections	for	the	two	main	models:	
entry	into	the	RRT	programme	model,	and	a	mortality	model.	
6.2.3.1 Entry into the RRT programme models 
For	peritoneal	dialysis	(PD)	and	hemodialysis	(HD)	entries	into	the	RRT	
programme	were	identified	by	patient	registrations.	Patients	who	had	a	kidney	
transplant	(KT)	were	identified	as	entering	into	the	programme	according	to	
their	date	of	transplantation.		
For	the	dataset	of	entry	into	the	RRT	programme,	only	those	who	used	such	
treatment	were	retained.	Three	variables	in	the	three	models,	namely	age,	
period,	and	date	of	birth	were	generated	from	the	pooled	data	of	all	individuals.	
Age	denotes	number	of	years	between	the	year	of	birth	and	the	year	of	first	
registration	in	the	RRT	programme.	Period	is	calendar	years	spent	registered.	
Cohort	refers	to	individuals’	years	of	birth.		
To	calculate	rates	of	registrations,	numbers	of	new	registrations	with	PD	or	HD	
or	numbers	of	transplantation	were	used	as	numerators.	The	reference	
population,	the	denominator,	was	the	annual	number	of	new	patients	diagnosed	
with	ESRD.	The	period	for	studying	entry	into	the	RRT	programme	was	2008	to	
2013.	This	is	because	the	RRT	programme	started	in	January	2008,	and	data	
was	available	from	this	point.	Rates	were	expressed	as	rates	per	100	new	ESRD	
diagnoses	(PD,	HD)	and	1,000	new	ESRD	diagnoses	(KT).	
6.2.3.2 Mortality models 
There	are	three	types	of	mortality	models:	1)	the	death	rate	of	ESRD	patients,	2)	
the	ESRD	case	fatality	rate,	and	3)	the	RRT	mortality	rate.	These	all	differ	in	
terms	of	numerators	and	denominators	used.	
To	construct	the	dataset	of	the	death	cohort	from	the	main	dataset,	only	those	
who	died	were	kept.	Next,	individual	records	were	collapsed	in	order	to	create	
aggregate	level	data	for	age,	period,	and	cohort.	In	these	models,	age	denotes	
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the	number	of	years	between	the	year	of	birth	and	the	year	of	death.	Period	is	
the	calendar	year	of	death.	Cohort	refers	to	an	individual’s	year	of	birth.	
i. Death rate of ESRD patients 
Death	rates	of	ESRD	patients	were	calculated	to	estimate	deaths	of	patients	with	
an	ESRD	diagnosis	among	the	UCS	population.	All‐cause	death	counts	of	those	
with	ESRD	in	each	age	group	were	used	as	the	numerator.	The	denominator	
was	the	number	of	mid‐year	UCS	members.	Rates	were	expressed	as	rates	per	
100,000	UCS	population.	The	follow	up	period	to	estimate	all‐cause	mortality	
was	2005	to	2013.	
ESRD death rate   =    Number of deaths from all causes among patients with ESRD x 100,000 
                                               Number of mid-year UCS members 
Age‐standardised	mortality	rates	were	estimated	to	compare	all‐cause	
mortality	rates	of	patients	with	ESRD	over	time,	in	case	there	was	a	change	in	
the	age	structure	of	the	UCS	population.	Rates	were	calculated	by	the	direct	
method	using	the	WHO	world	population	(2000)	as	the	reference	and	
expressed	as	rates	per	100,000	UCS	population.			
ii. Case fatality rate (CFR) 
The	case	fatality	rate	is	a	measure	of	the	severity	of	a	disease.	It	is	the	
proportion	of	persons	with	the	disease	who	die	from	it.	In	this	study,	it	was	
calculated	using	the	formula	below:	
CFR	 =						 Number of deaths from all causes among patients with ESRD x 100 
               Number of all patients with ESRD 
Gordis	(2008)	suggested	that	the	CFR	is	ideally	suited	for	measuring	the	
severity	of	short‐term	diseases	or	acute	conditions.	For	example,	Mason	and	
Goldacre	(2004)	used	the	CFR	of	emergency	admissions	to	compare	hospital	
performance.	The	current	study	calculated	the	CFR	to	estimate	the	trend	of	
deaths.	This	made	it	possible	to	compare	deaths	among	ESRD	patients	(in	this	
section)	with	deaths	in	the	UCS	population	(in	section	i).		
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iii. RRT mortality 
RRT	mortality	was	calculated	in	order	to	reveal	mortality	rates	in	patients	who	
were	maintaining	RRT.	The	numerator	was	death	counts	from	any	cause	of	
those	UCS	members	using	any	RRT	modality	(peritoneal	dialysis,	hemodialysis,	
and	kidney	transplant).	The	denominator	was	the	number	of	UCS	members	who	
were	on	RRT.	Rates	were	expressed	as	rates	per	1,000	patient	years	at	risk.	The	
age‐standardised	mortality	rate	was	calculated	by	the	direct	method	using	the	
WHO	world	population	(2000)	as	the	reference.	The	formula	is	shown	below.	
RRT mortality rate  			=		   Number of deaths from all causes among patients on RRT x 1,000 
                 Number of all patients on RRT 
6.2.4 Age-period-cohort analysis  
There	were	two	steps	of	age‐period‐cohort	analysis.	The	first	step	was	to	select	
the	model	which	yielded	the	lowest	deviance	in	comparison	to	the	standard	
model	(or	the	null	model	which	contains	only	the	age	parameter).	The	second	
step	was	to	model	effects	of	age,	period,	and	cohort.	They	are	presented	in	the	
assessing	goodness‐of‐fit	section	and	modeling	effects	of	age,	period,	and	cohort	
section	respectively.	
6.2.4.1 Assessing goodness-of-fit  
A	set	of	nested	models	(likelihood‐ratio	test)	was	used	to	compare	the	
goodness‐of‐fit	within	a	set	of	models.	This	was	done	by	first	comparing	the	
deviance	of	any	model	that	deviates	from	linear	effects	(the	null	model).	The	
deviance	was	then	compared	in	this	manner	until	the	deviance	of	the	last	pair	
models	was	obtained.	The	preferred	model	was	selected	by	the	lowest	deviance.	
There	were	five	models	to	be	compared	with	the	null	model:	1)	Age‐drift	(linear	
effect),	2)	Age‐period,	3)	Age‐cohort,	4)	Age‐period‐cohort,	and	5)	Age‐drift	
(non‐linear	effect).	The	best	fitting	model	would	be	further	used	to	estimate	
effects	of	age,	period,	and	cohort. 
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6.2.4.2 Modeling effects of age, period, and cohort  
This	study	modeled	effects	of	age,	period,	and	cohort	using	the	parametrisation	
method	proposed	by	Carstensen	(2007).	After	identifying	the	best	model,	the	
effects	of	the	key	variables	(age,	period,	and	cohort)	were	estimated	by	using	a	
log‐linear	Poisson	regression.	For	parametrisation,	drift	was	extracted	by	the	
weight	average	method.	Knots	(parameters)	were	equally	spaced.	Equal	
numbers	of	knots	were	allocated	to	age,	period	and	cohort.	The	study	used	five	
knots	in	all	models.	As	this	study	sought	to	explain	the	effects	of	calendar	time	
on	death	and	registration,	drift	was	put	on	the	period	variable.	Then	the	cohort	
effect	was	constrained	to	have	no	overall	slope	and	to	be	zero	on	average	on	the	
log	scale.	After	adjustment	of	the	cohort	effect,	the	age	effect	was	estimated	for	
the	selected	reference	period	(year	2010).			
Data	analyses	and	graphical	presentations	in	this	study	were	conducted	by	
using	Stata	version	12.	Modelling	was	carried	out	using	the	apcfit	command	
(Rutherford,	Lambert	et	al.	2010).	Only	goodness	of	fit	was	assessed	using	R	
studio	version	3.0.2.	All	confidence	intervals	are	95%	confidence	intervals.	
Selected	Stata	commands	were	shown	in	Appendix	7.	
6.3 Results 
In	this	section,	descriptive	analysis	is	presented	first.	It	is	followed	by	the	age‐
period‐cohort	model	fitting.	The	results	of	entry	into	the	RRT	programme	(for	
hemodialysis,	peritoneal	dialysis,	and	kidney	transplant)	and	mortality	are	
separately	reported.	
6.3.1 Entry into the RRT programme 
Entry	into	the	RRT	programme	was	represented	by	new	registrations	with	the	
two	dialysis	modalities	or	undergoing	transplantation.	The	selected	time	period	
to	conduct	data	analysis	was	six	years	between	1	January	2008	and	31	
December	2013.	
CHAPTER 6  The changing patterns of access to service and mortality of the RRT programme overtime 
163 
	
6.3.1.1 Descriptive analysis 
Table	6‐4	and	Table	6‐5	show	numbers	of	new	patients	with	ESRD,	aged	20‐89,	
registered	with	PD	and	HD	programmes	respectively.	From	2008	to	2013,	
annual	figures	of	new	PD	patients	increased	over	time	and	the	total	number	of	
new	PD	registrations	in	this	period	was	27,386.		
Table 6‐4  Numbers of new peritoneal dialysis registrations 2008‐2013 
Age 2008 2009 2010 2011 2012 2013 %Total 
20-24  63   94   80   104   132   113  2.17% 
25-29  66   130   106   129   138   121  2.55% 
30-34  94   144   179   155   167   201  3.37% 
35-39  101   201   208   251   247   259  4.56% 
40-44  150   315   330   346   412   460  7.15% 
45-49  185   428   498   571   608   641  10.42% 
50-54  196   518   639   729   813   838  13.36% 
55-59  201   557   734   837   955   1,078  15.67% 
60-64  118   506   699   839   992   1,101  15.58% 
65-69  76   362   495   636   726   838  11.58% 
70-74  42   196   362   399   476   555  7.61% 
75-79  18   103   148   216   225   304  3.93% 
80-84  7   33   48   80   91   90  1.50% 
85-89  -    7   15   22   18   21  0.54% 
Total 1,317   3,594  4,541  5,314  6,000   6,620  100.00% 
In	the	same	period	and	for	the	same	age	groups,	the	number	of	new	HD	
registrations	was	lower than	that	of	PD	at	a	total	of	19,055	registrations.	In	
2008,	figures	of	HD	registrations	were	high	as	a	consequence	of	the	policy	that	
allowed	current	self‐funded	HD	users	to	enter	the	RRT	programme	and	access	
free	HD.	Total	numbers	of	HD	registration	increased	to	a	peak	in	2011	and	
declined	slightly	after	that,	Table	6‐5.		
Table 6‐5  Numbers of new hemodialysis registrations, 2008‐2013  
Age 2008 2009 2010 2011 2012 2013 %Total 
20-24  141   141   141   141   141   141  4.44% 
25-29  161   29   65   69   58   51  2.27% 
30-34  206   45   88   86   87   75  3.08% 
35-39  288   52   99   127   110   129  4.22% 
40-44  403   81   163   177   148   142  5.85% 
45-49  534   90   205   264   267   219  8.29% 
50-54  788   110   280   336   316   308  11.22% 
55-59  874   150   343   433   426   445  14.02% 
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Age 2008 2009 2010 2011 2012 2013 %Total 
60-64  901   134   386   482   465   469  14.89% 
65-69  893   97   287   364   374   313  12.22% 
70-74  725   73   252   319   275   265  10.02% 
75-79  434   37   132   199   182   146  5.93% 
80-84  194   12   69   87   101   57  2.73% 
85-89  58   4   22   27   33   14  0.83% 
Total 6,600   1,055   2,532   3,111   2,983   2,774  100.00% 
The	total	numbers	of	ESRD	patients	who	had	a	kidney	transplant	increased	
slowly	from	2008	until	2012.	After	that,	a	slight	drop	was	observed	in	2013.	The	
age	group	35‐39	accounted	for	the	highest	proportion	at	around	15%	of	overall	
cases.	From	2008,	there	was	a	total	of	992	kidney	transplants	(see	Table	6‐6).	
Table 6‐6  Numbers of kidney transplants 2008‐2013 
Age 2008 2009 2010 2011 2012 2013 %Total 
20-24 9 9 17 39 31 18 12.40% 
25-29 6 17 16 19 33 21 11.29% 
30-34 13 12 17 34 37 28 14.21% 
35-39 15 20 16 37 37 22 14.82% 
40-44 15 9 20 17 33 32 12.70% 
45-49 12 24 11 19 35 26 12.80% 
50-54 11 11 22 12 27 27 11.09% 
55-59 12 12 14 25 11 20 9.48% 
60-64 0 0 4 0 3 5 1.21% 
Total 93 114 137 202 247 199 100.00% 
Table	6‐7	shows	annual	numbers	of	UCS	patients	who	were	newly	diagnosed	
with	end‐stage	renal	disease	in	the	corresponding	age	groups	and	periods. New	
ESRD	diagnoses	decreased	from	a	maximum	of	35,186	diagnoses	in	2008	and	
then	fluctuated	between	15,000‐34,000	diagnoses	per	year.	Although	there	was	
a	variation	in	the	total	numbers,	percentages	of	patients	within	each	age	group	
did	not	much	change	after	the	initial	year	(2008).		
Table 6‐7  Numbers of new ESRD diagnoses with percentages in parentheses 
2008‐2013 
Age 2008 2009 2010 2011 2012 2013 
20-24 418 (1.2%) 168 (1.1%) 284 (0.8%) 360 (1.1%) 293 (0.9%) 174 (0.9%) 
25-29 638 (1.8%) 285 (1.9%) 400 (1.2%) 474 (1.4%) 377 (1.2%) 218 (1.1%) 
30-34 970 (2.8%) 411 (2.7%) 612 (1.8%) 689 (2.0%) 535 (1.7%) 329 (1.6%) 
35-39 1257 (3.6%) 511 (3.4%) 771 (2.3%) 936 (2.7%) 795 (2.5%) 481 (2.4%) 
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Age 2008 2009 2010 2011 2012 2013 
40-44 1825 (5.2%) 769 (5.1%) 1206 (3.5%) 1392 (4.1%) 1185 (3.7%) 802 (4.0%) 
45-49 2549 (7.2%) 1084 (7.2%) 1804 (5.3%) 2210 (6.5%) 1828 (5.7%) 1208 (6.0%) 
50-54 3677 (10.5%) 1410 (9.4%) 2663 (7.8%) 2995 (8.8%) 2688 (8.4%) 1719 (8.5%) 
55-59 4392 (12.5%) 1811 (12.1%) 3339 (9.8%) 3841 (11.3%) 3680 (11.5%) 2425 (11.9%) 
60-64 4407 (12.5%) 1904 (12.7%) 3830 (11.2%) 4509 (13.2%) 4326 (13.5%) 2849 (14.0%) 
65-69 4613 (13.1%) 1943 (13.0%) 3741 (11.0%) 4394 (12.9%) 4274 (13.3%) 2758 (13.6%) 
70-74 4555 (12.9%) 1872 (12.5%) 3919 (11.5%) 4632 (13.6%) 4460 (13.9%) 2577 (12.7%) 
75-79 3448 (9.8%) 1553 (10.4%) 3320 (9.7%) 4054 (11.9%) 3782 (11.8%) 2388 (11.8%) 
80-84 1776 (5.0%) 863 (5.8%) 2017 (5.9%) 2507 (7.4%) 2650 (8.3%) 1635 (8.1%) 
85-89 661 (1.9%) 419 (2.8%) 872 (2.6%) 1113 (3.3%) 1207 (3.8%) 733 (3.6%) 
Total 35,186 (100%) 15,003 (100%) 28,778 (100%) 34,106 (100%) 32,080 (100%) 20,296 (100%) 
i. Peritoneal Dialysis 
Results	from	the	peritoneal	dialysis	database	show	a	broad	range	of	new	
registration	rates	across	age	groups,	calendar	years,	and	cohort	groups	(Figure	
6‐2	a‐d).	
Figure	6‐2 a	and	c	
Over	the	six‐year	period,	it	is	clear	that	registration	rates	decreased	with	
increasing	age.	Although	the	registration	rate	in	2008	was	low	due	to	the	start	
of	the	programme,	in	2009,	the	rates	went	up	to	a	peak	across	most	age	groups	
and	then	gradually	decreased	in	successive	years.	Between	2010	and	2012,	PD	
registration	rates	went	down	and	were	approximately	equal	within	same	age	
groups.	In	2013,	most	age	groups	showed	significantly	increasing	registration	
rates.	
Figure	6‐2 b	and	d	
An	increase	in	the	registration	rates	among the	more	recent	cohort	groups	
(birth	cohorts	1956‐60	to	1991‐93)	and	younger	patients	(20‐24	to	50‐54	years	
old)	was	observed.	In	contrast,	earlier	cohort	groups	(birth	cohorts	1916‐20	to	
1936‐40)	and	older	patients	registration	rates	(65‐69	to	85‐89	years	old)	
increased	but	at	a	slower	rate.	
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    Figure 6‐2  Registration rates of new peritoneal dialysis cases 2008‐2013 
	
ii. Hemodialysis 
Figure	6‐3 a‐d	give	information	about	registration	rates	of	ESRD	patients	into	
the	UCS’s	hemodialysis	programme	between	2008	and	2013	by	calendar	year,	
age	group,	and	cohort	group.		
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Figure	6‐3 a	and	c	
In	2008	HD	registration	rates	were	high,	at	around	20	cases	per	100	new	ESRD	
diagnoses,	and	were	more	apparent	in	patients	under	65.	This	however,	was	a	
consequence	of	the	transfer	of	existing	self‐funded	HD	patients	into	the	UCS	
programme.	From	2009	to	2012,	hemodialysis	registration	rates	went	down	
and	were	fairly	homogeneous	across	patients	aged	20‐60 years,	at	around	10‐
15	cases	per	100	ESRD	diagnoses.	In	2013,	rates	in	these	age	groups	rose	to	15‐
25	cases	per	100	new	ESRD	diagnoses.	
Figure	6‐3	b	and	d	
The	majority	of	cohorts	showed	a	decreasing	trend	over	the	study	period.	There	
were	some	cohorts	that	showed	a	slight	upward	trend	of	registration	into	HD	as	
they	aged,	which	were	1966‐1970	and	1976‐1980	cohorts.		
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   Figure 6‐3  Registration rate of new hemodialysis cases, 2008‐2013 
	
iii. Kidney transplant 
Kidney	transplant	rates	in	patients	aged	20‐60	years	were	expressed	as	a	rate	of	
new	transplantations	per	1,000	new	ESRD	diagnoses,	Figure	6‐4	a‐d.	
Unlike	registrations	for	PD	and	HD,	it	is	clear	that	transplant	rates	increased	
over	time	from	2008.	However,	rates	decreased	rapidly	with	age.	Patients	aged	
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20‐35	years	had	the	highest	transplantation	rates,	with	80‐100	cases	per	1,000	
new	ESRD	diagnoses.	Rates	went	down	to	20	or	less	cases	per	1,000	new	ESRD	
diagnoses	in	patients	aged	over	44	(see	Figure	6‐4	a	and	c).		
Transplant	rates	increased	significantly	in	1961	and	subsequent	cohorts	while	
cohorts	before	1961	had	low	and	stable	rates,	see	Figure	6‐4	b	and	d.		
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   Figure 6‐4  Kidney transplant rates of new ESRD diagnoses 2008‐2013 
	
6.3.1.2 Model fitting 
Table	6‐8	shows	the	model	selection	procedure	for	the	age‐period‐cohort	
analysis.	For	both	peritoneal	and	hemodialysis	dialysis,	the	age‐cohort	model	
and	age‐period	model	were	comparable	in	terms	of	calculated	deviance	
difference	(48	and	52	in	peritoneal	dialysis	and	12	and	16	in	hemodialysis	
respectively)	and	far	better	than	the	full	age‐period‐cohort	model	(D	195	in	
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peritoneal	dialysis	and	D	14911	in	hemodialysis).	These	results	showed	that	
either	age‐cohort	or	age‐period	was	enough	to	explain	registration	rates	over	
time.	As	this	study	was	more	focused	on	the	period	effect	than	the	cohort	effect,	
the	age‐period	model	was	selected	for	age‐period‐cohort	analysis.	
Table 6‐8  Comparison of age‐period‐cohort sub‐models 
 Model Effect Da/ Residual df Db/ p-value 
PD Age Reference 2713.9 539 Reference  
 Age-drift |Ac/ 2659.7 538 54.127 <0.001 
 Age-Cohort C|Ad/ 2612.2 534 47.535 <0.001 
 Age-Period-Cohort P|A,Ce/ 2416.8 530 195.357 <0.001 
 Age-Period C|A,Cf/ 2469.2 534 -52.409 <0.001 
 Age-drift C|Ag/ 2659.7 538 -190.483 <0.001 
HD Age Reference 25537 542 Reference  
 Age-drift |Ac/ 21934.1 541 3602.9 <0.001 
 Age-Cohort C|Ad/ 21922.3 537 11.9 0.018 
 Age-Period-Cohort P|A,Ce/ 7011.3 533 14911 <0.001 
 Age-Period C|A,Cf/ 7027.6 537 -16.3 0.002 
 Age-drift C|Ag/ -14906.6 541 -14906.6 <0.001 
a/ Residual deviance 
b/ Increase in residual deviance from the next upper model   
c/ Linear effect of cohort or period adjusted for age 
d/ Non-linear cohort effect adjusted for age 
e/ Non-linear period effect adjusted for age and cohort 
f/ Non-linear cohort effect adjusted for age and period  
g/ Non-linear period effect adjusted for age	
6.3.1.3 Effects of age and period 
Estimated	effects	of	age	and	period	on	entry	into	peritoneal	dialysis,	
hemodialysis,	and	kidney	transplant	are	presented	in Figure	6‐5.	In	the	
reference	year	2010,	effects	of	age	on	both	types	of	dialysis	were	strongest	for	
patients	aged	20‐60	years.	Among	patients	aged	20	to	60	years	in	the	chosen	
reference	period	(2010),	peritoneal	dialysis	saw	many	more	new	registrations	
than	hemodialysis	at	the	rate	of	around	220	PD	patients	per	1,000	new	ESRD	
diagnoses	for	the	20‐60	age	group.	This	meant	PD	could	take	up	to	220	new	
patients	in	this	age	group	for	every	1,000	new	ESRD	diagnoses	in	2010.	Above	
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age	60,	registration	rates	for	both	PD	and	HD	fell	rapidly.	The	hemodialysis	
registration	rate	stood	at	around	15	patients	per	1,000	new	ESRD	diagnoses.	
These	meant	there	were	15	new	HD	registrations	for	every	1,000	new	ESRD	
diagnoses	in	2010	(Figure	6‐5 a	and	c).	The	kidney	transplant	rate	decreased	
exponentially	with	age.	It	started	with	a	rate	of	60	cases	per	1,000	new	ESRD	
diagnoses	at	age	20,	and	fell	to	2	cases	per	1,000	new	ESRD	diagnoses	at	age	60	
(Figure	6‐5	e).	
Period	(calendar	year	of	registration)	showed	fluctuating	trends	in	both	dialysis	
modalities	and	in	kidney	transplant.	For	peritoneal	dialysis	registration,	there	
was	a	sharp	increase	between	2008	and	2010.	Just	after	2011,	numbers	of	
registrations	dropped,	followed	by	an	increase	by	the	end	of	2013,	Figure	6‐5 b.	
Hemodialysis	registration	rates	were	at	their	highest	between	2008	and	2009,	
as	reflected	by	the	rate	ratio	at	40.	This	means	that	in	this	period,	HD	registered	
40	times	more	new	patients	than	in	2010.	After	this	period	the	ratio	fell	and	
was	followed	by	a	sharp	increase	at	the	beginning	of	2011.	Like	the	trend	of	
peritoneal	dialysis,	hemodialysis	registrations	decreased	in	2011‐2012	then	
started	to	increase	again	in	2013,	Figure	6‐5	d.	Kidney	transplant	in	2008‐2012	
was	performed,	at	best,	at	around	1.5	times	the	rate	in	2010.	However,	after	the	
middle	of	2012,	the	rate	increased, Figure	6‐5 f.	
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Figure 6‐5  Effects of age (a, c, and e) and period (b, d, and f) on dialysis 
registrations and transplant  
	
HD= hemodialysis, PD=peritoneal dialysis, KT=kidney transplant  
Note: Figures a, c, and e show estimated rates by age of (a) peritoneal dialysis: PD, (c) hemodialysis: HD, and (e) 
transplantation: KT. Rate ratios in Figures b, d, and f compare new registration rates of PD (b), HD (d), and 
transplantation rates (f) in a particular year and the rate in the reference year (2010). Shaded areas are 95% 
confidence intervals 
6.3.2 ESRD mortality 
6.3.2.1 Descriptive analysis 
Table	6‐9	shows	numbers	of	deaths	of	adult	patients	with	end‐stage	renal	
disease	from	2005	to	2012.	Table	6‐10	shows	numbers	of	the	UCS	population	in	
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corresponding	periods.	There	were	75,131	deaths	in	total,	increasing	from	
2,658	in	2005	to	12,811	in	2012,	then	reducing	to	10,754	in	2013.	Deaths	were	
most	concentrated	in	patients	aged	between	55	and	79	years,	accounting	for	11‐
13%	of	all	deaths	between	2005	and	2013.	The	population	of	UCS	members	
aged	20‐89	years	increased	from	30	million	in	2005	to	32	million	in	2013.		
Table 6‐9  Numbers of deaths in patients aged 20‐89 who were diagnosed with 
ESRD, 2005‐2013 
Age 2005 2006 2007 2008 2009 2010 2011 2012 2013 %Total 
20-24 49 42 46 52 48 57 60 41 48 0.59 
25-29 44 60 70 74 86 69 78 84 65 0.84 
30-34 73 81 107 93 100 123 114 119 101 1.21 
35-39 103 125 157 149 167 179 185 181 154 1.86 
40-44 152 208 261 292 301 313 345 358 242 3.29 
45-49 189 297 387 419 487 512 556 593 449 5.18 
50-54 272 378 577 725 745 838 937 964 776 8.27 
55-59 286 451 644 830 1066 1187 1313 1365 1074 10.94 
60-64 281 469 627 846 1171 1450 1707 1753 1368 12.87 
65-69 351 512 681 908 1297 1598 1729 1921 1590 14.09 
70-74 276 434 639 891 1347 1743 2032 2146 1642 14.84 
75-79 171 288 468 663 1139 1545 2005 2094 1510 13.15 
80-84 73 134 246 370 647 1058 1350 1532 1163 8.75 
85-89 33 76 92 166 323 439 607 785 572 4.12 
Total 2,658 3,588 5,045 6,419 8,587 10,716 12,478 12,811 10,754    100.00 
Table 6‐10  UCS population aged 20‐89, 2005‐2013 
Age 2005 2006 2007 2008 2009 2010 2011 2012 2013 %Total 
20-24 3,091,952 3,081,401 3,006,693 2,954,843 3,063,563 3,130,619 3,237,013 3,361,135 3,423,030 10.02 
25-29 2,867,485 2,801,673 2,637,599 2,581,614 2,582,281 2,580,171 2,505,985 2,620,408 2,550,342 8.39 
30-34 3,497,324 3,371,738 3,235,964 3,117,867 3,032,949 2,955,463 2,777,820 2,874,706 2,828,223 9.79 
35-39 3,871,765 3,846,779 3,760,168 3,657,674 3,602,595 3,538,083 3,333,770 3,393,167 3,291,369 11.42 
40-44 3,754,485 3,846,979 3,792,642 3,836,540 3,853,588 3,818,217 3,764,295 3,810,279 3,717,279 12.09 
45-49 3,247,610 3,336,704 3,357,882 3,448,739 3,543,271 3,617,283 3,711,115 3,749,433 3,796,563 11.24 
50-54 2,768,381 2,847,564 2,815,610 2,873,622 2,982,492 3,072,667 3,195,213 3,255,673 3,339,159 9.60 
55-59 2,136,423 2,270,491 2,312,280 2,429,176 2,517,530 2,602,010 2,692,012 2,725,311 2,779,112 7.94 
60-64 1,640,010 1,666,310 1,658,030 1,749,639 1,867,292 2,018,386 2,205,744 2,261,073 2,373,041 6.16 
65-69 1,439,750 1,440,314 1,425,979 1,430,170 1,459,139 1,482,657 1,545,203 1,554,247 1,633,569 4.74 
70-74 1,086,790 1,117,640 1,091,743 1,133,569 1,180,408 1,219,016 1,266,427 1,269,010 1,261,197 3.76 
75-79 722,991 725,753 724,144 756,237 808,702 843,941 915,930 909,758 931,894 2.59 
80-84 406,112 404,181 395,234 427,276 463,313 501,880 556,589 552,467 561,637 1.51 
85-89 221,151 208,110 201,662 211,995 227,994 239,342 273,002 263,901 273,429 0.75 
Total 30,752,229 30,965,637 30,415,630 30,608,961 31,185,117 31,619,735 31,980,118 32,600,568 32,759,844 100.00 
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The	age‐standardised	mortality	rate	(ASMR)	of	UCS	patients	who	had	end‐stage	
renal	disease	increased	from	5	per	100,000	UCS	population	in	2005	to	24	per	
100,000	UCS	population	in	2012,	then	dropped	to	18	per	100,000	UCS	
population	in	2013,	Figure	6‐6.		
Figure 6‐6  Age‐standardised mortality rates (ASMR) per 100,000 UCS 
population for UCS patients with end stage renal disease 2005‐2013 
 
Figure	6‐7	a	and	c	show	crude	death	rates	for	UCS	patients	who	had	ESRD	per	
100,000	UCS	population.	Rates	are	shown	against	age	at	death	and	calendar	
year,	while	Figure	7b	and	d	compare	crude	death	rates	of	the	same	patient	
group	by	age	at	death	and	year	of	birth.		
Figure	6‐7a	and	c	
Figure	7a	and	c	show	that	the	crude	death	rate	for	ESRD	patients	increased	
between	2005	and	2013.	Death	rates	tended	to	increase	from	age	45.	Between	
2005	and	2008,	rates	were	low	and	there	was	not	much	difference	across	all	age	
groups.	They	stood	below	50	deaths	per	100,000	UCS	population.	After	that	in	
2009	to	2013,	death	rates	among	the	elderly	ESRD	patients,	especially	patients	
aged	70	years	and	higher,	rose	significantly,	ranging	from	100	to	250	deaths	per	
100,000	UCS	population.		
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Figure	6‐7b	and	d	
Examination	of	birth	cohorts	indicates	a	continuing	increase	in	mortality	rates	
among	older	ESRD	cohorts	with	high	variation.	The	mortality	rates	of	older	
cohorts	ranged	from	50	to	250	deaths	per	100,000	UCS	population.	For	those	
born	in	1945	and	before,	there	were	increasing	rates	with	declining	slopes	
afterward,	meaning	the	death	rate	tended	to	decrease	with	increasing	birth	
year.	In	more	recent	cohorts,	those	born	after	1951,	death	rates	were	low	and	
less	varied,	at	less	than	50	deaths	per	100,000	UCS	population.		
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Figure 6‐7  Mortality rates per 100,000 UCS population for UCS patients with 
ESRD aged 20‐89 years by age at death, calendar year, and birth year 
	
6.3.2.2 Age-period-cohort analysis 
i. Model fitting 
Analysis	of	deviance	indicated	that	change	in	the	mortality	of	end‐stage	renal	
disease	is	complex	and	is	not	well	explained	by	a	linear	trend	over	time	(see	
Table	6‐11).	The	age‐drift	model,	referring	to	the	change	that	occurred	from	
linear	effects	of	cohort	and/or	period,	showed	a	significant	deviance	from	the	
age	model	at	8696.	The	age‐period	model	improved	the	model	fit	over	the	age‐
drift	model	and	gave	the	lowest	deviance	difference	at	180	when	compared	to	
other	models.	Consequently,	the	age‐period	model	was	selected	as	the	best	
fitting	model	and	will	be	used	in	the	age‐period‐cohort	analysis.	
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Table 6‐11  Comparison of age‐period‐cohort sub‐models 
Model Effect Da/  Db/ p value 
1. Age - 10765.1 (828) Reference Reference 
2. Age-drift  |A c/ 2069.5   (827) 8695.6 0.001 
3. Age-Period P|A d/ 1889.8   (816) 179.7 0.001 
4. Age-Period-Cohort C|A,P e/ 374.0     (670) 1515.8 0.001 
5. Age-Cohort P|A,C f/ 597.7     (680) -223.7 0.001 
6. Age-drift C|A g/ 2069.5   (827) -1489.8 0.001 
a/ Residual deviance 
b/ Increase in residual deviance from the next upper model   
c/ Linear effect of cohort or period adjusted for age 
d/ Non-linear cohort effect adjusted for age 
e/ Non-linear period effect adjusted for age and cohort 
f/ Non-linear cohort effect adjusted for age and period  
g/ Non-linear period effect adjusted for age	
ii. Effects of age and period 
The	effect	of	age	on	mortality	shows	an	S‐curve	and	the	mortality	rate	increased	
significantly	when	patients	were	in	their	forties	or	above	(Figure	6‐8a).	In	the	
reference	year	(2010),	mortality	rates	of	ESRD	patients	reached	a	peak	at	140	
deaths	per	100,000	UCS	population	in	their	late	seventies,	meaning	in	2010	
there	were	140	deaths	(from	all	causes)	of	patients	with	an	ESRD	diagnosis	per	
100,000	UCS	population.	The	rate	then	gradually	levelled	off.		
Period	(calendar	year	of	death)	showed	a	strong	effect	on	mortality,	as	reflected	
by	the	upward	trend	of	the	period	graph	(Figure	6‐8b).	The	mortality	ratio17	
rose	rapidly	from	2005	to	2007,	and	after	that	continued	increasing	at	a	slower	
rate.	In	the	short	period	of	mid	2009	to	2011,	the	death	rate	became	stable,	
followed	by	a	slow	increase	thereafter.	In	2012,	patients	with	an	ESRD	
diagnosis	had	a	risk	of	death	1.5	times	greater	than	those	in	the	reference	year	
2010.		
																																																								
17 Risk ratio for the death outcome is also known as relative risk. It is the risk of an event (eg. death and 
registration) in a particular year in comparison to the reference year, and can be calculated by the rate in that 
particular year divided by the rate in the reference year. 
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Figure 6‐8  Effects of age (a) and period (b) on ESRD mortality 
	
Note: Figure a shows estimated ESRD mortality rates by age in 2010 and Figure b shows mortality rate ratios 
(relative difference measure of mortality rate in any particular year divided by rate in the reference year-2010) 
for calendar years of death. Shaded areas are 95% confidence intervals. 
6.3.3 Case fatality rate (CFR) 
6.3.3.1 Descriptive analysis 
The	numbers	of	UCS	patients	diagnosed	with	end‐stage	renal	disease	are	used	
as	denominators	to	calculate	the CFR	and	are	shown	in	Table	6‐12.	Numbers	of	
adults	with	ESRD	increased	over	time.	In	2010	there	was	a	significant	increase	
by	43%.	Patients	in	the	55‐59	to	70‐74	age	groups	accounted	for	the	highest	
proportions	of	total	ESRD	patients.	
Table 6‐12  End‐stage renal disease patients of the UCS, 2008‐2012 
Age 2008 2009 2010 2011 2012 2013 %Total 
20-24 433 537 741 1,033 1,207 1,333 1.63 
25-29 630 803 1,098 1,480 1,708 1,785 2.35 
30-34 968 1,219 1,664 2,193 2,496 2,673 3.52 
35-39 1,241 1,511 2,076 2,767 3,201 3,433 4.44 
40-44 1,707 2,019 2,806 3,711 4,230 4,756 5.96 
45-49 2,317 2,705 3,749 5,162 5,858 6,620 8.15 
50-54 3,264 3,536 5,079 6,812 7,700 8,696 10.86 
55-59 3,831 4,076 5,821 7,946 8,994 10,467 12.62 
60-64 3,789 3,998 5,866 8,047 9,073 10,755 12.67 
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Age 2008 2009 2010 2011 2012 2013 %Total 
65-69 3,863 3,938 5,571 7,507 8,231 9,675 11.98 
70-74 3,758 3,804 5,429 7,291 7,882 9,084 11.59 
75-79 2,736 2,704 3,961 5,383 5,745 6,727 8.45 
80-84 1,345 1,353 1,966 2,718 2,873 3,478 4.22 
85-89 477 468 758 1,046 1,043 1,242 1.56 
Total 30,359 32,671 46,585 63,096 70,241 80,724 100 
Figure	6‐9	shows	case	fatality	rates	for	UCS	patients	who	had	an	ESRD	
diagnosis. 
Figure	6‐9	a	and	c	
It	is	clear	that	the	case	fatality	rate	increases	with	age,	Figure	6‐9a.	There	were	
declining	trends	over	time,	from	2008	to	2013	(see	Figure	6‐9c).	Between	2012	
and	2013,	rates	of	all	age	groups	went	down	approximately	5%‐20%.	Patients	
aged	55‐75	tended	to	have	greatest	decreasing	case	fatality	rates.	
Figure	6‐9	b	and	d		
The	case	fatality	rate	showed	a	decreasing	trend	across	all	age	groups	born	
after	1935.	Conversely,	for	those	born	in	1936	and	before,	there	was	a	
significant	increasing	trend	(see	three	rightmost	lines	on	Figure	6‐9b).	
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Figure 6‐9  Case fatality rates for patients with ESRD aged 20‐89 years 
	
Note: Rates were percentages of all-cause death counts of UCS patients diagnosed with ESRD divided by numbers 
of all UCS patients diagnosed with ESRD. Rates are presented by age at death, calendar year, and year of birth. 
6.3.3.2 Effects of age and period 
Figure	6‐10a	shows	the	age	effect	on	the	case	fatality	rate	and	fatality	rate	ratio.	
After	age	30,	the	fatality	rate	increased	exponentially.	In	the	reference	year	
2010,	the	case	fatality	rate	at	age	40	years	was	10%	and	increased	to	25%	at	
age	60	years.	This	meant	in	2010,	there	were	10	deaths	for	every	100	ESRD‐
diagnosed	patients	aged	40,	and	25	deaths	for	every	100	ESRD‐diagnosed	
patients	aged	60.		
The	period	effect	had	the	highest	peak	in	2009	when	patients	with	an	ESRD	
diagnosis	had	a	1.2	times	greater	risk	of	death	than	those	in	the	reference	year	
2010.	A	downward	trend	was	observed	just	after	the	peak,	which	reached	the	
lowest	point	in	mid‐2012.	At	this	point,	risk	of	death	among	patients	having	
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ESRD	was	0.4	times	lower	than	that	in	2010.	After	this	period	the	rate	started	
increasing	again	(see	Figure	6‐10b).	
Figure 6‐10  Effects of age (a) and period (b) on case facility  
	
Note: Figures show estimated case fatality rate by age in 2010 (a) and case fatality rate ratio (relative difference 
measure of fatality rate in any particular year divided by rate in the reference year-2010) in 2008-2013 (b).    
6.3.4 RRT mortality 
Numbers	of	total	deaths	among	ESRD	patients	who	were	on	RRT	increased	
between	2008	and	2012,	then	began	to	drop	significantly	in	2013,	Table	6‐13.		
Table 6‐13  Numbers of deaths among patients on RRT by age group and modality, 
2008‐2013 
Age RRT 2008 2009 2010 2011 2012 2013 Total %Total 
20-24 HD            2           4          6             5           6           6      159  1.1% 
PD            7         17         17           25         31        25  
KT          -             -           1             3           2           2  
25-29 HD            3         13          5             9         12           5          235  1.6% 
PD            9         24         39           33         43         36  
KT          -             -             -              3           1            -   
30-34 HD            5          9        14           16         21         11     
292  
2.0% 
PD            6         23        45           35         62        44  
KT          -             -             -             -             -            1  
35-39 HD            3         12         23           25         32         12       350  2.3% 
PD            9         34         42           48         59        50  
KT          -             -             -             -           1            -   
40-44 HD          11        29         27           31        46         24          616  4.1% 
PD          14        53        74           98      118        86  
KT          -             -              1             1             2             1  
45-49 HD            8         43        45           65        70        41    1,048  7.0% 
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Age RRT 2008 2009 2010 2011 2012 2013 Total %Total 
PD          29         83       138          160       205       156  
KT          -             -           3             1            -            1  
50-54 HD          26         95         77           88        96         74       1,590  10.6% 
PD          28       111      189          249      294      252  
KT          -             -             -              1          6          4  
55-59 HD          25      106     105          151      170        97    2,121  14.2% 
PD          26       144       222          350      413       299  
KT          -            1          3             2          3          4  
60-64 HD          23      125      137          191      222      147       2,394  16.0% 
PD          19         96       278          347       448      345  
KT          -             -           3             4          4           5  
65-69 HD          33      147      161          193      243      136      2,198  14.7% 
PD            4        90       189          275      404       314  
KT          -            1          2             2          2           2  
70-74 HD          23       137      148          206      226       136       1,903 12.7% 
PD            5        57      169          243       315       233  
KT          -             -            2             1          2            -   
75-79 HD          25       129      106          138      190      111      1,266 8.5% 
PD            2         36         80          135       198       116  
KT  N/A   N/A   N/A   N/A   N/A   N/A  
80-84 HD 11 35 69 86 105 46 575 3.8% 
PD 1 16 27 63 72 44 
KT N/A N/A N/A N/A N/A N/A 
85-89 HD 6 18 26 37 50 28 226 1.5% 
PD - 5 5 22 18 11 
KT N/A N/A N/A N/A N/A N/A 
Total  363 1,693   2,478      3,342  4,192    2,905     14,973   100.0% 
HD= hemodialysis, PD=peritoneal dialysis, KT=kidney transplant  
Over	the	six‐year	period,	numbers	of	live	ESRD	patients	aged	20‐89	who	were	
maintaining	RRT	increased	from	7,310	to	23,566	(Table	6‐14).	Patients	aged	
55‐59	accounted	for	the	highest	proportion,	at	15%	of	overall	patients.	
Table 6‐14  Numbers of annual UCS patients aged 20‐89 years who were 
receiving RRT, 2008‐2013 
Age 2008 2009 2010 2011 2012 2013 %Total 
20-24 174 290 388 501 603 657 2.7 
25-29 187 339 458 583 683 753 3.2 
30-34 217 424 617 783 886 1,000 4.1 
35-39 358 579 800 1,069 1,241 1,421 5.8 
40-44 513 825 1,176 1,513 1,759 2,025 8.2 
45-49 661 1,082 1,553 2,090 2,420 2,735 11.1 
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Age 2008 2009 2010 2011 2012 2013 %Total 
50-54 909 1,326 1,906 2,529 2,931 3,286 13.6 
55-59 1,002 1,481 2,156 2,785 3,200 3,694 15.1 
60-64 968 1,387 1,992 2,647 3,034 3,476 14.2 
65-69 926 1,145 1,538 1,998 2,148 2,361 10.6 
70-74 739 807 1,066 1,280 1,292 1,396 6.9 
75-79 424 392 477 589 525 573 3.1 
80-84 188 182 199 209 182 180 1.2 
85-89 44 43 46 33 19 9 0.2 
Total  7,310   10,302   14,372   18,609   20,923   23,566   100  
Figure	6‐11	presents	the	age‐standardised	mortality	rates	(ASMR)	for	UCS	
patients	aged	20‐89	years	who	were	on	RRT.	After	adjustment,	mortality	rates	
decreased	from	around	80	deaths	per	1,000	patient	years	at	risk	in	2009‐2012	
to	60	deaths	per	1,000	RRT	patient	years	at	risk	in	2013.	
Figure 6‐11  Adjusted mortality rates per 1,000 patient years at 
risk for UCS patients who had RRT aged 20‐89, 2008‐2013 
	
Unadjusted	mortality	rates	for	ESRD	patients	who	used	RRT	are	shown	in	
Figure	6‐12.		Due	to	large	differences	in	mortality	rates	between	patients	on	
RRT	aged	20‐64	years	and	the	elderly	aged	65‐89	years,	results	were	presented	
in	two	graphs.	In	2008,	rates	were	low	across	all	age	groups,	which	might	be	a	
consequence	of	the	fact	that	the	new	RRT	programme	could	not	enroll	many	
patients.	From	2009,	as	expected,	mortality	rates	increased	by	age	and	were	
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considerably	higher	after	age	65.	Between	2009	and	2012,	rates	were	quite	
consistent	within	each	age	group	in	patients	aged	35‐65	years.	Mortality	rates	
were	75	deaths	per	1,000	patient‐years	for	those	aged	35	years	at	death	and	
200	deaths	per	1,000	patient‐years	for	those	aged	60	years.	In	2013,	rates	for	
patients	aged	35‐65	years	fell	by	50	deaths	per	1,000	patient‐years.	For	the	
elderly,	mortality	rates	seemed	to	increase	over	time	until	2012,	then	dropped	
slightly	in	2013	(Figure	6‐12).	
Figure 6‐12  Mortality rates for UCS patients who had RRT aged 20‐64 years (a) 
and 65‐89 years (b) 
	
Age	effects	on	the	mortality	rate	for	UCS	patients	who	used	RRT	is	shown	in	
Figure	6‐13a.	The	mortality	rate	increased	dramatically	after	the	age	of	40.	In	
the	reference	year	2010,	the	rate	for	those	aged	40	was	75	deaths	per	1,000	
patient‐years	and	250	deaths	per	1,000	patient‐years	for	those	aged	70.		
The	period	(calendar	year	of	death)	effect	increased	rapidly	and	reached	a	peak	
in	2010.	After	that,	the	rate	showed	a	slight	downward	trend.	By	2012	the	
mortality	rate	began	to	increase	again,	reaching	twice	that	of	the	reference	
period	in	2013	(see	Figure	6‐13b).		
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Figure 6‐13  Effects of age (a) and period (b) on RRT death  
	
Note: Estimated mortality rate for RRT patients by age in 2010 (a) and mortality rate ratio (relative difference 
measure of mortality rate in any particular year divided by rate in the reference year-2010) in 2008-2013 (b). 
6.3.5 The patients in 2013 
Key	points	for	2013	are	summarised	here	to	provide	recent	information	about	
the	incidence	(the	occurrence)	of	adult	ESRD	patients	in	the	UCS,	access	of	these	
patients	to	RRT,	and	mortality	of	those	who	were	maintaining	RRT	in	
comparison	to	death	rates	of	overall	UCS	members.		
The	incidence	for	access	to	RRT	is	represented	by	a	count	(number	of	cases)	or	
by	a	rate.	The	rate	was	expressed	per	million	population	(pmp)	per	year.	For	
all‐cause	mortality	rates,	they	were	expressed	as	deaths	per	1,000	patient‐
years.	
Incidence	
 There	were	a	total	of	20,296	adults	in	the	UCS	newly	diagnosed	with	
ESRD,	a	decrease	of	37%	from	new	diagnoses	in	2012.	The	modal	age	
group	was	60‐65	years	(14%	of	all	new	ESRD	patients).		
 The	number	of	adult	ESRD	patients	newly	starting	RRT	was	9,593	
registrations	(47%	of	all	new	ESRD	patients).	The	modal	age	groups	
were	55‐59	years	and	60‐65	years	(16%	of	all	new	RRT	patients	each).	
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 The	total	new	RRT	patients	above	represented	an	incidence	rate	of	197	
pmp18.		
Access	to	RRT	modalities	
 Of	the	above	newly	diagnosed	ESRD	patients;	6,620	patients	(33%	of	
newly	diagnosed	ESRD	patients)	went	on	to	receive	PD.		
 2,774	patients	(14%	of	newly	diagnosed	ESRD	patients)	went	on	to	
receive	HD,	possibly	because	they	were	contraindicated	to	PD	or	because	
they	failed	PD	then	had	modality	changes	to	HD.	
 Just	a	small	number	of	ESRD	patients	(199	or	1%	of	newly	diagnosed	
ESRD	patients)	were	able	to	exit	to	transplantation.	
 There	were	10,703	patients	(53%	of	newly	diagnosed	ESRD	patients)	
who	did	not	agree	to	start	RRT.	
All‐cause	mortality	rate:	
 The	age‐standardised	mortality	rates	(ASMR)	for	adults	in	the	UCS	who	
were	on	RRT	reduced	from	around	80	deaths	per	1,000	patient‐years	at	
risk	in	2009‐2012,	to	60	deaths	per	1,000	RRT	patient‐years	at	risk	in	
2013.	
 Figure	6‐14	compares	age‐adjusted,	all‐cause	mortality	rates	in	RRT	
patients	and	the	overall	UCS	population19.	Relative	risk	is	shown	on	the	
right	hand	axis,	which	compares	adjusted	death	rates	of	RRT	patients	
over	the	UCS	population.	Adjusted	rates	of	death	for	RRT	patients	were	7	
to	20	times	greater	than	for	individuals	in	the	general	age‐matched	UCS	
population,	and	the	relative	risk	of	death	on	RRT	decreased	with	age.	
This	means	that	the	more	RRT	patients	age,	the	closer	their	death	rate	
becomes	to	the	overall	UCS	population.	
																																																								
18 The denominator used for this rate was the entire UCS population including patients under 20 years old. 
When population aged less than 20 years were excluded from the denominator, the incidence rate was 293 pmp.   
19 Using the UCS population in 2013 as the reference population	
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Figure 6‐14  Age‐adjusted mortality rates in RRT and UCS population 
	
RRT= renal replacement therapy 
6.4 Discussion 
6.4.1 Concerns of age-period-cohort model fitting 
Using	the	age‐period‐cohort	approach	can	eliminate	the	identifiability	problem	
that	occurs	from	the	relation:	age	=	period‐cohort.	The	age‐period‐cohort	
models	may	separate	the	effects	of	age	from	the	effects	of	cohort	and	period	by	
the	parametrisation	technique	proposed	by	Carstensen	(2007).	There	are,	
however,	questions	raised	from	the	parametrisation	technique	about	the	
number	of	knots,	placement	of	knots,	and	reference	point	used.	These	
parameters	are	user	defined,	meaning	any	selection	can	alter	results	
(Carstensen	2007).	An	example	from	this	study	is	the	dips	in	most	period	
graphs.	When	using	a	lower	number	of	knots	(such	as	3	instead	of	5),	graph	
lines	became	smoother,	there	was	no	dip	presented.	Nonetheless,	the	fact	was	
that	a	smooth	graph	cannot	detect	the	small	effect	from	events	occurring	in	that	
period.	Interpreting	results	from	age‐period‐cohort	models	and	other	
information,	such	as	descriptive	analysis	and	key	events	in	various	time	periods	
is,	therefore,	necessary.	
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6.4.2 Summary of findings 
i. Registration rates 
Assessing	the	rate	of	registration	into	the	RRT	programme	by	the	age‐period‐
cohort	method	revealed	fairly	stable	patterns	with	upward	trends	of	
registration	rates	in	all	three	RRT	modalities.	There	were	notable	drops	in	
dialysis	registration	rates	and	transplant	rates	between	2011	and	2012.	In	
2013,	the	incidence	of	RRT	patients	began	to	increase	again.	PD	accounted	for	
more	registered	patients	in	comparison	to	HD,	in	2010	at	roughly	220	and	15	
patients	per	1,000	new	ESRD	patients	respectively.	These	rates,	however,	fell	
sharply	in	patients	aged	65	years	and	older.	
A	descriptive	analysis	of	registration	into	the	PD	programme	showed	
decreasing	registration	rates	among	older	patients,	aged	65	years	and	over,	
despite	the	increasing	rates	among	younger	patients,	aged	20‐54	years.			
ii. Mortality rates 
All‐cause	mortality	rates	of	patients	with	ESRD	diagnoses	among	the	UCS	
population	increased	with	age	as	presented	by	an	S‐shaped	age	effect	in	the	
analysis.	At	age	40	the	death	rate	was	approximately	8	patients	per	100,000	
UCS	population‐years,	and	increased	exponentially	with	age.	When	age	
increased	to	60	years,	the	death	rate	rose	to	50	cases	per	100,000	UCS	
population‐years,	and	became	fairly	stable	at	age	70	years	and	above,	at	140	
cases	per	100,000	UCS	population‐years.	Patients	on	RRT	might	benefit	from	
their	treatments	as	their	mortality	rates	increased	rapidly	later	than	those	of	
overall	ESRD	patients,	when	the	former	are	aged	70	years	and	more	as	
observed	in	Figure	6‐13	and	Figure	6‐8.		
From	2005	to	2008,	the	age‐period‐cohort	analysis	showed	that	overall,	the	
mortality	rate	among	patients	with	ESRD	increased	over	time.	It	started	with	a	
sharp	increase	until	2007.	After	that,	the	death	rate	started	to	level	off	and	was	
followed	by	a	stable	period	between	2009	and	2011.	However,	after	2011,	the	
death	rate	increased	rapidly	to	what	it	had	been	before	the	2007	period.	This	
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was	in	contrast	to	the	result	from	the	descriptive	analysis,	where	the	death	rate	
appeared	to	decrease	after	it	reached	a	peak	in	2012.		
The	age	effect	and	period	effect	of	ESRD	deaths	among	UCS	members	were	in	
accordance	with	those	of	RRT	patients,	since	their	trend	lines	in	rate	ratio	
graphs	showed	similar	shapes.	Rates	started	with	sharp	increases	until	2009,	
followed	by	relatively	stable	trends	until	2012.	Both	rates	showed	increasing	
trends	from	2012.		
The	case	fatality	rate	analysis	suggested	different	findings,	in	particular	during	
the	period	2008‐2012.	While	calculated	rates	of	the	other	two	types	were	
increasing	in	this	period,	case	fatality	rates	were	decreasing.	However,	in	2013	
all	types	of	rates	increased.		
6.4.3 Discussion of findings 
The	variation	in	trends	in	access	to	RRT	services,	and	overall	mortality	of	ESRD	
patients	and	patients	who	use	RRT,	may	be	explained	by	the	introduction	of	the	
RRT	programme,	changes	in	the	RRT	policy,	and	environmental	events.		
Linking	the	timeline	of	the	RRT	programme	with	dialysis	registration	and	
mortality	provided	more	explanations	for	their	trends,	Figure	6‐15.	The	
opening	of	pilot	PD	centres	may	be	a	possible	explanation	for	the	declining	
death	trend	in	2007.	After	the	RRT	programme	was	fully	implemented	in	2008,	
both	dialysis	modalities	could	have	high	registration	rates,	resulting	in	an	
immediate	effect	of	the	new	programme	on	patients	who	had	never	previously	
had	RRT	coverage.	Consequently,	the	programme	brought	a	large	number	of	
patients	into	all	three	RRT	modalities	and	reduced	the	increasing	death	rate	
between	2008	and	2011.	
After	commencement	of	the	RRT	programme,	the	registration	rate	might	have	
responded	to	the	new	policy	since	registration	trends	increased	after	each	new	
reimbursement	started.	This	was	evident	in	2009,	when	the	NHSO	started	to	
reimburse	erythropoietin20	for	PD	users,	effectively	making	the	medication	
																																																								
20 for the treatment of anemia of ESRD patients 
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cost‐free.	This	benefit	is	likely	to	have	boosted	the	PD	registration	rate	until	
2010.		
Deep	drops	in	dialysis	registration	and	transplantation	in	2011	could	be	a	
consequence	of	flooding	that	affected	major	cities	in	63	out	of	77	provinces	in	
Thailand.	More	than	600	public	health	facilities	could	not	open	as	usual	and	
many	private	clinics	were	temporarily	closed	down	(The	World	Bank	2013).	
The	Nephrology	Society	of	Thailand	estimated	that	30%	or	12,000	dialysis	
patients21	resided	in	flooded	areas.	Hemodialysis	patients	were	affected	the	
most	since	they	could	not	go	to	receive	care	at	dialysis	units.	Peritoneal	dialysis	
patients	could	perform	home	dialysis	as	the	NHSO	guaranteed	home‐delivery	of	
dialysis	solution	(The	Nephrology	Society	of	Thailand	2011).	Although	there	
was	collaboration	between	various	agencies	to	mitigate	the	situation,	
registration	rates	of	PD	and	HD	went	down	in	this	period.		
Increases	in	PD	and	HD	registrations	in	late	2012‐	2013	might	be	explained	in	a	
number	of	ways.	The	first	explanation	is	the	harmonisation	of	RRT	benefits	
across	the	three	public	health	insurance	schemes,	namely	the	Social	Security	
Scheme,	the	UCS	and	the	Civil	Servant	Medical	Benefit	scheme.	The	
harmonisation	made	for	easier	access	to	RRT	services,	since	the	three	schemes	
agreed	to	use	the	same	standard	guidelines	in	taking	on	and	caring	for	ESRD	
patients.	Patients	who	changed	their	insurance	schemes	to	another	scheme	had	
no	barrier	to	continue	RRT	care	in	their	transition	phase.	The	RRT	programme	
also	benefited	from	the	harmonised	data	management	system,	coherent	and	
standard	procedures,	and	standard	validation	processes.	Consequently,	data	
quality	improved	and	timely	information	was	available.		
HD	patients	gained	great	advantages	from	the	harmonisation.	This	is	because	
within	the	other	two	schemes,	the	majority	of	dialysis	users	were	HD.	After	the	
harmonisation,	all	three	schemes	had	to	allow	new	beneficiaries	to	retain	their	
previous	dialysis	mode.	Therefore,	these	HD	patients	could	enter	the	UCS	RRT	
programme	without	using	the	PD‐first	policy.	Additionally,	in	2012	more	
benefits	were	added	to	HD,	for	example	free	erythropoietin	and	exemption	from	
																																																								
21 of all 3 public schemes and all over the country 
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copayment.	In	addition	to	the	harmonisation,	UCS	patients	who	were	self‐
funding	for	hemodialysis	might	register	to	use	free	dialysis	as	they	had	more	
confidence	in	the	quality	of	RRT	services	provided	by	the	UCS.			
 	
2005 2006 2007 2008 2009 2010 2011 2012 2013Year
All-cause mortality
PD registration
HD registration
 
Note: adjusted from the rate ratio graphs of registration into the RRT programme and mortality.  
Y-axis is not the actual scale, UCS=universal coverage scheme, PD=peritoneal dialysis, HD=hemodialysis 
The	increase	of	the	mortality	rate	during	2011‐2013	could	be	a	combined	effect	
of	epidemiology	of	chronic	renal	disease,	a	disproportionate	number	of	new	
registrations	given	increasing	patients	with	ESRD,	and	loss	of	follow	up	while	
flooding.	Given	the	fact	that	90%	of	ESRD	patients	who	do	not	receive	proper	
dialysis	will	die	within	3‐6	months	(Tantivess,	Werayingyong	et	al.	2013),	these	
patients	were	sensitive	to	the	change	in	the	availability	of	the	RRT	benefit	in	
2008.	As	a	result,	patients	who	had	ESRD	before	the	programme	started	could	
prolong	their	life	when	they	used	dialysis.	However,	this	effect	was	transient	
since	dialysis	could	only	slow	the	progress	of	kidney	disease,	not	cure	it.	This	is	
Figure 6‐15		Comparison of registration rates and all‐cause mortality
with RRT programme’s key events 
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a	likely	explanation	for	the	increase	in	death	rates	after	2012.	To	support	this	
account,	we	can	look	at	an	analysis	of	kidney	function	(eGFR:	estimated	
Glomerular	Filtration	Rate	level)	of	patients	first	entering	into	the	programme,	
Figure	6‐16	found	that	most	patients	in	the	RRT	programme	had	a	late	start22.	
This	means	70‐75%	of	these	patients	were	likely	to	die	within	3	years	(Wright,	
Klausner	et	al.	2010).		
Figure 6‐16  eGFR levels at registration into the RRT programme of 
PD patients between 2007 and 2014 
	
  eGFR: estimated Glomerular Filtration Rate 
From	the	decreasing	trend	of	case	fatality	rates	(CFR),	we	can	infer	that	those	
who	have	ESRD	were	more	likely	to	survive	with	the	introduction	of	the	RRT	
programme.	However,	this	finding	contrasted	with	the	ESRD	mortality	rate	
which	showed	a	reverse	sign.	The	percentage	of	new	ESRD	patients	per	UCS	
population	is	a	possible	explanation	as	to	why	the	results	of	the	mortality	rate	
and	CFR	were	different.	Figures	in	Table	6‐15	suggest	that	there	were	growing	
numbers	of	new	patients	with	ESRD	diagnoses	relative	to	the	UCS	population	
2010‐2012.	Calculations	of	the	ESRD	death	rate	among	UCS	population23	and	
																																																								
22	eGFR levels lower than 10ml/min/1.73m2 
23	ESRD mortality rate= (Number of deaths from all causes among patients with ESRD x 100)/	Number of mid-year 
UCS members	
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CFR24	employed	same	numerators	but	different	denominators.	When	the	
denominators	of	CFR	increased,	the	calculated	figures	of	CFR	decreased.	
Moreover,	looking	at	the	share	of	new	patients	with	an	ESRD	diagnosis	in	the	
UCS	population	(Table	6‐15),	there	were	growing	numbers	of	patients	with	
ESRD,	in	particular,	among	the	elderly	population	(65	years	old	and	above),	
who	have	a	high	risk	of	mortality.	However,	lower	numbers	of	elderly	patients	
were	registered	with	the	RRT	programme.	These	figures	may	account	for	the	
high	CFR	in	elderly	ESRD	patients	between	2010	and	2012.	
Table 6‐15  Percentages of new ESRD diagnoses and overall UCS population, 
2008‐2013 
Age 2008 2009 2010 2011 2012 2013 
20-24 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 
25-29 0.02% 0.01% 0.02% 0.02% 0.01% 0.01% 
30-34 0.03% 0.01% 0.02% 0.02% 0.02% 0.01% 
35-39 0.03% 0.01% 0.02% 0.03% 0.02% 0.01% 
40-44 0.05% 0.02% 0.03% 0.04% 0.03% 0.02% 
45-49 0.07% 0.03% 0.05% 0.06% 0.05% 0.03% 
50-54 0.13% 0.05% 0.09% 0.09% 0.08% 0.05% 
55-59 0.18% 0.07% 0.13% 0.14% 0.14% 0.09% 
60-64 0.25% 0.10% 0.19% 0.20% 0.19% 0.12% 
65-69 0.32% 0.13% 0.25% 0.28% 0.27% 0.17% 
70-74 0.40% 0.16% 0.32% 0.37% 0.35% 0.20% 
75-79 0.46% 0.19% 0.39% 0.44% 0.42% 0.26% 
80-84 0.42% 0.19% 0.40% 0.45% 0.48% 0.29% 
85-89 0.31% 0.18% 0.36% 0.41% 0.46% 0.27% 
Total 0.11% 0.05% 0.09% 0.11% 0.10% 0.06% 
Note: bold figures represented relatively high percentages of elderly in comparison to overall UCS 
population, 2010-2012 
Further	comparison	of	new	RRT	registrations	and	numbers	of	patients	with	an	
ESRD	diagnosis	is	shown	in	Table	6‐16.	Proportions	of	most	age	groups	were	
increasing,	with	slight	drops	in	2010‐2011.	Despite	rapidly	growing	
proportions	of	new	RRT	registrations	among	young	patients,	less	than	half	of	
patients	aged	65	years	and	older	enrolled	in	the	RRT	programme.	This	situation	
might	explain	the	increase	in	all	types	of	death	rates	in	2013.		
																																																								
24	CFR= Number of deaths from all causes among patients with ESRD x 100/ Number of all patients with ESRD	
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Table 6‐16  Proportions of new RRT registrations as percentage of new 
ESRD diagnoses by year and age group 
Age 2008 2009 2010 2011 2012 2013 
20-24 51.0% 145.2% 83.8% 78.9% 100.0% 100.0% 
25-29 36.5% 61.8% 46.8% 45.8% 60.7% 88.5% 
30-34 32.3% 48.9% 46.4% 39.9% 54.4% 92.4% 
35-39 32.1% 53.4% 41.9% 44.3% 49.6% 85.2% 
40-44 31.1% 52.7% 42.5% 38.8% 50.0% 79.1% 
45-49 28.7% 50.0% 39.6% 38.6% 49.8% 73.3% 
50-54 27.1% 45.3% 35.3% 36.0% 43.0% 68.2% 
55-59 24.7% 39.7% 32.7% 33.7% 37.8% 63.6% 
60-64 23.1% 33.6% 28.4% 29.3% 33.7% 55.3% 
65-69 21.0% 23.6% 20.9% 22.8% 25.7% 41.7% 
70-74 16.8% 14.4% 15.7% 15.5% 16.8% 31.8% 
75-79 13.1% 9.0% 8.4% 10.2% 10.8% 18.8% 
80-84 11.3% 5.2% 5.8% 6.7% 7.2% 9.0% 
85-89 8.8% 2.6% 4.2% 4.4% 4.2% 4.8% 
Total 22.8% 31.7% 25.1% 25.3% 28.8% 47.3% 
Note: bold figures represented relatively constant or low increasing percentages of elderly in comparison to 
overall UCS population, 2010-2012 
6.4.4 Other evidence supporting the findings 
This	study	used	NHSO	data	routinely	collected	from	its	health	care	facilities	to	
estimate	numbers	of	patients	with	ESRD	(chronic	kidney	disease	stage	5),	
yielding	an	ESRD	prevalence	of	0.14%	(in	2010)	and	0.24%	(in	2013)	among	
the	UCS	population.	Another	study	estimated	the	prevalence	of	chronic	kidney	
disease	(stages	1‐5)	in	Thai	adults	by	conducting	a	national	survey	in	2004	
(Ong‐ajyooth,	Vareesangthip	et	al.	2009).	The	study	collected	samples	of	3,117	
of	the	Thai	population	aged	15	years	and	above	in	2004.	The	different	stages	of	
kidney	disease	were	assessed	by	laboratory	tests25	and	the	prevalence	of	ESRD	
stage	5	was	reported	as	0.2%	(see	Table	6‐17).	The	national	study	was	
conducted	in	2004,	and	therefore,	current	national	figures	should	be	higher.	
This	finding	may	suggest	that	there	might	be	a	large	number	of	UCS	members	
who	have	chronic	kidney	disease	stage	5	but	have	not	been	given	ESRD	
diagnoses	in	the	UCS	databases	during	the	study	period	(2005‐2013).		
																																																								
25 Proteinuria and serum creatinine 
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In	reality,	the	probability	of	giving	an	ESRD	diagnosis	might	have	increased	
over	time	after	launching	the	RRT	programme.	This	is	because	the	availabilities	
of	treatment	and	disease	management	of	the	RRT	system	(such	as	the	patient	
identification,	guideline	protocols,	payment	mechanism,	and	coordinating	
system)	provide	incentives	to	providers	to	take	patients	into	the	programme.	
However,	the	number	of	patients	with	ESRD	diagnoses	in	the	UCS	database	
might	be	lower	than	the	reality	for	a	number	of	reasons.	Given	the	fact	that	
chronic	kidney	disease	is	a	silent	disease,	patients	are	likely	to	know	they	have	
this	disease	only	when	they	are	severely	ill	and	at	the	late	stage,	generally	when	
they	are	taken	to	hospital	and	given	a	diagnosis.	In	addition,	RRT	centres	are	
mostly	concentrated	in	urban	areas,	they	might	be	beyond	reach	of	some	
patients	who	live	far	away	to	receive	care	and	be	diagnosed.	
Table 6‐17  Chronic kidney disease stage 5 prevalence in Thai  
and UCS population 
Age group Thai population 2004(%)1/ UC population 2010(%)2/ 
15-29 0 0.03 
30-44 0.2 0.06 
45-59 0.2 0.16 
>60 0.5 0.37 
Overall 0.2 0.14 
1/Prevalence of chronic kidney disease in Thai adults: a national health survey (Ong-ajyooth, 
Vareesangthip et al. 2009) 
2/Results from this study   
6.5 Conclusions 
After	launching	the	RRT	programme	in	2008,	registration	rates	of	all	three	RRT	
modalities	showed	fairly	stable	patterns	in	their	first	years	followed	by	
increasing	trends	in	recent	years.	The	RRT	programme	was	able	to	enroll	a	
higher	percentage	of	young	patients,	in	particular	patients	in	the	55‐54	age	
group.	In	contrast,	access	to	care	by	patients	aged	70	years	and	over	was	low,	
and	tended	to	decrease	with	age,	despite	their	high	and	growing	proportion	
amongst	those	with	ESRD	diagnoses.		
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In	terms	of	mortality,	all‐cause	mortality	rates	of	adult	RRT	patients	increased	
over	time	through	2010,	then	tended	to	level	off.	In	2013,	the	age‐standardised	
mortality	rate	(ASMR)	for	adult	RRT	patients	reduced	from	its	peak	at	80	deaths	
per	1,000	patient‐years	at	risk	in	2010,	to	60	deaths	per	1,000	RRT	patient‐
years	at	risk.	Patients	who	received	RRT	had	a	significantly	high	mortality	rate	
later	in	life	compared	to	overall	ESRD	patients.		
The	disease	management	approach	of	the	RRT	programme	appeared	to	link	to	
these	promising	results,	in	the	way	ESRD	patients	were	identified,	registered,	
and	received	treatment.	In	addition,	changes	in	the	RRT	benefit,	UCS	policy,	and	
environmental	events	such	as	free	erythropoietin	for	HD	users,	the	
harmonisation	among	the	three	public	schemes,	and	flooding,	could	also	affect	
numbers	of	patients	entering	into	the	RRT	programme	and	their	mortality	
rates.		
6.6 Limitations 
There	are	a	number	of	limitations	in	this	study	which	may	influence	the	results.	
These	limitations	come	from	many	sources	including	the	databases	used,	
patient	subjects	in	the	study,	and	data	analysis	methods.	
6.6.1 ESRD coding 
Most	studies	from	developed	countries	use	the	number	of	patients	who	are	
treated	with	RRT	to	represent	numbers	of	patients	with	ESRD	(El	Nahas	and	
Bello	2005).	There	is	doubt	of	whether	the	number	of	RRT	patients	can	
represent	overall	ESRD	patients.	As	mentioned	above,	chronic	kidney	disease	is	
a	silent	disease.	There	is	a	time	lag	between	when	patients	start	to	have	ESRD	
and	when	they	are	diagnosed	and	treated.	This	situation	is	true	in	Thailand	
despite	the	availability	of	a	national	UCS	screening	programme.	Therefore,	
coding	ESRD	to	everyone	who	has	entered	chronic	kidney	disease	stage	5	is	
practically	impossible.		
In	addition,	the	Thai	Nephrology	Society	guidelines	suggest	that	patients	with	
ESRD	diagnoses	will	be	asked	to	start	RRT	when	their	GFRs	have	reached	6	
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mL/min	per	1.73m2.	This	means	there	will	be	patients	who	have	an	ESRD	
diagnosis	but	have	not	yet	started	RRT	because	they	still	have	relatively	good	
clinical	signs	and	symptoms.	A	study	by	Limwattananon	and	Limwattananon	
(2013)	showed	that	up	to	41%	of	UCS	patients	who	had	an	ESRD	diagnosis	were	
registered	with	the	RRT	programme.	This	finding	reflects	the	problem	
identified;	that	using	the	number	of	patients	undergoing	RRT	to	represent	
numbers	of	patients	with	ESRD	would	be	an	underestimate,	since	there	were	a	
large	number	of	patients	who	have	end‐stage	kidney	disease	but	did	not	use	
RRT	for	some	reasons.	This	is	why	the	current	study	employed	the	number	of	
all	patients	who	have	an	ESRD	diagnosis,	rather	than	the	number	of	patients	
who	use	RRT,	to	represent	the	ESRD	population.	
6.6.2 Nature of data sources 
There	were	some	limitations	in	the	use	of	NHSO	databases.	These	databases	are	
intended	to	be	used	in	reimbursement	for	health	services,	and	there	are	several	
causes	of	data	inaccuracies.	The	first	drawback	of	this	use	was	that	the	claims	
data	may	not	be	completely	up‐to‐date.	Since	the	NHSO	allows	its	health	
facilities	to	claim	up	to	one	year	late,	observations	of	patients	in	recent	years,	
particularly	in	2013,	might	not	be	the	most	up‐to‐date.	Second,	by	using	
patients’	citizen	numbers	to	merge	various	databases	and	construct	the	main	
dataset,	some	records	could	not	be	matched	with	any	citizen	number	and	were	
discarded.		
Next,	there	was	an	adjustment	of	ICD‐10	coding	of	ESRD	in	2012.	This	change	
might	affect	numbers	of	diagnoses	used	in	this	study.	Furthermore,	when	
information	from	all	relevant	NHSO	databases	was	used	to	calculate	numbers	of	
patients	with	end‐stage	renal	disease,	the	figures	were	lower	than	the	national	
survey.	This	might	indicate	that	there	are	a	large	number	of	patients	who	are	
not	identified	as	they	have	not	been	diagnosed	with	ESRD	in	last	5‐8	years.		
Finally,	providers	might	have	changed	their	coding	practice.	This	is	because	
availabilities	of	treatment	and	disease	management	of	the	RRT	system	might	
motivate	them	to	take	more	patients	into	the	programme.	As	a	consequence,	
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patients	have	higher	probabilities	to	be	diagnosed	with	ESRD	than	they	were	
before	the	RRT	programme	started	in	2008.	
In	addition	to	the	diagnosis	issue,	patients	who	come	to	outpatient	departments	
usually	come	with	various	symptoms	and	may	not	be	diagnosed	accurately.	
These	patients	are,	therefore	under‐reported	cases.	All	these	reasons	might	
affect	numbers	of	patients	with	end‐stage	renal	disease	discussed	in	this	study.		
6.6.3 Account of patient characteristics 
The	next	limitation	came	from	the	models,	which	did	not	take	account	of	patient	
characteristics	such	as	gender,	and	clinical	measures,	such	as	glomerular	
filtration	rate	or	comorbidities.	This	is	because	this	study	lacks	information	on	
overall	population	estimates	regarding	the	proportions	of	these	clinical	
measures.	
6.6.4 Study period 
The	short	study	period,	from	2005	to	2013,	was	another	limitation.	Providing	
only	6‐9 years	of	study,	lines	in	cohort	graphs	(all	figures	b	and	d	in	descriptive	
analyses)	are	not	long	enough	to	compare	and	observe	trends	adequately	
across	most	cohort	groups.	
CHAPTER 6  The changing patterns of access to service and mortality of the RRT programme overtime 
200 
	
 
	
	
	
	
	
	
	
	
	
	
	
	
CHAPTER 7  Long term projections of RRT patients and costs of the RRT programme  
201 
	
CHAPTER 7 Long term projections of RRT patients and costs 
of the RRT programme 
7.1 Introduction 
Prior	chapters	of	this	thesis	looked	at	the	renal	replacement	therapy	(RRT)	
programme	in	terms	of	the	response	to	a	high‐cost	condition	by	people	at	
various	levels	of	the	health	system,	the	programme	design,	and	its	effects	in	
terms	of	accessibility,	and	of	mortality	of	patients	who	were	diagnosed	with	
end‐stage	renal	disease.	Results	in	Chapter	5	show	that	the	RRT	disease	
management	programme	has	facilitated	the	growth	of	RRT	units	and	dialysis	
professionals	in	order	to	increase	access	to	RRT	services	and	to	reduce	
catastrophic	health	spending.	Disease	management	was	employed	as	an	
intervention	to	facilitate	the	use	of	care	through	a	patient	identification	process	
and	the	use	of	a	guideline	protocol.	It	was	evident	in	Chapter	6	that	the	number	
of	patients	enrolling	on	the	programme	has	been	growing.	Meanwhile,	the	
programme	retained	increasing	numbers	of	patients,	as	receiving	proper	
dialysis	care	resulted	in	extended	life	expectancy.		
Many	countries	have	achieved	the	universal	health	coverage	goal	of	protecting	
patients	(in	this	case,	those	suffering	from	end‐stage	renal	disease)	from	
catastrophic	health	spending.	Nonetheless,	they	face	the	challenge	of	increasing	
care	costs	(De	Vecchi,	Dratwa	et	al.	1999;	Soroka,	Kiberd	et	al.	2005;	Knauf	and	
Aronson	2009;	Su,	Tsai	et	al.	2010).	For	this	reason,	many	countries’	focus	has	
been	on	factors	influencing	costs	of	health	care	(Gerdtham	and	Jönsson	2000),	
and	how	to	control	them	as	they	impact	overall	health	spending.			
A	number	of	cost	drivers	have	been	described	as	being	the	cause	for	increases	
of	health	expenditure,	including	each	country’s	disease	burden,	and	
investments	in	materials	and	machines	(Karopadi,	Mason	et	al.	2013).	In	
addition,	each	RRT	modality	may	be	driven	by	different	cost	drivers.	In	the	case	
of	peritoneal	dialysis,	the	main	cost	drivers	are	material	expenses	such	as	
solutions	and	catheters.	Costs	for	hemodialysis	are	driven	by	the	fixed	costs	of	
facility	space	and	staff	salary	(Just,	de	Charro	et	al.	2008).	A	study	from	Thailand	
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(Suksamran,	Kongsin	et	al.	2012)	reported	that	the	cost	of	medications	
accounted	for	the	largest	proportion	of	transplantation	costs	(although	the	
study	did	not	provide	a	breakdown	of	costs).		
From	its	beginning	in	2008,	the	Thai	Universal	Coverage	Scheme	(UCS)	RRT	
programme	has	achieved	its	aim	to	increase	access	to	care	and	provide	financial	
protection	for	patients	against	catastrophic	spending.	At	the	same	time,	the	
programme’s	numbers	of	patients	and	spending	have	both	grown	significantly,	
and	the	increasing	demand	for	RRT	may	challenge	the	country’s	health	care	
budget	and	human	resources	for	health.	In	2014	the	total	cost	of	the	RRT	
programme	to	the	UCS	amounted	to	4%	of	the	total	UCS	budget26,	although	
individuals	who	were	maintaining	RRT	accounted	for	only	0.07%	of	the	general	
UCS	members	(NHSO	2014).		
In	addition	to	the	small	number	of	studies	defining	the	major	cost	drivers	to	
RRT,	there	are	a	limited	numbers	of	cost	studies	conducted	in	developing	
countries	from	the	perspective	of	the	public	payer.	Moreover,	there	is	a	lack	of	
recent	studies	forecasting	the	number	of	patients	and	budget	needs	for	the	RRT	
programme	in	Thailand,	and	none	of	the	previous	studies	have	defined	cost	
drivers	for	this	high‐cost	health	condition.	 
This	study	draws	evidence	from	the	previous	chapters	to	estimate	the	long	term	
financial	consequences	of	the	RRT	programme	by	developing	a	model	for	
calculating	1)	future	numbers	of	patients	in	each	RRT	modality,	2)	the	unit	cost	
of	each	RRT	modality,	and	3)	publically‐funded	budget	needs	from	the	public	
payer’s	perspective	over	the	next	ten	years	(2014‐2023).	The	chapter	further	
uses	RRT	to	identify	effects	of	cost	drivers	on	future	expenditure	of	a	high‐cost	
treatment.	The	main	cost	drivers	included	here	are:	number	of	patients,	labour	
costs,	material	costs,	and	capital	costs.		
Firstly,	this	chapter	summarises	the	methodology,	with	a	framework	of	data	
analysis.	Next,	it	reports	results	of	the	two	sections:	forecast	numbers	of	RRT	
patients	and	estimated	costs	of	the	RRT	programme	over	the	next	ten	years.	
																																																								
26Total UCS budget including salary was 154,285 mBaht. Total spending on claims of the RRT programme was 
6,023 mBaht. 
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Results	from	these	two	sections	were	drawn	on	to	calculate	the	programme’s	
budget	needs	during	the	period.	A	discussion	and	conclusions	are	provided	at	
the	end	of	this	chapter.	
7.2 Methodology 
The	methodology	section	is	divided	into	three	subsections:	for	forecasting	
numbers	of	patients;	estimating	costs	of	the	RRT	programme;	and	predicting	
future	budget	needs	for	the	programme.	It	details	how	each	model	was	
obtained,	how	each	component	was	calculated,	and	what	assumptions	were	
used.	
7.2.1 Forecasting numbers of RRT patients 
Numbers	of	patients	needing	RRT	is	important	to	estimate	the	budget	for	
treating	them.	This	section	shows	the	method	of	forecasting	numbers	of	RRT	
patients	into	the	next	ten	years.	The	three	RRT	modalities	were	separately	
modelled	and	forecasted.	The	forecast	method	was	based	on	the	autoregressive	
integrated	moving	average	(ARIMA)	technique,	which	is	the	most	widely	used	
time‐series	approach	in	health	research.	It	predicts	future	behaviour	of	a	
variable	of	interest	by	taking	previous	observations	as	the	basis	(Linden,	Adams	
et	al.	2003).	There	are	four	steps	of	the	ARIMA	modelling:	1)	constructing	the	
analytical	dataset,	2)	identification,	3)	estimation	and	testing,	and	4)	
forecasting.		
7.2.1.1 Constructing the analytical dataset 
NHSO	databases	provide	observations	of	individuals	of	all	ages	who	were	
registered	and	retained	in	the	RRT	programme	between	the	fiscal	year	2008‐
2013	(1st	October	2007‐30th	September	2013)	stratified	by	RRT	modality	and	
month	of	registration.	Table	7‐1	is	a	part	of	the	analytical	dataset.	Differenced	
series27 of	PD,	HD,	and	KT	were	produced	in	this	stage.	Numbers	of	PD,	HD,	and	
KT	in	columns	2‐4	are	cumulative	numbers	of	live	patients	by	month;	they	are	
summed	in	column	5.	Differenced	series	of	PD,	HD,	and	KT	are	calculated	by	
																																																								
27 For example, PD differenced series at time t=PDt - PD(t-1) 
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subtracting	the	number	of	patients	in	the	previous	month	(t‐1)	from	the	
number	of	patients	in	the	present	month	(t).	Differenced	series	were	used	to	
identify	trends	in	time	series	plots.	
Table 7‐1  Selected ten observations from the dataset 
Time No.PD No.HD No.KT
Total 
No.RRT 
PD 
differenced 
series 
HD 
differenced 
series 
KT 
differenced 
series 
Jan2009 1,232 6,271 39 7,638 130 -86 7
Feb2009 1,429 6,280 47 7,881 197 9 8
Mar2009 1,621 6,240 56 8,056 192 -40 9
Apr2009 1,849 6,215 99 8,387 228 -25 43
May2009 2,054 6,170 116 8,591 205 -45 17
Jun2009 2,296 6,134 127 8,826 242 -36 11
Jul2009 2,533 6,083 148 9,068 237 -51 21
Aug2009 2,741 6,046 162 9,270 208 -37 14
Sep2009 2,976 5,978 178 9,464 235 -68 16
Oct2009 3,204 6,008 190 9,746 228 30 12
PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant 
7.2.1.2 Identification 
The	identification	process	was	conducted	to	determine	whether	a	
transformation	of	the	data	was	needed	to	stabilise	the	variance.	For	this,	
observations	from	each	RRT	modality	were	plotted	against	time.	All	RRT	
modalities	showed	non‐stationary	patterns,	therefore	the	first	differenced	
series	were	compared	with	the	initial	series	in	order	to	identify	the	right	
models.		
7.2.1.3 Estimation and testing 
The	purpose	of	estimation	and	testing	was	to	determine	the	most	appropriate	
model.	This	step	started	by	first,	plotting	the	Autocorrelation	function	(ACF)	
and	partial	autocorrelation	(PACF)	to	all	RRT	modalities	and	their	differenced	
series,	then	determining	numbers	of	appropriate	AR(p)	or	MA(q)	terms	for	the	
appropriate	model.	Finally,	a	number	of	statistics	were	produced	to	identify	
accurately	fitted	models.	These	were;	i)	unit	root	test,	ii)	autocorrelations	test,	
iii)	Akaike’s	Information	Criterion	(AIC),	and	iv)	test	of	residuals.	
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i. Unit root 
If	a	unit	root	presents,	the	series	are	non‐stationary	and	need	differencing.	A	
unit	root	can	be	identified	by	the	appearance	of	autocorrelations	of	the	original	
series	and	their	differenced	series.	If	autocorrelations	are	positive	to	a	high	
number	of	lags,	the	series	may	need	one	or	more	number	of	differencing	(Nau	
2014).	Also,	there	is	a	formal	test	for	the	unit	root,	called	the	Dickey‐Fuller	test,	
where	the	null	hypothesis	is	that	there	is	a	unit	root	(Fisher	2010).	
ii. Autocorrelations 
Autocorrelation	is	a	statistical	measure	used	to	describe	correlations	between	
values	of	the	time	series	at	different	time	periods	or	time	lags	(Makridakis,	
Wheelwright	et	al.	1998).	This	study	performed	three	tests	to	detect	serial	
correlations	including	1)	the	Durbin‐Watson	statistic,	2)	Durbin’s	alternative	
test,	3)	the	Breusch‐Godfrey	test.	Their	null	hypothesis	is	that	there	is	no	serial	
correlation.		
iii. Akaike’s Information Criterion (AIC) 
The	AIC	provides	a	measure	of	goodness‐of‐fit	to	a	model.	It	is	commonly	used	
with	ARIMA	models	to	decide	the	appropriate	model	order	(Makridakis,	
Wheelwright	et	al.	1998).	A	model	with	the	lowest	AIC	is	preferred.	
iv. Residuals 
A	well‐fitted	model	is	measured	by	the	white	noise	of	residuals.	The	Q	statistic	
(Portmanteau	test	of	autocorrelations)	was	performed	to	test	the	white	noise.	
The	null	hypothesis	is	that	the	series	are	white	noise.	In	addition,	a	cumulative	
periodogram	was	assessed	to	test	the	distribution	and	spread	of	the	residuals.	
The	residuals	should	have	a	mean	of	zero,	constant	variance,	and	be	normally	
distributed	(Hyndman	and	Athanasopoulos	2015).	
Tests	for	unit	root,	serial	correlations,	white	noise,	and	AIC	are	presented	in	
Appendices	8‐9.	
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7.2.1.4 Forecasting 
After	the	preferred	models	had	been	identified,	they	were	used	to	produce	
mean	values	for	the	next	120	observations,	that	is,	monthly	data	of	the	next	ten	
year	period.	The	product	of	this	step	was	predicted	numbers	of	patients	by	RRT	
modality.	They	were	used	to	calculate	future	budget	needs	in	subsection	3	
(7.3.3).	Confidence	intervals	of	95%	were	applied	to	give	upper	and	lower	limits	
of	mean	values.	All	statistical	analyses	and	graphical	presentations	in	this	
section	were	conducted	using	Stata13.	Figure	7‐1	summarises	how	the	
predicted	number	of	patients	are	obtained.	Results	from	fitting	ARIMA	models	
(for	PD,	HD,	and	KT)	are	shown	in	Appendix	10.	
Figure 7‐1  Three steps in forecasting the number of patients 
	
PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant 
7.2.2 Estimating the costs of the RRT programme 
Information	about	costs	of	RRT	services	is	important	to	inform	policy	decisions	
in	many	ways.	For	example,	from	the	payer’s	perspective,	hospital	costs	are	
important	for	determining	reimbursement	rates,	and	providers	may	want	to	
compare	the	true	cost	of	their	services	to	the	reimbursement	that	they	receive.	
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This	section	used	information	from	NHSO	reimbursement	and	payment	to	
estimate	the	unit	cost	of	each	RRT	modality.	The	unit	cost	was	then	broken	
down	into	three	types	of	cost	objects:	material	costs,	labour	costs,	and	
investment	costs	using	proportions	from	the	reviewed	studies	on	costing.	
7.2.2.1 Unit cost per patient 
NHSO	reimbursement	and	payment	in	2014	were	used	as	the	basis	for	
estimating	the	unit	cost	of	each	RRT	modality.	The	NHSO	reimburses	services	
relating	to	the	RRT	programme	in	various	ways.	This	study	divided	them	into	
three	groups.	They	were	(i)	reimbursements	for	service	bundles	which	relate	to	
the	amount	used	by	a	patient	per	year;	(ii)	medicines	and	medical	devices,	
which	are	centrally	purchased	and	allocated	to	RRT	units;	and	(iii)	additional	
reimbursements	for	services	which	are	used	by	particular	groups	of	patients.	
Only	the	first	and	second	types	(service	bundles	and	medication/medical	
devices)	were	used	to	calculate	the	unit	cost	per	patient	per	year.	The	third	type	
(additional	services)	was	used	to	calculate	the	future	budget	need	in	the	last	
subsection.	
Table	7‐2	explains	what	is	included	in	each	group	and	how	the	unit	cost	is	
calculated.	The	PD	service	bundle	was	paid	to	RRT	units	on	a	per	patient/per	
month	basis.	HD	and	KT	payments	were	made	per	session	and	transplantation	
respectively.	The	second	group	of	costs	includes	medicine	and	medical	devices	
which	were	centrally	purchased	and	allocated	to	RRT	units	on	the	basis	of	use.	
The	third	group	comprises	those	PD	patients	who	needed	temporary	
hemodialysis	before	starting	normal	PD,	vascular	access	which	was	applied	to	
all	new	HD	patients,	erythropoietin	for	patients	who	were	self‐paying	HD,	and	
lifelong	immunosuppressive	drugs	for	patients	at	various	stages	of	kidney	
transplant.		
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Table 7‐2  Composition of NHSO reimbursements  
(i)  Service bundle 
 PD  
 HD  
 Transplantation 
(ii) Medicine and medical device 
 For PD: fluids, catheters, EPO 
 For HD: EPO  
 For KT: IS in the first year 
 
(iii)  Additional reimbursements 
 For PD: temporary HD 
 For HD: vascular access 
            : EPO for self-pay HD 
 For KT: IS in subsequent 
years 
PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant, EPO=erythropoietin, IS= immunosuppressants 
An	NHSO	administrator	revealed	in	an	interview	(Chapter	5)	that	NHSO	
payment	was	intended	to	cover	the	full	cost	for	caring	for	patients	in	the	RRT	
programme.	However,	the	payment	is	paid	to	RRT	units	in	a	total	amount,	
details	for	each	type	of	costs	(such	as	salaries,	drugs	(excluding	the	second	type	
that	supported	by	the	NHSO),	and	maintenance)	were	not	clarified	anywhere.		
Unit	costs	of	PD	and	HD	
The	unit	cost	per	patient‐year	was	estimated	using	the	following	steps.	For	PD	
and	HD	average	use	per	patient	was	calculated	from	the	total	annual	use	
divided	by	the	number	of	using	patients,	see	the	formula	below.	For	example,	a	
figure	of	72.43	EPO	(erythropoietin)	vials	per	month	was	calculated	from	the	
total	vials	dispensed	per	year,	divided	by	the	total	number	of	patient	claims.		
ܣݒ݁ݎܽ݃݁	ݑݏ݁	݌݁ݎ	݌ܽݐ݅݁݊ݐ	݌݁ݎ	ݕ݁ܽݎ	 ൌ 	 ݐ݋ݐ݈ܽ	ݑݏ݁	݋݂	݈݈ܽ	݌ܽݐ݅݁݊ݐݏ	݅݊	2014ݐ݋ݐ݈ܽ	݌ܽݐ݅݁݊ݐݏ	݅݊	2014  
The	unit	cost	per	patient	per	year	was	computed	by	working	out	the	average	
use	of	each	reimbursed	item	and	then	multiplying	the	average	use	by	its	
reimbursement	rate.	Next,	the	unit	cost	per	patient	was	the	total	of	all	results	in	
the	first	and	the	second	group	of	reimbursements,	see	the	formula	below.	
ܷ݊݅ݐ	ܿ݋ݏݐ	݌݁ݎ	݌ܽݐ݅݁݊ݐ	݌݁ݎ	ݕ݁ܽݎ	 ൌ 		ݐ݋ݐ݈ܽ	݋݂	ሺܽݒ݁ݎܽ݃݁	ݑݏ݁ ∗ ݎܾ݁݅݉ݑݎݏ݁݉݁݊ݐ	ݎܽݐ݁ሻ		
Note	that	the	NHSO	divided	HD	patients	into	three	categories:	general	HD	
patients,	elderly	HD	patients	who	are	reimbursed	at	different	rates	but	costs	to	
both	groups	were	averaged	here,	and	self‐pay	HD	patients	who	pay	out‐of‐
pocket	for	HD	sessions	but	are	eligible	to	receive	free	erythropoietin	from	the	
NHSO.	The	average	of	HD	bundles	was	worked	out	by	(1)	calculating	average	
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reimbursement	per	patient	per	month	by	adding	up	all	reimbursements	in	both	
age	groups;	(2)	dividing	this	total	by	the	total	number	of	patients;	and	(3)	
adding	the	cost	of	all	claims	per	patient‐month	to	gain	the	total	claims	cost	per	
patient‐year.	
	 Unit	cost	of	KT	
The	unit	cost	of	KT	was	calculated	by	a	different	method.	Instead	of	using	the	
average	use	per	patient,	the	total	number	of	claims	of	each	item	for	
transplantation	(for	both	donors	and	recipients	and	extra	claims	for	
complications)	were	used	and	multiplied	by	their	reimbursement	rates,	and	
then	summed	to	produce	the	total	payment	per	year	(2014).	The	unit	cost	of	KT	
was	calculated	by	dividing	this	total	by	the	total	number	of	successful	
transplant	operations,	see	formula	below.			
ܶ݋ݐ݈ܽ	݌ܽݕ݉݁݊ݐ	݌݁ݎ	ݕ݁ܽݎ	 ൌ 		ݐ݋ݐ݈ܽ	݋݂	ሺ݊ݑܾ݉݁ݎ	݋݂	݈ܿܽ݅݉ݏ ∗ ݎܾ݁݅݉ݑݎݏ݁݉݁݊ݐ	ݎܽݐ݁ሻ	
ܷ݊݅ݐ	ܿ݋ݏݐ		 ൌ 			 ݐ݋ݐ݈ܽ	݌ܽݕ݉݁݊ݐ	݌݁ݎ	ݕ݁ܽݎݐ݋ݐ݈ܽ	ܭܶ	݋݌݁ݎܽݐ݅݋݊ݏ 	
7.2.2.2 Material cost, labour cost, and capital cost 
As	mentioned	above,	NHSO	payments	and	reimbursements	are	intended	to	
cover	all	costs	for	patient	care.	This	would	imply	that	they	include	salaries	(for	
everyone	working	for	the	RRT	unit),	medications,	consumables,	overheads,	and	
investments	(excluding	patients’	travel	costs,	carers,	and	lost	wages);	but	this	
has	never	been	specified	anywhere.		
This	study	used	the	calculated	unit	cost	to	estimate	the	components	of	material,	
labour,	and	capital	costs	by	using	the	unit	cost	per	patient‐year	and	proportions	
from	the	reviewed	studies.	These	studies	were	conducted	in	Thailand	using	the	
activity‐based	costing	method	where	all	departments,	namely	cost	centres,	
relevant	to	RRT	services	were	included.	These	cost	centres	allocated	direct	
costs	(material,	labour	and	capital	costs	of	the	RRT	unit)	and	indirect	costs	
(material,	labour	and	capital	costs	of	other	supporting	departments	such	as	
administration,	laboratory,	and	laundry)	to	each	RRT	modality.	
CHAPTER 7  Long term projections of RRT patients and costs of the RRT programme  
210 
	
For	peritoneal	dialysis,	figures	from	the	study	by	Laonapaporn,	Punthunane	et	
al.	(2014)	were	used.	This	is	because	this	study	was	recent	and	included	
detailed	costs	of	each	service.	In	this	study,	proportions	of	material	cost	(MC):	
labour	cost	(LC):	capital	cost	(CC)	were	at	a	ratio	of	74:25:1.	For	hemodialysis,	
various	figures	were	available.	The	proportions	of	MC:LC:CC	equalled		43:40:17	
in	the	study	of	Tisayaticom,	Patcharanarumol	et	al.	(2003).	Although	the	study	
was	not	the	most	recent,	it	was	conducted	across	a	wide	range	of	health	
facilities	across	the	country.	In	addition,	proposed	proportions	seem	to	be	
consistent	with	the	fact	that	hemodialysis	relies	heavily	on	skilled	professionals	
in	comparison	to	home	dialysis	such	as	PD.	For	kidney	transplant,	the	
proportions	of	LC:MC:CC	were	79:18:3.	This	was	taken	from	the	study	of	
Suksamran,	Kongsin	et	al.	(2012)	to	estimate	the	amount	of	material,	labour,	
and	capital	costs	contributing	to	one	case	of	kidney	transplantation.	
In	this	study	material	costs	comprise	the	cost	of	medications/devices	which	are	
centrally	purchased	and	distributed	to	RRT	units,	and	costs	of	other	medicines	
and	materials	that	hospitals	purchase	and	use	them	for	providing	RRT	services.	
Labour	costs	refer	to	remuneration	given	to	everyone	working	for	providing	
RRT	services.	Capital	costs	refer	to	depreciation	and	maintenance	costs	of	
equipment	and	buildings	in	the	care	of	RRT.		
The	product	of	this	stage	was	the	unit	cost	per	patient	in	each	RRT	modality	per	
year	consisting	of	estimated	amounts	of	material	costs,	labour	costs,	and	capital	
costs.	The	unit	cost	represented	the	initial	cost	in	2014	(the	initial	year	of	the	
forecast	period),	and	was	used	to	calculate	annual	budget	needs	from	the	
payer’s	perspective	over	the	next	ten	years	in	the	next	section.	Figure	7‐2	
summarises	how	the	unit	cost,	material	costs,	labour	costs,	and	capital	costs	
were	calculated.			
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Figure 7‐2  Summary of the unit cost calculation 
Reimbursement
Service bundle
(PD, HD, KT)
Medication/device
(EPO,IS,TK)
Average use
(uses/patient-year)
Unit cost (Baht/patient-year)
PD
MC:LC:CC 
= 74:25:1
HD
MC:LC:CC 
= 43:40:17
KT
MC:LC:CC 
=79:18:3
II. Estimating unit cost from the payer’s perspective
Multiply with payment rate
	
PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant,  
TK= Tenckhoff catheter, EPO=erythropoietin, IS=immunosuppressive drugs, 
MC=material costs, LC=labour costs, CC=capital costs 
7.2.3 Budget needs in the future 
This	section	used	results	from	previous	sections	to	calculate	the	final	results.	
They	were:	1)	the	total	RRT	programme	budget	needs	2014‐2023	and	2)	effects	
of	cost	drivers:	number	of	patients,	labour	costs,	material	costs,	and	capital	
costs.	The	latter	is	to	explain	effects	of	these	drivers:	how	they	influence	the	
unit	cost	of	each	RRT	modality,	and	to	suggest	ways	to	control	care	costs	during	
such	ten‐year	period.		
The	section	first	provides	information	on	the	selected	scenarios.	After	that	it	
explains	how	costs	were	calculated.	The	forecast	figures	are	presented	and	
discussed	in	terms	of	2014‐constant	Baht.		
7.2.3.1 Future scenarios 
It	is	possible	that	the	unit	cost	will,	in	the	next	ten	years,	deviate	from	what	it	
was	in	2014.	Chapter	5	provided	insights	into	what	future	scenarios	could	be,	
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and	three	scenarios	which	are	likely	to	happen	were	selected.	All	three	
scenarios	used	numbers	of	projected	future	patients	to	model	cost.	There	were	
three	costing	parameters:	material	costs,	labour	costs,	and	capital	costs.	While	
labour	costs	and	capital	costs	were	the	same	in	all	scenarios,	material	costs	
were	varied,	Table	7‐3.		
     Table 7‐3  Variations of costing parameters in three scenarios 
Scenario Material cost Labour cost Capital cost 
1   
2   
3   
= increasing, = decreasing,  = unchanging	
A	number	of	assumptions	were	employed	to	propose	scenarios,	thus	the	
selected	scenarios	were	close	to	the	real	process	of	government’s	budgets.	All	
three	selected	scenarios	assumed	the	numbers	of	patients	in	each	RRT	modality	
would	be	as	projected	in	subsection	7.3.1.		
This	section	assumed	that	the	capital	cost	would	behave	like	a	fixed	cost,	and	
therefore	the	total	capital	cost	of	treating	the	patient	population	of	2014	would	
not	vary	as	the	patient	number	increases.	It	is	possible	that	the	payer	may	want	
to	control	RRT	spending	by	keeping	the	cost	of	new	investment	stable	during	a	
time	period.	The	total	capital	cost	supported	by	the	NHSO	was	assumed	to	be	a	
flat	rate	annually	for	the	total	patient	population	and	remains	unchanged	from	
the	cost	in	2014	over	the	next	ten‐year	period.		
Labour	costs	and	material	costs	were	assumed	to	behave	like	variable	costs,	
increasing	as	the	number	of	patients	rises.	In	reality,	staff	salaries	and	wages	
increase	each	year.	For	this	reason,	this	section	assumed	wage	rates	would	
grow	by	7.2%‐7.9%	in	real	terms	annually	as	Sakulpanit,	Jitsuchon	et	al.	(2015)	
projected	for	wage	growth	in	the	public	service	sector,	therefore	the	total	
labour	cost	increases	as	a	consequence	of	increasing	patients	(and	more	staff	
needed)	and	wage	growth.		
Material	costs	of	each	reimbursed	item	were	varied	across	scenarios	1	to	3.	In	
scenario	1,	material	costs	per	patient‐year	would	remain	unchanged	in	2014‐
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2023.	In	scenario	2,	it	was	assumed	that	pharmaceutical	companies	want	to	
gain	more	profits	and	would	not	keep	their	prices	of	medicines	and	devices	
stable,	meaning	material	costs	per	patient‐year	would	increase	at	10%	per	year	
in	real	terms,	as reported	by	Sakulpanit,	Jitsuchon	et	al.	(2015).		
In	the	future,	it	is	likely	that	PD	solutions,	erythropoietin,	and	
immunosuppressive	drugs	will	be	made	locally	by	the	Government	
Pharmaceutical	Organization	(GPO).	When	locally	made,	costs	of	transportation	
and	bulk	storage	would	be	cheaper,	and	therefore	large	savings	would	be	
expected.	A	study	by	Akaleephan,	Wibulpolprasert	et	al.	(2009)	reported	that	a	
generic	brand	would	cost	approximately	30%‐80%	of	its	innovator	brand	in	the	
first	year	of	substitution.	The	third	scenario	(that	generic	brands	are	used	in	
2014‐2023)	took	the	figure	of	80%	of	the	original	2014	price	to	calculate	
material	costs	per	patient‐year	for	each	reimbursed	item.	
7.2.3.2 Cost calculation method 
The	two	previous	sections	estimated	numbers	of	future	patients	and	costs	per	
patient‐year.	Referring	to	Table	7‐2,	reimbursements	were	divided	into	three	
groups:	(i)	reimbursements	for	service	bundles,	(ii)	medications/devices,	and	
(iii)	reimbursements	for	additional	payments;	these	were	separately	calculated.	
Reimbursements	for	service	bundles	and	costs	of	medications/devices	(group	1	
and	group	2)	were	combined	in	order	to	calculate	the	unit	cost	per	patient.	In	
this	section,	the	total	cost	to	the	payer	for	each	RRT	modality	was	estimated	
into	the	future.	Figure	7‐3	summarises	the	calculation	process	for	assessing	
future	financial	implications.		
First,	the	unit	cost	per	patient	from	the	previous	section	was	broken	down	into	
three	cost	objects:	material	costs,	labour	costs,	and	capital	costs.	Next,	the	cost	
object	was	varied	for	three	selected	scenarios.	At	this	stage,	each	cost	object	
was	multiplied	by	the	predicted	number	of	patients	in	each	RRT	modality	to	
give	the	total	cost	of	each	cost	object.	Finally,	the	total	cost	to	the	payer	was	
calculated	by	adding	up	all	the	computed	cost	products	by	each	RRT	modality.	
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The	third	group	of	reimbursements	(additional	services)	was	computed	to	
identify	its	total	cost	in	the	same	way	as	the	other	two	groups,	but	only	the	
relevant	number	of	patients	was	used.	For	example,	to	calculate	the	total	
material	cost	of	temporary	hemodialysis	sessions	used	by	new	PD	patients,	the	
number	of	relevant	patients	was	new	PD	patients	(not	all	PD	patients).	
Additionally,	throughout	the	next	10‐year	period,	it	was	assumed	that:	
 temporary	HD	was	assumed	to	be	used	only	by	new	PD	patients	and	
the	average	use	of	temporary	HD	sessions	by	new	PD	patients	would	
remain	unchanged,	
 the	cumulative	number	of	self‐pay	HD	patients	would	increase	at	a	
decreasing	rate,	and	the	rate	used	in	calculations	would	be	equal	to	
those	of	HD	patients	each	year,		
 the	number	of	old	case	KT	patients28	would	remain	unchanged.		
7.2.3.3 Effects of cost drivers  
To	identify	the	effects	of	cost	drivers,	the	individual	estimated	unit	costs	from	
2014	to	2023	were	calculated	by	dividing	the	total	costs	to	the	payer	by	the	
total	number	of	patients	in	each	modality.	This	was	to	show	the	changing	trend	
of	unit	costs	by	RRT	modality	over	the	next	ten‐year	period	in	the	selected	
scenarios.	However,	these	unit	costs	were	not	intended	to	provide	unit	cost	
projections	in	the	future.	
																																																								
28 Meaning patients who had transplantation by self-financing or other means before the start of the RRT 
programme in 2008.	These patients are supported with free EPO by the NHSO.  
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Figure 7‐3  Framework for assessing budget needs, numbers of patients, and 
future financial implications 
    
   1/cost per patient of the third group (see Table 7-2), 2/ unit cost per patient of the second group (see Table 7-2) 
   MC=material cost, LC=labour cost, CC=capital cost, S1=scenario 1, S2=scenario 2, S3=scenario 3    
7.3 Results 
This	section	presents	results	of	cost	estimations,	forecasting	numbers	of	
patients	and	projecting	budget	needs	into	the	next	ten	years.	
7.3.1 Forecasting numbers of patients 
Historical	data	for	PD,	HD,	and	KT	patients	were	plotted	against	time	from	the	
beginning	of	2008	to	the	end	of	2013,	Figure	7‐4.	Although	there	is	a	slight	drop	
in	numbers,	PD	patients	have	shown	a	constant	increase.	By	the	end	of	2013,	
the	figure	increased	to	12,000	patients.	HD	patients	showed	slowly	increasing	
rates	until	mid‐2013.	After	that	the	rate	increased	at	similar	rates	to	PD.	In	
December	2013,	there	were	10,000	patients	using	HD	(Figure	7‐4a).	Numbers	
of	KT	were	increasing	but	the	figures	were	much	lower	in	comparison	to	those	
of	PD	and	HD.	At	the	end	of	2013,	there	were	approximately	800	patients	who	
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had	had	a	kidney	transplant,	Figure	7‐4b.	Note	that	low	figures	of	dialysis	
patients	during	2013	might	be	a	consequence	of	1)	merging	several	databases	
and	2)	claims	data	given	from	2013	may	not	be	completely	up	to	date.		
Figure 7‐4  Numbers of patients by RRT modality 
	
PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant 
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7.3.1.1 Model identification 
It	is	clear	from	Figure	7‐4	that	trend	patterns	exist	in	the	time	series	plots	of	PD,	
HD,	and	KT.	To	statistically	measure	these	nonstationary	patterns,	unit	root	
tests	for	stationarity	in	time	series	were	performed.	Results	show	the	presence	
of	unit	roots	in	all	models,	see	Appendices	8	and	9.	These	results	suggest	that	
each	model	needs	at	least	one	differencing.		
Next,	autocorrelation	function	(ACF)	and	partial	autocorrelation	(PACF)	plots	
were	used	to	identify	the	number	of	autoregressive	(AR)	and	moving	average	
(MA)	terms	in	each	model.	Results	from	the	original	series	were	compared	
against	the	differenced	series.	
i.			ACFs	and	PACFs	of	peritoneal	dialysis	
Figures	4a	and	b	are	ACF	and	PACF	of	the	original	series,	while	Figures	4c	and	d	
are	those	of	the	differenced	series.	ACF	plots	of	the	original	series	decay	very	
slowly	(Figures	4a)	and	the	ACF	of	the	differenced	series	(Figures	4c)	shows	a	
cut‐off	at	lag	1.	PACF	plots	of	both	original	and	differenced	series	are	infinite	
and	dominated	by	dampened	sine	waves	(Figures	4b	and	4d).	All	these	features	
indicate	the	model	ARIMA(0,1,1).	
Figure 7‐5  ACFs and PACFs of peritoneal dialysis 
	
pd=peritoneal dialysis, Dpd=differenced series 
Shaded areas represent 95% confidence bands 
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ii.			ACFs	and	PACFs	of	hemodialysis	
Figure	7‐6a	and	b	are	the	ACF	and	PACF	of	the	original	series,	and	Figures	5c	
and	5d	are	those	of	the	differenced	series.	From	Figure	7‐6a,	we	can	see	that	the	
ACF	of	the	original	series	decays	to	zero	and	the	PACF	shows	a	significant	spike	
at	lag	1	then	a	cut‐off	(Figure	7‐6b).	Both	ACF	and	PACF	of	the	differenced	series	
show	insignificant	lags	as	there	are	no	lag	spikes	out	of	the	95%	confidence	
bands	(Figure	7‐6c	and	d).	Because	the	ACF	plots	of	the	differenced	series	are	
all	negative	and	show	no	patterns,	differencing	might	not	be	necessary.	
Therefore,	the	model	with	one	AR	term	and	without	differencing,	AR(1)	was	
selected.	
 Figure 7‐6  ACFs and PACFs of hemodialysis 
	
hd=hemodialysis, Dhd=differenced series of hemodialysis 
Shaded areas represent 95% confidence bands 
iii.			ACFs	and	PACFs	of	kidney	transplant	
Similar	to	those	of	the	PD	models,	ACF	plots	of	the	original	series	gradually	
decay	(Figure	7‐7a)	and	the	ACFs	of	the	differenced	series	display	a	sharp	cut‐
off,	significant	at	lag	1,	Figure	7‐7c.	PACF	plots	of	both	original	and	differenced	
series	are	infinite,	and	are	dominated	by	dampened	sine	waves	(Figure	7‐7b	
and	6d).	This	feature	suggests	the	ARIMA(0,1,1).	
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Figure 7‐7  ACFs and PACFs of kidney transplant 
	
kt=kindey transplant, Dkt=differenced series of kidney transplant 
Shaded areas represent 95% confidence bands 
7.3.1.2 Estimation 
i.			PD	model	and	KT	model:	ARIMA	(0,1,1)		
The	equation	for	an	ARIMA(0,1,1)	is	
Ŷt  =  μ + Yt-1 – θ1et-1 
where	Ŷ	denotes	forecast	value	at	time	t, μ is	the	constant (PD	model	=167.44	
and	KT	model=11.79),	and θ	is	the	moving	average	parameter	(PD	model	=‐
0.48,	KT	model=‐0.76).	The	term		et‐1	is	the	error	term	at	time	t‐1	(see	details	in	
Appendix	10).	
ii.			Hemodialysis:	ARIMA(1,1,0)	
A	model	with	one	AR	term	seemed	to	fit	the	data	best.	However,	p‐values	of	all	
coefficients	of	this	model	were	insignificant	(see	Appendix	10).	When	trying	to	
fit	a	mixed	model	ARIMA(1,1,1),	all	parameters	were	significant.	Makridakis,	
Wheelwright	et	al.	(1998)	and	Nau	(2014)	explained	that	it	is	possible	that	the	
AR	term	and	the	MA	term	cancel	each	other's	effects	even	though	both	may	
appear	significant	in	the	model	when	judged	by	the	p‐value	of	their	coefficients.	
Furthermore,	fitting	the	model	ARIMA(1,1,1),	the	parameter	estimation	process	
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took	many	iterations	to	converge.	In	this	case,	reducing	one	AR	or	MA	term	
might	be	appropriate,	as	suggested	by	Nau	(2014).	Consequently,	the	
ARIMA(1,1,0)	was	selected.	
The	equation	for	a	differenced	series	of	ARIMA(1,1,0)	is	
Ŷt    =   μ + Yt-1 + φ (Yt-1 - Yt-2) 
where Ŷt  represents	the	expected	number	of	patients	at	time	t.		The term	μ	is	
the	constant	(146.32)	and	φ	denotes	the	autoregressive	coefficient	(‐0.131).	 
iii.			Tests	of	residuals	
Cumulative	periodograms	of	all	models	remain	close	to	the	45	degree	line	and	
within	the	confidence	band,	while	the	residuals	show	no	deviation	to	white	
noise	(see	Appendix	11).	
7.3.1.3 Forecasting 
Figure	7‐8	shows	the	actual	historical	and	predicted	numbers	of	RRT	patients	
according	to	the	selected	models.	It	was	estimated	that	by	the	end	of	2018,	
numbers	of	PD,	HD,	and	KT	patients	would	increase	to	22,364	±1,683;	
19,155±1,716;	and	1,526±126	patients	respectively.	After	that,	by	the	end	of	
2023,	these	figures	were	forecast	to	be	32,410	±1,683;	27,935±1,716;	and	
2,234±126	respectively.	It	is	clear	that	confidence	intervals	of	PD	and	KT	are	
very	close	to	their	predicted	lines,	which	might	be	because	these	two	modalities	
showed	strong,	stable	historical	trends.	For	this	reason,	only	the	central	
numbers	of	the	three	RRT	modalities	will	be	used	in	calculations	from	here	on.	
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PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant 
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Figure 7‐8		Actual and predicted PD, HD, and KT patients to the year 2024 
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Forecast	values	for	all	RRT	modalities	at	the	end	of	each	year	from	2014‐2023	
are	given	in	Table	7‐4.	Over	the	next	ten	years,	numbers	of	PD,	HD,	and	KT	
patients	were	expected	to	grow	with	decreasing	rates.	The	ARIMA	models	
predicted	that	the	number	of	RRT	modalities,	PD,	HD,	and	KT	would	increase	by	
14.0%,	14.5%,	and	14.7%	respectively	in	2015	and	by	6.6%,	6.7%,	and	6.8%	
respectively	in	2023.	Their	average	increases	were	10.2%,	12.5%,	and	10.6%	
annually.	The	total	number	of	patients	in	2023	was	forecast	to	be	62,579.				
Table 7‐4  Forecast total numbers of patients by RRT modality  
from 2014 to 2023 
Year PD HD KT Total 
2014      14,327   12,132          960     27,420  
2015      16,336   13,888       1,102     31,326  
2016      18,346   15,644       1,243     35,233  
2017      20,355   17,399       1,385     39,139  
2018      22,364   19,155       1,526     43,046  
2019      24,373   20,911       1,668     46,953  
2020      26,383   22,667       1,809     50,859  
2021      28,392   24,423       1,951     54,766  
2022      30,401   26,179       2,092     58,672  
2023      32,410   27,935       2,234     62,579  
% average annual growth rate 10.2 12.5 10.6 10.3 
PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant 
7.3.2 Costs of the RRT programme 
7.3.2.1 PD cost calculation 
NHSO	reimbursements	of	PD	were	divided	into	three	components.	They	
consisted	of	reimbursements	for	temporary	HD,	PD	services,	and	erythropoietin	
injections.	Table	7‐5	shows	calculated	costs	by	activity,	as	well	as	the	total	cost	
that	the	NHSO	expected	to	pay	for	a	PD	patient	in	2014.	The	total	cost	was	
224,514	Baht	per	PD	patient‐year,	of	which	the	cost	of	the	PD	solution	
accounted	for	the	largest	proportion	of	the	total	cost,	at	78%.	This	amount,	
however,	did	not	include	reimbursements	for	temporary	HD	sessions	(HD	
sessions	given	to	some	patients	before	they	start	permanent	PD).	In	2014,	new	
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patients	registering	with	the	PD	programme	used	an	average	of	7.45	sessions	
before	they	started	PD.	This	amounted	to	11,175	Baht	per	patient.		
Table 7‐5  Annual payment for activities for one PD patient in 2014 (in Baht) 
Activity Reimbursement Average use payment/patientyear 
Temporary HD* 1,500 Baht/session 7.45 sessions N/A 
PD service 2,500 Baht/month 12 times/year 30,000 
PD solution (bag) 120 Baht/bag** 1,460 bags/year 175,200 
EPO 200 Baht/vial** 72.43 vials/year 14,486 
EPO administration 50 Baht/time 47.34 times/year 2,367 
Tenckhoff catheter 4,172 Baht/catheter** 0.59 catheters/year 2,461 
Total (Baht)   224,514 
HD=hemodialysis, PD=peritoneal dialysis, EPO=erythropoietin 
*Temporary HD was classified as additional cost to the NHSO and excluded in the unit cost per patient-year  
  calculation 
**Prices that NHSO purchased in 2014 
7.3.2.2 HD cost calculation 
For	HD,	there	were	four	components	to	be	reimbursed;	reimbursements	for	
undergoing	a	vascular	access,	HD	sessions,	erythropoietin,	and	erythropoietin	
administration.	The	vascular	access	is	done	just	once	before	a	patient	starts	
hemodialysis.	This	activity,	however,	was	not	included	in	the	total	cost	per	
patient‐year	calculation.	In	practice,	there	are	two	types	of	reimbursements	for	
HD	sessions;	1,500	Baht	for	patients	aged	0‐60	years	and	1,700	Baht	for	elderly	
patients	or	those	who	have	complications.	This	study	used	an	average	HD	cost	
of	1,52929.		
The	total	cost	for	HD	patients	was	calculated	as	219,132	Baht	per	patient‐year.	
This	amount	is	dominated	by	reimbursements	for	hemodialysis	sessions.	Apart	
from	general	HD	patients,	the	NHSO	also	supports	provision	of	erythropoietin	
to	HD	patients	who	self‐pay.	These	costs	amounted	to	17,788	per	patient‐year,	
Table	7‐6.		
																																																								
29 The amount was calculated from the total claim cost of HD sessions divided by the total number of claims 
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Table 7‐6  Annual payment for activities for one HD patient in 2014 (in Baht) 
Activity Reimbursement Average use Payment/patientyear 
Vascular access* 5,000-12,000 Bath/operation 1 time N/A 
HD session 1,529.34 Bath/session** 131.65 times/patient-year 201,344 
EPO 200 Baht/vial 77.55 vials/patient-year 15,510 
EPO administration 50 Bath/time 45.56 times/patient-year 2,278 
Total (Bath)  General HD  
Self-pay HD 
219,132   
17,788 
HD=hemodialysis, EPO=erythropoietin 
*Vascular access was classified as additional cost to the NHSO and excluded in the unit cost per patient-year  
  calculation,  
**Calculated from total claims costs divided by total number of claims 
7.3.2.3 KT cost calculation 
For	KT,	costs	covered	operations	for	both	donors	and	recipients.	There	were	
four	protocols	of	kidney	transplant	operations	which	varied	in	complexity.	If	
there	were	complications,	an	extra	23,000‐500,000	Baht	per	patient	may	have	
been	spent	for	additional	treatments.	In	2014	the	total	number	of	successful	
operations	was	183	operations.	On	average,	one	transplant	operation	cost	
960,000	Baht	(see	Table	7‐7).		
Table 7‐7  Payment for a kidney transplant procedure in 2014 (in Baht) 
Activity Total payment 
Living donor pre-operation and nephrectomy  27,200,300  
Deceased donor nephrectomy       9,300,300  
Recipient’s transplant programme30      39,421,280  
Kidney transplant operation 
      Protocol 1  
      Protocol 2  
      Protocol 3  
      Protocol 4 
      5,788,900  
      12,216,500  
      2,928,000  
     38,190,680	 
Transplant with complications 
      ARC_A 
      ARC_B 
      AMR_A  
			
1,865,000 
3,600,100 
6,605,700 
																																																								
30 Including panel reactive antibody, an immunological laboratory test routinely performed on the blood of people 
awaiting transplantation 
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Activity Total payment 
      AMR_B 
      DGF_A 
      DGF_B 
      DGF_C 
9,328,600 
12,776,000 
1,804,800 
4,709,400 
Total payment  to 183 operations 175,735,560 
Unit cost  per operation 960,304 
All	patients	who	have	had	a	kidney	transplant	need	immunosuppressant	drugs	
after	they	go	back	to	daily	life.	The	reimbursement	depends	on	which	stage	the	
patient	is	in.	For	a	patient	who	is	in	the	first	six	months	after	the	operation,	the	
RRT	unit	received	30,000	Baht	per	month	and	after	the	second	year,	the	
reimbursement	decreased	to	15,000	Baht.	Overall	in	2014,	a	total	of	35,695,000	
Baht	went	to	1,815	claims	of	patients	in	various	stages,	Table	7‐8.	
Table 7‐8  Reimbursements (in Baht) of immunosuppressant drugs in 2014 
 Reimbursement Total payment/patient-year 
IS in first 1-6 months 30,000/month 
330,000   IS in next 7-12 months 25,000/month 
IS in next 13-24 months 20,000/month 240,000   
IS after 24 months 15,000/month 180,000   
IS =	immunosuppressants	
The	total	costs	for	PD,	HD,	and	KT	per	patient	are	all	summarised	in	Table	7‐9.	
The	total	cost	of	each	RRT	modality	was	broken	down	into	material	costs,	
labour	costs,	and	capital	costs.	Material	costs	included	costs	of	consumables;	
laboratory	tests	and	medications31.	Labour	costs	included	remuneration	of	
professionals	for	work	in	the	RRT	unit.	Capital	costs	refer	to	depreciation	and	
maintenance	costs	of	equipment	and	buildings	in	the	care	of	RRT.		
A	large	proportion	(96%)	of	PD	costs	was	spent	on	materials.	For	HD,	47%	and	
37%	of	the	total	cost	went	on	material	and	labour	costs,	respectively.	Total	
costs	of	PD	and	HD	were	comparable,	at	approximately	225,000	Baht	and	
219,000	Baht	per	patient‐year	respectively.	The	total	cost	of	KT	was	much	
																																																								
31 Medications here assumed to include both items that were purchased in bulk quantities at the central NHSO 
then allocated to hospitals and items that hospitals bought by themselves. 
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higher	than	the	other	two	modalities	in	the	year	of	transplantation.	The	total	
cost	of	KT	(1,290,000	Baht)	is	for	one	kidney	transplant	and	medication	
(immunosuppressants)	given	to	a	patient	in	the	first	year	of	transplantation.	
The	total	cost	for	transplantation	alone	was	960,000	Baht.		
Table 7‐9  Estimated costs per patient‐year for each RRT modality (in Baht) 
 PD (%) HD (%) KT (%) 
Material cost        216,099 (96)         103,068 (47) 467,931 (46) 
Labour cost          8,092 (4)         81,449 (37)  172,855 (38)  
Capital cost            324 (<1)         34,616 (16)  28,809  (16)  
     Total cost       224,514 (100)        219,132 (100)        1,290,304*(100)  
PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant 
*Figure represents costs for donor nephrectomy, recipient’s transplant programme, PRA test, transplantation 
with complications, and immunosuppressant in the first year.  
Figure	7‐9	is	a	graph	comparing	each	cost	component	of	the	three	RRT	
modalities.	Self‐pay	HD	and	KT	patients	in	their	second	year	and	above	were	
included	in	the	graph	to	show	the	costs	of	medication.	It	is	clear	that	costs	of	PD	
and	HD	were	comparable	and	cost	just	one‐sixth	of	KT	in	the	first	year.	After	the	
first	year	of	transplantation,	however,	costs	for	patients	who	maintain	KT	were	
significantly	lower.	In	the	second	and	third	year	and	beyond,	only	
immunosuppressants	were	supported	for	KT	patients,	meaning	total	
reimbursements	after	the	second	year	would	be	slightly	lower	than	those	of	PD	
and	HD.		
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Figure 7‐9  Comparison of costs and their components 
	
PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant 
7.3.3 Future budget needs of RRT programme 
7.3.3.1 Scenario 1 
In	this	scenario,	reimbursement	rates	were	adjusted	for	wage	increases	at	
7.2%‐7.8%	annually.	Reimbursements	for	material	and	investment	costs	would	
remain	unchanged.	Budget	needs	in	2014‐2023	were	projected	as	shown	in	
Table	7‐10.	In	2023,	reimbursements	of	PD,	HD,	and	KT	costs	were	predicted	to	
be	7,500	million	Baht,	8,000	million	Baht	and	700	million	Baht	respectively,	
giving	a	total	cost	of	16,200	million	Baht.	Overall	the	total	RRT	budget	need	was	
expected	to	grow	by	a	mean	annual	rate	of	11%.	
Table 7‐10  Forecast budget needs in Scenario 1 (million Baht) 
Year PD HD KT Total 
2014 3,239 2,773 411 6,422 
2015 3,700 3,195 439 7,334 
2016 4,164 3,649 467 8,280 
2017 4,632 4,137 494 9,263 
2018 5,104 4,660 522 10,286 
2019 5,581 5,227 550 11,358 
2020 6,063 5,835 578 12,476 
2021 6,551 6,503 606 13,660 
 -
 200,000
 400,000
 600,000
 800,000
 1,000,000
 1,200,000
PD HD Self-pay
HD
KT 2nd yr KT >2yr KT
Co
st
 p
er
 p
at
ien
t-y
ea
r (
Ba
ht
)
Capital cost
Labour cost
Material cost
CHAPTER 7  Long term projections of RRT patients and costs of the RRT programme  
228 
	
Year PD HD KT Total 
2022 7,046 7,226 635 14,907 
2023 7,547 8,009 664 16,220 
% average annual 
growth rate 10 13 6 11 
PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant 
Note: numbers were rounded to the nearest million, in terms of 2014-constant Baht 
7.3.3.2 Scenario 2 
If	reimbursements	were	adjusted	for	wage	increase	at	7.2‐7.8%,	and	for	
material	increase	at	10%	each	year,	a	greater	budget	would	be	spent	on	dialysis,	
particularly	on	PD.	In	2023,	the	various	RRT	modalities	would	incur	a	total	of	
30,700	million	Baht.	PD	was	expected	to	cost	at	around	17,000	million	Baht.	
Both	dialysis	modalities	would	require	95%	of	the	total	RRT	budget.	KT	would	
spend	less	budget	at	around	1,500	million	Baht	(see	Table	7‐11).	In	this	
scenario	the	total	budget	need	would	grow	at	the	highest	rate	in	comparison	to	
the	other	two	scenarios,	at	around	19%	annually.	
Table 7‐11  Forecast budget needs in Scenario 2 (million Baht) 
Year PD HD KT Total 
2014 3,239 2,770 411 6,420 
2015 4,054 3,343 480 7,877 
2016 4,999 4,004 557 9,560 
2017 6,091 4,760 646 11,497 
2018 7,351 5,623 747 13,721 
2019 8,803 6,611 861 16,275 
2020 10,469 7,732 991 19,192 
2021 12,381 9,017 1,138 22,535 
2022 14,570 10,474 1,305 26,349 
2023 17,071 12,126 1,494 30,691 
% average annual 
growth rate 
20 18 15 19 
PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant 
Note: numbers were rounded to the nearest million, in terms of 2014-constant Baht 
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7.3.3.3 Scenario 3 
If	the	PD	solution,	erythropoietin,	and	immunosuppressants	can	be	
manufactured	locally,	substantial	budget	could	be	saved,	particularly	on	PD.	In	
the	situation	that	these	subsidised	medications	would	be	replaced	by	locally	
made	types,	the	possible	percentage	saving	was	estimated	at	20%	of	the	2014	
purchase	price.	Costs	of	all	RRT	modalities,	PD,	HD,	and	KT,	would	increase	
slowly	and	reach	the	amounts	of	6,100	million	Baht,	7,400	million	Baht	and	500	
million	Baht	respectively	in	2023.	All	three	RRT	modalities	would	incur	a	total	
of	14,000	million	Baht.	The	total	RRT	programme	budget	would	be	expected	to	
grow	by	a	mean	of	9%	each	year.	
Table 7‐12  Forecast budget needs in Scenario 3 (million Baht) 
Year PD HD KT Total 
2014 3,239 2,770 411 6,420 
2015 2,992 2,889 357 6,238 
2016 3,369 3,304 380 7,053 
2017 3,750 3,753 402 7,906 
2018 4,135 4,237 425 8,798 
2019 4,526 4,766 448 9,739 
2020 4,921 5,335 471 10,727 
2021 5,322 5,964 494 11,780 
2022 5,730 6,648 518 12,896 
2023 6,144 7,393 542 14,078 
% average annual 
growth rate 8 12 3 9 
PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant 
Note: numbers were rounded to the nearest million, in terms of 2014-constant Baht 
Figure	7‐10	compares	estimated	figures	from	the	three	scenarios.	It	is	clear	that	
PD	would	be	influenced	the	most	if	there	were	changes	in	material	costs	and	it	
would	benefit	most	from	switching	to	generic	substitutions	in	scenario	3.	
Estimated	savings	would	be	in	the	region	of	700‐1,400	million	Baht	in	
comparison	to	scenario	1	(in	which	purchase	prices	of	medications	would	remain	
unchanged).	In	contrast,	if	material	prices	of	PD	are	uncontrollable,	the	total	cost	
of	PD	would	increase	rapidly	and	would	rise	faster	than	the	other	two	modalities.	
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Figure 7‐10  Comparison of reimbursement costs from three different 
scenarios 
	
S1=scenario 1, S2=scenario 2, S3=scenario 3, PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant 
7.3.3.4 Estimated unit cost in the future 
Behaviours	of	the	three	cost	drivers	were	explained	by	the	estimated	unit	costs	
over	time	of	PD,	HD,	and	KT	from	scenarios	1	to	3	(Figure	7‐11).	Scenario	1	
assumed	that	labour	costs	would	increase	approximately	7%	each	year	with	
unchanged	material	and	capital	costs.	Estimated	unit	costs	of	PD	and	HD	would	
gradually	decrease,	in	contrast	to	that	of	KT,	whose	unit	cost	would	increase	
over	time	(Figure	7‐11).	In	scenario	2,	material	costs	were	assumed	
uncontrolled	and	would	increase	at	10%	annually,	while	labour	and	capital	
costs	would	act	as	described	in	scenario	1.	All	estimated	unit	costs	would	
increase	over	time.	
In	scenario	3,	material	costs	were	assumed	to	decrease	by	20%	in	2015.	These	
savings	would	make	each	unit	cost	of	RRT	modalities	decrease	from	its	original	
scenario	1	value,	then	reach	a	low	point.	After	that,	the	unit	costs	of	PD	would	
remain	rather	stable	over	time.	However,	unit	costs	of	HD	and	KT	would	
increase	after	reaching	a	low	point	in	2015.	
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Figure 7‐11  Estimated unit costs of PD, HD, and KT from scenarios 1 to 3 
2014‐2023 
	
	
	
S1=scenario 1, S2=scenario 2, S3=scenario 3 
PD=peritoneal dialysis, HD=hemodialysis, KT=kidney transplant 
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7.4 Discussion 
This	section	summarises	and	discusses	results	on	the	predicted	number	of	RRT	
patients,	their	unit	costs,	and	budget	needs	in	the	future.	It	then	relates	the	
findings	of	the	cost	drivers	to	how	to	control	care	costs	of	the	RRT	programme.	
Finally	it	compares	the	study’s	findings	with	others	conducted	in	Thailand	and	
other	countries.		
7.4.1 Future numbers of patients  
This	study	predicted	that	the	number	of	RRT	patients	would	increase	at	around	
10%	annually	for	the	next	ten‐year	period.	There	are	various	factors	influencing	
the	increase	of	RRT	patients	at	this	rate.	Firstly,	the	high	number	of	ESRD	
patients	can	be	a	consequence	of	the	growing	prevalence	of	ESRD	risk	factors	in	
the	general	population.	A	national	survey	in	2004	in	Thailand	(Ong‐ajyooth,	
Vareesangthip	et	al.	2009)	found	that	age,	diabetes,	hypertension,	and	body	
mass	index	were	strongly	associated	with	chronic	kidney	disease.	In	this	regard,	
a	report	from	Thai	Health	(2014)	confirmed	the	increasing	body	mass	index.	
Also,	the	Chronic	Diseases	Surveillance	of	the	Ministry	of	Public	Health	
(Tonghong,	Tepsitta	et	al.	2012)	reported	the	increasing	prevalence	of	diabetes	
and	hypertension	among	the	Thai	population.		
Secondly,	comparing	these	findings	to	studies	from	other	countries	which	
focused	on	hemodialysis	found	similar	results.	For	example,	a	study	in	
Australia’s	Northern	territory	(projected	between	2001	and	2004	in	the	
Aboriginal	population)	suggested	that	the	number	of	HD	patients	would	grow	at	
a	decreasing	rate,	giving	an	average	increase	of	12%	per	year	respectively.	This	
similarity	might	relate	to	the	fact	that	patients	are	in	the	early	phase	of	access	to	
the	RRT	programme.	In	countries	where	there	is	a	long	history	of	RRT	benefit,	
growth	in	the	prevalence	of	RRT	patients	is	much	lower.	A	study	in	Ontario,	
Canada	(Quinn,	Laupacis	et	al.	2009)	(projected	between	2005	and	2011)	and	a	
study	in	the	US	(Gilbertson,	Liu	et	al.	2005)	(projected	between	2010	and	2015)	
expected	annual	increases	of	5.5%	and	3.8%	respectively.	
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Thirdly,	the	treatment	guidelines	may	affect	the	number	of	patients	entering	
into	the	programme	by	changing	nephrologists’	practices.	For	instance,	it	is	
evident	in	Chapter	6	that	at	present,	patients	who	are	recruited	into	the	RRT	
programme	have	a	low	level	of	eGFR,	less	than	15	ml/min/1.73	m2.	If	the	
threshold	level	is	raised,	the	number	of	RRT	patients	will	increase	significantly.		
Finally,	changes	in	the	payer’s	policy	could	influence	the	popularity	of	RRT	
modalities,	affecting	numbers	of	patients	and	therefore	the	expenditure	of	the	
RRT	programme.	In	a	prior	example	from	2012,	the	NHSO	started	reimbursing	
all	types	of	HD	for	erythropoietin,	which	resulted	in	a	significant	increase	in	
numbers	of	HD	patients	(see	details	in	Chapter	6).		
In	contrast	to	the	projections	of	increases	in	RRT	patients,	a	more	positive	
outlook	is	possible.	This	could	be	due	to	effective	prevention	and	screening	
programmes	of	ESRD	risk	factors,	all	of	which	are	essential	to	manage	these	risk	
factors	and	to	decrease	the	number	of	patients	entering	into	the	RRT	
programme.	Along	with	the	RRT	programme,	the	NHSO	provides	a	screening	
programme	for	the	risk	factors	of	diabetes	and	hypertension	to	all	Thai	adults	
over	30,	regardless	of	their	health	insurance	status.	A	secondary	prevention	
programme	is	also	given	to	those	who	are	already	diagnosed	with	diabetes	and	
hypertension.	Coverage	of	these	programmes,	together	with	effective	public	
health	campaigns	to	reduce	risk	behaviours,	will	help	reduce	the	growth	in	the	
RRT	patients	(James,	Hemmelgarn	et	al.	2010),	and	therefore	the	growth	in	long	
term	health	care	expenses.		
Despite	being	a	more	cost‐effective	RRT	modality	over	PD	and	HD,	KT	suffers	
from	the	low	numbers	of	donated	kidneys	for	transplant.	In	each	year,	around	
7%	of	all	patients	(including	patients	from	the	other	two	public	schemes)	who	
were	waiting	for	a	kidney	were	able	to	have	transplantation.	Additionally,	until	
now	only	11%	of	all	patients	who	had	transplantation	were	UCS	members	(Thai	
Transplantation	Society	2014).	A	study	has	pointed	out	that	the	major	flaw	is	
because	the	organ	donation	system	in	Thailand	suffers	from	a	lack	of	concrete	
policy	and	guidelines	to	support	the	system	(Onsuwan,	Bunnak	et	al.	2015).	
Despite	KT	being	more	cost‐effective,	because	of	limited	numbers	of	organ	
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donors,	the	increasing	numbers	of	patients	with	RRT	needs	have	been	put	on	
dialysis	modalities.	This	study	predicted	that	in	2023	there	would	be	thirty	
times	more	patients	on	dialysis	than	KT	patients.		
7.4.2 How to control programme costs? 
The	concept	of	economies	of	scale	provides	ways	to	control	programme	costs.	
They	are	the	circumstance	that	the	unit	cost	of	a	service	decreases	with	
increasing	output	as	its	fixed	costs	are	spread	across	more	units	of	output.	
According	to	McPake,	Normand	et	al.	(2013)	economies	of	scale	in	health	care	
may	be	achieved	by	two	ways:	1)	increasing	output	with	constant	fixed	costs.	
This	is	because	increases	in	numbers	of	outputs,	although	resulting	in	the	
increase	of	the	total	material	cost,	may	not	affect	fixed	costs	such	as	labour	costs	
and	capital	costs	and	2)	using	available	capacity	intensively,	for	example	by	
sharing	resources	such	as	professionals	and	care	units	to	fill	spare	capacity.		
It	is	possible	that	future	costs	of	RRT	modalities	will	change	from	what	they	are	
presently.	This	study	suggested	three	possible	scenarios	and	explained	how	the	
RRT	programme	might	grow	in	the	next	ten	years	and	how	to	control	care	costs	
by	focusing	on	four	cost	drivers:	number	of	patients,	labour	costs,	material	
costs,	and	capital	costs.	In	all	scenarios	numbers	of	patients	and	labour	costs	
would	increase	each	year,	at	around	10%	and	7%,	in	real	terms	respectively,	
and	capital	costs	would	remain	constant	across	the	study	period.	Material	costs	
were	varied:	remain	constant	in	scenario	1,	increase	in	scenario	2,	and	decrease	
in	scenario	3.		
Findings	from	this	study	suggested	that	the	total	costs	in	scenarios	1‐3	were	
estimated	to	grow	by	9‐19%	annually.	Despite	increases	in	the	total	budget,	
some	scenarios	showed	that	the	unit	cost	may	be	lower	or	may	increase	slowly	
by	focusing	on	the	four	cost	drivers,	see	Figure	7‐11.		
7.4.2.1 Number of patients 
The	number	of	patients	is	one	of	the	most	powerful	cost	drivers	of	the	RRT	
programme.	Its	effect	is	notable	when	comparing	the	total	cost	of	KT	to	PD	and	
HD	costs.	The	unit	cost	per	patient‐year	of	KT	is	large,	at	1.3	million	Baht,	while	
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PD	and	HD	were	both	at	220	thousand	Baht	in	2014.	However,	the	number	of	
KT	patients	is	minimal	in	comparison	to	PD	and	HD,	and	their	amounts	of	total	
costs	become	more	distanced	from	each	other	over	time.		
KT	requires	high	investments	in	professionals	and	equipment,	and	the	low	
number	of	patients	is	an	obstacle	to	increasing	the	efficiency	of	KT	units.	Other	
cost	drivers	(material,	labour,	and	capital	costs)	show	minimal	effects	on	unit	
costs	of	KT.	It	is	evident	in	Figure	7‐10	that	total	KT	costs	would	remain	low	in	
comparison	to	costs	of	dialysis	in	all	scenarios.	The	unit	cost	of	KT	per	patient,	
however,	is	high,	and	would	not	decrease	in	any	scenarios,	in	contrast	to	the	
other	two	RRT	modalities	(see	Figure	7‐11).	One	explanation	for	this	is	that	the	
denominator	used	to	calculate	the	unit	cost	of	KT	was	the	number	of	new	
transplant	cases32, which	was	projected	to	be	stable	across	the	studied	period.	
Many	more	patients	have	to	undertake	transplantation	in	order	to	spread	the	
total	cost	and	reduce	the	unit	cost	of	KT.		
Apart	from	the	need	to	promote	numbers	of	donated	kidneys	for	
transplantation,	filling	spare	capacity	might	be	a	solution	to	control	costs	of	KT.	
In	Thailand,	although	there	is	no	study	assessing	spare	capacity	of	operating	
theatres	in	hospitals,	a	nationwide	charity	campaign	in	2006	showed	that	the	
number	of	kidney	transplantation	could	be	boosted	to	over	200%	of	its	target33.	
This	suggested	that	there	might	be	spare	capacity	in	the	KT	system.	Filling	the	
capacity	with	optimum	use	of	existing	theatres	with	a	large	pool	of	specialist	
services	may	help	RRT	units	control	costs,	and	in	addition	it	was	reported	in	a	
study	(Bowers	and	Mould	2002)	that	concentrating	health	services	in	operating	
centres	which	had	more	surgical	specialists	might	increase	quality	of	care	by	
providing	more	opportunities	for	ongoing	specialty	training.	
	
	
	
																																																								
32 Old transplant cases were assumed that they have exited from the system and were not included in the 
denominator, unlike PD and HD that denominators were cumulative cases. 
33 http://www.kidneythai.org/newsdetail30.php 
CHAPTER 7  Long term projections of RRT patients and costs of the RRT programme  
236 
	
7.4.2.2 Material costs 
Material	costs	account	for	the	largest	proportion	in	the	total	costs	of	PD,	HD,	
and	KT.	It	is,	therefore,	the	most	important	cost	to	contain	from	the	public	
payer’s	perspective.	In	scenarios	1	and	3,	material	costs	per	patient	over	the	
study	period	were	assumed	unchanged	and	decreased	respectively.	As	a	result,	
unit	costs	of	PD	would	be	lower	with	increasing	numbers	of	patients.	However,	
the	result	of	this	study	shows	that	this	would	not	be	the	case	for	HD	and	KT.	
This	is	because	HD	comprises	high	staff	costs	and	numbers	of	KT	patients	are	
too	low	and	it	would	not	affect	the	large	amount	of	its	total	cost	as	explained	
above.	Although	unit	costs	of	HD	and	KT	would	not	be	lower	with	increasing	
numbers	of	patients,	they	would	increase	at	slow	rates.	
Controlling	the	price	of	materials	is	central	to	a	cost	containment	strategy.	This	
was	evident	in	scenario	3,	in	which	the	cost	of	PD	benefited	the	most	because	it	
contains	a	large	proportion	of	material	cost	(74%),	and	the	majority	of	
materials	were	assumed	to	reduce	in	price	once	locally	made.	KT	costs	also	
comprised	a	large	proportion	of	material	cost	(79%)	but	just	a	small	number	of	
patients	would	have	transplantation,	and	therefore	the	total	cost	of	KT	would	
not	benefit	much	from	this	strategy.		
7.4.2.3 Labour costs and capital costs 
The	labour	cost	is	a	small	proportion	of	PD	and	KT	costs,	at	25%	(Laonapaporn,	
Punthunane	et	al.	2014)	and	18%	(Suksamran,	Kongsin	et	al.	2012)	
respectively.	All	scenarios	in	this	study	assumed	that	wages	would	vary	with	
increasing	patients	and	grow	at	7%	annually,	but	total	costs	of	PD	and	KT	were	
dominated	by	changing	material	costs	and	effects	of	the	labour	cost	did	not	
show	clearly.	The	costs	of	HD	contains	a	significant	proportion	of	labour	cost	
(40%),	because	of	this	the	noticeable	effect	in	this	study	was	that	the	total	cost	
of	HD	increase	slowly	but	would	not	gain	much	advantage	from	switching	to	
locally	made	brands,	compared	to	the	total	cost	of	PD.		
HD	also	has	slightly	higher	labour	and	capital	costs	than	PD	and	KT.	This	is	in	
line	with	the	fact	that	HD	units	have	to	invest	more	in	salaries	in	order	to	hire	
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professionals,	dialysis	machines,	and	areas	in	the	dialysis	unit	to	care	for	
patients.	With	an	increase	in	HD	patients,	the	costs	of	professionals	and	
investments	are	likely	to	grow	proportionally.	In	contrast,	an	increase	in	PD	
patients	may	not	require	more	PD	nurses,	machines,	or	areas.	This	is	because	
PD	is	home‐based	dialysis	and,	because	patients	rely	mainly	on	their	self‐care	
management,	is	less	labour‐intensive	(Liu,	Gao	et	al.	2014).		
7.4.3 Comparison to the prior study of the UCS 
Predictions	for	the	growth	of	RRT	patients	and	budget	needs	of	the	RRT	
programme	were	previously	reported	in	the	study	of	Kasemsap,	Prakongsai	et	
al.	(2006).	At	the	time,	the	UCS	RRT	programme	was	not	yet	set	up,	and	the	
study	used	a	number	of	assumptions	(incidence	rates	from	the	US	renal	registry	
and	survey	prices	from	Thai	RRT	providers)	to	estimate	numbers	and	budget	
needs	of	the	RRT	programme.	Predictions	from	this	study	were	far	from	the	
reality,	which	might	be	due	to	imprecise	cost	and	incidence	estimations.		
Survey	prices	of	dialysis	procedures	and	medications	were	much	higher	than	
real	reimbursement	rates	and	purchase	prices	of	medication	in	the	RRT	
programme.	For	example,	the	price	per	HD	patient‐year,	excluding	EPO,	was	
calculated	at	272,190	Baht	(current	study=209,344	Baht);	the	price	per	PD	
patient‐year	excluding	EPO	was	276,708	Baht	(current	study=218,836	Baht).	
The	greatest	variation	between	this	study	and	reality	was	that	the	price	of	EPO	
in	2001	was	anything	from	80%‐95%	higher	than	the	current	price.		
Incidence,	which	refers	to	the	number	of	new	patients,	was	another	cause	of	
imprecision	in	the	previous	study.	The	previous	study	employed	the	ESRD	
incidence	rate	of	300	per	million	population	(pmp)	per	year	and	assumed	all	
new	ESRD	patients	would	enter	the	RRT	programme.	However,	this	current	
study	(Chapter	6)	found	the	true	incidence	rate	of	RRT	patients	in	the	UCS	was	
just	197	pmp	per	year	in	2013	and	that	around	half	of	the	diagnosed	patients	
entered	the	RRT	programme.		
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7.4.4 Cost comparison to other countries 
Direct	comparison	of	RRT	costs	between	countries	is	not	very	straightforward.	
This	is	because	costs	from	each	study	might	be	calculated	from	a	different	
perspective	(such	as	payer’s,	provider’s,	or	societal	perspective).	Also,	items	
included	in	cost	calculations	may	vary.	In	addition	to	these	differences,	the	
characteristics	of	a	country	play	an	important	role	in	the	preferred	RRT	
modality,	and	therefore	the	costs	of	RRT	may	vary	significantly	across	the	
world.	These	characteristics	(Karopadi,	Mason	et	al.	2014)	include	gross	
domestic	product	per	capita,	health	care	resources,	how	provision	is	split	
between	public	and	private,	financing	structures,	and	reimbursements	for	
providers	of	RRT	care.		
For	example,	from	the	payer’s	perspective,	reimbursements	in	high	income	
countries	such	as	Germany,	the	US,	and	the	UK	are	costly.	For	PD	and	HD,	
reimbursements	per	patient‐year	range	from	27,000‐58,000	US$	and	36,000‐
61,000	US$,	respectively	(Vanholder,	Davenport	et	al.	2012).	Looking	at	other	
countries	which	belong	to	the	same	middle‐income	group	and	same	region	as	
Thailand	(Asia),	costs	of	each	RRT	modality	are	different	depending	on	each	
country’s	specific	characteristics	and	which	perspective	is	assessed	(see	Table	
7‐13).	Note	that	costs	for	PD	and	HD	in	Table	7‐13	include	direct	costs	for	
dialysis	services,	professional	fees,	medications,	and	routine	laboratory	tests	
excluding	hospitalisation.	KT	costs	are	only	for	transplantation	and	exclude	
dialysis	and	medication	after	transplantation.	For	Mexico	and	Brazil,	costs	were	
assessed	from	the	provider’s	view,	and	reimbursements	from	their	insurance	
schemes	may	be	different.	For	example	in	Brazil,	reimbursements	(in	October	
2006)	were	US$52.40	per	HD	session	and	US$716	per	month	for	PD.		
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Table 7‐13  Average annual cost (US$) per patient‐year in selected countries 
 PD HD KT 
Thailand (current study)* 7,242 6,968 30,009 
Mexico (2013)** 8,695 N/A N/A 
Brazil (2013)**  23,404 23,411 N/A 
India (2012, 2013)*** 6,275 6,382 Up to 12,924 
*Figures were calculated from the payer’s perspective 
** Figures were calculated from the provider’s perspective including medical costs and professional fees 
excluding costs for emergency visits and hospitalisation 
***Costs for out-of-pocket payment 
Sources: Mexico: Cortés-Sanabria, Paredes-Cesena et al. (2013); Brazil: de Abreu, Walker et al. (2013); India: 
PD and HD from Jeloka, Upase et al. (2012), KT from Ramachandran and Jha (2013) 
7.5 Conclusions 
Results	of	this	study	are	expected	to	provide	new	insights	into	how	the	RRT	
programme	would	grow	over	time,	in	terms	of	the	number	of	patients	and	
budget	needs	over	the	next	ten	years.	
In	the	next	ten	years	the	number	of	RRT	patients	was	forecasted	to	grow	at	
around	10%	annually.	These	patients	would	need	a	large	amount	of	the	UCS	
budget,	and	the	total	amount	of	the	RRT	programme	was	estimated	to	increase	
in	the	region	of	9‐19%	annually.	The	unit	cost	per	patient	of	PD	could	be	lower	
than	its	price	in	2014	and	the	unit	costs	per	patient	of	HD	and	KT	could	increase	
at	slow	rates.	This	would	depend	on	whether	costs	of	technologies,	in	particular	
expensive	medications,	can	be	lower	or	remain	unchanged	in	the	next	ten	years,	
regardless	of	normal	increases	in	the	number	of	health	staff	and	wage	rate	at	
around	7%	annually.	
Although	these	predictions	may	not	provide	exact	calculations,	they	can	be	an	
approximation	to	the	health	care	payer	for	planning	future	budget,	health	
facilities,	and	human	resources	relating	to	the	RRT	programme,	and	how	to	
adjust	the	plan	as	new	information	becomes	available.	Comparing	the	actual	
expenditure	of	the	RRT	programme	against	historical	predictions	provides	an	
idea	to	policy	makers	of	whether	the	programme	has	performed	as	it	was	
planned,	and	if	not,	what	may	contribute	to	such	results.				
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In	addition	to	this,	examining	behaviours	of	the	four	cost	drivers	(the	number	of	
patients,	material	costs,	labour	costs,	and	capital	costs)	can	help	policy	makers	
decide	which	proportions	of	the	RRT	payment	can	be	regulated	to	suit	the	
actual	situation	and	the	government’s	available	budget.	For	example,	if	cost	
components	are	adjusted,	at	what	percentages	or	at	what	prices	this	should	be	
done.	Also,	the	study	described	which	cost	components	can	be	contained	and	
suggestions	for	how	to	do	so.	
A	number	of	components	in	the	disease	management	approach	may	have	
helped	the	UCS	control	health	care	costs.	These	include	the	focus	on	a	target	
population	(ESRD)	and	the	guideline	protocols	that	are	linked	with	predefined	
payment	rates.	These	components	provide	information	on	the	number	of	
patients	and	budget	needed	to	run	the	RRT	programme,	and	help	control	the	
programme	payment	to	fit	the	available	RRT	budget.		
7.6 Limitations 
7.6.1 Quality of data 
This	study	employed	the	most	recent	data	available.	The	limitation	of	this	use	
was	that	the	claims	may	not	be	the	most	up	to	date.	Since	the	NHSO	allows	its	
health	facilities	to	claim	up	to	one	year	post‐expenditure,	more	claims	for	the	
fiscal	year	2014	can	be	expected.		
7.6.2 Threats to validity 
The	time‐series	approach	is	used	to	project	numbers	of	patients	in	the	renal	
replacement	therapy	programme	because	it	controls	most	factors	that	other	
population	approach	designs	cannot	control	for	(Linden,	Adams	et	al.	2003).	
However,	there	remain	two	issues	of	validity	to	discuss:	internal	validity	and	
external	validity.	
i. Internal validity: long term effect 
The	advantage	of	the	time‐series	approach	is	that	it	can	eliminate	the	effects	of	
other	factors	that	may	influence	the	variable	of	interest.	However,	the	approach	
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depends	substantially	on	historical	values.	This	means	that	the	closer	the	
projected	values	are	to	historical	values,	the	more	precise	they	are.		
ii. External validity: generalisability 
Since	the	RRT	programme	is	designed	to	serve	a	specific	population,	the	result	
is	not	meant	to	explain	or	be	used	in	other	groups	of	patients.	
7.6.3 Proportions and assumptions used 
Another	limitation	was	that	this	study	used	results	of	the	past	studies	to	
estimate	costs	of	material,	labour,	and	investments	for	each	RRT	modality.	
Some	of	these	studies	were	conducted	on	a	large	scale	but	some	were	
conducted	in	just	one	hospital.	Additionally,	some	cost	objects	may	have	
different	definitions	in	other	settings	and	may	include	different	items.	For	
example,	overhead	costs	were	one	of	the	most	difficult	items	to	identify	because	
sometimes	they	included	training,	education,	and	research,	in	addition	to	costs	
for	hospital	administration,	interest,	and	housing.	This	is	why	results	from	
different	settings	may	give	different	figures.		
Predictions	in	this	study	are	vulnerable	to	inaccuracies	due	to	a	number	of	
factors.	Most	importantly,	assumptions	used	have	an	effect	on	the	estimated	
budget	needs.	If	what	happens	in	reality	deviates	substantially	from	what	was	
assumed,	it	threatens	the	accuracy	of	the	forecasts.	Finally,	on	some	occasions	a	
patient	encounters	an	infection	due	to	the	dialysis,	generating	costs	which	the	
NHSO	has	to	pay	for,	but	they	are	not	covered	in	this	study.
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CHAPTER 8 Discussion 
8.1 Introduction 
In	the	previous	chapters,	this	study	reviewed	high‐cost	conditions,	their	
impacts	on	households	and	health	systems,	and	empirical	evidence	from	
population‐based	disease	management	programmes.	Research	gaps	were	then	
identified	and	used	to	formulate	the	research	questions,	aims,	and	objectives	of	
this	study.		
Disease	management	has	a	number	of	uses,	for	example	to	control	increasing	
health	care	costs,	promote	quality	of	care,	and	reduce	fragmentation	in	the	
health	system.	This	study	viewed	the	approach	as	an	intervention	to	increase	
access	to	a	high‐cost	treatment	(renal	replacement	therapy,	or	RRT)	in	the	
Universal	Coverage	Scheme	(UCS),	Thailand.	This	study	aimed	to	use	RRT	as	a	
tracer	to	explore	the	introduction	and	functioning	of	a	high‐cost	health	benefit	
programme	of	the	UCS,	and	then	to	assess	how	a	disease	management	approach	
has	facilitated	the	inclusion	of	RRT	in	the	UCS	benefit	package.	
There	were	three	objectives.	The	first	was	to	describe	the	rationale	behind	the	
initiation	of	a	high‐cost	health	benefit	programme	and	the	application	of	the	
disease	management	approach.	It	employed	qualitative	methods	to	triangulate	
evidence	from	multiple	data	sources.	These	methods	included	document	
review,	semi‐structured	interview,	focus	group	discussion,	and	structured	
observation.	The	second	objective	was	to	assess	the	output	and	outcome	of	the	
RRT	programme:	access	to	RRT	services	and	mortality.	It	identified	changing	
patterns	of	access	to	RRT	services	and	mortality	of	patients	who	were	
diagnosed	with	end‐stage	renal	disease	(ESRD),	both	those	who	were	
maintaining	any	modality	of	RRT	and	those	who	were	living	without	RRT,	by	
using	the	age‐period‐cohort	analysis.	The	third	objective	was	to	carry	out	long	
term	projections	of	the	RRT	programme,	in	terms	of	the	number	of	future	
patients	and	estimated	budget	from	the	public	payer’s	perspective.	This	study	
employed	cost	modelling	and	time‐series	analysis	methods.	Possible	future	
scenarios	were	identified	to	define	cost	drivers	of	the	RRT	programme.	
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This	chapter	synthesises	findings	from	analytical	chapters	and	embeds	them	
within	the	context	of	the	literature	review	and	research	questions.	These	
accounts	lead	to	the	discussion	of	approaches	to	the	monitoring	and	evaluation	
of	disease	management	programmes,	and	how	the	study	methodology	can	be	
used	and	applied.	They	also	raise	issues	of	the	study	strengths	and	weaknesses	
in	relation	to	the	interpretation	of	overall	results.		
8.1 Methodological issues  
This	study	applied	both	qualitative	and	quantitative	methods	to	cope	with	the	
complex	nature	of	the	disease	management	programme	and	they	
complemented	each	other.	This	section	summarises	the	methodologies	used	
and	links	them	to	a	broader	range	of	designs	and	methods	for	disease	
management	programme	evaluation.	
8.1.1 Qualitative approach 
Qualitative	methods	are	essential	in	the	early	phase	of	any	research,	in	
particular	for	data	collection,	qualitative	description	and	result	interpretation	
(Murphy,	Dingwall	et	al.	1998).	In	disease	management	programme	evaluation,	
they	are	even	more	important	because	most	disease	management	programmes	
always	have	complex	designs,	multifaceted	interventions,	and	participatory	and	
collaborative	practices.	
Chapter	5	of	this	study	used	qualitative	approaches	to	collect	data	from	multiple	
sources	including	reviews,	interviews,	a	focus	group	discussion,	and	
observations.	Findings	from	the	qualitative	analysis	were	used	to	explain	the	
RRT	programme	in	greater	detail,	and	provide	evidence	on	the	application	of	
disease	management	interventions	and	the	links	between	various	stakeholders	
in	the	health	system.		
Results	from	qualitative	methods	in	Chapter	5	were	also	used	as	preliminary	to	
the	quantitative	method.	They	supported	findings	from	the	quantitative	method	
in	Chapter	6	in	terms	of	outputs	and	outcomes	by	revealing	why	around	half	of	
patients	with	ESRD	diagnoses	decided	not	to	register	with	the	RRT	programme.	
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The	qualitative	approach	also	offered	insights	into	how	best	to	support	these	
patients	with	their	opt‐out	choice.		
In	previous	literature,	the	in‐depth	interview	and	focus	group	discussion	were	
conducted	to	probe	patients’,	providers’,	or	other	stakeholders’	attitudes	
(Blakeman,	Macdonald	et	al.	2006),	beliefs	and	concerns	(Jerant,	von	
Friederichs‐Fitzwater	et	al.	2005),	as	well	as	patients’	quality	of	life	(Dongbo,	
Ding	et	al.	2006).	Qualitative	information	was	also	used	to	describe	disease	
management	interventions	and	to	support	analysis	of	the	programme’s	effect	as	
assessed	by	quantitative	methods	(Weingarten,	Henning	et	al.	2002).	
8.1.2 Quantitative approach 
The	selected	quantitative	methods	in	this	study	are	recognised	as	powerful	
tools.	The	age‐period‐cohort	analysis	in	Chapter	6	is	a	modelling	technique	to	
summarise	and	report	routinely	collected	information	from	administrative	
records	or	disease	registries	(Carstensen	2007).	The	ARIMA	modelling	in	
Chapter	7	is	the	most	widely	used	time‐series	approach	in	health	research	
(Linden,	Adams	et	al.	2003).	The	use	of	administrative	data	detailed	to	the	
individual	level	of	this	study	provided	strength	to	the	quantitative	analysis	since	
they	did	not	need	a	population	estimate	and	NHSO	payment	estimate	since	this	
used	information	derived	from	the	true	UCS	population	and	patients.	This	
therefore	helped	increase	the	validity	of	the	study.		
8.1.2.1 Data source 
This	study	used	the	facility‐based	administrative	data	that	were	collected	from	
routine	services	of	UCS	health	facilities	across	the	country.	This	use	allowed	the	
study	to	undertake	a	facility‐based	analysis	of	patients	who	had	ESRD	diagnoses	
from	three	types	of	databases:	outpatient,	inpatient,	and	the	RRT	disease	
management	programme.		
The	UCS	administrative	data	used	in	this	study	included	all	patients	who	sought	
care	from	such	services	from	2008,	both	those	receiving	RRT	and	those	who	
were	not,	although	these	might	not	represent	the	entire	prevalent	population	of	
patients	with	ESRD	and	the	total	UCS	population.	This	is	because	there	may	be	a	
CHAPTER 8  Discussion  
246 
	
number	of	the	UCS	members	who	have	never	used	any	UCS	service	(but	may	
receive	care	elsewhere	in	private	facilities),	or	never	been	diagnosed	as	ESRD,	
and	therefore	were	left	out	of	the	UCS	databases.		
In	addition	to	the	advantage	of	the	UCS	databases,	they	provided	citizen	
identification	numbers	that	were	encoded	before	handing	to	any	third	party.	
The	use	of	encoded	citizen	identification	numbers	allowed	matching	between	
databases	without	violating	patients’	confidentiality.			
Chapters	6	and	7	provided	examples	of	using	administrative	data	for	
programme	monitoring	and	evaluation	purposes.	Administrative	data	or	claims	
data	result	from	the	health	care	delivery	system	by	registering	members	into	
health	schemes	or	programmes	and	reimbursing	for	health	care	costs.	They	
contain	demographic	characteristics,	diagnoses,	and	procedures	given	to	
patients	and	are	often	used	in	health	care	evaluation	(Iezzoni	1997).	This	study	
used	NHSO	administrative	data	and	gained	a	number	of	benefits.	Firstly,	the	
databases	were	readily	available	to	the	NHSO	and	were	inexpensive	to	acquire	
for	research	purposes.	Secondly,	they	were	frequently	updated	due	to	the	
reimbursement	process.	Thirdly,	they	encompassed	a	large	group	of	
populations,	that	is,	the	UCS	population	and	RRT	patients	which	were	relevant	
to	this	study’s	aims	and	objectives.	Finally,	databases	were	computerised,	the	
International	Classification	of	Diseases	(ICD)	system	was	used	as	a	standard	
diagnosis	tool,	and	they	contained	encoded	patients’	citizen	identification	
numbers.	These	allowed	the	merging	of	various	databases	into	analytical	
datasets.		
The	Thailand	Renal	Replacement	Therapy	Registry	was	a	potential	data	source	
but	it	was	not	used	in	this	study	for	a	variety	of	reasons.	The	renal	registry	
covers	information	on	various	aspects	of	all	patients	who	are	maintaining	RRT	
in	Thailand,	including	patients	who	are	beneficiaries	of	the	other	two	public	
health	insurance	schemes.	However,	the	focus	of	this	study	was	only	on	the	
access	to	RRT	of	ESRD‐diagnosed	UCS	members,	not	RRT	patients	in	general.	
Information	in	the	renal	registry,	therefore,	is	not	enough	to	fulfill	the	study’s	
aims	and	objectives.	In	addition,	the	database	did	not	include	individuals’	
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citizen	identification	numbers	which	were	the	key	variable	for	combining	
databases	in	this	study.		
The	NHSO	administrative	data	have	limitations.	Despite	containing	rich	
information,	administrative	data	lack	precise	patient	socioeconomic	
information	which	is	one	of	the	factors	determining	the	use	of	health	care	(Aday	
and	Andersen	1974),	therefore	this	may	undermine	comparisons	of	access	to	
health	services	amongst	different	social	classes	in	future	research.		
Data	quality	is	another	challenge	of	using	administrative	databases:	there	are	
several	causes	of	data	inaccuracies.	Firstly,	their	main	purpose	is	administrative	
function.	Consequently,	fields	which	are	not	relevant	for	claims	processing	are	
frequently	incomplete.	The	use	for	other	purposes	such	as	assessing	health	
indicators	and	the	performance	of	the	system	can	be	limited.	Secondly,	claims	
data	sent	to	obtain	reimbursement	for	treatment	may	not	be	completely	up	to	
date,	since	the	NHSO	allows	its	health	facilities	to	claim	up	to	a	year	later.	
Finally,	DRG	(diagnosis	related	group)	creep	in	order	to	increase	hospital	
income	has	been	a	major	concern	of	diagnosis	procedure	in	Thailand	and	
elsewhere	(Pongpirul,	Walker	et	al.	2011).		
To	deal	with	these	problems,	the	NHSO	has	introduced	an	audit	process	with	
incentives	for	providers	if	there	are	no	coding	errors	found,	and	penalties	are	
given	to	mistakes.		
8.1.2.2 Study design 
In	general,	methods	used	in	disease	management	programme	evaluation	vary	
greatly	and	they	can	affect	studies’	findings.	The	literature	review	in	Chapter	3	
found	that	many	population‐based	disease	management	evaluations	had	moved	
towards	more	practical	study	designs	of	non‐experimental	studies	aiming	to	
evaluate	programme	effectiveness.	Most	of	these	reviewed	studies	compare	
effects	of	an	intervention	group	(patients	in	disease	management	programme)	
against	a	control	group	(usual	care	group)	using	a	number	of	measures,	such	as	
costs	of	care,	service	utilisation,	and	patients’	health	outcomes.	Results	from	
these	studies,	however,	were	mixed	and	inconclusive.	This	might	because	
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limitations	in	study	designs	meant	that	they	could	not	control	for	possible	
biases,	confounders,	and	the	multifaceted	characteristics	of	disease	
management	interventions.	
Chapter	6	of	this	study	assessed	the	RRT	disease	management	programme,	in	
terms	of	the	changing	patterns	in	access	to	RRT	services	and	ESRD	patients’	all‐
cause	mortality.	The	method	introduced	in	this	chapter	was	the	age‐period‐
cohort	analysis.	The	analysis	modelled	effects	of	age,	year	of	registration	(or	
death),	and	birth	cohort	intended	to	assess	the	changing	patterns	of	RRT	
programme	registration	rates	and	all‐cause	mortality	rates	among	UCS	
members	overtime	in	particular	years	against	the	reference	year.	Modelling	
effects	of	such	variables	eliminated	the	identifiability	problem	that	occurs	from	
the	relation:	period	=	age	+	cohort,	faced	by	other	linear	models	as	they	have	
two	variables	as	well	as	their	sum	in	the	same	model.	
The	age‐period‐cohort	analysis	has	been	adopted	by	many	studies	to	model	and	
describe	trends	in	mortality	rates	and	incidence	rates	from	routinely	collected	
databases	and	disease	registries	(Carstensen	2007),	however	it	has	had	limited	
use	in	chronic	kidney	disease	or	renal	replacement	therapy.	Many	longitudinal	
studies	on	patients	with	chronic	kidney	disease	frequently	used	the	cohort	
study	design	to	assess	longitudinal	effects,	and	all‐cause	mortality	was	often	
included	as	a	primary	outcome.	For	example,	those	were	conducted	by	O'Hare,	
Choi	et	al.	(2007);	Wen,	Cheng	et	al.	(2008);	and	Neovius,	Jacobson	et	al.	(2014).	
There	are	numerous	studies	conducted	to	quantify	costs	and	financial	
implications	relating	to	RRT.	These	studies	varied	considerably,	in	particular	in	
terms	of	cost	components	included.	This	is	due	to	variations	in	which	
perspective	(payer,	provider,	or	societal)	is	assessed	and	in	definitions	used	to	
define	each	cost	item.	For	example,	‘overheads’	may	refer	to	dissimilar	items	in	
different	studies.		
Chapter	7	estimated	the	future	financial	implications	of	the	RRT	programme	by	
using	cost	modelling	and	time	series	projection.	It	chose	the	payer’s	perspective	
to	estimate	the	unit	cost	of	each	RRT	modality.	The	study	then	calculated	future	
numbers	of	patients	in	each	RRT	modality	using	the	ARIMA	time	series	
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technique.	Finally,	the	study	used	the	calculated	unit	cost	and	the	projected	
patient	numbers	to	estimate	the	long	term	financial	consequences	of	the	RRT	
programme.		
This	study	found	a	number	of	methodological	issues	that	might	affect	accuracies	
of	forecast	values.	First,	time	series	modelling	required	a	large	number	of	
observations	(such	as	at	least	60	observations	in	a	row)	to	perform	an	ARIMA	
time	series	analysis.	This	can	be	a	challenge	to	a	newly	launched	programme	
such	as	RRT	because	if	using	monthly	data	as	in	this	current	study,	there	have	to	
be	data	available	for	at	least	five	years.	In	addition,	this	approach	depends	
substantially	on	historical	values.	This	means	that	the	closer	the	projected	
values	are	to	historical	values,	the	more	precise	they	are.	
Secondly,	costs	were	conducted	from	the	payer’s	perspective	using	NHSO	
reimbursements	and	payments	as	the	basis.	The	NHSO	assumed	that	they	
covered	the	full	cost	for	providing	RRT	care.	In	reality	there	might	be	some	type	
of	costs	that	were	not	taken	into	account.	For	example	from	the	providers’	
perspective	there	might	be	some	costs	incurred	from	the	care	process	which	
were	not	covered	in	NHSO	payments.		
Finally,	this	study	used	information	from	past	studies	and	a	number	of	
assumptions	to	estimate	future	costs	of	the	RRT	programme.	Some	of	these	past	
studies	were	conducted	on	a	limited	numbers	of	hospitals	and	might	not	
represent	the	whole	country	which	has	various	kinds	of	RRT	units.	The	
assumptions	used	might	affect	the	future	budget	need	in	a	way	that	if	what	will	
happen	in	the	future	differs	from	these,	it	threatens	the	accuracy	of	the	
forecasts.		
8.1.2.3 Designs used by other studies evaluating disease 
management programmes 
The	selection	of	data	collection	methods	can	affect	studies’	findings	(Linden,	
Adams	et	al.	2003)	and	the	data	obtained	in	a	disease	management	programme	
evaluation	can	roughly	determine	the	methodology	used	and	indicators	to	be	
assessed	(Busse	and	Stahl	2014).	Routinely	collected	sources	such	as	
CHAPTER 8  Discussion  
250 
	
administrative	data,	claims	data,	or	patient	records	are	often	used	to	assess	the	
care	process,	utilisation,	outputs,	and	outcomes;	while	newly	collected	sources	
such	as	surveys	and	interviews	are	mostly	used	to	probe	patient	and	provider	
experiences	(Busse	and	Stahl	2014).		
Studies	assessing	the	disease	management	approach	have	used	a	range	of	
methods	to	evaluate	the	effects	of	nationwide	disease	management	
programmes.	According	to	a	review	by	Conklin	and	Nolte	(2013),	the	cross‐
sectional	(pre‐post	or	post	only),	observational	study	design	was	the	most	
frequently	used.	This	is	because	experimental	studies,	particularly	randomised	
control	trials,	are	considered	the	gold	standard	for	evaluating	the	effectiveness	
of	an	intervention,	but	are	controversial	in	practice.	This	is	because	
experimental	studies	may	be	unlikely	in	disease	management	programmes	that	
are	implemented	nationwide.	Additionally,	there	are	issues	about	ethical	
considerations,	since	providers	may	hesitate	to	offer	better	services	to	a	
subgroup	of	patients	(Nolte,	Conklin	et	al.	2012).	
Comparing	the	effects	of	disease	management	with	a	reference	group,	or	before	
and	after	launching	the	programme,	is	a	common	strategy	for	assessing	disease	
management	programmes.	Conklin	and	Nolte	(2013)	conducted	a	review	and	
pointed	out	that	the	reference	groups	can	be	the	general	population	or	patients	
with	the	same	health	condition	but	who	received	conventional	care	or	typical	
care	instead	of	disease	management	interventions.	Using	an	external	reference	
group	as	a	benchmark	was	another	comparison	strategy	and	the	groups	
selected	varied	greatly.	They	included,	for	example,	international	or	
interregional	comparison,	performance	targets,	and	a	national	or	regional	
standard	(Conklin	and	Nolte	2013).	Selecting	which	comparators	to	use,	
however,	is	a	key	challenge	for	assessing	disease	management	programmes	due	
to	the	nature	of	study	subjects.	They	are	likely	to	change	over	the	study	period	
as	a	result	of	the	nature	of	progressive	chronic	diseases	(Linden,	Adams	et	al.	
2003).		
Some	specific	approaches,	referred	to	as	statistical	techniques,	can	be	used	to	
evaluate	the	effects	of	a	programme.	For	example,	the	difference‐in‐difference	
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approach	compares	changes	in	the	outcome	of	interest	in	the	control	(or	pre‐
intervention)	group	with	changes	in	the	intervention	(or	post‐intervention)	
group	in	the	same	time	period	(Athey	and	Imbens	2006).	An	example	of	this	
method	is	a	study	conducted	in	Medicaid	diabetes	disease	management	
programmes	(Conti	2013).	The	study	used	administrative	data	to	compare	
inpatient	costs	and	the	number	of	emergency	admissions	in	three	states	of	the	
US	against	those	in	states	without	such	programmes.	An	interrupted	time	series	
is	a	rather	powerful	quasi‐experimental	design	to	evaluate	longitudinal	effects	
of	interventions.	The	segmented	regression	analysis	of	an	interrupted	time	
series	uses	statistical	models	to	estimate	level	and	trend	pre‐	and	post‐
intervention	(Wagner,	Soumerai	et	al.	2002).	An	example	of	this	study	design	is	
the	assessment	of	the	effect	of	a	new	payment	system	on	quality	of	care	and	
clinical	outcomes	for	patients	with	hypertension	in	the	UK	(Serumaga,	Ross‐
Degnan	et	al.	2011).	
8.2 Discussion on the research findings 
In	this	section,	the	research	findings	are	summarised	and	discussed.	It	starts	
with	an	introduction	to	the	functioning	of	the	UCS	RRT	programme.	It	is	
followed	by	the	effects	of	the	disease	management	approach	on	patients	
including	patient	decision	making,	changes	in	access	to	care,	and	changes	in	all‐
cause	mortality	of	ESRD	patients.	Finally,	the	future	financial	implications	of	the	
programme	are	discussed.	
8.2.1 What are the rationale and functioning of the RRT programme? 
The	RRT	programme	is	the	result	of	attempts	from	various	stakeholders	to	
respond	to	the	implications	of	high‐cost	conditions.	This	study	highlighted	the	
combination	of	leadership	roles	from	three	elements:	the	academicians	who	
gather	new	information,	public	actions,	and	politicians	who	push	ahead	the	new	
RRT	policy.	
The	programme	is	one	of	the	few	UCS	disease	management	programmes	that	
has	all	the	basic	interventions	of	the	disease	management	concept.	This	section	
summarises	and	discusses	the	definition	of	high‐cost	and	catastrophic	
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conditions,	then	covers	the	introduction	and	functioning	of	the	RRT	programme	
focusing	on	the	UCS	disease	management	approach.	
8.2.1.1 High-cost and catastrophic definitions 
Exploring	the	introduction	of	the	RRT	benefit	of	the	UCS	found	that	RRT	fell	into	
the	definition	of a	high	cost	condition	as	proposed	by	Wyszewianski	(1986).	
This	is	because	the	health	budget	spent	on	caring	for	a	small	number	of	patients	
with	ESRD	accounted	for	a	significant	proportion	of	the	health	care	budget.	In	
2014,	the	total	cost	of	the	RRT	programme	to	the	UCS	amounted	to	4%	of	the	
total	UCS	budget,	although	individuals	who	were	maintaining	RRT	accounted	
for	only	0.07%	of	general	UCS	members	(NHSO	2014).	Evidence	from	other	
countries	suggests	similar	results.	In	the	UK,	around	1‐2%	of	the	annual	NHS	
budget	goes	to	treat	0.05%	of	individuals	with	renal	failure	(Baboolal,	McEwan	
et	al.	2008;	Kerr,	Brey	et	al.	2012).	In	the	US,	ESRD	patients	comprising	less	than	
1%	of	the	total	Medicare	population	received	6%	of	the	annual	Medicare	budget	
in	recent	years	(United	States	Renal	Data	System	2014).		
Seeking	treatment	for	kidney	failure	can	cause	a	patient	and	family	financial	
catastrophe,	especially	the	poor	and	those	without	effective	insurance	coverage.	
When	patients	pay	out‐of‐pocket	for	dialysis	care,	and	the	amount	exceeds	their	
ability	to	pay,	they	have	to	reduce	normal	consumption	of	food	and	other	
necessities.	Some	families	use	up	savings,	sell	property,	raise	loans,	or	stop	their	
children’s	education.	Many	patients	decide	not	to	use	care	simply	because	they	
cannot	afford	it.	These	effects	are	evident	in	countries	(Sakhuja	and	Kohli	2006;	
Prakongsai,	Palmer	et	al.	2009;	Luyckx,	Naicker	et	al.	2013;	Ramachandran	and	
Jha	2013)	where	RRT	services	may	be	available	but	are	not	covered	by	health	
insurance.		
While	the	focus	of	Wyszewianski	(1986)’s	definition	of	high‐cost	conditions	is	
on	cost	containment	by	policy	makers,	the	concern	over	catastrophic	conditions	
is	more	about	protecting	patients	against	excessive	payment	of	care	costs.		
CHAPTER 8  Discussion  
253 
	
8.2.1.2 Response to ESRD by stakeholders  
End‐stage	renal	disease	is	an	example	of	a	chronic	condition	that	can	rapidly	
bring	a	patient	without	insurance	coverage	into	financial	catastrophe.	This	
happens	because	each	episode	of	treatment	is	expensive	and	treatment	is	
needed	regularly	to	sustain	a	patient’s	life.	This	is	in	marked	contrast	to	other	
chronic	conditions	such	as	hypertension	and	diabetes,	where	most	of	the	health	
spending	is	likely	to	be	covered	by	a	benefit	package	of	health	insurance.	
The	commencement	of	the	RRT	programme	in	the	UCS	was	a	result	of	the	
response	to	ESRD	by	people	at	various	levels	in	the	health	system.	Before	the	
RRT	programme	started	in	2008,	patients	and	families	paid	all	they	had,	with	
some	taking	out	loans	or	making	distressed	sales	of	property	to	finance	their	
treatment.	Some	patients	gathered	into	a	patient	group	and	called	for	their	
rights	to	affordable	health	benefits.	Policy	makers	and	providers	took	into	
account	the	consequences	of	these	conditions	and	the	financial	catastrophe	they	
cause	for	patients.	Together	with	the	patient	group,	they	created	knowledge,	
societal	movement,	and	got	politicians	involved,	and	eventually	were	successful	
in	the	introduction	of	the	RRT	benefit.		
In	particular,	the	introduction	of	the	RRT	programme	was	a	move	that	went	
with	the	creation	of	knowledge,	the	public,	and	the	strong	ministerial	leadership	
as	proposed	by	Wasi	(2000).	This	move	was	essential	to	protect	UCS	patients	
and	their	families	from	catastrophic	health	spending.	It	differed	from	most	
countries	(for	example	the	UK,	continental	European	countries,	and	Japan)	that	
have	implemented	universal	health	coverage	with	RRT	included	from	the	
outset.	An	example	of	another	country	that	attempted	to	make	a	change	to	its	
health	care	benefit	was	the	US.	The	federal	government	led	the	move	to	extend	
Medicare	benefits	to	cover	RRT	in	1972.	From	that	point,	patients	with	ESRD	
were	defined	as	disabled	by	their	chronic	illness	and	were	covered	in	Medicare	
regardless	of	age	(Iglehart	1993).	
The	move	to	introduce	the	RRT	benefit	in	Thailand	and	the	US	may	be	explained	
by	inequities	in	access	to	essential	health	care,	as	with	many	countries	when	
they	introduced	their	universal	health	coverage.	Before	commencing	the	UCS	
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RRT	programme,	the	right	to	equal	access	to	care	was	raised	and	compared	
with	the	other	two	public	health	schemes:	the	CSMBS	and	the	SSS.	In	Thailand	
and	also	in	Mexico,	another	developing	country	implementing	universal	health	
coverage,	unequal	access	to	the	treatment	of	end‐stage	renal	disease	has	been	
mentioned	as	a	cause	of	fragmentation	in	the	health	system	(Kierans,	Padilla‐
Altamira	et	al.	2013).	One	study	(Garcia‐Garcia,	Renoirte‐Lopez	et	al.	2010)	
argued	that	extending	the	Mexican	Seguro	Popular	health	insurance	scheme	to	
cover	the	treatment	for	end‐stage	renal	disease	nationwide	would	be	one	
strategy	to	reduce	the	existing	inequality	in	that	country.	
8.2.1.3 Disease management approach of the RRT programme 
Bringing	a	high‐cost	treatment	into	the	health	benefit	basket	may	be	a	challenge	
to	any	developing	country.	It	is	essential	to	separate	a	high‐cost	programme	
from	the	mainstream	in	order	to	facilitate	patient	access	to	care.	This	is	because	
the	payment	in	the	mainstream	system	may	not	motivate	providers	to	take	
patients	into	the	programme	and	provide	expensive	care.	In	addition,	Thailand	
and	a	number	of	developing	countries	(Van	Bui	2007;	Jha	2008;	Odubanjo,	
Oluwasola	et	al.	2011;	Luyckx,	Naicker	et	al.	2013),	in	particular,	share	some	
limitations	in	the	service	system	including	the	shortfall	or	geographically	
skewed	distribution	of	specialists,	nurses,	and	health	facilities.	They	also	lack	
effective	guidelines	and	the	database	management	system	which	are	crucial	for	
working	between	departments	or	sections	of	providers	and	different	sectors	in	
the	health	system.	
8.2.1.4 Which of disease management interventions works? 
Components	of	disease	management	were	used	as	interventions	in	the	UCS	RRT	
programme	to	overcome	the	system’s	inadequacies	and	set	up	the	service	
provision	nationwide,	where	it	was	once	hard	to	reach	for	UCS	beneficiaries.	
The	key	interventions	used	by	the	NHSO	were	the	evidence‐based	guideline	
protocol	and	reporting	system.	The	evidence‐based	guideline	set	up	by	the	
NHSO	laid	down	the	procedure	for	the	providers,	based	on	medical	evidence.	
The	guideline	was	bound	with	the	payment	mechanism	and	led	to	other	
components	of	disease	management	which	were:	patient	identification,	
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collaborative	practice,	reporting	system,	and	self‐management	by	patients	and	
families.		
Disease	management	programmes	that	had	wider	support	such	as	a	national	
policy	or	protocol	have	been	found	to	be	more	successful	and	sustainable	than	
those	programmes	that	were	stand‐alone	and	dependent	on	a	local	champion	
(Schang	L,	Thomson	S	et	al.	2016).	Other	disease	management	interventions	
and	contextual	factors	can	provide	support	for	ongoing	disease	management	
programmes.	Programmes	with	multifaceted	interventions	are	more	likely	to	
show	positive	outcomes	(Brusamento,	Legido‐Quigley	et	al.	2012;	Smith,	Soubhi	
et	al.	2012).	In	the	case	of	the	UCS	RRT	programme,	patients	with	an	ESRD	
diagnosis	are	targeted	and	selected	to	enroll	for	the	programme	according	to	
the	guideline	protocol	and	are	then	trained	and	educated	about	self‐care	
management.	Payments	are	paid	back	to	RRT	units	by	the	reporting	system.	The	
collaborative	practice	is	an	integral	part	of	the	RRT	programme	between	and	
within	the	groups:	policy	maker,	provider,	and	patient.	Interviewees	mentioned	
this	practice,	in	that	it	contributed	to	the	rapid	expansion	of	RRT	facilities	
across	the	country.	UCS	interventions	are	regarded	as	a	means	of	increasing	
access	to	care	and	improving	the	quality	and	efficiency	of	care	for	patients	with	
end‐stage	renal	disease.	These	interventions	are	in	line	with	the	finding	of	a	
systematic	review	(Comino,	Davies	et	al.	2012)	of	interventions	to	increase	
access	to	health	care	for	patients	with	chronic	conditions.	The	latter	study	
reported	that	the	combining	of	disease	management	interventions	facilitated	
access	to	health	services.	
Linking	provider	payment	to	the	standard	protocol	is	a	key	strategy	to	promote	
programme	implementation	and	patient	identification,	and	therefore	access	to	
care.	In	countries	where	disease	management	programmes	are	implemented	
nationwide,	like	Germany,	the	national	standard	protocol	which	links	to	
payment	mechanisms	has	been	highlighted	as	an	important	factor	in	facilitating	
the	success	of	nationwide	implementation	of	disease	management	programmes.	
In	contrast,	the	programme	in	Austria	lacks	a	national	standard	protocol,	
implementation	is	limited	in	some	regions	and	there	are	low	numbers	of	newly	
registered	patients	(Schang,	Thomson	et	al.	2016).	Meanwhile,	the	introduction	
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of	routine	reporting	of	GFR34 and	financial	incentives	as	a	part	of	disease	
management	programmes	caused	increases	in	the	identification	and	referral	of	
patients	with	chronic	kidney	disease	stages	3‐5	in	primary	to	secondary	care	in	
the	UK	(Richards,	Harris	et	al.	2008)	and	Canada	(Hemmelgarn,	Zhang	et	al.	
2010).		
Disease	management	interventions,	however,	are	complex	and	multifaceted,	so	
individual	intervention	components	should	not	be	linked	with	specific	
outcomes	(Smith,	Soubhi	et	al.	2012).	
8.2.2 What are effects of the RRT disease management programme? 
After	the	RRT	programme	has	commenced	there	are	many	issues	to	be	
considered,	as	they	influence	the	programme’s	efficiency	and	sustainability:	
firstly	whether	this	programme	was	costly	to	start	and	maintain,	and	should	it	
be	kept	separate	from	the	mainstream	system;	secondly,	whether	this	
programme	has	reduced	the	patients’	difficulties	paying	for	care	costs,	
improved	patient	access	to	care,	and	facilitated	quality	health	services;	thirdly,	
on	the	provider	and	payer	sides,	how	much	amount	of	budget	is	needed	to	
spend	on	RRT	services,	and	whether	there	is	a	way	to	adjust	it	to	suit	provider	
and	payer	preferences.	
8.2.2.1 Starting and setting up the RRT programme  
From	the	beginning	of	the	RRT	programme,	its	administrative	functions	and	
financing	system	have	been	separated	from	the	UCS	mainstream.	This	is	
intended	to	promote	patients’	access	to	this	high‐cost	care.	Inevitably,	the	
programme	required	initial	investment	in	setting	up	and	then	getting	the	
programme	to	a	steady	state.	The	programme	began	with	specific	expenses	
relating	to	arrangements	of	target	patients,	protocol	guidelines,	and	
information	system	for	the	programme’s	maintenance	and	monitoring	process.	
These	contributed	to	a	high	amount	of	administrative	costs	to	the	programme	
initiation	and	maintenance	of	all	programme	processes.		
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At	present	the	RRT	programme	is	still	separate	from	the	mainstream	system	
and	its	administrative	costs	are	ongoing	as	the	programme	has	not	yet	achieved	
its	aims	to	eliminate	poor	patient	access	to	care	and	to	prevent	catastrophic	
payment	from	care	costs.	By	linking	these	aims	and	findings	from	this	study,	the	
steady	state	of	the	RRT	programme	may	include	1)	providing	good	programme	
coverage	nationwide;	2)	reducing	treatment	costs	by	ensuring	the	exploitation	
of	lower	cost	production	of	materials;	3)	ensuring	treatment	costs	are	
reasonable	and	do	not	prevent	providers	from	giving	services;	and	4)	ensuring	
affordable	access	for	patients.	
8.2.2.2 Effects on patients 
This	section	summarises	and	discusses	findings	from	Chapters	5	and	6.	
Qualitative	studies	of	Chapter	5	provided	insights	into	patient	decision	making,	
catastrophic	payment,	and	alternative	therapy	for	ESRD	patients.	The	age‐
period‐cohort	analysis	in	Chapter	6	provided	knowledge	on	the	changing	trends	
of	patients’	access	to	care	and	their	all‐cause	mortality.	Ideally,	evaluating	a	
disease	management	programme	should	be	conducted	by	a	study	design	that	
provides	a	counterfactual	to	demonstrate	that	the	changing	trends	were	the	
effect	of	the	programme.	This	study	did	not	address	the	counterfactual	due	to	
limitations	in	the	study	setting	and	available	data.	It	showed	evidence	on	
improvements	in	patients’	entry	into	the	RRT	programme	and	their	all‐cause	
mortality	after	commencing	the	RRT	programme	in	2008.		
i. Patient decision making, catastrophic payment, and 
alternative therapy 
In	this	study,	most	patients	with	an	ESRD	diagnosis	who	were	referred	to	the	
RRT	unit	in	the	university	hospital	intended	to	use	RRT	to	prolong	their	life.	
Patients	were	eligible	for	free	health	services,	however,	some	of	them	
mentioned	difficulties	such	as	travel	cost	and	opportunity	cost	to	themselves	as	
well	as	family	members.	These	costs	could	bring	a	patient	to	incur	financial	
catastrophe.	
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In	the	PD	first	policy,	PD	patients	reported	advantages	of	PD	that	it	increased	
their	self‐reliance,	reduced	travel	for	treatment,	and	allowed	patients	to	manage	
their	daily	life	almost	as	usual	(Chaudhary,	Sangha	et	al.	2011;	Liu,	Gao	et	al.	
2014).	A	systematic	review	of	patient	views	on	whether	to	undergo	dialysis	
concluded	that	patients	considered	impacts	of	treatment	on	their	lifestyle	to	be	
more	important	than	the	medical	outcome	(Morton,	Tong	et	al.	2010).	
At	the	community	level,	there	were	numbers	of	patients	with	ESRD	diagnoses	
who	refused	to	start	dialysis	in	the	RRT	programme.	Patient	characteristics	
played	an	important	role	in	decision	making	for	living	without	dialysis.	These	
included	advanced	age,	having	multiple	comorbidities,	belonging	to	an	
underprivileged	family,	low	levels	of	education,	and	no	carer.	This	study	also	
found	that	being	the	sole	person	responsible	for	family	members	and	social	
norms	could	hinder	starting	dialysis.	A	qualitative	study	in	the	UK	reported	a	
number	of	reasons	that	patients	gave	as	to	why	they	chose	not	to	have	dialysis.	
These	included	that	they	felt	too	old,	had	difficulty	travelling	to	the	dialysis	unit,	
fear	of	dialysis,	multiple	illnesses,	and	insufficient	information	about	dialysis	
(Noble,	Meyer	et	al.	2009).	Patients	who	initially	opted	to	live	without	dialysis	
in	England,	however,	reported	in	a	study	that	they	might	have	changed	their	
decision	and	started	dialysis	(Rayner,	Baharani	et	al.	2014).	
Although	not	included	in	the	RRT	programme	protocol,	the	community	hospital	
in	this	study	established	conservative	therapy	for	patients	with	chronic	
conditions.	Patients	with	ESRD	diagnoses	living	in	this	community	had	a	choice	
between	dialysis	or	conservative	therapy.	Conservative	therapy	for	chronic	
kidney	disease	by	a	multidisciplinary	team	has	been	developed	in	a	number	of	
countries	as	an	alternative	to	dialysis	(Morton,	Turner	et	al.	2012;	O'Connor	and	
Kumar	2012).	It	may	include	careful	attention	to	fluid	balance,	treatment	of	
anemia,	correction	of	acidosis	and	hyperkalemia,	and	monitoring	blood	
pressure	and	calcium/phosphorus	metabolism	(O'Connor	and	Kumar	2012).	In	
the	UK’s	chronic	kidney	disease	programmes,	ESRD	patients	without	dialysis	
are	given	multidisciplinary	nephrology	care	before	they	pass	away	(Rayner,	
Baharani	et	al.	2014).	It	was	evident	in	a	systematic	review	that	elderly	ESRD	
patients	with	multiple	comorbidities	who	were	on	conservative	therapy	had	
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equal	quality	of	life	to	those	who	were	maintaining	dialysis	(O'Connor	and	
Kumar	2012).	A	study	in	the	UK	found	that	elderly	people	with	conservative	
therapy	might	have	better	survival	and	lower	acute	hospital	admissions	in	
comparison	to	those	on	RRT,	and	be	more	likely	to	die	at	home	or	in	a	hospice	
(Hussain,	Mooney	et	al.	2013).	Conservative	management	of	ESRD,	therefore,	
could	be	a	practical	option	for	certain	groups	of	ESRD	patients	in	the	UCS.	This	
includes	elderly	patients	or	patients	with	multiple	comorbidities	and	burdens	
who	have	made	an	explicit	choice	not	to	have	dialysis.		
Even	in	developed	countries,	where	the	role	of	a	multidisciplinary	team	has	
long	been	highlighted,	there	are	limitations	to	this	practice	that	deter	
development	and	assessment.	Firstly,	there	is	a	lack	of	common	terminology	
and	definitions,	meaning	arrangements	vary	greatly	(Okamoto,	Tonkin‐Crine	et	
al.	2015).	Secondly,	despite	the	importance	of	conservative	management	as	an	
option	for	patients	with	ESRD,	many	clinicians	are	unfamiliar	with	this	
approach	and	lack	the	information	to	properly	counsel	patients	and	families.	
Consequently,	many	dialysis	patients	are	not	aware	of	conservative	therapy	as	
an	option	(O'Connor	and	Kumar	2012;	Okamoto,	Tonkin‐Crine	et	al.	2015).	
Finally,	the	scale	of	implementation	is	limited,	and	a	single	centre	may	have	to	
be	responsible	for	patients	from	a	vast	geographical	area	(Bowen	2014).		
ii. Access to care 
After	launching	the	RRT	programme	in	2008,	there	was	a	sudden	increase	in	the	
registration	rate	as	those	who	were	previously	unrecognised	were	identified	
and	registered.	A	steady	state	of	registration	rates	in	all	RRT	modalities	
developed	in	the	18	months	following	the	introduction	of	the	programme.	
Around	half	(53%)	of	newly	diagnosed	ESRD	patients	were	unable	to	use	or	
refused	to	start	RRT.	This	proportion	was	slightly	lower	than	an	estimate	in	the	
previous	study	(64%)	(Limwattananon	and	Limwattananon	2013),	but	was	
much	higher	than	those	reported	in	the	UK	and	Australia	(both	at	14%	of	ESRD	
patients)	(Morton,	Turner	et	al.	2012;	Rayner,	Baharani	et	al.	2014).	
Examining	the	proportion	of	RRT	patients	to	ESRD	patients	by	age	group	(see	
Table	6‐15),	the	RRT	programme	was	able	to	enroll	a	higher	percentage	of	
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young	patients	needing	RRT,	in	particular	patients	younger	under	70.	The	55‐64	
age	group	had	the	highest	registration	rates.	In	contrast,	access	to	care	by	
patients	aged	70	years	and	over	was	low,	and	their	registration	rates	tended	to	
decrease	with	age,	despite	the	high	and	growing	proportion	of	those	with	ESRD	
diagnoses	in	this	age	group	(see	Table	6‐14).	This	finding	corresponded	to	that	
of	the	previous	chapter	(Chapter	5)	and	some	prior	studies	(Morton,	Tong	et	al.	
2010;	Morton,	Turner	et	al.	2012;	Rayner,	Baharani	et	al.	2014)	that	elderly	
people	(approximately	>75	years)	with	ESRD,	who	had	multiple	illnesses	and	
lack	family	support,	were	likely	to	refuse	to	start	dialysis.		
The	RRT	programme	provides	three	RRT	modalities:	peritoneal	dialysis	(PD),	
hemodialysis	(HD),	and	kidney	transplant	(KT).	PD	has	the	highest	number	of	
new	registrations	as	there	is	the	‘PD	first	policy’,	which	means	PD	is	the	
preferred	modality	under	the	UCS.	In	the	study	period,	2008	to	2013,	some	
circumstances	might	influence	registration	rates	on	the	RRT	programme.	For	
example,	flooding	affected	major	cities	of	Thailand	and	clearly	brought	down	
the	number	of	new	registrations.	The	abolition	of	co‐payment	for	HD,	including	
fees	for	dialysis	and	erythropoietin,	appeared	to	have	boosted	new	HD	
registrations.	
Results	from	other	literature	have	indicated	that	HD	is	the	least	cost‐effective	
treatment	option,	while	PD	and	KT	represent	more	cost‐effective	approaches	
(Sennfalt,	Magnusson	et	al.	2002;	Kontodimopoulos	and	Niakas	2008;	Haller,	
Gutjahr	et	al.	2011).	In	addition,	the	cost	of	KT	contributes	both	to	a	significant	
reduction	of	future	costs	and	to	a	greater	number	of	expected	patient	life	years	
(Kontodimopoulos	and	Niakas	2008).	However,	rates	of	kidney	transplantation	
remain	low	globally	and	in	Thailand	due	to	the	limited	number	of	organ	donors	
(White,	Chadban	et	al.	2008;	WHO	2012).		
A	cross‐country	comparison	among	104	countries	reported	that	numbers	of	
kidney	transplants	performed	each	year	in	Thailand	was	5	per	million	
population	(pmp),	comparable	to	others	in	South‐East	Asia	(4	pmp),	but	
significantly	lower	than	Continental	European	countries	(25	pmp)	and	the	UK	
(30	pmp)(WHO	2012).	Moreover,	the	proportion	of	UCS	patients	who	
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underwent	KT	accounted	for	just	one‐third	of	all	kidney	transplants	in	Thailand	
(Thai	Transplantation	Society	2014),	despite	the	fact	that	the	UCS	is	the	largest	
public	health	scheme	and	covers	76%	of	all	Thais.	
This	study	confirmed	the	low	number	of	transplants	each	year	and	projected	
that	this	situation	would	remain	unchanged	in	the	next	decade,	but	did	not	
explore	this	further.	Some	prior	studies	have	provided	the	explanation	that	the	
organ	donation	decision	is	complex	and	based	strongly	on	personal	beliefs,	such	
as	religious	and	cultural	beliefs,	which	are	often	mentioned	as	reasons	for	a	
refusal	to	donate	(Irving,	Tong	et	al.	2012).	There	are	some	other	complex	
issues,	such	as	disincentives	for	living	organ	donation,	distrust	of	the	medical	
system	for	deceased	donors,	and	failure	to	arrange	an	effective	organ	donation	
system,	in	particular	donation	after	death	(Klein,	Messersmith	et	al.	2010;	
Irving,	Tong	et	al.	2012).		
A	number	of	countries,	such	as	Singapore,	Switzerland,	Norway,	Italy,	Austria,	
France	(Kwek,	Lew	et	al.	2009)	and	the	UK,	have	introduced	the	presumed	
consent	system.	In	this	system	individuals	are	presumed	to	have	agreed	for	
their	organs	to	be	donated	after	death	unless	they	opt	out.	A	systematic	review	
study	concluded	that	presumed	consent	legislation	contributed	to	higher	organ	
donation	rates.	However,	the	extent	might	vary	depending	on	country	
characteristics.	These	included	rates	of	mortality	from	road	accidents,	numbers	
of	transplant	centres,	gross	domestic	product	per	capita,	and	health	expenditure	
per	capita	(Rithalia,	McDaid	et	al.	2009).	In	Thailand,	there	has	been	very	little	
research	assessing	people’s	attitudes	towards	organ	donation	and	how	to	
increase	the	number	of	donors	in	the	future.	
iii. Deaths of ESRD and RRT patients 
All‐cause	mortality	rates	among	RRT	and	ESRD	patients	were	used	as	indicators	
to	assess	patients’	health	status	within	the	RRT	programme	in	this	study.	All‐
cause	mortality	rates	in	ESRD	patients	increased	exponentially	with	age	after	
patients	reached	their	late	forties.	However,	if	patients	received	RRT,	the	rapid	
increase	of	mortality	rates	arrived	later	in	life,	after	patients	reached	their	
seventies	(see	Figures	6‐8a,	6‐10a,	and	6‐13a).	It	is	interesting	to	look	at	trends	
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in	death	rates	over	time.	Although	the	number	of	deaths	increases	(as	dialysis	is	
not	a	true	cure)	and	the	programme	constantly	accepts	more	patients,	all‐cause	
mortality	rates	in	patients	with	ESRD	diagnoses	and	patients	who	used	RRT	
show	decreasing	trends	since	2009.	These	behaviours	reflect	demographic,	
ESRD	epidemiological	and	health	care	changes	in	access	to	RRT	among	UCS	
members.		
The	results	of	this	study	correspond	to	findings	from	a	number	of	studies	that,	
after	the	mid	sixties,	ESRD	patients	had	much	higher	risks	of	death	in	
comparison	to	younger	patients	(O'Hare,	Choi	et	al.	2007;	Hallan,	Matsushita	et	
al.	2012).	Additionally,	adjusted	rates	of	all‐cause	mortality	are	7	to	20	times	
greater	for	RRT	patients	than	for	individuals	in	the	general	age‐matched	UCS	
population.	In	comparison	to	other	countries,	adjusted	mortality	rates	in	UCS	
RRT	patients	were	much	lower	than	those	in	all	age	groups	who	received	RRT	
under	Medicare	(United	States	Renal	Data	System	2014).	Crude	mortality	rates	
on	RRT	in	UCS	patients	were	higher	than	those	in	the	UK	(Steenkampa,	Raoa	et	
al.	2014)	but	comparable	to	dialysis	patients	in	Sweden	(Neovius,	Jacobson	et	al.	
2014).	These	variations	may	reflect	underlying	differences	among	countries	in	
factors	such	as	epidemiology	of	ESRD	and	the	management	of	the	condition.		
8.2.2.3 Financial implications in the future 
Costs	for	arranging	and	delivering	RRT	services	may	put	a	challenge	to	the	
health	care	budget	in	the	long	term.	This	study	has	sought	to	explain	behaviours	
of	the	four	cost	drivers	(numbers	of	future	patients,	material	cost,	labour	cost,	
and	capital	cost)	towards	future	programme	costs.	From	the	public	payer’s	
perspective,	material	costs	accounted	for	the	largest	proportion	of	the	costs	of	
PD,	HD,	and	KT.	In	the	long	term,	it	represents	the	most	powerful	cost	driver	for	
the	total	costs	of	PD	and	HD.	Referring	to	Figure	7‐11,	in	the	scenario	that	
material	costs	of	the	three	RRT	modalities	increase,	the	unit	cost	of	all	RRT	
modalities	will	increase	rapidly	in	the	future.	In	contrast	in	another	scenario	
where	the	costs	of	materials	are	assumed	to	be	controllable,	and	would	not	cost	
more	than	the	purchase	price	in	2014	as	a	result	of	central	purchasing	or	the	
use	of	locally	made	medications,	the	unit	cost	of	PD	will	be	lower	in	the	future.	
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This	is	because	the	unit	cost	is	derived	from	dividing	the	total	cost	(the	sum	of	
material	costs,	labour	costs,	and	capital	costs)	by	the	number	of	patients,	and	in	
the	next	ten	years,	the	number	of	patients	was	projected	to	increase	over	time.	
Increases	in	labour	and	capital	costs	do	not	affect	the	unit	cost.		
Apart	from	the	material	cost,	numbers	of	patients	is	another	powerful	cost	
driver.	Transplant	numbers	are	projected	to	be	constant,	not	increasing	over	
the	next	ten	years.	These	numbers	were	low	relative	to	the	amount	of	their	total	
costs,	which	were	large	and	increasing	each	year.	The	unit	cost	of	KT	(equals	to	
the	total	cost	divided	by	number	of	transplants)	would	not	decrease	like	that	of	
PD	but	would	instead	increase	as	wages	increase,	independent	of	the	material	
cost.	
Labour	costs	are	a	concern	among	policy	makers;	that	is,	the	growing	level	of	
wages	as	Thailand	has	become	richer.	This	study	has	shown	that	if	labour	costs	
increase	by	the	increasing	number	of	patients	and	wage	growth	at	not	more	
than	7%	each	year,	it	would	not	have	much	effect	on	the	size	of	the	unit	cost	of	
PD	and	KT.	As	HD	requires	a	high	proportion	of	staff	costs,	cheap	material	costs	
may	not	contribute	to	the	low	unit	cost	in	the	future	as	that	of	PD,	however	the	
total	HD	budget	would	increase	slowly,	see	Figure	7‐10	and	Figure	7‐11.		
A	prior	study	(Kasemsap,	Prakongsai	et	al.	2006)	which	projected	RRT	
programme’s	future	expenses,	overestimated	the	likely	budget	of	the	
programme	by	2.3‐4.5	times	(£287‐£480	million	instead	of	£87	million	in	
2013).	This	result	provides	insights	into	cost	containment	strategies	and	
emphasises	the	significance	of	controlling	a	programme’s	material	costs	and	
numbers	of	patients.	There	are	some	possible	explanations	for	this	lower	cost	
that	link	to	the	disease	management	approach.	First	the	guideline	protocol	
controls	types	of	reimbursable	RRT	services	and	their	reimbursement	rates,	
therefore	reduces	unnecessary	items.	In	addition,	the	protocol	has	made	RRT	
services,	in	particular	PD,	become	commonplace	in	the	UCS.	This	provides	the	
NHSO	with	increased	bargaining	power	in	central	purchasing	of	a	range	of	
medicines	and	medical	products.		
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From	the	beginning	of	the	RRT	programme,	the	NHSO	has	used	its	purchasing	
power	to	obtain	many	medications	and	medical	devices	at	best	prices.	For	
example,	the	current	price	of	erythropoietin	is	cheaper	by	80%‐95%	than	its	
original	price.	In	addition,	the	NHSO	is	able	to	purchase	PD	solutions	at	the	
lowest	price	in	the	world	(Karopadi,	Mason	et	al.	2014).	However,	the	primary	
and	secondary	prevention	programmes	have	yet	to	prove	whether	they	can	
reduce	enrollment	of	new	patients	with	ESRD	diagnoses	on	the	RRT	programme	
as	well	as	reducing	programme	costs	over	the	long	term.	
8.3 Strengths and weaknesses of the study 
This	study	was	conducted	to	explore	the	introduction	and	functioning	of	a	high‐
cost	health	benefit	programme	as	part	of	a	universal	coverage	scheme.	There	
were	limitations	from	the	data	and	methodology	used,	detailed	in	the	end	of	
Chapters	4‐7.	This	section	summarises	the	strengths	and	discusses	the	
weaknesses	of	the	study	in	relation	to	the	overall	interpretation	of	the	results.		
8.3.1 Strengths 
The	strengths	of	this	study	have	been	mentioned	in	the	methodological	issues	
section	of	this	chapter.	They	are	outlined	as	follows:	
 This	study	focused	on	multiple	aspects	of	the	RRT	disease	management	
programme.	These	included;	
• Input:	rationale	for	using	disease	management	and	the	
introduction	of	the	RRT	programme	
• Process:	the	functioning	of	the	disease	management	interventions	
in	the	RRT	programme	
• Output:	programme	registration	rates	
• Outcome:	mortality	of	patients	with	ESRD	
• Future	implications:	number	of	patients	and	budget	needs	
 The	mixed‐method	approach	of	both	qualitative	and	quantitative	
methods	was	applied	to	cope	with	the	complexity	of	the	disease	
management	programme,	since	one	approach	could	not	provide	all	the	
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information	required.	The	study	methods	complemented	each	other	and	
led	to	improved	study	validity.			
 The	facility‐based	study	enhanced	validity	by	capturing	most	individuals	
of	interest	and	results	were	representative	of	the	studied	population.	
 Electronic	databases	containing	patient	diagnoses	and	encoded	citizen	
identification	numbers	allowed	the	merging	of	databases	from	various	
sources	without	violating	patients’	anonymity.		
 The	quantitative	method	used,	namely	age‐period‐cohort	analysis,	is	
regarded	as	a	powerful	tool	in	modelling	and	analysing	routinely	
collected	information	from	administrative	records	or	disease	registries.		
Also,	the	ARIMA	modelling	technique	is	the	most	widely	used	time‐series	
approach	in	health	research.		
8.3.2 Weaknesses 
An	experimental	study	design	was	not	possible	in	practice	for	this	study	setting,	
in	which	a	nationwide	disease	management	programme	was	implemented.	This	
might	lead	to	the	major	weakness	of	this	study;	it	could	be	questioned	whether	
the	conclusions	derive	from	the	true	effects	of	the	disease	management	
interventions	(Nolte,	Conklin	et	al.	2012).	Additionally,	it	lacked	comparison	or	
control	groups,	a	strategy	used	in	most	disease	management	evaluations	
(Conklin	and	Nolte	2013)	when	assessing	effects	of	the	RRT	programme.	This	
study	applied	the	age‐period‐cohort	analysis,	a	descriptive	tool	to	describe	
changes	in	the	key	measures,	which	were	numbers	of	registrations	and	deaths	
in	any	study	period,	and	compared	them	against	those	of	the	reference	year.	
The	analysis	did	not	directly	demonstrate	causal	relationships	between	the	
disease	management	interventions	and	outputs	or	outcomes.	Similarly	to	other	
age‐period‐cohort	studies,	it	is	essential	to	provide	and	interpret	the	study	
results	with	environmental	circumstances	(such	as	commencing	the	RRT	
programme	and	new	RRT	benefits,	flooding	in	Thailand)	to	explain	the	likely	
causes	of	the	changes	found	in	the	studied	period.	
The	other	two	public	health	insurance	schemes,	namely	the	Social	Security	
Scheme	and	the	Civil	Servant	Medical	Benefit	Scheme,	could	possibly	be	used	as	
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comparison	groups,	because	no	disease	management	programmes	operated	in	
these	two	schemes.	However,	some	reasons	hindered	the	use	of	their	data.	First,	
patients	in	these	two	schemes	represent	different	demographic	and	
socioeconomic	conditions,	and	use	of	care,	from	those	of	UCS	patients.	
Additionally,	the	two	schemes	had	very	different	proportions	of	RRT	patients	
from	the	UCS,	and	were	mainly	treated	with	hemodialysis	not	peritoneal	
dialysis.		
Another	weakness	was	generalisability,	the	degree	to	which	the	results	can	be	
applied	to	a	wider	population	of	interest.	Since	the	RRT	programme	was	
designed	to	serve	a	specific	population,	it	has	unique	characteristics	in	terms	of	
the	policy	support,	delivery	system,	and	community	participation;	the	findings	
were	not	meant	to	explain	results	for	other	groups	of	patients	with	different	
disease	management	interventions.	In	addition,	this	study	had	few	opt‐out	
patient	interviewees,	and	all	of	them	share	some	characteristics	including	
residing	in	a	rural	area,	living	in	poverty,	and	low	literacy	levels.	Ability	to	
generalise	conclusions	to	a	wider	group	of	opt‐out	patients	can	be	limited,	in	
particular	those	who	are	better	off	or	living	in	urban	areas.				
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CHAPTER 9 Conclusions and policy recommendations 
This	study	set	out	to	explore	the	introduction	and	functioning	of	a	high‐cost	UCS	
health	benefit	programme,	using	the	renal	replacement	therapy	(RRT)	
programme	as	a	tracer.	It	then	aimed	to	assess	how	a	disease	management	
approach	can	facilitate	the	inclusion	of	RRT	in	the	benefit	package,	now	and	in	
the	longer	term,	and	with	what	results.	The	findings	of	this	study	are	intended	
to	build	evidence	to	highlight	the	role	of	the	disease	management	approach	in	
supporting	a	policy	of	including	a	high‐cost	health	benefit	such	as	RRT	in	the	
context	of	a	developing	country.	
This	chapter	summarises	what	this	study	has	accomplished.	It	next	brings	in	the	
contribution	to	knowledge,	then	identifies	the	policy	implications	for	disease	
management	of	high‐cost	health	conditions.	Finally,	the	chapter	draws	out	
suggested	directions	for	future	research.	
9.1 Conclusions of findings 
This	study	emphasised	the	significance	of	the	definitions	of	high‐cost	and	
catastrophic	spending,	and	the	policy	implications	suggested	by	Wyszewianski	
(1986).	RRT	is	an	example	of	the	treatment	that	is	both	high	cost	and	can	cause	
catastrophic	spending.	Before	the	commencement	of	the	RRT	programme	in	the	
UCS,	RRT	was	recognised	as	a	high‐cost	treatment	that	could	impoverish	a	
patient	and	their	family.	At	the	time	concerns	were	focused	on	how	to	introduce	
the	health	care	benefit	to	protect	the	patients	from	such	consequences	and	on	
how	to	increase	access	to	this	high‐cost	health	care.		
Despite	resource	constraints,	governments	in	every	country	have	a	
responsibility	to	ensure	that	their	citizens	are	looked	after	and	have	the	care	
and	treatment	they	need	when	they	fall	ill.	The	expense	of	health	treatment	can	
hinder	people	from	receiving	essential	services;	either	patients	stop	using	
services	they	cannot	afford,	or	continued	treatment	pushes	patients	and	their	
families	into	poverty.				
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In	the	commencement	of	the	UCS	in	2001,	there	was	a	concern	on	the	scheme’s	
fiscal	constraints	and	an	unprepared	system.	As	a	consequence,	UCS	policy	
makers	decided	not	to	include	RRT	in	the	benefit	package.	Later	in	2008,	RRT	
was	added	in	the	UCS	benefit	package,	as	a	result	of	efforts	from	various	
stakeholders	responding	to	the	implications	of	high‐cost	conditions.	This	study	
highlighted	the	combination	of	leadership	between	three	components:	the	
scholars	who	create	knowledge,	public	actions,	and	politicians	who	push	ahead	
the	new	RRT	policy.	
There	were	two	key	reforms	to	the	new	RRT	programme.	First,	the	RRT	
payment	system	was	separated	from	mainstream	UCS	services.	This	is	because	
capitation	and	diagnosis	related	group	(DRG)	with	global	budget	payment	
tended	to	prevent	providers	from	providing	high‐cost	treatment	such	as	RRT	
and	the	shift	to	a	fee	schedule	aimed	to	encourage	provision	of	RRT	services	
among	providers.	Second,	the	disease	management	approach	was	not	only	used	
in	the	RRT	service	delivery	at	the	provider	level,	but	also	in	arranging	the	entire	
RRT	system	by	incorporating	a	range	of	interventions:	i)	population		
identification,	ii)	evidence‐based	guidelines,	iii)	reporting	systems,	iv)	process	
and	outcome	measurements,	v)	collaborative	practice,	and	vi)	self‐care	
management	support. 		
Results	from	this	study	pointed	out	that,	since	the	introduction	of	the	RRT	in	the	
UCS,	patients	diagnosed	with	end‐stage	renal	disease	(ESRD)	had	better	access	
to	care.	Overall,	after	a	stable	period	between	2009	and	2011,	new	adult	ESRD	
patients	registered	in	all	RRT	modalities	had	a	significant	increase.	Particularly,	
there	was	considerable	success	in	taking	up	patients	in	younger	age	groups.	In	
2013,	the	proportion	of	adult	ESRD	patients	newly	starting	RRT	was	47%	of	all	
newly	diagnosed	ESRD	patients.	The	rest	had	not	yet	started	RRT	for	some	
reasons.	In	the	next	ten	years,	the	total	number	of	RRT	patients	was	projected	
to	increase	by	10%	annually.		
After	launching	the	RRT	programme	in	2008,	the	all‐cause	mortality	rate	of	
adult	RRT	patients	increased	over	time	through	2010.	Now	it	tends	to	have	
leveled	off.	In	2013,	the	age‐standardised	mortality	rate	(ASMR)	for	adult	RRT	
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patients	reduced	from	a	peak	at	80	deaths	per	1,000	patient‐years	at	risk	in	
2010,	to	60	deaths	per	1,000	RRT	patient‐years	at	risk.	
RRT	continues	to	account	for	a	high	proportion	of	the	government	health	
budget.	Consequently,	the	policy	concern	around	RRT	has	shifted	from	
protecting	patients	against	catastrophic	spending	to	controlling	health	care	
costs	to	the	government.	In	the	near	future,	the	RRT	programme	budget	is	
expected	to	increase	in	the	region	of	9‐19%	annually.	
Results	from	long	term	projections,	however	pointed	out	that	RRT	costs	can	be	
made	more	affordable	to	the	health	care	payer.	Controlling	cost	per	unit	in	the	
RRT	programme	can	be	achieved	by	1)	for	KT,	filling	spare	capacity	of	operating	
theaters	and	2)	for	PD	and	HD,	controlling	or	reducing	material	costs	while	
labour	costs	are	increased	as	normal	and	capital	costs	are	kept	constant.		
Interviewing	policy	makers,	providers,	and	patients	in	all	types	of	RRT	
modalities,	including	patients	on	conservative	therapy,	revealed	interesting	
results.	The	majority	of	RRT	patients	reported	a	good	quality	of	life,	which	it	
was	possible	with	sufficient	knowledge	and	self‐care	management	skills.	Some	
interviewees	mentioned	difficulties	with	the	care	process	and	dialysis‐related	
costs	that	patients	still	had	to	take	on.	Patients	living	with	conservative	therapy	
reported	that	poverty,	frailty,	and	weak	or	no	family	support	deterred	them	
from	starting	dialysis.	Nonetheless,	these	issues	demonstrate	a	potential	for	
development	of	the	RRT	benefit	and	care	process	to	better	suit	the	needs	of	all	
patients,	those	living	close	to	town	centres	and	those	in	remote	areas.		
This	study	also	found	that although	there	is	now	RRT	coverage,	it	still	has	the	
characteristics	of	a	high‐cost	and	catastrophic	condition,	although	the	
catastrophic	effect	on	patients	is	diminished. The	remaining	effect	is	generally	a	
consequence	of	some	types	of	costs	outside	coverage,	for	instance,	frequent	
journeys	to	dialysis	units,	out‐of‐pocket	costs	relating	to	dialysis,	and	patients’	
or	families’	opportunity	costs.		
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9.2 Contribution to knowledge  
The	focus	of	previous	studies	worldwide	has	been	on	the	cost‐effectiveness	of	
health	care	interventions,	or	quantifying	numbers	of	households	with	
catastrophic	spending:	there	has	been	less	study	on	how	to	prevent	patients’	
impoverishment	due	to	high‐cost	but	essential	health	services.		
The	number	of	and	investment	in	disease	management	programmes	is	growing,	
but	programme	evaluations	have	mainly	been	conducted	in	the	US	and	
European	countries.	In	these	countries,	disease	management	has	been	used	as	a	
means	to	improve	quality	of	care	in	patients	with	chronic	conditions.	Although	
treatment	costs	for	these	conditions	are	not	expensive,	multiple	episodes	of	
treatment	sum	to	a	large	amount	and	can	be	a	burden	on	countries’	health	care	
budget	in	the	long	term.	The	aims	of	disease	management	programmes	are	
generally	to	improve	health	and	cost	outcomes,	while	in	the	UCS,	disease	
management	was	used	with	a	different	aim.	In	the	context	of	a	developing	
country,	Thailand	encountered	a	challenge	on	equal	access	to	high‐cost	
treatments	and	the	aim	of	applying	UCS	disease	management	programmes	was	
to	increase	access	to	high	cost	health	care.	In	this	instance,	the	rationale,	
process,	performance,	and	effect	of	these	programmes	were	unknown.		
When	a	government	decides	to	support	patients’	access	to	high‐cost	treatment	
by	using	public	money,	there	may	be	concerns	about	1)	what	tools	to	use	and	
how	to	use	them,	and	2)	whether	the	results	will	be	measurable,	those	intended,	
and	represent	value	for	money.	This	study	has	highlighted	the	application	of	the	
disease	management	approach	as	an	intervention	to	arrange	service	provision	
and	to	promote	patients’	access	to	less‐accessible	and	expensive	treatments	
that	may	otherwise	lead	patients	into	impoverishment	in	the	context	of	one	
condition	and	one	developing	country.		
The	study	was	conducted	in	Thailand,	a	developing	country	achieving	universal	
health	coverage.	Various	so‐called	disease	management	programmes	have	been	
implemented,	and	these	programmes	need	continued	monitoring	and	
evaluation	to	feed	back	into	the	policy	formulation	process.	By	focusing	on	the	
health	care	payer’s	perspective,	this	study	has	filled	a	knowledge	gap	about	the	
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rationale,	process,	output,	and	outcome	of	a	UCS	disease	management	
programme	for	a	high	cost	disease	(the	RRT	programme)	from	beginning	to	
end.		
This	study	shows	that	investments	in	the	RRT	programme	have	returned	
promising	results.	After	launching	the	RRT	programme,	more	than	half	of	
patients	with	ESRD	diagnoses	are	able	to	start	RRT	and	that	makes	them	more	
likely	to	survive.	The	study	further	contributed	to	estimating	the	long	term	
financial	consequences	of	the	RRT	programme	and	identifying	potential	cost	
drivers	of	high‐cost	disease	management	programmes	and	suggested	ways	to	
adjust	payment	to	suit	the	preferences	of	both	health	care	providers	and	the	
payer.		
The	study	introduced	approaches	to	monitoring	access	to	care	and	the	health	
status	of	patients.	It	further	provided	a	cost	modelling	method	for	projecting	
future	financial	implications	and	defining	cost	drivers	of	such	high‐cost	
programmes.	This	study	also	revealed	some	limitations	of	disease	management	
programme	evaluation	if	purely	quantitative	methods	are	used.	Disease	
management	administrative	data	and	disease	registry	data	account	for	patients	
who	seek	care	and	are	registered	in	their	databases.	In	reality,	many	patients	
with	ESRD	diagnoses	never	start	dialysis.	Qualitative	methods	in	this	study,	
such	as	in‐depth	interview	and	focus	group	discussion,	supported	quantitative	
findings	by	providing	insights	to	why	patients	refuse	dialysis.	
Despite	being	a	middle‐income	country,	Thailand	is	an	innovator	in	a	number	of	
areas	relating	to	universal	health	coverage.	Strong	leadership	of	the	NHSO	and	
of	the	policy	community	plays	an	important	role	in	pushing	ahead	for	
continuous	improvements	to	ensure	members’	equitable	access	to	care.	The	
RRT	programme	is	an	example	of	this.	Experiences	from	the	management	of	
high‐cost	diseases	in	Thailand	can	provide	lessons	learned	to	other	countries	
seeking	interventions	to	arrange	service	provision	for	high‐cost	diseases.	
Findings	from	this	study	can	be	beneficial	to	the	process	of	health	policy	
formulation,	especially	where	a	government	needs	to	know	what	should	be	
invested	for	a	benefit	package	which	covers	high‐cost	conditions.	 
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9.3 Policy recommendations 
This	section	proposes	policy	recommendations	related	to	high‐cost	treatment	in	
two	main	areas:	1)	general	recommendations	for	any	country	looking	for	ways	
to	introduce	a	high‐cost	health	benefit	and	2)	specific	recommendations,	
regarding	high‐cost	conditions	and	disease	management	programmes,	for	the	
UCS	context.		
9.3.1 Recommendations for other countries 
Each	country	has	a	different	context	which	contributes	to	differences	in	
resources,	people’s	health	needs,	and	the	organisation	of	health	care.	
Experiences	from	this	study	can	provide	lessons	learned	to	any	country	with	or	
without	universal	coverage,	as	long	as	their	health	system	has	limitations	in	
funding,	health	workforce,	and	infrastructure.		
 I. Including high-cost treatment in a benefit package 
This	study	has	provided	an	example	on	making	a	policy	change	to	include	a	
high‐cost	treatment	(RRT)	in	a	benefit	package.	The	key	processes	are	
summarised	here	and	could	be	a	general	guideline	for	other	countries.		
First,	a	group	of	scholars	gathered	evidence	on	1)	what	other	countries	do	to	
provide	this	benefit,	2)	available	infrastructure	of	the	system:	workforce	and	
facilities,	3)	estimated	numbers	of	patients	who	will	use	this	treatment	and	
budget	needs,	4)	Studies	on	cost‐effectiveness	of	the	treatment,	5)	public	
opinion	of	the	new	benefit.	Next,	relevant	stakeholders	were	invited	to	
participate	at	an	early	stage,	these	included	medical	professionals,	scholars,	
patient	groups,	and	politicians	including	the	Minister	of	Public	Health.	These	
people	got	involved	in	designing	the	RRT	benefit	in	many	ways,	both	formal	and	
informal.	After	the	stakeholder	participation	had	been	carried	out,	the	result	
was	first	implemented	in	a	pilot	project	to	review	possibilities	of	large	scale	
arrangements	regarding	staffing	and	service	provision.	Finally	the	RRT	
programme	was	launched.	The	overall	process	took	about	three	years	and	a	half	
to	finish.	
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II. Disease management approach 
Disease	management	has	various	forms	and	definitions.	Components	used	in	
the	UCS,	although	different	from	disease	management	approaches	used	in	many	
developed	countries,	have	been	shown	in	this	thesis	to	be	effective	in	arranging	
service	provision	for	a	high‐cost	condition.	These	may	help	other	countries	
assess	the	value	of	disease	management	for	them.	The	key	effective	components	
are	highlighted	as	follows.		
i. Population identification processes to select patients  
The	term	target	population	refers	to	individuals	that	have	the	same	health	
needs	or	have	the	selected	condition;	they	are	selected	by	frontline	providers	
according	to	an	agreed	guideline	protocol.	For	this	reason,	setting	criteria	for	
patient	selection	is	important,	and	patients	are	prospectively	identified	from	
routine	review	of	patient	profiles.	This	study	found	that	the	population	
identification	process	is	the	starting	point	for	providers	to	include	patients	in	
the	RRT	programme.	For	the	payer,	this	process	helps	to	identify	the	number	of	
patients	who	are	expected	to	use	services	and	therefore	to	estimate	the	budget	
need.		
ii. Nationwide evidence-based protocol linked to provider payment  
An	evidence‐based	protocol	is	essential	to	lay	down	the	working	procedures	for	
providers.	The	protocol	should	be	based	on	clinical	practice	guidelines	that	are	
adjusted	to	suit	the	local	context	of	individual	countries.	In	addition,	the	
protocol	should	be	linked	to	the	payment	mechanism	in	order	to	ensure	
providers	are	paid	at	predefined	rates	once	services	are	provided	to	patients.	
This	study	found	that	a	fee	schedule	suits	payment	to	providers	better	than	a	
capitation	payment,	as	it	provides	incentives	for	providers	to	scale	up	service	
provision.	However,	making	a	guideline	protocol	that	suits	everybody’s	
preference	can	be	a	challenge	to	policy	makers,	in	particular	when	linking	a	
protocol	with	payment.	In	addition,	it	needs	frequent	updates,	and	any	new	
information	should	be	clear	to	providers,	including	what	they	should	do	to	fulfill	
their	duty.	
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iii. Collaborative practice which includes health care teams and 
external stakeholders 
It	is	impossible	for	the	health	care	payer	to	work	alone:	there	must	be	
collaborative	practice	from	the	beginning	when	setting	up	a	high‐cost	health	
benefit	and	organising	the	service	provision.	Collaborative	practice	is	likely	to	
be	central	to	a	sustainable	system.	In	this	study,	the	collaboration	included	
people	at	all	levels.	For	example,	providers	and	academicians	identified	the	
system	capacities	and	developed	working	protocols	for	the	health	staff.	The	
protocols	were	based	on	clinical	practice	guidelines	adapted	to	the	country	
context.	Patients	groups	were	supported	in	order	to	create	links	between	the	
payer,	providers,	and	local	communities;	in	these	groups	patients	were	able	to	
voice	their	needs	and	exchange	useful	information.	
iv. Routine reporting system and ongoing process/outcomes 
measurement and evaluation  
A	routine	reporting	system	provides	administrative	data	which	is	used	for	
reimbursement	purposes	and	as	an	essential	source	of	information	for	the	
monitoring	and	evaluation	process.	Computerised	databases	would	provide	
more	utilisable	data	than	paper	based	reports.		
The	monitoring	and	evaluation	process	is	important	in	order	to	ascertain	
whether	the	programme	has	yielded	the	preferred	results,	and	whether	those	
results	represent	value	for	money.	In	addition,	findings	from	the	programme	
evaluation	can	be	used	to	improve	future	provision	and	inform	any	expansion	
to	provision	of	other	high‐cost	conditions.		
In	the	disease	management	programme	monitoring	and	evaluation,	this	study	
found	challenges	about	data	inaccuracies	in	administrative	data.	This	can	be	
because	of	the	data	recording	process	and	the	nature	of	these	data	that	are	not	
meant	to	be	used	for	monitoring	and	evaluation	purposes.	An	effective	audit	
system	is	therefore	essential	to	assess	recording	practice	among	providers.	It	
should	be	in	place	as	a	continuing	process,	similar	to	that	of	the	monitoring	and	
evaluation	process.	This	is	to	ensure	and	maintain	the	quality	of	reporting	sent	
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back	to	the	payer,	since	it	affects	the	accuracy	of	claims	data	used	for	
reimbursements,	as	well	as	the	production	of	monitoring	and	evaluation	
reports.	
v. Self-care management and educational programmes that may 
include raising awareness of secondary prevention, adherence to 
treatment, and behaviour modification  
The	literature	review	of	this	study	found	that	in	most	other	disease	
management	programmes,	patient	education	and/or	patient	reminders	are	
basic	strategies	used	to	prompt	patient	self‐care	in	order	to	better	control	
conditions	and	reduce	care	costs.	This	component,	although	not	highlighted	as	a	
key	feature	of	the	success	of	the	UCS	RRT	programme,	helps	patients	with	
managing	their	condition	and	maintaining	everyday	life.	It	also	complements	
other	disease	management	components	by	facilitating	collaboration	between	
patients	and	their	health	care	professionals.		
9.3.2 Recommendations for UCS policy makers 
The	recommendations	proposed	in	this	section	are	obtained	from	evidence	
from	the	RRT	disease	management	programme.	Section	i	provides	
recommendations	for	disease	management	programmes	in	general.	Sections	ii‐
v	focus	on	arrangements	for	and	management	of	the	RRT	programme	in	the	
UCS,	but	some	recommendations	can	be	applied	to	other	disease	management	
programmes.		
i. Future directions of the UCS disease management programmes 
The	UCS	has	introduced	many	so‐called	disease	management	programmes.		
However,	most	of	these	have	only	a	few	components	of	the	disease	management	
approach	and	are	not	focused	on	service	delivery.	This	study	found	that	the	RRT	
programme	encompassed	all	components,	and	has	benefited	from	each	one.	It	
has	also	achieved	its	aims	to	increase	access	to	care	and	prolong	patients’	lives.			
The	research	implies	that	implementing	just	a	few	components	of	a	disease	
management	programme	that	is	not	focused	on	arranging	service	provision	is	
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likely	to	incur	unfavourable	results.	For	example,	without	a	clear	target	
population	and	protocol,	a	programme	budget	cannot	be	estimated,	and	payers	
and	providers	may	be	unsure	how	to	begin	and	roll	out	the	programme.			
There	have	been	many	disease	management	programmes	in	the	UCS.	Each	of	
them	needs	to	be	reviewed	in	terms	of	efficiency	and	effectiveness.		
Programmes	that	produce	unpromising	results	could	be	terminated,	while	more	
successful	programmes	could	be	expanded	until	there	is	good	coverage	and	
costs	of	technologies	are	reduced.	It	may	not	be	necessary	to	manage	these	
programmes	separately;	they	could	be	brought	into	mainstream	UCS	services,	
for	which	criteria	need	to	be	developed.				
ii. Decreasing the need for dialysis 
Controlling	numbers	of	patients	retained	in	the	RRT	programme	might	be	the	
best	solution	to	deal	with	the	increasing	cost	of	the	programme.	This	can	be	
done	by	decreasing	numbers	of	patients	taken	into	the	programme,	delaying	
entry,	and	boosting	numbers	of	patients	exiting	the	programme	via	
transplantation.		
Early	detection	and	effective	intervention	in	the	early	stages	of	kidney	disease	
are	essential	to	prevent	or	delay	the	development	of	chronic	kidney	disease.	At	
the	moment,	the	NHSO	has	set	up	several	primary	prevention	programmes	that	
focus	on	improving	health	and	reducing	risk	factors	contributing	to	chronic	
diseases,	and	a	secondary	prevention	programme	that	consists	of	measures	for	
early	detection	in	those	who	have	already	developed	diabetes	mellitus	and	
hypertension	in	order	to	prevent	the	progression	of	the	disease	and	reduce	or	
delay	long‐term	complications	such	as	chronic	kidney	disease.	Given	that	
chronic	kidney	disease	is	a	silent	disease,	a	patient	may	be	living	unaware	of	the	
condition	until	it	reaches	an	advanced	stage.	A	guideline	focusing	on	educating	
and	taking	patients	into	the	prevention	programmes,	particularly	those	residing	
in	remote	areas,	is	needed.	
This	study	found	that	there	have	been	low	numbers	of	kidney	transplants	and	
this	situation	may	continue	if	no	action	is	taken.	The	study	did	not	explore	the	
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solutions	to	this	situation.	Possible	suggestions	may	include	establishing	an	
effective	and	reliable	organ	donation	system	in	accordance	with	international	
guidelines	(WHO	2009).	Although	many	developing	countries	have	introduced	
presumed	consent,	the	majority	of	Thai	people	still	have	limited	information	
about	and	negative	attitudes	towards	organ	donation.	Therefore,	
implementation	of	this	system	at	the	moment	would	be	controversial,	and	likely	
unsuccessful.	Promoting	positive	public	perceptions	of	organ	donation	is	
therefore	a	high	priority	and	may	address	the	most	difficult	issues	in	the	organ	
donation	process.			
iii. Promoting conservative therapy at the community level 
This	study	found	many	patients	of	a	community	hospital	chose	not	to	start	
dialysis,	but	instead	accepted	ongoing	support	by	a	multidisciplinary	team	
including	general	practioners,	nurses,	a	pharmacist,	a	nutritionist,	and	a	
physiotherapist.	Conservative	therapy	is	therefore	another	option	for	ESRD	
patients	apart	from	the	three	RRT	modalities	as	the	RRT	programme	continues	
to	expand.	Conservative	therapy	should	be	promoted	and	implemented	in	
community	hospitals	nationwide	to	ensure	that	opt‐out	patients	are	not	
completely	abandoned,	but	are	supported	by	the	health	care	team	until	the	end	
of	their	life.	Overall	this	could	reduce	or	delay	entry	into	the	RRT	programme	
and	help	reduce	the	high	cost	of	dialysis	treatment	within	the	RRT	programme,	
since	many	patients	may	never	start.				
iv. Controlling costs of materials and setting up optimal payment 
proportions 
The	results	of	this	study	suggested	that	the	material	cost	influenced	the	unit	
cost	of	each	RRT	modality,	and	it	can	be	adjusted	to	control	programme	costs.	
The	material	cost	of	medications	such	as	dialysis	solutions,	catheters,	and	
erythropoietin,	should	be	controlled	by	introducing	local	manufacturing	of	or	
controlling	purchase	prices.	Labour	costs	can	be	increased	annually	to	fit	the	
wage	rate	of	the	local	labour	market	in	order	to	persuade	and	motivate	
providers.	Reimbursements	for	machines	and	buildings	can	be	increased	then	
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fixed	for	their	life	cycle	periods.	Altogether,	proportions	of	these	three	cost	
drivers:	material,	labour,	and	capital	costs	can	be	adjusted	in	order	to	set	the	
optimal	payment	rate.		
v. Investing in effective information systems for monitoring and 
evaluation 
An	effective	information	system	is	central	to	programme	administration.	The	
information	system	should	include	continuous	monitoring	of	the	working	
processes	of	frontline	providers	and	of	the	central	NHSO.	Examples	of	such	
monitoring	include:	inspecting	DRG	coding	manipulation,	measuring	accuracy	
and	completeness	of	patient	records	stored	in	claims	data,	measurements	of	
programme	outputs,	and	coverage	of	disease	management	programmes.	
In	addition,	there	is	a	need	for	updated	research	studies	to	provide	evidence	
from	assessing	disease	management	programmes,	whether	they	have	achieved	
their	ultimate	aims	and	whether	they	represent	value	for	money.	This	is	
explained	in	greater	detail	in	the	next	section.	
9.4 Areas for future research 
There	is	a	constant	need	for	updated	research	studies	to	provide	new	evidence	
to	inform	policy	changes	and	support,	monitor,	and	evaluate	existing	policy	
decisions.	This	study	has	provided	some	examples,	there	are	questions	that	this	
study	has	not	yet	answered	and	could	therefore	provide	scope	for	future	
research.	Potential	areas	for	future	studies	are	described	here.			
9.4.1 High-cost and catastrophic definition 
Wyszewianski	(1986)	differentiated	between	the	terms	high‐cost	and	
financially	catastrophic.	Although	sometimes	used	interchangeably,	in	fact	they	
affect	policy	formulation	in	different	ways.	This	study	used	Wyszewienski’s	
definitions	to	give	an	example	of	a	high‐cost	and	catastrophic	condition	(ESRD)	
and	to	describe	how	ESRD	affects	patients,	providers,	and	policy	makers	in	this	
sense.		
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A	number	of	conditions	fall	under	the	definition	of	‘high‐cost’,	referring	to	
conditions	that	affect	small	numbers	of	patients	but	account	for	a	significant	
proportion	of	the	health	care	budget.	From	the	provider’s	perspective,	
identifying	the	most	expensive	conditions	and	the	patient	characteristics	that	
predispose	to	expensive	treatments	would	be	essential	in	order	to	effectively	
select	conditions	or	groups	of	patients	to	manage	in	this	way.		
9.4.2 Costs and costing of treatment for chronic kidney disease  
The	provision	of	treatment	for	chronic	kidney	disease	is	costly.	There	is	a	need	
for	further	research	on	the	costs	of	treatment	for	chronic	kidney	disease.	From	
the	providers’	perspective,	detailed	costing	of	each	activity	is	required.	
Comparing	costs	with	other	hospitals,	or	comparing	to	past	hospital	
performance,	reveals	opportunities	for	efficiency	improvement.	From	the	
payer’s	perspective,	costing	of	treatment	is	important	in	order	to	estimate	its	
impact	on	the	health	care	payer’s	budget.	Also,	costs	can	be	used	as	an	input	to	
set	the	prices	for	the	programme	reimbursement	rate.		
Assumptions	used	in	this	study	came	from	the	reviewed	studies,	which	were	
quite	old	or	used	data	collected	from	small	numbers	of	health	facilities.	Large‐
scale	studies	are	needed	to	estimate	the	true	cost	to	hospitals	(the	providers’	
perspective).	
9.4.3 RRT programme monitoring and evaluation  
Increasing	access	to	care	is	the	main	aim	of	the	RRT	disease	management	
programme	and	this	should	be	an	ongoing	process.	From	the	literature	review	
in	this	study,	there	are	numbers	of	ways	to	measure	access	to	care	and	other	
health	outcomes.		
This	current	study	provided	examples	of	these	but	it	lacked	a	comparator	to	
demonstrate	a	cause‐and‐effect	relationship	for	disease	management	
interventions.	Future	research	may	consider	adding	a	comparison	strategy	to	
interpret	results.	This	might	include	a	comparator	group	(internal,	external,	or	
general	population)	and	benchmarks	(general	population	or	target).	Suggested	
topics	might	include	whether	variations	in	access	to	care	or	other	health	
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outcomes	are	likely	to	be	explained	by	differences	in	geographical	regions,	
social	classes,	age	structures	and	health	schemes.	In	addition,	this	study	found	a	
number	of	patients	in	a	remote	area	had	made	the	decision	not	to	start	dialysis.	
It	should	be	explored	further	in	a	wider	group	of	population	about	factors	and	
patient	characteristics	that	might	influence	this	decision.	
9.4.4 Kidney transplant  
Kidney	transplant	is	the	most	preferred	and	cost‐effective	treatment	modality	
for	ESRD	patients.	However,	the	potential	to	increase	the	number	of	
transplantations	has	been	limited	by	a	shortage	of	donated	kidneys.	This	study	
confirmed	the	low	number	of	transplants	each	year	and	projected	that	this	
situation	would	remain	unchanged	in	the	next	decade,	however	the	study	did	
not	explore	this	further.	In	addition,	there	have	been	limited	published	papers	
in	Thailand	about	kidney	transplant.	These	could	be	opportunities	for	future	
research	to	identify	ways	to	increase	organ	donations.	Possible	topics	may	
include,	for	example	attitudes	towards	organ	donation	among	different	groups	
of	people,	system	barriers,	and	attitudes	towards	the	presumed	consent	system.		
Filling	spare	capacity	of	operating	theatres	is	a	way	that	this	study	suggested	to	
increase	efficiency	of	the	KT	system.	This	study	assumed	that	spare	capacity	
existed	but	has	not	proved	it.	This	could	be	another	area	to	explore,	that	is	the	
extent	to	which	operating	theatres	are	managed	and	used,	whether	there	is	
spare	capacity	and	what	impacts	are.		
9.4.5 Human resource for RRT programme 
Apart	from	sufficient	budget	to	care	for	patients	with	ESRD,	increasing	needs	for	
RRT	may	also	challenge	human	resources	for	health.	This	study	has	projected	
future	numbers	of	patients	by	RRT	modality.	This	information	could	be	used	as	a	
basis	to	estimate	numbers	of	health	professionals	required	in	the	RRT	system,	
and	whether	the	available	workforce	will	be	enough	to	meet	this	need.	
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9.4.6 New technologies in dialysis 
The	dominant	modes	of	dialysis	in	Thailand	are	in‐centre	hemodialysis	and	
continuous	ambulatory	peritoneal	dialysis.	In	addition	to	these,	there	are	other	
types	of	dialysis	such	as	automated	peritoneal	dialysis	(in	which	dialysis	
solution	is	changed	at	night	when	patients	are	asleep)	and	home	hemodialysis.	
Both	are	popular	in	many	developed	countries	(Nitsch,	Steenkamp	et	al.	2011;	
Vanholder,	Davenport	et	al.	2012)	but	are	rarely	used	in	Thailand.	None	of	these	
types	is	perfect,	they	have	advantages	and	disadvantages.		
Due	to	the	limited	use	of	other	types	of	dialysis,	studies	relating	to	them,	in	
terms	of	costs,	clinical	outcomes,	and	patients’	quality	of	life,	are	rare.	This	
knowledge	gap	could	be	addressed	by	future	research	to	assess	the	potential	for	
adopting	other	types	of	dialysis	as	part	of	the	UCS	benefit	package.	This	would	
also	provide	a	chance	for	patients	to	have	the	dialysis	method	that	best	suits	
their	personal	situation.	
9.4.7 Approaches to implement disease management programmes  
Disease	management	has	been	used	in	the	UCS	as	an	intervention	to	cope	with	
patients’	difficulties	and	inequities	in	access	to	health	services.	However,	this	
study	found	a	number	of	remaining	challenges	within	the	RRT	programme.	For	
example;	many	patients	in	a	remote	area	decided	not	to	start	RRT;	some	
patients	were	maintaining	RRT	and	facing	very	high	indirect	costs;	the	use	of	a	
multidisciplinary	team	produced	positive	results	in	a	community	hospital	and	
there	may	be	a	way	to	scale	up	this	practice.			
Implementation	research	applied	to	these	instances	could	support	existing	
policy	decisions	and	provides	information	as	to	whether	the	disease	
management	components	work,	which	would	work	best,	how	best	to	adjust	
them,	and	how	to	expand	the	use	of	a	disease	management	approach	to	some	
other	UCS	services	that	encounter	similar	problems.		
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9.5 Conclusions 
In	the	UCS,	the	aim	of	disease	management	programmes	is	different	from	that	of	
the	US	and	European	programmes.	In	Thailand,	disease	management	is	an	
answer	to	managing	high‐cost	and	catastrophic	conditions.	It	is	a	tool	for	policy	
makers	to	increase	access	to	care	for	particular	health	conditions	and	reduce	
catastrophic	patient	payments.	Key	features	of	the	Thai	programme	include	the	
guideline	protocol,	linked	to	a	payment	system	that	focuses	on	a	specific	
population	group.	The	protocol	links	to	other	components	affecting	patients’	
access	to	care:	collaborative	practice,	routine	reporting,	monitoring	and	
evaluation	systems,	and	self‐care	management.		
The	RRT	programme	and	the	UCS	have	achieved	their	aims	in	terms	of	
protecting	many	Thai	households	from	health‐care	payments	which	may	drive	
them	into	poverty	(Evans,	Chowdhury	et	al.	2012),	while	at	the	same	time	
promoting	access	to	essential	health	services	and	likely	improving	health	
outcomes.	Lessons	learned	from	the	disease	management	approach	might	be	
extended	to	other	high‐cost	conditions	within	the	UCS	and	can	be	applied	to	
other	developing	countries.	
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Appendices 
Appendix 1 EMBASE search results   
No. Terms Number retrieved 
1 "disease management".ti,ab. 13,216  
2 effect$.ti,ab. 6,600,707 
3 nation$.ti,ab. 544,626 
4 region$.ti,ab. 1,487,746 
5 sickness fund.ti,ab. 226  
6 decentral$.ti,ab. 6,866  
7  (county or counties).ti,ab. 59,065 
8 countr$.ti,ab. 378,593 
9 3 or 4 or 5 or 6 or 7 or 8 2,314,026 
10 1 and 2 and 9 923  
11 limit 10 to (abstracts and english language and yr="2003 - 2015") 768 
Appendix 2 Interview questions for policy makers and health care 
providers 
Main question Additional question 
I. general questions 
1. What are your job 
descriptions/responsibilities? 
• How many year you’ve been working on this job? 
II. High cost disease 
2. From your experience, have you ever seen a 
patient who paid for health care until 
bankrupted 
• What kind of disease the patient had, general 
disease(s) or chronic disease(s)? 
• What was the main reason? 
3. In your opinion, what are the characteristics 
of a disease that can cause the patient 
bankrupt? 
• Before the existing of NHSO and after NHSO, are 
they different? 
III. Disease management of RRT programme 
4. How do you diagnose a patient having last 
stage of chronic kidney disease 
(ICD10=N185)? 
• In the case that you or the patient does not want to 
start a dialysis at the moment, how do you diagnose 
that patient? 
5. How about the referral system?  • From community hospital to higher level 
• From health centre to community hospital 
6. How do you manage the HR for the PD first 
programme) 
• How many nephrologist, GPs, nurses, and patients 
you have? 
7. In your opinion, what are advantages and 
disadvantages of separating the RRT 
programme from other treatments which are 
paid by capitation payment. 
• Increase access to high cost treatment? 
• (keyword: Patient identification, payment, guideline 
protocol    
8. What about the reporting system?  
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:	interview	questions	for	patients	
	
	
	
IV. Holistic care/ palliative care  
9. Do you offer both holistic care/ palliative care 
to CKD patients? 
• What kind of activities you have? 
• Can you describe the flow/patient journey? 
• Do patients who have dialysis and patients who 
choose conservative therapy (no RRT) receive the 
same palliative care?  
10. In what stage that a patient can deny RRT • Generally, who is the one who makes decision 
(GP/nurse/patient/family) 
11. How do you evaluate a patient and get him 
ready for the conservative therapy? 
• Are there any processes of counseling and asking 
patient’s feedback?  
  
12. From the beginning of the RRT programme, 
what changing pattern do you observe?  
• Eg. No of patients on PD in comparison to HD and KT 
• Withdrawal and refusal of RRT in the first place 
• Effects of new policies  
13. Quality of life of ESRD patients  • Dialysis/KT/conservative patients 
14. Community supports  
IV. Opinion on RRT programme 
Main question Additional question 
1. Ask general questions about … • Age, place of birth, career, source of income, 
education, history of illness, and carer 
2. How did you about your condition (ESRD)? • When was that and who told you? 
• Were you worried, what about? 
• How did you cope with the condition? 
3. Before that have you got screening tests? • In which hospital, how and by who? 
4. After you know about your condition, what 
happen then? 
• What did you/family think? 
• Did you go to receive the treatment? 
5. Could you tell about the decision making 
process? 
• Did you/family have an opportunity to make 
decision about your treatment? 
• Did you know ‘PD first’? 
6.  (If received treatment) when did you register 
with the programme? 
• Did it take long to start the treatment? 
• How about your treatment? 
• How do you come to the hospital, how often, and 
anyone come along? 
• Are there any things you have to pay from your 
pocket? 
• Have you experienced a complication? 
7. (If not received treatment) what is the main 
reason of denying the treatment? 
• Who made the decision, you/family/doctor? 
• Did doctors give you enough information? 
• Is there any form of support you are given? 
8. How about your quality of life at the moment?  
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Appendix 3 Observation checklist 
Name:   Address:                         Date of collection: 
1.  Socio-economic information 
Age  
Sex  Male            Female 
Birthplace (Province) 
Marital status  Married        Single         Widow/separate 
Highest education  Primary or lower    Secondary     Bachelor’s or higher  
Career        
Household size                          Person(s) 
Household income                          Baht/month 
Main carer   
2.  History of illness 
Month/year diagnosed with ESRD  
Month/year starting dialysis    
Complication(s) from dialysis  No             Yes, …………………….. 
Comorbidity(ies)  
3.  Features of the house 
House type 
 House    Flat     Other 
Patient’s bedroom 
Own bedroom?         Yes                   No 
Good air flow?          Yes                    No  
Cleanliness?             Conform            Not conform 
House’s perimeter 
Cleanliness?             Conform            Not conform               
Hygiene?                  Conform            Not conform               
Pet?     No             Yes, kept away from exchange area   
                                 Yes, kept near exchange area   
Water source 
 Tap water      Ground water      Rain water       Other 
Exchange area 
Have a separate room?     Yes                  No 
Cleanliness?                       Conform         Not conform               
Stock of dialysis bags 
Separate area?        Yes              No 
Good air flow?          Yes             No  
Direct sunlight          Yes             No 
Cleanliness?            Conform      Not conform               
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Remaining bags 
 
4. Changing practice 
1) General information 
How often do you do exchange?   
How do you get dialysis bags?   Srinagarind hospital    Health centre  		 Home delivery 
Normally, who do the changing?    Yourself                      Carer 
2) Equipment 
1. Table/ flat surface  Have            Don’t have 
2. Liquid soap  Have            Don’t have 
3. Alcohol  Have            Don’t have 
4. Hand towel  Have            Don’t have 
5. Cotton ball  Have            Don’t have 
6. Water resistance, adhesive bandage  Have            Don’t have 
7. Hook/pole with hook  Have            Don’t have 
8. Hanging scale  Have            Don’t have 
9. Bucket to place empty bag in  Have            Don’t have 
10. Bucket to place used hand towel in  Have            Don’t have 
11. Sink with single lever faucet  Have            Don’t have 
3) Exchange technique 
1. Arranging equipment  Correct          Incorrect 
2. Hand washing  Correct          Incorrect 
3. Surface cleaning  Correct          Incorrect 
4. Checking the unused bag  Correct          Incorrect 
5. Combining and connecting exchange devices  Correct          Incorrect 
6. Weighing of used dialysis solution  Correct          Incorrect 
7. Updating health records  Correct          Incorrect 
8. Waste disposal  Correct          Incorrect 
9. Arranging equipment  Correct          Incorrect 
10. Hand washing  Correct          Incorrect 
11. Surface cleaning  Correct          Incorrect 
12. Checking the unused bag  Correct          Incorrect 
13. Combining and connecting exchange devices  Correct          Incorrect 
5. Exit site  
Cleanliness   Clean            Infected 
Dressing technique  Correct          Incorrect 
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Appendix 4 Coding framework 
Root code Sub code 
High-cost disease View on high-cost disease 
 Coping high-cost disease 
Chronic renal failure  Reason to select chronic renal failure to manage 
 Reason to separate from other diseases 
 How to select disease 
HR HR allocation knowledge 
 View on HR allocation 
Payment Reimbursement knowledge 
 Motivation from payment 
 View on payment 
Protocol Guideline/protocol knowledge 
 View on guideline/protocol 
Reporting/M&E Report, M&E knowledge 
 View on report, M&E 
Collaboration practice Provider-patientpractice 
 Purchaser-providerpractice 
 View on collaborative practice  
Family/community support View on family support 
 View on community support 
Patient journey Patient journey knowledge 
Patient characteristics Demographic 
 Socio-economic 
 Beliefs 
Patients’ decision making Reasons 
 By whom  
Patient self- management Location 
 Equipment 
 Technique 
	App
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Appendix 6 Research articles conducted to advocate including the RRT 
benefit in the UCS  
Dimension Aim Type/Method 
Results 
1. Access to RRT 
(Kasemsap, 
Tangcharoensathien et 
al. 2001) 
To raise the 
importance of the 
problem  
Review articleof 
situations in Thailand 
and other countries 
Access to RRT was limited only to those 
who were well-off, at around 23% of all 
ESRD patients  
2. Access to RRT 
(Tangcharoensathien, 
Teerawattananon et al. 
2001) 
To give possibilities 
of including RRT 
benefit into the UCS 
Policy analysis There is a need to take action on planning 
of service provision of RRT(including 
resources:HR/unit/budget), as well as 
programme expenditure 
3. Cost-effectiveness of 
RRT(Chewchanwattana, 
limwattananon et al. 
2003) 
To compared costs of 
2 mode of dialysis 
(HD and CAPD) 
Cost-utility analysis Using secondary data input from the US. 
renal data system (2002), ICER of CAPD in 
comparison to HD was 6.15 million Baht per 
QALY 
4. Supply 
(physician/nurse/HD 
machine/health facility) 
of the RRT(Krairittichai, 
Supaporn et al. 2003) 
To report current 
situations regarding 
infrastructures of the 
RRT 
Annual report of TRT 
registry 
Thailand Registry of Renal Replacement 
Therapy started its mission in 1997. Until 
2003 there were201 registered RRT units. 
Incidence and prevalence of ESRD in 2001 
were 23.4 and 112.7 pmp respectively. 
5. Cost-effectiveness of 
RRT (Teerawatananon 
2006) 
To compared costs of 
2 mode of dialysis 
(HD and CAPD) and 
without  treatment  
Cost-utility analysis CAPD had more cost-benefit 
and(Kasemsap, Teerawatananon et al. 
2006) cost-utility in comparison to HD in all 
age groups. Both dialysis modes were not 
cost-effectiveness when using GDP or 3 
times GDP as indicators. 
6. Demand of the 
programme (Kasemsap, 
Teerawatananon et al. 
2006) 
To estimate numbers 
of patients who need 
to use RRT 
Calculations of 
incidence rate and 
survival rate 
Under the circumstance of every ESRD 
patients can use RRT, there were 14,000 
patients in 2005, would increase to 50,000 
in 2009. 
7. Public opinion 
(Tangcharoensathien, 
Vasavid et al. 2006) 
To seek opinion from 
the public regarding 
the RRT benefit of 
the UCS 
Descriptive analysis 
of the survey 
Most Thais supported including the RRT 
benefit into the UCS. Just half of 
respondent agreed about paying a small 
amount of contribution (of less than 800  
Baht -approx.₤17-per month) 
8. Budget impact 
(Kasemsap, Prakongsai 
et al. 2006) 
To estimate budget 
needed for 
programme 
implementation 
Budget estimate In the first year of the programme, it would 
require 4,000-6,500 mBaht/year. These 
amounts would increase to more than 
50,000mBaht/year in the 14th year. 
9. Access to 
RRT(Prakongsai, 
Tangcharoensathien et 
al. 2006) 
To provide policy 
options regarding 
RRT benefit 
Literature 
review/qualitative 
analysis/policy 
analysis 
Including the RRT benefit into the UCS was 
essential to protect its beneficiaries from 
financial catastrophic due to service costs. 
Prioritising to those with more health needs 
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might help sustain the programme.  
10. Economic impact  
(Prakongsai, Palmer et 
al. 2009) 
To assessed impact 
of RRT costs on Thai 
households of 
different economic 
status 
In-depth interview Households spent 25%–68% of their total 
income for dialysis. All poor patients faced 
catastrophic health spending while well-off 
patients had adequate dialyses, therefore 
more survival rates and better quality of life. 
Note: RRT=renal replacement therapy, ESRD=end stage renal disease, CAPD=continuous ambulatory peritoneal dialysis, 
HD=hemodialysis, UCS=Universal Coverage Scheme, ICER=incremental cost-effectiveness ratio, QALY=quality-adjusted life 
year	
Appendix 7 Selected Stata commands for entry into the RRT programme 
(For hemodialysis) 
**CONSTRUCT ANALYTIC DATASETS 
use "ESRD_OPIP_HDPDKT_2008to2013r2",clear 
keep if rrt==1 
keep pid C dateRegister 
gen P=year(dateRegister) 
drop dateRegister 
gen A=P-C 
label variable A "Age at Registration" 
sort pid  
display _N 
keep C P A 
contract P A C 
rename _freq D 
label variable D "Number of HD registration" 
drop if A<20 
drop if A>89 
drop if P>2013 
sort P A 
 
*AGE RANGES 
gen ageRange=. 
replace ageRange=0 if A>=0&A<5 
replace ageRange=5 if A>=5&A<10 
replace ageRange=10 if A>=10&A<15 
replace ageRange=15 if A>=15&A<20 
replace ageRange=20 if A>=20&A<25 
replace ageRange=25 if A>=25&A<30 
replace ageRange=30 if A>=30&A<35 
replace ageRange=35 if A>=35&A<40 
replace ageRange=40 if A>=40&A<45 
replace ageRange=45 if A>=45&A<50 
replace ageRange=50 if A>=50&A<55 
replace ageRange=55 if A>=55&A<60 
replace ageRange=60 if A>=60&A<65 
replace ageRange=65 if A>=65&A<70 
replace ageRange=70 if A>=70&A<75 
replace ageRange=75 if A>=75&A<80 
replace ageRange=80 if A>=80&A<85 
replace ageRange=85 if A>=85&A<90 
 
*COHORT RANGES 
gen CRange=. 
replace CRange=1991 if C>=1991&C<1994 
replace CRange=1986 if C>=1986&C<1991 
replace CRange=1981 if C>=1981&C<1986 
replace CRange=1976 if C>=1976&C<1981 
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replace CRange=1971 if C>=1971&C<1976 
replace CRange=1966 if C>=1966&C<1971 
replace CRange=1961 if C>=1961&C<1966 
replace CRange=1956 if C>=1956&C<1961 
replace CRange=1951 if C>=1951&C<1956 
replace CRange=1946 if C>=1946&C<1951 
replace CRange=1941 if C>=1941&C<1946 
replace CRange=1936 if C>=1936&C<1941 
replace CRange=1931 if C>=1931&C<1936 
replace CRange=1926 if C>=1926&C<1931 
replace CRange=1921 if C>=1921&C<1926 
replace CRange=1916 if C>=1916&C<1921&C!=. 
 
*PERIOD RANGES 
gen PRange=. 
replace PRange=2005 if P>=2005&P<2006 
replace PRange=2006 if P>=2006&P<2007 
replace PRange=2007 if P>=2007&P<2008 
replace PRange=2008 if P>=2008&P<2009 
replace PRange=2009 if P>=2009&P<2010 
replace PRange=2010 if P>=2010&P<2011 
replace PRange=2011 if P>=2011&P<2012 
replace PRange=2012 if P>=2012&P<2013 
replace PRange=2013 if P>=2013&P<2014&P!=. 
tempfile x 
quietly save `x', replace 
 
*DESCRIPTIVE HD POPULATION 
use `x',clear 
keep D ageRange PRange 
egen pop=sum(D), by(PRange ageRange) 
label define ageRange 20"20-24" 25"25-29" 30"30-34" 35"35-39" 40"40-44" 
45"45-49" ///   
50"50-54" 55"55-59" 60"60-64" 65"65-69" 70"70-74" 75"75-79" 80"80-84" 
85"85-89"  
label value ageRange ageRange 
label variable ageRange "Age" 
contract pop ageRange PRange 
drop _freq 
rename ageRange Age 
rename PRange Year  
sort Year Age 
reshape wide pop, i(Age) j(Year) 
forvalue i=2008/2013 { 
quietly format pop`i' %5.0fc 
} 
**APC ANALYSIS 
*POPRISK 
use `x',clear 
poprisktime using popESRD_Allnewdata_r2, age(A) period(P) cohort(C) 
cases(D) /// 
agemin(20) agemax(89) permin(2008) permax(2013) missingreplace  
drop if Y==0 
drop if Y==. 
label variable Y "Poprisktime" 
 
*APC FIT: AP MODEL,REFERENCE PERIOD=2010,DF=5 
apcfit, age(A) period(P) cases(D) poprisktime(Y) nper(1000) refper(2010) 
param(AP) 
 
*CREATE GRAPH FOR AGE 
twoway (rarea agefitted_uci agefitted_lci A, sort pstyle(ci) color(orange) 
fintensity(inten50)) /// 
       (line agefitted A, sort lc(cranberry) clpattern(solid)) /// 
       , yscale(log)  name(A,replace) title("HD" "c.",position(11)) 
legend(off) /// 
         ylabel(2 5 10 20, angle(h)) xlabel(20(20)80) /// 
  Appendices  
310 
	
         xtitle("Age") ytitle("Rate per 1,000 ESRD diagnosis-years") 
scheme(sj) 
 
*CREATE GRAPH FOR PERIOD  
twoway (rarea perfitted_uci perfitted_lci P, sort pstyle(ci) 
color(eltgreen)  /// 
        fintensity(inten50)) (line perfitted P, sort lc(emerald) 
clpattern(solid)) /// 
        ,legend(off) name(P,replace) title(" " "d.",position(11)) /// 
        xtitle("Calendar Time") ytitle("Rate Ratio") yscale(log) /// 
  ylabel(1 2 4 15 50) xlabel(2009 2011 2013)  
*COMBINE AGE AND PERIOD GRAPHS 
graph combine A P, nocopies imargin(2 2 2 2) scheme(sj) ysize(4) xsize(8) 
name(hd,replace)   
 
 
**DESCRIPTIVE GRAPHS OF ACCESS TO HD (ESRD INCEDENCE AS DENOMINATOR) 
clear 
clear matrix 
set more off 
cd "D:\..." 
  
*CONSTRUCT ANALYTIC DATASETS 
use "ESRD_OPIP_HDPDKT_2008to2013r2",clear 
keep if rrt==1 
keep pid C dateRegister 
gen P=year(dateRegister) 
drop dateRegister 
gen A=P-C 
label variable A "Age at Registration" 
sort pid  
display _N 
keep C P A 
contract P A C 
rename _freq D 
label variable D "Number of HD registration" 
drop if A<20 
drop if A>89 
sort P A C 
tempfile a 
quietly save `a',replace 
  
**DESCRIPTIVE GRAPHS 
use popESRD_Allnewdata_r2,clear 
sort P A C 
merge 1:1 P A C using `a' 
keep if _merge==3 
drop _merge 
drop if P>2013 
display _N 
tempfile hd 
quietly save `hd', replace 
 
*1)GRAPHS RATE VS AGE BY PERIOD 
use `hd',clear 
egen Dpa=sum(D), by(P ageRange) 
egen Poppa=sum(pop), by(P ageRange) 
contract P ageRange Dpa Poppa  
drop _freq 
gen Rate=Dpa*100/Poppa 
format Rate %5.0f 
keep P ageRange Rate 
reshape wide Rate, i(ageRange) j(P) 
graph twoway (connected Rate* ageRange,sort name(HDdes1,replace) /// 
 title("Hemodialysis" "a",position(11)) /// 
 ytitle("Rate per 100 new ESRD diagnoses", margin(l=3 r=3)) /// 
 xtitle("Age at Registration") /// 
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 ylabel(0(10)30) xlabel(20(10)85) ytick(5(5)30) msymbol(O D T S Oh Dh 
Th Sh) /// 
 clwidth(medthick medthick medthick medthick medthick medthick 
medthick medthick medthick) /// 
 legend(label(1 "2008") label(2 "2009") label(3 "2010") label(4 
"2011") label(5 "2012") label(6 "2013")  /// 
  rows(4) colfirst subtitle("Calendar Year"))) 
 
*2)GRAPHS RATE VS AGE BY COHORT 
use `hd',clear 
egen Dca=sum(D), by(ageRange CRange) 
egen Popca=sum(pop), by(ageRange CRange) 
contract ageRange CRange Dca Popca  
drop _freq 
gen Rate=Dca*100/Popca 
format Rate %5.0f 
keep CRange ageRange Rate 
reshape wide Rate, i(ageRange) j(CRange) 
graph twoway (connected Rate* ageRange,sort name(HDdes2,replace) /// 
 title(" " "b",position(11)) /// 
 ytitle("Rate per 100 new ESRD diagnoses",margin(l=2 r=2)) xtitle("Age 
at Registration",margin(t=1 b=1)) /// 
 ylabel(0(10)30) xlabel(20(10)85) ytick(5(5)30) /// 
 msymbol(O D T S + Oh Dh Th Sh X o d t s p smplus)  /// 
 clwidth(medthick medthick medthick medthick medthick medthick 
medthick medthick medthick /// 
 medthick medthick medthick medthick medthick medthick medthick) /// 
 legend(label(1 "1916-20") label(2 "1921-25") label(3 "1926-30") 
label(4 "1931-35") /// 
  label(5 "1936-40") label(6 "1941-45") label(7 "1946-50") 
label(8 "1951-55") /// 
  label(9 "1956-60") label(10 "1961-65") label(11 "1966-70") 
label(12 "1971-75") /// 
  label(13 "1976-80") label(14 "1981-85") label(15 "1986-90") 
label(16 "1991-93") /// 
 rows(4) colfirst subtitle("Birth Year") symxsize(6)keygap(0))) 
  
*3)GRAPHS RATE VS PERIOD BY AGE 
use `hd',clear 
egen Dpa=sum(D), by(P ageRange) 
egen Poppa=sum(pop), by(P ageRange) 
contract P ageRange Dpa Poppa  
drop _freq 
gen Rate=Dpa*100/Poppa 
format Rate %5.0f 
keep P ageRange Rate 
reshape wide Rate, i(P) j(ageRange) 
graph twoway (connected Rate* P,sort name(HDdes3,replace) title(" " 
"c",position(11)) /// 
 ytitle("Rate per 100 new ESRD diagnoses", margin(l=3 r=5)) 
xtitle("Calendar Year",margin(t=1 b=1)) /// 
 ylabel(0(10)30) xlabel(2008(1)2013) ytick(5(5)30) /// 
 msymbol(O D T S + Oh Dh Th Sh X o d t s) /// 
 clwidth(medthick medthick medthick medthick medthick medthick 
medthick /// 
  medthick medthick medthick medthick medthick medthick 
medthick) /// 
 legend(label(1 "20-24") label(2 "25-29") label(3 "30-34") label(4 
"35-39") label(5 "40-44") /// 
  label(6 "44-49") label(7 "50-54") label(8 "55-59") label(9 
"60-64") label(10 "65-69") /// 
  label(11 "70-74") label(12 "75-79") label(13 "80-84") label(14 
"85-89") rows(4) colfirst /// 
  subtitle("Age at Registration") symxsize(9))) 
 
*4)GRAPHS RATE VS COHORT BY AGE 
use `hd',clear 
egen Dca=sum(D), by(CRange ageRange) 
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egen Popca=sum(pop), by(CRange ageRange) 
contract CRange ageRange Dca Popca  
drop _freq 
gen Rate=Dca*100/Popca 
format Rate %5.0f 
keep CRange ageRange Rate 
replace Rate=. if Rate==0 
reshape wide Rate, i(CRange) j(ageRange) 
graph twoway (connected Rate* CRange,sort name(HDdes4,replace) title(" " 
"d",position(11)) /// 
 ytitle("Rate per 100 new ESRD diagnoses",margin(l=2 r=2)) 
xtitle("Birth Year",margin(t=1 b=1)) /// 
 ylabel(0(10)30) xlabel(1915(10)1990) ytick(5(5)30) /// 
 msymbol(O D T S + Oh Dh Th Sh X o d t s) /// 
 clwidth(medthick medthick medthick medthick medthick medthick 
medthick /// 
  medthick medthick medthick medthick medthick medthick 
medthick) /// 
 legend(label(1 "20-24") label(2 "25-29") label(3 "30-34") label(4 
"35-39") label(5 "40-44") /// 
  label(6 "44-49") label(7 "50-54") label(8 "55-59") label(9 
"60-64") label(10 "65-69") /// 
  label(11 "70-74") label(12 "75-79") label(13 "80-84") label(14 
"85-89") rows(4) colfirst /// 
  subtitle("Age at Registration") symxsize(8) keygap(0)))  
 
*COMBINE 4 GRAPHS AND SAVE 
graph combine HDdes1 HDdes2 HDdes3 HDdes4,row(2) col(2) ycommon imargin(b=1 
t=1) iscale(.4) /// 
graphregion(margin(l=0 r=3)) ysize(11) xsize(8) 
 
 
Appendix 8 Test for unit root, serial correlations, white noise in the error 
terms, and AIC before differencing  
Test 
Model 
PD HD KT 
Dicky-Fuller * 0.804 0.244 0.824 
Durbin-Watson d-statistic** 0.057 0.110 0.061 
Durbin's alternative** <0.001 <0.001 <0.001 
Breusch-Godfrey LM** <0.001 <0.001 <0.001 
Portmanteau (Q) statistic*** <0.001 <0.001 <0.001 
AIC 1388.328 1345.492 1008.531 
*H0=No presence of a unit root 
**H0=no serial correlation 
***H0=No presence of a white noise 
Appendix 9 Test for unit root, serial correlations, white noise in the error 
terms, and AIC after first differencing 
Test 
Model 
PD HD KT 
Dicky-Fuller * <0.001   <0.001 <0.001 
  Appendices  
313 
	
Test 
Model 
PD HD KT 
Durbin-Watson d-statistic N/A N/A N/A 
Durbin's alternative** <0.001 0.266 <0.001 
Breusch-Godfrey LM** <0.001 0.263 <0.001 
Portmanteau (Q) statistic*** 0.999 1.000 0.982 
AIC 1163.646 1169.222 1171.975 
*H0=No presence of a unit root 
**H0=no serial correlation 
***H0=No presence of a white noise  
Appendix 10 Results from fitting ARIMA models 
PD  
------------------------------------------------------------------------------ 
             |                 OIM 
        D.pd |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
pd           | 
       _cons |   167.4371   48.15384     3.48   0.001     73.05733    261.8169 
-------------+---------------------------------------------------------------- 
ARMA         | 
          ma | 
         L1. |  -.4828109   .1099371    -4.39   0.000    -.6982837   -.2673381 
-------------+---------------------------------------------------------------- 
      /sigma |    773.312   64.89882    11.92   0.000     646.1126    900.5114 
------------------------------------------------------------------------------ 
HD 
------------------------------------------------------------------------------ 
             |                 OIM 
        D.hd |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
hd           | 
       _cons |   146.3224   93.61479     1.56   0.118    -37.15922     329.804 
-------------+---------------------------------------------------------------- 
ARMA         | 
          ar | 
         L1. |  -.1310408   .1168015    -1.12   0.262    -.3599675    .0978858 
-------------+---------------------------------------------------------------- 
      /sigma |   890.7188   74.74747    11.92   0.000     744.2164    1037.221 
------------------------------------------------------------------------------ 
KT 
------------------------------------------------------------------------------ 
             |                 OIM 
        D.kt |      Coef.   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
kt           | 
       _cons |   11.79115   1.514517     7.79   0.000     8.822747    14.75955 
-------------+---------------------------------------------------------------- 
ARMA         | 
          ma | 
         L1. |  -.7633019   .1043864    -7.31   0.000    -.9678955   -.5587082 
-------------+---------------------------------------------------------------- 
      /sigma |   50.95865   4.278565    11.91   0.000     42.57282    59.34449 
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Appendix 11 Cumulative periodograms of the residuals  
PD 
	
HD 
 
KT  
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